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Introduction
Rationale
Cardiovascular disease is common in the general population, affecting 40-60% of adults older
than 60 years of age. Many lines of evidence indicate an important role of early life events in in-
fluencing later susceptibility to cardiovascular disease. Barker and Osmond demonstrated that
areas of Britain with the highest neonatal mortality rates early in the 20th century also tended to
have the highest rates of coronary heart disease many decades later.1 After this, observational
studies showed that low birth weight and weight at one year were associated with an increased
risk of later cardiovascular disease2, especially in subjects who show a postnatal catch-up growth
and become obese as adults.3,4 The most commonly studied risk factors for cardiovascular disease
include blood pressure and total cholesterol levels.5,6 Several studies showed small but consistent
effects.7-9 These observations resulted in the “fetal origins of adult disease” hypothesis. More
recently, this hypothesis has been transformed to a more general “developmental plasticity hy-
pothesis”10, which suggests that an organism may develop in various ways, depending on the
particular environment or setting.11 In this process, adverse environmental exposures in fetal
and early postnatal life lead to adaptations that permanently program the fetus’ structure, phys-
iology and metabolism. These adaptations may be beneficial in the short term but have adverse
consequences at birth and in postnatal life, leading to both low birth weight and cardiovascular
disease in adulthood. Thus, cardiovascular disease may at least partly originate in early fetal
life.
Birth weight has been the most widely studied measure of fetal growth in studies exam-
ining the associations of birth-related measures with risk factors of disease in later life.12-14 The
effect size of low birth weight on cardiovascular disease and blood pressure in adulthood seems
to be small and the major limitation of current studies is that the specific adverse exposures and
underlying mechanisms are not known.5 Also, residual confounding may still be an issue. To fur-
ther explore the underlying mechanisms and to assess whether these associations are causal,
research has to move onwards from birth weight association studies to adverse fetal exposure,
and detailed early cardiovascular development studies.
We designed a prospective cohort study from early fetal life until the age of two years to
identify mechanisms underlying the associations between low birth weight and cardiovascular
disease (Figure 1). We used both maternal and fetal characteristics as specific exposures of
both fetal growth retardation and cardiovascular developmental changes in fetal life and early
childhood. The main focus was on cardiovascular and renal development, since adaptations in
these organs may be associated with cardiovascular and renal disease in adulthood.

In
tr
od
uc
tio
n
Figure . Associations studied in this thesis
Aims
The specific aims of this thesis were to study:
1. Genetic determinants of growth characteristics in fetal and early postnatal life. The main in-
terest was in genetic variants related to insuline and insuline-like growth factors, and to
glucocorticoid sensitivity.
2. Early determinants of kidney growth and development from fetal life until childhood. Deter-
minants of interest were maternal smoking and anthropometrics, as a measure of fetal
nutrition, and fetal growth and blood flow characteristics measured in second and third
trimester of pregnancy.
3. Genetic and environmental determinants of growth and development of the heart and blood
vessels in fetal life and early childhood. Determinants of interest were maternal smoking
and anthropometrics, and fetal growth and blood flow characteristics measured in second and
third trimester of pregnancy
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General design
Most studies were embedded in the Generation R Study. This is a population-based prospective
cohort study from fetal life until young adulthood in Rotterdam, the Netherlands.15,16 The Generation
R Study is designed to identify early environmental and biological determinants of growth, develop-
ment and health in fetal life and childhood. All pregnant women living in the study area with a
delivery date between April 2002 and January 2006 were eligible for enrolment in the Generation
R Study. While the aim was to have participants enrole during pregnancy, it was possible until the
birth of the child. Measurements were planned in early pregnancy (<18 weeks of gestation), mid-
pregnancy (18-25 weeks of gestation), and late pregnancy (≥25 weeks of gestation). In total,
9,778 women were included, of whom 8,880 were enrolled in the prenatal part of the study
(Figure 2). Detailed assessments of fetal growth and development were conducted in the Genera-
tion R Focus cohort.15, 16 In this subgroup of 1,232 Dutch pregnant women and their children,
we performed detailed assessments, such as Doppler ultrasounds of the placental, and fetal cere-
bral and cardiac arteries, and renal ultrasounds in prenatal life and cardiac and renal ultrasounds
at the postnatal ages of 1.5, 6 and 24 months. This subgroup is ethnically homogeneous to ex-
clude confounding or effect modification by ethnicity.
Figure 2. Flow chart Generation R Cohort
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Enrolment Total Cohort (Caucasians)
4,458 Mothers
Birth
4,527 Children
1,688 Children no DNA available
2,839 Children for follow-up studies
Postnatal follow-up
6 months 81% (n = 2,274)
14 months 75% (n = 2,136)
24 months 68% (n = 1,929)
Enrolment Focus Cohort
1,232 Mothers
Focus visits
1.5 months 81% (n = 900)
6 months 81% (n = 901)
24 months 77% (n = 856)
Birth
1,246 Children
1,106 Children for follow-up studies
One study was performed in the Avon Longitudinal Study of Parents and Children (ALSPAC).
ALSPAC is a similar population-based prospective cohort study as the Generation R Study and in-
vestigates the health and development in children (www.alspac.bris.ac.uk).17 Detailed information
about the children has been collected from questionnaires administered through childhood, and
clinical measurements have been performed on the entire cohort annually since the age of seven
years. In total, 6,668 mother-offspring pairs, approximately 65% of those invited, attended the
nine year follow-up clinic.
Outline of thesis
In chapter 2, the associations between genetic determinants with fetal and postnatal growth are
presented. These genetic determinants include variation in the insulin-like growth factor-1 (IGF1)
gene (chapter 2.), insulin gene variable number of tandem repeats (INS-VNTR) (chapter 2.2) and
genetic variants in the glucocorticoid receptor gene (chapter 2.). Chapter  demonstrates early
determinants of kidney growth and development from third trimester of pregnancy until the age
of two years. Reliability of kidney ultrasound measurements and renal reference growth curves
for kidney growth from third trimester of pregnancy until the age of two years are presented in
chapters . and .2. Studies focused on kidney growth determinants, such as maternal smoking
during pregnancy, fetal and placental blood flow characteristics and fetal and postnatal growth
characteristics are presented in chapters ., . and .. In chapter  we studied early deter-
minants of cardiac growth and development until the age of two years. Reliability of cardiac
ultrasound measurements is demonstrated in chapter .. Studied genetic and environmental
determinants included glucocorticoid receptor-9β polymorphism, maternal smoking and anthro-
pometrics during pregnancy, and fetal and postnatal growth. These results are presented in
chapters .2, ., . and .. In chapter ., the associations of hypertensive disorders of preg-
nancy with blood pressure in the offspring are presented. Finally, chapter  provides a general
discussion focused on our and other epidemiological studies designed to identify mechanisms
underlying the associations of low birth weight with development of cardiovascular disease in
adulthood. This discussion concludes with implications for future research and clinical practice.
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Abstract
Background: The objective of this study was to examine whether variants of the insulin-like growth
factor-1 (IGF1) gene are associated with growth patterns from fetal life until infancy.
Methods: This study was embedded in the Generation R Study, a population-based prospective
cohort study from fetal life. Fetal growth (head circumference, abdominal circumference, femur
length, estimated fetal weight) was assessed by ultrasounds in early, mid- and late pregnancy.
Growth in infancy was assessed at birth (weight) and at the ages of 6 weeks, 6 months and 14
months (head circumference, length, weight). IGF1 promoter region genotype was determined in
738 children.
Results: Eight alleles of the IGF1 promoter region were identified. In total, 43% of the subjects
were homozygous for the most common 192-bp allele (wild-type), 45% were heterozygous, and
12% were non-carrier of the 192-bp allele. No differences were found in birth weight between the
three groups. However, non-carriers had a lower estimated fetal weight in mid-pregnancy (p =
0.040), followed by an increased growth rate until 6 months (p <0.005) in comparison to 192-
bp homozygotes. A similar difference in growth rate was found for length (p <0.001).
Conclusions: Variants of the IGF1 promoter region are not associated with birth weight. However,
non-carriers of the 192-bp allele tend to have a smaller fetal size, followed by an increased growth
rate from mid-pregnancy to early infancy. Studies in larger cohorts are necessary to replicate our
findings and to examine whether these effects persist throughout childhood.
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Introduction
Birth weight is inversely associated with type 2 diabetes and cardiovascular disease in adulthood.1
The fetal insulin hypothesis proposes that these associations are explained by common genetic
variants.1 Insulin and insulin like growth factors are important fetal growth factors.2 Genetic factors
related to insulin or insulin-like growth factors production and sensitivity may lead to both impaired
fetal growth and to type 2 diabetes and cardiovascular disease in later life.1
Insulin-like growth factor-1 (IGF-1) is an essential regulator of both fetal and postnatal
growth.3-5 IGF-1 is also important for growth of insulin-producing β cells in the pancreas.6 It has
been suggested that IGF-1 is involved in postnatal changes in body composition, insulin sensitivity
and development of type 2 diabetes and cardiovascular disease.7, 8 A polymorphism in the
promoter region of the IGF1 gene has been identified, which has been associated with circulating
IGF-1 levels.9, 10 Previous studies have shown that the absence of the common 192-bp allele of
the IGF1 gene is associated with lower IGF-1 levels, lower birth weight and adult height, and an
increased risk of type 2 diabetes and myocardial infarction.7, 11-14 However, other studies were
not able to replicate these findings.15, 16 The inconsistent findings of studies examining the as-
sociations of this IGF1 gene variant with birth weight may be explained by the fact that birth
weight is an inappropriate measure of fetal growth. It has been shown that not children with low
birth weight per se but those who are small at birth and have a subsequent postnatal accelerated
weight gain leading to a normal or increased weight from childhood onwards are at increased
risk of development of type 2 diabetes and cardiovascular disease.17-19 Recently, the absence of the
192-bp allele was shown to increase the risk for accelerated weight gain in the first year of life.20
We hypothesized that variants of the IGF1 gene may be stronger related to longitudinally
measured growth in pre- and postnatal life than to one specific growth characteristic such as
birth weight. Therefore, we examined in the Generation R study, a prospective prenatally recruited
birth-cohort study, the associations of the IGF1 promoter polymorphism with growth measured in
different periods from fetal life to infancy.
Methods
Design
This study was embedded in the Generation R Study, a population-based prospective cohort study
from fetal life until young adulthood. This study is designed to identify early environmental and
genetic determinants of growth, development and health from fetal life until young adulthood and
has been described previously in detail.21, 22 In total, the cohort includes 9,778 mothers and their
children living in Rotterdam, the Netherlands. A vast majority (69%) of all mothers was enrolled
in the first trimester of pregnancy.22 Assessments in pregnancy included physical examinations,
2
Va
ria
tio
n
in
th
e
in
su
lin
-li
ke
gr
ow
th
fa
ct
or
-1
ge
ne
an
d
gr
ow
th
in
fe
ta
ll
ife
an
d
in
fa
nc
y
fetal ultrasounds, biological samples and questionnaires. These were planned in early (gesta-
tional age <18 weeks), mid- (gestational age 18-25 weeks) and late pregnancy (gestational age
≥25 weeks) to collect information about fetal growth and its main determinants. Their partners
were assessed once during this period. The children were born between April 2002 and January
2006 and form a prenatally recruited birth-cohort that is currently being followed until young adult-
hood. Of all eligible children, 61% participated in the study at birth. Additional, more detailed
assessments of fetal and postnatal growth and development were conducted in a subgroup of
1,232 parents and their children, referred to as the Generation R Focus cohort. This subgroup is
ethnic homogeneous to exclude possible confounding or effect modification by ethnicity. Of all ap-
proached women, 80% was enrolled in this subgroup study in late pregnancy (gestational age of
30 weeks). In this subgroup, postnatal examinations were performed at the ages of 6 weeks, 6
months, and 14 months. The study has been approved by the Medical Ethics Committee of the
Erasmus Medical Center, Rotterdam. Written informed consent was obtained from all participants.
Population for analysis
In total, 1,232 women were enrolled in the Generation R Focus Study. Twin pregnancies (n = 15)
and pregnancies leading to perinatal death (n = 2) were excluded from the present analysis. Of
the remaining singleton 1,215 live births, IGF1 genotyping was achieved in 61% (n = 738) of the
subjects. Growth characteristics in mid- and late pregnancy, and birth weight were available in all
these subjects. In total, 554 (75%), 551 (75%) and 538 (73%) of these subjects participated in
the postnatal assessments at the ages of 6 weeks, 6 months and 14 months, respectively.
Genotyping assay IGF1 gene
DNA was collected from cord blood samples of the children at birth. Cord blood for DNA isolation
was available in 85% of all children participating in the Focus cohort. Missing of cord blood sam-
ples was mainly due to logistic constraints. Polymerase chain reaction (PCR) was performed using
oligonucleotide primers designed to amplify the polymorphic cytosine-adenine (CA) repeat 1 kb
upstream of the human IGF1 gene.23 The reaction was carried out in a final volume of 10 ml con-
taining 50 ng of genomic DNA obtained from peripheral blood cells, 0.5 nmol/l forward primer
(‘5-ACCACTCTGGGAGAAGGGTA-3’), 0.5 nmol/l reverse primer (‘5-GCTAGCCAGCTGGTGTTATT-3’),
0.25 mmol/l 2’-dNTP, 2.2 mmol/l MgCl2, 0.01% W1 (Gibco BRL), and 0.4 Taq DNA polymerase
(Gibco BRL). PCR was performed in 284 well plates (94˚C 10 min; 35 PCR cycles of 30 s at 94˚C,
30 s on 55˚C, and 30 s on 72˚C; 72˚C 10 min; 4˚C hold). Forward primers were labeled with FAM,
HEX or NED to determine the size of PCR products by autosequencer (ABI 3100, POP 4, filter set
D, collecting time array 36 cm 7 s, peak-height between 100 and 2000, each lane containing three
samples). The size of the PCR products was determined in comparison with internal ROX-size
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standard (Perkin Elmer). Eight different alleles of the IGF1 promoter region were identified (Table
1). The genotype frequency was similar to those found in previous studies and the frequency dis-
tribution did not deviate from the Hardy-Weinberg equilibrium (Chi-square = 0.005, p >0.9).7, 20 As in
previous studies, IGF1 genotypes were categorized in the following categories based on their
192-bp allele: homozygous (wild-type), heterozygous and non-carrier.11, 15, 16, 20 In our study, IGF-1
levels were not available due to logistical and financial constraints.
Table . IGF1 promoter polymorphism- and genotype frequency distributions of the study
population (n = 738)
Polymorphism
Allele (base pairs) (CA)n Boys Girls
(n = 376) (n = 362)
186 16 2 (0.3) 0
188 17 20 (2.7) 17 (2.4)
190 18 37 (4.9) 39 (5.4)
192 (wild-type) 19 494 (65.7) 474 (65.5)
194 20 146 (19.4) 129 (17.8)
196 21 51 (6.7) 55 (7.6)
198 22 2 (0.3) 9 (1.2)
200 23 0 1 (0.1)
Genotypes
Homozygous 192-bp 166 (44.1) 151 (41.7)
Heterozygous 192-bp 162 (43.1) 172 (47.5)
Non-carriers 192-bp 48 (12.8) 39 (10.8)
Values are number of children (%). The allele distribution is based on 2 alleles per infant.
(CA)n: number of cytosine-adenine repeats; wild type allele: most frequent allele in this population.
Fetal growth and birth characteristics
Fetal ultrasound examinations were carried out at the visits in one of the research centers in
early, mid- and late pregnancy. These fetal ultrasounds were used for establishing gestational
age and for assessing fetal growth characteristics.24 Pregnancy dating curves were constructed
on subjects in the study with complete data on gestational age measured by ultrasound and last
menstrual period. Crown-rump length was used for pregnancy dating in early pregnancy (gesta-
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tional age until 12 weeks and 5 days, crown-rump length smaller than 65 mm) and biparietal
diameter was used for pregnancy dating thereafter (gestational age from 12 weeks and 5 days
onwards, biparietal diameter larger than 20 mm).25, 26 Fetal growth measurements used for the
present study included head circumference (HC), abdominal circumference (AC) and femur length
(FL) in mid- and late pregnancy, measured to the nearest mm using standardized ultrasound pro-
cedures.27 Estimated fetal weight (EFW) was calculated using the formula by Hadlock using head
circumference, abdominal circumference and femur length (log10 EFW = 1.5662 – 0.0108 (HC) +
0.0468 (AC) + 0.171 (FL) + 0.00034 (HC)2 – 0.003685 (AC * FL)).28 Early pregnancy was not in-
cluded since these fetal ultrasound examinations were primarily performed to establish
gestational age. Gestational age-adjusted standard deviation scores (SDS) were constructed for
all fetal growth measurements. These were based on reference growth curves from the whole
study population.
Postnatal growth characteristics
Birth weight, date of birth and gender were obtained from community midwife and hospital
registries. At the age of 6 weeks, 6 months and 14 months, subjects visited the research center.
Anthropometrics were measured without clothes. Weight was measured to the nearest gram using
electronic scales. Length was measured to the nearest millimeter in supine position using a
neonatometer at the ages of 6 weeks and 6 months, and in up-right position at the age of 14
months. Head circumference was measured to the nearest millimeter.
Covariates
Information on maternal age, parity and weight before pregnancy was obtained by the first ques-
tionnaire at the enrolment in the study. Maternal smoking habits were assessed in each
questionnaire. Maternal height and weight (in mid- and late pregnancy) was measured without
shoes at our research center, and body mass index (weight/height2 (kg/m2)) was calculated. The
occurrence of gestational diabetes was obtained from midwife or obstetric records. Information
about duration of breastfeeding was obtained by postnatal questionnaires at the ages of 2, 6 and
12 months.
Statistical analysis
First, differences of maternal, fetal and postnatal characteristics between the IGF1 genotype
groups were assessed by the independent sample t-test or Mann-Whitney U test for continuous
variables and the chi-square test for categorical variables. Subsequently, we performed multiple
linear regression models to assess the associations of the IGF1 gene with weight and length at
2
ch
ap
te
r
2
.1
each age cross-sectionally (prenatally: mid- and late pregnancy; at birth; postnatally: 6 weeks, 6
months and 14 months). For length, we used femur length as a proxy for body length in the pre-
natal data and to compare the effect estimates, we used standard deviation scores for the
cross-sectional analyses.29 These models were adjusted for (gestational) age and gender of the
child, maternal weight and height before pregnancy, increase in maternal weight during pregnancy,
smoking, and breastfeeding (only postnatal growth). Since no data about maternal diet was avail-
able for this study, maternal weight gain was used as a proxy for nutritional status.30 Age of
mother, parity and the occurrence of gestational diabetes did not change the effect estimates and
were therefore not included from the analyses.
Second, to assess longitudinally measured weight and length patterns from fetal life to
infancy, we performed repeated measures regression analysis with (estimated) weight and (femur)
length in fetal life and infancy as outcome. In these models, IGF1 genotype group was included
as both intercept and interaction with age. To account for (gestational) age at each specific
measurement, these analyses were conducted with age-adjusted standard deviation scores. The
models can be written as:
Weight (SDS) or length (SDS) = β0 + β1*age + β2*IGF1 genotype + β3*IGF1 genotype*age.
In this model, the term including ‘β0’ reflects the intercept and the term including ‘β1’ reflects
the slope of growth (in weight or length) per week for the reference group (192-bp homozygous
individuals). The terms including ‘β2‘ and ‘β3’ reflect the age independent difference and the
growth differences in weight (and length) between the different categories of the IGF1 genotype,
respectively. These models were adjusted for the same covariates as in the multiple linear re-
gression models.31
Thirdly, using binary logistic regression analyses and taking the covariates into account,
the associations of IGF1 genotype with weight realignment in different periods were examined.
Main interest was in realignment towards an increase in weight in infancy (“positive growth re-
alignment”), which was defined as a change of weight of more than +0.67 SDS (meaning, for
example, an increase from the 3rd to the 10th percentile).32-34
All effect estimates are presented with their 95% confidence interval (95% CI). Statistical
analyses were performed using the Statistical Analysis System version 8.2 (SAS, Stata corporation,
College station, TX, USA), including the PROC MIXED module for unbalanced repeated measure-
ments and the Statistical Package of Social Sciences version 11.0 for Windows (SPSS Inc,
Chicago, IL, USA).
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Results
Subject characteristics for the three genotype groups are shown in Tables 2, 3 and 4. In total, 317
(43%) subjects were 192-bp homozygous, 334 (45%) were 192-bp heterozygous and 87 (12%)
subjects were non-carriers. No differences in maternal, fetal and postnatal growth characteristics
were observed between these groups.
Table 2. Maternal characteristics according to the fetal IGF1 genotype
Homozygous Heterozygous Non-carrier
92-bp allele 92-bp allele 92-bp allele
(n = 317) (n = 334) (n = 87)
Maternal characteristics
Age (years) 31.6 (4.0) 31.5 (4.4) 31.8 (3.8)
Weight before pregnancy (kg) 69.2 (12.7) 68.4 (12.7) 70.6 (13.5)
Height (cm) 171.1 (6.5) 170.9 (6.4) 171.8 (7.0)
Body mass index before pregnancy (kg/m2) 23.7 (4.2) 23.3 (3.9) 23.8 (4.5)
Weight gain during pregnancy (kg) 10.0 (4.6) 10.1(4.5) 10.3 (4.4)
Parity (% nulliparous) 59.0 59.3 56.3
Gestational diabetes (%) 0.3 1.5 0
Smoking (%)
No 76.0 76.6 80.5
Yes, until pregnancy 8.8 9.6 5.7
Yes, throughout pregnancy 15.1 13.8 13.8
Values are means (standard deviation) or percentages. Differences were tested using independent sample t-test or Chi-square test
(all p-values >0.05). Of the total group, data were missing on maternal weight and body mass index before pregnancy (n=175),
maternal weight gain (n=189), parity (n=4), gestational diabetes (n=4), and smoking (n=1).
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Table . Fetal characteristics according to the fetal IGF1 genotype
Homozygous Heterozygous Non-carrier
92-bp allele 92-bp allele 92-bp allele
(n = 317) (n = 334) (n = 87)
Fetal characteristics mid-pregnancy
Gestational age (weeks) 20.6 (1.0) 20.5 (1.0) 20.5 (0.9)
Head circumference (mm) 178.6 (12.9) 178.1 (12.9) 177.5 (11.9)
Abdominal circumference (mm) 157.4 (13.5) 157.2 (13.8) 154.7 (11.6)
Femur length (mm) 33.2 (3.3) 32.9 (3.2) 32.6 (2.7)
Estimated fetal weight (grams) 379 (83) 374 (83) 360 (66)
Fetal characteristics late pregnancy
Gestational age (weeks) 30.5 (1.1) 30.4 (1.0) 30.5 (0.9)
Head circumference (mm) 287.0 (11.7) 285.9 (11.6) 286.2 (11.5)
Abdominal circumference (mm) 266.6 (16.5) 266.8 (16.0) 265.2 (14.9)
Femur length (mm) 57.5 (3.0) 57.1 (2.8) 57.4 (2.9)
Estimated fetal weigh (grams) 1649 (265) 1639 (248) 1626 (228)
Values are means (standard deviation). Differences were tested using independent sample t-test or Chi-square test (all p-values
>0.05). Of the total group, data were missing on mid-pregnancy gestational age (n=8), head circumference (n=13), abdominal cir-
cumference (n=13), femur length (n=13), estimated fetal weight (n=18), late pregnancy head circumference (n=3), abdominal
circumference (n=3), femur length (n=3), and estimated fetal weight (n=6).
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Table . Birth and postnatal characteristics according to the IGF1 genotype
Homozygous Heterozygous Non-carrier
92-bp allele 92-bp allele 92-bp allele
(n = 317) (n = 334) (n = 87)
Birth
Weight (grams) 3536 (494) 3546 (511) 3565 (452)
Gestational age (weeks) 40.1 (36.6 - 42.4) 40.4 (36.8 - 42.5) 40.6 (35.8 - 42.3)
Gender (% boy) 52.4 48.5 55.2
Postnatal characteristics  weeks
Age at visit (weeks) 6.3 (4.5 - 12.0) 6.1 (4.6 - 13.1) 6.3 (4.2 - 10.9)
Head circumference (cm) 38.7 (1.3) 38.6 (1.6) 38.6 (1.5)
Weight (grams) 4946 (599) 4907 (762) 4970 (701)
Length (cm) 56.9 (2.5) 56.7 (2.8) 57.0 (2.3)
Postnatal characteristics  months
Age at visit (weeks) 27.6 (23.7 - 34.8) 27.3 (23.6 - 35.6) 27.1 (23.9 - 34.9)
Head circumference (cm) 43.9 (1.4) 43.9 (1.4) 44.0 (1.1)
Weight (grams) 7980 (842) 7886 (900) 8100 (941)
Length (cm) 68.7 (2.6) 68.7 (2.7) 69.1 (2.8)
Postnatal characteristics  months
Age at visit (months) 14.5 (13.4 - 16.4) 14.4 (13.4 - 17.6) 14.4 (13.1 - 18.9)
Head circumference (cm) 47.4 (1.4) 47.3 (1.4) 47.3 (1.7)
Weight (grams) 10556 (1042) 10481 (1074) 10675 (1263)
Length (cm) 79.0 (2.9) 79.1 (3.0) 79.4 (3.0)
Breastfeeding
Never (%) 15.2 14.0 14.5
Yes, shorter than 6 months (%) 37.1 41.7 50.0
Yes, 6 months or longer (%) 25.8 22.7 19.7
Yes, duration unknown (%) 21.9 21.7 15.8
Values are means (standard deviation), medians (95% range) for variables with skewed distribution or percentages. Differences
were tested using independent sample t-test, Mann-Whitney U test, or Chi-square test (all p-values >0.05). Of the total group, data
were missing at the age 6 of weeks on head circumference 6 weeks (n=207), weight (n=198), length (n=201), at the of age 6
months on head circumference (n=194), on weight (n=191), on length (n=193), at the age of 14 months on head circumference
(n=238), weight (n=208), length (n=214), and breastfeeding (n=79).
Differences in weight (SDS) and length (SDS) between the genotype groups at each age are given
in Figure 1 and 2. These estimated differences were based on multiple linear regression models.
In non-carriers, we found a lower weight in mid-pregnancy (difference: -0.24 (95% CI: -0.50, -0.01)
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SDS) than in the 192-bp homozygous group. Similar non-significant differences were found for
length (SDS), where femur length was shorter in mid-pregnancy in non-carriers (difference: -0.17
(95% CI: -0.42, 0.08) SDS). Moreover, length (SDS) at 6 months was significantly greater in non-
carriers (difference: 0.32 (95% CI: 0.04, 0.61) SDS). Birth weight was similar in all three genotype
groups and no differences in pre- and postnatal growth characteristics were observed between
the 192-bp homozygous and 192-bp heterozygous groups.
Figure . Mean weight difference between the three genotype groups using the homozygous 192-bp
genotype as the reference group
Values represent estimated differences in SDS (95% confidence interval) based on multiple linear regression models, adjusted
for (gestational) age and gender of the child, maternal weight and height before pregnancy, increase in maternal weight during
pregnancy, smoking, and breastfeeding (only postnatal growth).
 : difference between non-carrier en homozygous genotypes. ∆ : difference between heterozygous and homozygous genotypes.
Figure 2. Mean length difference between the three genotype groups using the homozygous 192-bp
genotype as the reference group
Values represent estimated differences in SDS (95% confidence interval) based on multiple linear regression models, adjusted
for (gestational) age and gender of the child, maternal weight and height before pregnancy, increase in maternal weight during
pregnancy, smoking, and breastfeeding (only postnatal growth). For the prenatal data, femur length was used as a proxy for body
length.29
 : difference between non-carrier en homozygous genotypes. ∆ : difference between heterozygous and homozygous genotypes.
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Table 5 shows the associations between IGF1 genotype and longitudinally measured weight and
length of all children. Compared to the 192-bp homozygous group, the non-carriers had a signifi-
cantly higher growth rate from mid-pregnancy to 6 months in both weight and length. After the age
of 6 months, no differences were found in growth rate between the genotype groups.
Table . Differences in weight and length gain between IGF1 genotypes
Weight Difference in weight gain Difference in weight gain
mid-pregnancy to  months From  to  months
((SDS /  weeks) * -2) ((SDS /  weeks) * -2)
Homozygous 192-bp Reference Reference
Heterozygous 192-bp
2.1 (-2.7, 7.0) 0.4 (-6.1, 6.9)
p = 0.3981 p = 0.8997
Non-carriers 192-bp
11.5 (3.5, 19.6) -2.2 (-12.8, 8.3)
p = 0.0048 p = 0.6752
Length Difference in length gain Difference in length gain
mid-pregnancy to  months From  to  months
((SDS /  weeks) * -2) ((SDS /  weeks) * -2)
Homozygous 192-bp Reference Reference
Heterozygous 192-bp
6.9 (2.0, 11.8) -1.6 (-8.5, 5.4)
p = 0.0059 p = 0.6562
Non-carriers 192-bp
14.4 (6.4, 22.4) -2.5 (-13.9, 8.8)
p = 0.0004 p = 0.6610
Estimates are based on repeated measures regression analysis.
Values are regression coefficients (95% confidence interval) and reflect the difference in weight and length gain ((SDS / 10 weeks)
* 10-2) for each IGF1 genotype adjusted for (gestational) age and gender of the child, maternal weight and height before pregnancy,
increase in maternal weight during pregnancy, and smoking.
The odds ratio’s for the associations between IGF1 genotype group and positive growth realignment
are shown in Table 6. Non-carriers showed positive growth realignment between mid-pregnancy
and the age of 14 months more frequently compared to 192-bp homozygous subjects. An increased
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frequency of positive growth realignment was also found between mid-pregnancy and birth
amongst non-carriers, though this association was not significant.
Table . Association of IGF1 promoter polymorphism with “positive growth realignment”
Odds ratio for positive growth realignment
Genotype
From mid-pregnancy From birth From mid-pregnancy
to birth (SDS) to  months (SDS) to  months (SDS)
Homozygous 192-bp Reference Reference Reference
Heterozygous 192-bp 1.38 (0.92, 2.05) 1.43 (0.95, 2.17) 1.79 (1.10, 2.90)*
Non-carriers 192-bp 1.77 (0.96, 3.23) 1.23 (0.63, 2.40) 2.28 (1.12, 4.67)*
*p-value <0.05 vs. homozygous 192-bp using binary logistic regression analyses, adjusted for (gestational) age and gender of the
child, maternal weight and height before pregnancy, increase in maternal weight during pregnancy, smoking, and breastfeeding
(only postnatal growth). Positive growth realignment was defined as growth realignment >+0.67 SDS.
Discussion
We showed that non-carriers of the 192-bp allele tend to be smaller in mid-pregnancy and have
a higher growth rate onwards compared to homozygous 192-bp individuals. This accelerated
weight and length gain continued until the age of 6 months, after which growth rate was equivalent
in all three groups. No differences were found between homozygous and heterozygous 192-bp
individuals.
To our knowledge, this study is the first prospective cohort that examined the association
between IGF1 gene promoter polymorphism with fetal growth and growth in infancy. DNA for geno-
typing was available in 738 subjects (61%). Of all genotyped subjects at baseline, 73-75%
participated in the follow-up measurements in infancy, which may lead to a loss of power and
underestimation of the effect of the IGF1 gene promoter polymorphism. Children who were not
genotyped had a shorter gestational age (difference: -0.34 (95% CI: -0.55, -0.12) weeks, p =
0.002) and were lighter at birth (difference: -70.0 (95% CI: -146.6, 6.7) grams, p = 0.074) than
subjects who were genotyped. Our effect estimates would be biased if the associations between
genotypes and growth characteristics differ between those with and without DNA available for
genotyping studies. This seems unlikely but cannot be excluded.
Several IGF1 polymorphisms have been shown to influence IGF-1 levels and postnatal
growth in small for gestational age children, though few have focused on the affect of the IGF1
gene promoter region.35 Vaessen et al. found that the absence of the 192-bp allele was associated
with a decreased adult height.7 In the same cohort, non-carriers of the 192-bp allele had a lower
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birth weight.11 In their study, information on birth weight was retrospectively collected and not ad-
justed for gestational age.11 In two other large cohorts studies, no associations were found
between this polymorphism and birth weight.15, 16 Recently, in a retrospective study in children, it
was found that the absence of the 192-bp allele had no effect on birth weight, but was an inde-
pendent risk factor for accelerated weight gain in the first year of life.20
In our study, we found that non-carriers of the 192-bp allele were smaller in mid-pregnancy
than homozygous 192-bp carriers, which may be an indication of growth restriction in early
pregnancy. Subsequently, non-carriers had an increased growth rate until the age of 6 months.
We also found an increased risk of positive growth realignment between mid-pregnancy and 14
months amongst non-carriers compared to the homozygous group. We did not find differences in
birth weight or postnatal growth characteristics between the genotype groups.
We could not replicate the previously demonstrated associations of IGF1 gene promoter
polymorphism with birth weight or postnatal catch-up growth.11, 20 These differences could be ex-
plained by differences in study design. One of the major strengths of our study is than we
examined the association of IGF1 gene promoter polymorphism with various growth characteristics
and patterns rather than, as previously performed, with only birth or postnatal weight. We believe
that if IGF1 gene promoter polymorphism is truly associated with growth in early life, associations
with longitudinally measured growth patterns are expected to be stronger than with only one or
two growth measurements. However, the number of subjects in our and previous studies may be
too small to show the longitudinal effects. Landmann et al. found accelerated weight gain from
birth during the first year amongst non-carriers, while we found an increased risk of positive growth
realignment between mid-pregnancy and 14 months.20 We only found a non-significant trend
towards an increased growth rate from birth to 14 months. Thus our results are not similar as
those of Landmann et al., but is interesting that both studies found an increased growth rate in
early life among non-carriers. We cannot explain the differences in results. Since Landmann’s
study does not provide fetal growth data, it is not possible to replicate our major findings in their
study. Thus far, our and previous studies show rather inconsistent associations with growth
characteristics in early life.11, 16, 20 Chance finding can therefore not be excluded. Further studies
in larger cohorts are necessary to study the effect of this IGF1 gene promoter polymorphism with
growth from fetal to early postnatal life.
Although associations of this IGF1 genotype with growth characteristics and type 2 diabetes
have been suggested, conflicting results have been published on the biological effect of this poly-
morphism and the functionality of this gene is not yet known.7, 9, 10, 15 It has been suggested that,
due to its close location to the transcription site, the IGF1 promoter region may have a regulatory
function.7, 9 The absence of the wild-type 192-bp allele might therefore alter the transcription rate
of IGF1. Alternatively, it has been suggested that the IGF1 promoter region may be in linkage dis-
equilibrium with other regulatory elements, which in turn influence IGF-1 levels.7, 9 Furthermore,
it has been shown that placental IGF1 gene expression is altered in intra-uterine growth restric-
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tion.36 The IGF1 gene promoter polymorphism may play an important role in placental development
and function in early pregnancy, thus influencing early fetal growth. We are not aware of any
previous studies relating this IGF1 genotype with IGF-1 levels measured in cord blood in fetal life
or at birth. Further studies are necessary to establish the functionality of this IGF1 gene poly-
morphism and its association with circulating IGF-1 levels at birth.
In summary, our results suggest for the first time that the IGF1 promoter polymorphism
may influence growth from early fetal life to infancy. Because of the inconsistent findings in studies
examining the associations of this genotype with growth characteristics in early life, studies in
larger cohorts seem to be needed and the functionality of this gene needs to be further explored.
Probably, more importantly, systematic searches for common genetic variants by means of
genome-wide association studies may enable us to obtain a more complete understanding of
the functionality of the entire IGF1 region and its relation to growth and morbidity in childhood and
later life.
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Abstract
Background: The aim of this study was to examine whether the insulin gene variable number of
tandem repeats (INS VNTR) is associated with growth patterns in fetal life and infancy.
Methods: This study was embedded in the Generation R Study, a population-based prospective
cohort study from fetal life until young adulthood. Fetal growth was assessed by ultrasounds in
early, mid-, and late pregnancy. Anthropometry in infancy was assessed at birth and at the ages
of 6 weeks, 6 months and 14 months. DNA for genotyping of the INS VNTR promoter region was
available in 859 children.
Results: The genotype distribution was I/I 50.8%; I/III 40.0%; and III/III 9.2%. III/III individuals
had a shorter gestational age (p <0.005 vs. I/I) and a lower birth weight (p <0.05 vs. I/I). There
were no differences in birth weight after adjusting for gestational age. Class III homozygotes had
a smaller abdominal circumference / head circumference ratio (p <0.005 vs. I/I) in mid-pregnancy
but not in late pregnancy. Also, III/III subjects had a relative decrease in head circumference
(SDS) from mid-pregnancy to the age of 14 months (p <0.05 vs. I/I). No other differences in pre-
and postnatal growth characteristics and patterns were found.
Conclusions: Class III homozygotes were born at an earlier gestational age. No association was
found between INS VNTR and birth weight adjusted for gestational age. Our data suggest that the
III/III genotype may be associated with asymmetrical growth in mid-pregnancy, but not in late
pregnancy.
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Introduction
Insulin is the most important fetal growth factor.1 Previous experimental and observational studies
have shown that reduced secretion of fetal insulin and insulin-like growth factors is associated with
low birth weight.1, 2 Several rare monogenic defects that affect insulin secretion have been shown
to be related to altered fetal growth.1, 3 It has been suggested that also more common genetic
polymorphisms related to insulin secretion and metabolism may explain part of the differences
in birth weight in the normal population.3
Variation at the insulin gene variable number of tandem repeats (INS VNTR) minisatellite
has been shown to influence pancreatic insulin gene transcription, both in the fetus and in adult-
hood.4, 5 The VNTR lies upstream of the imprinted insulin and insulin growth factor II genes on
chromosome 11p15.5 and has been suggested to influence transcription rate of these genes.5-7
INS VNTR has been suggested as a candidate genetic variant which influences fetal and early
postnatal growth in a normal population.8, 9 There are two main classes of the VNTR, namely class
I (30-44 repeat units) and class III (around 150 repeat units); class II is very rare in the Caucasian
population.5 Studies in the human pancreas have suggested that INS expression is lower in the
VNTR class II homozygous than in the VNTR class I homozygous individuals.5, 10 At birth, INS VNTR
class III homozygous individuals have been shown to have a larger mean head circumference.8
Among those subjects without postnatal growth realignment, birth weight and length were also
increased.8 However, other cohort studies found a lower birth weight in class III homozygotes or
no difference in birth weight at all.9, 11, 12 It has also been suggested that this genotype is involved
in childhood obesity and the development of metabolic syndrome13, 14 ,polycystic ovary syndrome15
and type 2 diabetes in adulthood.16,17 Nevertheless, two large cohort studies were unable to demon-
strate effects of INS VNTR on body composition or the risk of metabolic syndrome in adulthood.18,19
The inconsistent findings from studies examining the association between INS VNTR
genotype with birth size may be explained by the fact that size at birth alone is an inappropriate
measure for fetal growth. We hypothesized that variants of the INS VNTR may be stronger related
to longitudinally measured growth in pre- and postnatal life than to one specific growth charac-
teristic such as birth weight. Therefore, we examined in the Generation R Study, a prospective
prenatally recruited birth-cohort study, the associations of the INS VNTR genotype with growth
parameters measured in different periods from fetal life until infancy.
Methods
Design
This study was embedded in the Generation R Study, a population-based prospective cohort study
from fetal life until young adulthood. This study is designed to identify early environmental and
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genetic determinants of growth, development and health from fetal life until young adulthood and
has been described previously in detail.20, 21 In total, the cohort includes 9,778 mothers and their
children living in Rotterdam, the Netherlands. A vast majority (69%) of all mothers were enrolled
in the first trimester of pregnancy.20 Assessments in pregnancy included physical examinations,
fetal ultrasounds, biological samples and questionnaires. These were planned in early (gesta-
tional age <18 weeks), mid- (gestational age 18-25 weeks) and late pregnancy (gestational age
≥25 weeks) to collect information about fetal growth and its main determinants. Their partners
were assessed once during this period. The children were born between April 2002 and January
2006 and form a prenatally recruited birth-cohort that is currently being followed until young adult-
hood. Of all eligible children, 61% participated in the study at birth. Additionally, more detailed
assessments of fetal and postnatal growth and development were conducted in a subgroup of
1,232 parents and their children, referred to as the Generation R Focus cohort. This subgroup is
completely Caucasian to exclude possible confounding or effect modification by ethnicity. Of all
approached women, 80% was enrolled in this subgroup study in late pregnancy (gestational age
of 30 weeks). In this subgroup, postnatal examinations were performed at the ages of 6 weeks,
6 months, and 14 months. The study has been approved by the Medical Ethics Committee of the
Erasmus Medical Center, Rotterdam. Written informed consent was obtained from all participants
or their parents.
Population for analysis
In total, 1,232 women were enrolled in the Generation R Focus Study. Twin pregnancies (n = 15)
and pregnancies leading to perinatal death (n = 2) were excluded from the present analysis. Of
the remaining singleton 1,215 live births, INS VNTR genotyping was achieved in 71% (n = 859)
of the subjects. Growth characteristics in mid- and late pregnancy, and birth weight were available
in all these children. In total, 653 (76%), 653 (76%) and 605 (70%) children participated in the
postnatal assessments at the age of 6 weeks, 6 months and 14 months, respectively.
Genotyping INS VNTR gene
DNA was collected from cord blood samples at birth. Cord blood for DNA isolation was available
in 85% of all children participating in the Focus cohort. Missing cord blood samples were mainly
due to logistic constraints at the delivery. Polymerase chain reaction (PCR) was performed to amplify
the –23/HphI single nucleotide polymorphism (A/T), which is known to be in almost complete
linkage disequilibrium with INS VNTR class.22
The genotype distribution (AA 50.8%; AT 40.0%; and TT 9.2%) was similar to those found in previous
studies and the frequency distribution did not deviate from the Hardy-Weinberg equilibrium
(Chi-square = 1.28, p >0.1).8, 11, 19
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Fetal growth and birth characteristics
Fetal ultrasound examinations were carried out in one of the research centers in early, mid- and
late pregnancy. These fetal ultrasounds were used for both establishing gestational age and as-
sessing fetal growth characteristics.23 Pregnancy dating curves were constructed on subjects in
the study with complete data on gestational age measured by ultrasound and last menstrual pe-
riod. Crown-rump length was used for pregnancy dating in early pregnancy (gestational age until
12 weeks and 5 days, crown-rump length smaller than 65 mm) and biparietal diameter was used
for pregnancy dating thereafter (gestational age from 12 weeks and 5 days onwards, biparietal
diameter larger than 20 mm).24, 25 Fetal growth measurements used for the present study included
head circumference (HC), abdominal circumference (AC) and femur length (FL) in mid- and late
pregnancy, measured to the nearest mm using standardized ultrasound procedures.26 Abdominal
circumference / head circumference ratio was calculated, which has been shown to be useful in
distinguishing symmetrical from asymmetrical growth.27 Estimated fetal weight was calculated
using the formula by Hadlock using head circumference, abdominal circumference and femur
length (log10 EFW = 1.5662 – 0.0108 (HC) + 0.0468 (AC) + 0.171 (FL) + 0.00034 (HC)2 –
0.003685 (AC * FL)).28 Early pregnancy was not included since these fetal ultrasound examinations
were primarily performed to establish gestational age. Gestational age-adjusted standard deviation
scores (SDS) were constructed for all fetal growth measurements. These were based on reference
growth charts from the whole study population.
Postnatal growth characteristics
Date of birth, gender, and birth weight were obtained from community midwife and hospital registries.
At the age of 6 weeks, 6 months and 14 months, anthropometrics were measured without clothes.
Weight was measured to the nearest gram using electronic scales. Length was measured in supine
position to the nearest millimeter at the ages of 6 weeks and 6 months using a neonatometer,
and it up-right position at the age of 14 months. Head circumference was measured to the nearest
millimeter.
Covariates
Information about maternal age, parity and weight before pregnancy was obtained by the first
questionnaire at enrolment in the study. Maternal height was measured without shoes at our re-
search center, and body mass index (weight/height2 (kg/m2)) was calculated. Information on the
occurrence of hypertension, pre-eclampsia, gestational diabetes, and labour details (induced or
primary caesarean section, spontaneous) was obtained from midwife and obstetrician records.
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Statistical analysis
First, differences of maternal, fetal and postnatal characteristics between the INS VNTR genotypic
groups were assessed by independent sample t-test or Mann-Whitney’s U test for continuous
variables and the Chi-square test for categorical variables. Since the VNTR-INS-IGF2 region is
imprinted, with its paternally-inherited allele being expressed, the I/III heterozygote group can be
considered as an indeterminate group, consisting partly of individuals in whom the I allele is ex-
pressed, and partly of individuals in whom the III allele is expressed. Main interest in our analyses
considering etiological associations was on the difference between I/I and III/III heterozygous
subjects. For all analyses, the I/III and III/III genotype groups were both separately compared to
the I/I group (reference group). Subsequently, we used multiple linear regression models to assess
the associations of INS VNTR with gestational age at birth, adjusting for maternal age, parity,
hypertension, pre-clampsia, gestational diabetes, induced labour and primary caesarean section.
To assess the association without the extremes of gestational age or birth weight, we also per-
formed this analysis, excluding those children born prematurely (gestational age <37 weeks) and
small or large for gestational age (-2 SDS or +2 SDS, respectively). Multiple linear regression
models were also performed to study the association between genotype and (estimated) weight,
head circumference and abdominal circumference / head circumference ratio (AC/HC ratio) at
each age cross-sectionally (prenatally: mid- and late pregnancy; at birth; postnatally: 6 weeks, 6
months and 14 months). These models were adjusted for gender and age and postnatal data was
additionally adjusted for gestational age at birth. Next, to examine the associations of INS VNTR
with prospectively measured growth patterns, rather than growth characteristics at one age, we
studied the differences in (estimated) weight change (SDS) and head circumference (SDS) change
from mid-pregnancy to 14 months between genotypes using multiple linear regression models.
Since it has been suggested that in children from multiparous mothers and/or in children with
no postnatal growth realignment, the genetic contribution to birth weight is greater than in first
born and/or in children with growth realignment, we also examined the associations of INS VNTR
genotype and birth weight in strata of birth order and growth realignment.6 As previously described,
growth realignment was defined as a change, either increase or decrease, of weight between birth
and 14 months of more than 0.67 SDS (“changers” means, for example, a 3rd to 10th percentile
increase, and “non-changers” means a growth realignment less than 0.67 SDS).8, 17, 29 Finally,
using Pearson’s Chi-square, we compared the prevalence of catch-up growth between genotypes,
where catch-up growth was defined as a positive growth realignment of more than 0.67 SDS. All
effect estimates are presented with their 95% confidence interval (CI). Statistical analyses were
performed using the Statistical Package of Social Sciences version 11.0 for Windows (SPSS Inc,
Chicago, IL, USA).
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Results
Subject characteristics for the three genotypes are shown in Tables 1, 2 and 3. Genotype fre-
quency distribution was I/I 50.8%; I/III 40.0%; and III/III 9.2%. No differences between genotypes
were found in maternal characteristics. Gender distribution was similar in the three genotypes.
In mid-pregnancy, class III homozygotes had a smaller abdominal circumference and a reduced
abdominal circumference / head circumference compared to class I homozygotes. Subjects with
the III/III genotype were born at a significantly shorter gestational age and had a lower birth
weight than the I/I individuals. After adjusting for maternal age, parity, hypertension, pre-clampsia,
gestational diabetes, induced labour and primary caesarean section, gestational age remained
shorter in the homozygous III/III group (differences: -0.39 (95% CI: -0.71, -0.08) weeks versus
I/I). Also, when we excluded large and small for gestational age births and preterm births from
the analysis, the difference in gestational age was significant (differences: -0.34 (95% CI: -0.62,
-0.05) weeks versus I/I). The odds ratio for preterm birth in the III/III group versus the I/I group
was not significant (1.86 (95% CI: 0.58, 5.94)). No differences in birth weight SDS were found.
Table . Maternal characteristics according to fetal insulin gene VNTR class genotype
I / I I / III III / III
(n = 436) (n = 344) (n = 79)
Maternal characteristics
Age (years) 31.7 (4.1) 31.5 (4.3) 31.5 (4.0)
Weight (kg) 68.6 (11.9) 69.1 (13.1) 69.0 (12.3)
Height (cm) 171.0 (6.6) 171.1 (6.4) 170.6 (6.2)
Body mass index (kg/m2) 23.4 (3.9) 23.6 (4.1) 23.7 (3.9)
Parity (% nulliparous) 59.1 59.9 59.0
Hypertension (%) 5.1 4.4 7.7
Pre-eclampsie (%) 1.2 1.2 1.3
Gestational diabetes (%) 0.2 1.2 1.3
Induced labour (%) 26.2 24.1 34.2
Primary caesarean section (%) 3.1 3.1 5.1
Values are means (SDS) or percentages. Differences were tested using independent sample t-test or Chi-square test. Of the total
group, data were missing on maternal height before pregnancy (n=8), weight and body mass index (n=146), parity (n=12), hy-
pertension (n=4), pre-eclampsia (n=4), gestational diabetes (n=5), induced labour (n=35) and primary caesarean section (n=42).
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Table 2. Fetal characteristics according to fetal insulin gene VNTR class genotype
I / I I / III III / III
(n = 436) (n = 344) (n = 79)
Fetal characteristics mid-pregnancy
Gestational age (weeks) 20.6 (1.0) 20.5 (1.0) 20.4 (0.9)
Head circumference (mm) 179 (12.6) 178 (12.8) 178 (11.0)
Abdominal circumference (mm) 157 (13.1) 156 (13.1) 154 (12.0)*
Femur length (mm) 33.1 (3.1) 32.9 (3.1) 32.6 (3.0)
Abdominal / head circumference ratio 0.880 (0.043) 0.880 (0.040) 0.865 (0.035)†
Estimated fetal weight (grams) 377 (80) 371 (80) 359 (69)
Fetal characteristics late pregnancy
Gestational age (weeks) 30.4 (1.0) 30.4 (1.0) 30.5 (1.0)
Head circumference (mm) 286 (11.7) 286 (11.7) 287 (13.0)
Abdominal circumference (mm) 265 (15.7) 267 (16.7) 267 (18.0)
Femur length (mm) 57.1 (3.1) 57.4 (2.9) 57.3 (2.8)
Abdominal / head circumference ratio 0.928 (0.042) 0.933 (0.044) 0.931 (0.046)
Estimated fetal weight (grams) 1622 (255) 1648 (261) 1648 (267)
Values are means (SDS). Differences were tested using independent sample t-test. Of the total group, data were missing on mid-
pregnancy gestational age (n=10), head circumference (n=14), abdominal circumference (n=12), femur length (n=14), abdominal
circumference / head circumference ratio (n=36), estimated fetal weight (n=16), late pregnancy gestational age (n=6), head cir-
cumference (n=8), abdominal circumference (n=10), femur length (n=9), abdominal circumference / head circumference ratio
(n=22) and estimated fetal weight (n=10).
*p-value <0.05 vs. I/I genotype, †p-value <0.005 vs. I/I genotype
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Table . Birth and postnatal characteristics according to insulin gene VNTR class genotype
I / I I / III III / III
(n = 436) (n = 344) (n = 79)
Birth
Gestational age (weeks) 40.2 (36.7 - 42.4) 40.2 (37.6 - 42.4) 39.6 (36.0 - 42.3)*
Gestational age <37 weeks (%) 3.0 1.7 5.1
Weight (grams) 3510 (512) 3591 (478) 3396 (504)†
Weight (SDS) 0.01 (0.99) 0.14 (0.98) -0.01 (0.90)
Weight <-2 SDS (%) 3.2 2.3 2.5
Weight >+2 SDS (%) 2.1 3.2 1.3
Gender (% boy) 50.0 55.2 50.6
Postnatal characteristics  weeks
Age at visit (weeks) 6.9 (4.6 - 12.7) 6.5 (4.4 - 10.3) 7.1 (4.2 - 14.9)
Head circumference (cm) 38.6 (1.4) 38.6 (1.4) 38.5 (1.8)
Weight (grams) 4919 (710) 4918 (615) 4817 (802)
Length (cm) 56.7 (2.6) 57.0 (2.4) 56.3 (2.8)
Body mass index (kg/m2) 15.2 (1.5) 15.1 (1.4) 15.1 (1.4)
Postnatal characteristics  months
Age at visit (weeks) 27.7 (23.3 - 34.3) 28.4 (23.7 - 36.4) 28.3 (24.1 - 35.6)
Head circumference (cm) 43.8 (1.3) 44.0 (1.3) 43.9 (1.7)
Weight (grams) 7889 (859) 7998 (897) 7878 (907)
Length (cm) 68.4 (2.6) 69.0 (2.7) 68.6 (2.7)
Body mass index (kg/m2) 16.8 (1.3) 16.8 (1.3) 16.8 (1.5)
Postnatal characteristics  months
Age at visit (months) 14.7 (13.4 - 17.5) 14.5 (13.3 - 16.5) 14.6 (13.5 - 17.3)
Head circumference (cm) 47.3 (1.4) 47.4 (1.3) 47.0 (1.6)
Weight (grams) 10490 (1074) 10563 (1053) 10431 (1181)
Length (cm) 79.1 (2.9) 79.3 (3.0) 78.8 (3.2)
Body mass index (kg/m2) 16.8 (1.3) 16.8 (1.1) 16.8 (1.2)
Values are means (SDS), medians (95% range) for variables with skewed distribution, or percentages. Differences were tested using
independent sample t-test, Mann-Whitney’s U test, or Chi-square test. Of the total group, data were missing at 6 weeks head cir-
cumference (n=242), weight (n=232), length (n=235); at 6 months head circumference (n=234), weight (n=230), length (n=232);
at 14 months head circumference (n=293), weight (n=262), and length (n=270).
*p-value <0.05 vs. I/I genotype, †p-value <0.005 vs. I/I genotype
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Results from the cross-sectional multiple regression analyses of weight, head circumference
and abdominal circumference / head circumference ratio (prenatal) at each age are shown in
Figures 1, 2, and 3. No differences in weight (SDS) were found at any age. In class III homozygous
subjects, head circumference (SDS) tended to be larger in mid-pregnancy and smaller at the age
of 14 months compared to class I homozygotes (differences: 0.23 (95% CI: 0.00, 0.46) SDS
and -0.25 (95% CI: -0.49, 0.00) SDS, respectively) though these differences were not significant.
Abdominal circumference / head circumference ratio was significantly lower in III/III subjects than
in I/I individuals in mid-pregnancy (difference: -0.28 (95% CI: -0.47, -0.09) SDS), but not in late
pregnancy.
Figure . Mean weight difference between the three genotypes using the I/I genotype as reference
group
Values represent differences between genotypes in SDS (95% confidence interval) based on multiple linear regression models,
adjusted for (gestational) age and gender. Postnatal estimates are additionally adjusted for gestational age at birth.
Figure 2. Mean head circumference difference between the three genotypes using the I/I genotype
as reference group
Values represent differences between genotypes in SDS (95% confidence interval) based on multiple linear regression models,
adjusted for (gestational) age and gender. Postnatal estimates are additionally adjusted for gestational age at birth.
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Figure . Mean abdominal circumference / head circumference (AC/HC) ratio difference (in SDS)
between the three genotypes using the I/I genotype as reference group
Values represent differences between genotypes in SDS (95% confidence interval) based on multiple linear regression models,
adjusted for gestational age and gender.
From mid-pregnancy to 14 months, the III/III individuals had a significant mean decrease in head
circumference SDS compared to I/I subjects (Table 4). No difference between the genotype groups
in weight change were found during any period between mid-pregnancy and the age of 14 months.
Table . Differences in weight change and head circumference change from mid-pregnancy to
14 months using the I/I genotype as a reference group
Genotype Weight change (SDS) Head circumference change (SDS)
I/I Reference Reference
I/III -0.083 (-0.292, 0.127) -0.027 (-0.236, 0.181)
III/III -0.029 (-0.378, 0.320) -0.443 (-0.799, - 0.086)
Values represent differences in change in SDS (95% confidence interval). Differences were tested using multiple linear regression
models.
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The associations between INS VNTR genotypes and birth weight, stratified by birth order and
weight realignment, are shown in Table 5. Amongst the firstborn children, subjects with the I/III
genotype were significantly heavier than I/I individuals. Birth weight was similar in the three in
genotype groups amongst children born from multiparous mothers. No difference between the
three genotypes was found in birth weight amongst the “non-changers”. Amongst the “changers”,
however, the I/III subjects had a significantly higher birth weight after adjusting for age and gender
than I/I subjects. And finally, no differences were found between the three genotypes in the
prevalence of catch-up growth between birth and the age of 14 months (p >0.5, using Pearson’s
Chi-square).
Table . Birth weight per genotype, stratified by birth order and growth realignment
Genotype st pregnancy 2nd+ pregnancy Non-changers Changers
I/I 3421 (516) 3633 (476) 3498 (413) 3555 (541)
I/III 3512 (490)* 3668 (449) 3510 (421) 3695 (493)*
III/III 3398 (502) 3616 (467) 3462 (524) 3463 (526)
Values represent mean in grams (SDS). Differences were tested using multiple linear regression models, adjusting for gestational
age and gender. Change is defined as postnatal growth realignment between birth and 14 months, positive or negative, of more
than 0.67 SDS.
*p-value <0.05 vs. I/I genotype
Discussion
We showed that III/III individuals of INS VNTR had a shorter gestational duration compared to the
I/I subjects. No differences were found in birth weight adjusted for gestational age. Class III ho-
mozygous subjects had a smaller abdominal circumference / head circumference ratio in
mid-pregnancy but not in late pregnancy compared to I/I individuals. In III/III, we also found a
decreased growth rate in head circumference from mid-pregnancy to 14 months of age. No dif-
ferences were found for any other growth characteristics or patterns.
To our knowledge, this study is the first prospective cohort that examined the associations
between INS VNTR and growth in fetal life and infancy. DNA for genotyping was available in 859
Caucasian subjects (71%) and of all genotyped subjects at baseline about 70-75% participated
in the follow-up measurements in infancy. Children who were not genotyped had a shorter gesta-
tional age at birth (difference: -0.47 (95% CI: -0.72, -0.21) weeks, p <0.001) and a lower birth
weight (difference: -52.2 (95% CI: -143.7, 39.6) grams, p = 0.18). Our effect estimates would be
biased if the associations between INS VNTR genotype and growth characteristics differ between
those with and without complete data. This seems unlikely but cannot be excluded.
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The underlying mechanism explaining how INS VNTR influences growth remains unclear. In the
pancreas, INS expression has been found to be lower in the VNTR class III homozygous than in
the VNTR class I homozygous subjects.5, 10 It has also been hypothesized that the VNTR influences
IGF2, a neighbouring gene on chromosome 11p15.58, 10, though studies have been conflicting. The
VNTR class I allele is associated with higher IGF2 expression in the human placenta7, while VNTR
class III homozygotes have been shown to have higher IGF-II cord blood levels.6 INS and IGF2 are
both imprinted genes.30 In the human yolk sac, INS has been shown to be exclusively paternally
expressed30, and the imprinting of the IGF2/H19 region is known to affect growth in syndromes
with early growth disorders.31 Therefore, several studies have focused on paternal-specific allele
transmission of the VNTR-INS-IGF2 region in relation to growth and diseases. Paternally derived VNTR
class III allele has been shown to be associated with type 2 diabetes16 and polycystic ovary syn-
drome32, while paternally derived VNTR class I allele may be a risk factor for childhood obesity.33
These findings suggest that the greatest phenotypic difference would be between class I and
class III homozygous individuals, since, by definition, they have inherited an active paternal allele.
Other studies, however, show no parent-of-origin effect on birth weight or type 2 diabetes.6,9 Finally,
IGF2 in mice plays an important role in placental development and regulation.34 The VNTR may
affect the imprinting of IGF2 and subsequently impair placental circulation.34
Several studies have examined the association between INS VNTR and growth. In the
Avon Longitudinal Study of Parents and Children (ALSPAC) cohort, Dunger et al. was the first to
show an association between INS VNTR and birth size.8 In those individuals who had no postna-
tal weight realignment and in children from multiparous mothers, the class III genotype was
associated with a larger birth size.6, 8 It has been proposed that in these children the maternal
uterine factors are less important and the genetic contribution to growth is amplified.8 On the
other hand, in a Pima Indian population the class III genotype was associated with lower birth
weight and an increased prevalence of type 2 diabetes.9 Two other studies, one of which was per-
formed in a large Finnish cohort, could not replicate any of the results regarding birth weight,
also after stratifying for postnatal realignment.11, 12
In our study, we found no differences in weight in fetal life, at birth or in infancy. We also did
not find associations between patterns in weight growth from fetal life until infancy. Unexpectedly,
class III homozygous subjects had a shorter gestational age at birth than class I homozygous
subjects. No such association has previously been described. This difference remained significant
after adjusting for factors that may explain a shorter gestational period, such as birth weight
and pregnancy and delivery complications. Furthermore, this association was still present after
excluding all large and small for gestational age births and preterm births, and therefore cannot
be explained by outliers or skewed distributions. We have no explanation for this finding. It could
be hypothesized that altered intra-uterine growth patterns resulting in earlier maturation or changes
in placental function may cause an earlier delivery. However, this association remained significant
after adjustment for birth weight. Also additional adjustment for weight change between 20 weeks
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and birth did not materially affect our effect estimate (results not shown). On the other hand, this
association turned up without a previous hypothesis. Therefore, this finding could be due to
chance and further studies in other population-based cohorts are needed for replication.
Class III genotype subjects also had a considerably smaller abdominal circumference /
head circumference ratio in mid-pregnancy. We found that class III homozygote subjects tended
to have a larger head circumference and a smaller abdominal circumference in mid-pregnancy.
However, by late pregnancy head circumference SDS was decreased and abdominal circumference
SDS was increased in these fetuses, resulting in a similar abdominal circumference / head circum-
ference ratio as class I/I subjects. Abdominal circumference / head circumference ratio has been
shown to be useful in distinguishing symmetrical from asymmetrical growth.27 Asymmetrical
growth with a relatively large head circumference is also known as brain sparing. Our findings may
suggest that brain sparing occurs in early pregnancy in these individuals. Based on current literature,
we did not hypothesize beforehand to find such an association specifically. Therefore, further
studies are necessary to replicate these findings.
Epidemiological studies have demonstrated an inverse relationship between birth weight
and the risk of developing type 2 diabetes and cardiovascular disease in adulthood.35, 36 The fetal
insulin hypothesis proposes that genetic variants that regulate fetal insulin or sensitivity may
lead to both impaired fetal growth and to increased morbidity in later life.3 Several studies, however,
have suggested that not low birth weight per se but rather postnatal accelerated weight gain in
subjects with a small size at birth, leading to a normal or increased weight from childhood onwards,
increases the risk for adult disease.37-39 Animal models have shown that an altered fetal growth
trajectory may also lead to an increased risk of adult morbidity, even when birth weight is normal.40
We only found differences in early fetal growth patterns between INS VNTR genotype variants. In
our study postnatal growth characteristics were available until the age of 14 months. Studies
with a longer follow-up period are needed to assess whether this genotype is associated with
growth patterns in childhood that are related to development of type 2 diabetes and cardiovascular
disease in adulthood. It has also been suggested that prematurity, regardless of birth weight, can
lead to reduced insulin sensitivity and possibly type 2 diabetes in later life.41 Our finding that
shows an association between INS VNTR and gestational age is in line with the hypothesis that
common genetic variations may underlie the association between preterm birth and increased risk
of development of type 2 diabetes and cardiovascular disease.
In conclusion, this study demonstrates that INS VNTR is not associated with weight from
fetal life and until infancy. Our data suggest that INS VNTR is associated with asymmetrical growth
in early and mid-pregnancy, but not in late pregnancy. We found for the first time an association
between INS VNTR and gestational age at birth. Studies in larger cohorts are necessary to replicate
our findings. Also, systematic searches by genome-wide association studies may enable us to
obtain a more complete understanding of the functionality of the entire VNTR-INS-IGF2 region and
its relation to growth and morbidity in childhood and later life.
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Abstract
Background: Glucocorticoids have an important role in early growth and development. Glucocor-
ticoid receptor gene polymorphisms have been identified that contribute to the variability in
glucocorticoid sensitivity. We examined whether these glucocorticoid receptor gene polymor-
phisms are associated with growth in fetal and early postnatal life.
Methods: This study was embedded in a population-based prospective cohort study from fetal life
onwards. The studied glucocorticoid receptor gene polymorphisms included BclI (rs41423247),
TthIIII (rs10052957), GR-9β (rs6198), N363S (rs6195) and R23K (rs6189 and 6190). Fetal
growth was assessed by ultrasounds in second and third trimester of pregnancy. Anthropometric
measurements in early childhood were performed at birth and at the ages of 6, 14 and 24 months
postnatally. Analyses were based on 2,414 healthy, Caucasian children and focused on weight,
length and head circumference.
Results: Glucocorticoid receptor gene polymorphisms were not associated with fetal weight, birth
weight and early postnatal weight. Also, no associations were found with length and head cir-
cumference. Neither were these polymorphisms associated with the risks of low birth weight or
catch-up growth from birth to 24 months of age.
Conclusions: We found in a large population-based cohort no evidence for an effect of known glu-
cocorticoid receptor gene polymorphisms on fetal and early postnatal growth characteristics.
Further systematic searches for common genetic variants by means of genome-wide association
studies will enable us to obtain a more complete understanding of what genes and polymor-
phisms are involved in growth in fetal life and infancy.
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Introduction
Glucocorticoids are important regulators of growth, development and metabolism. The effects of
these hormones, including cortisol, are mediated by glucocorticoid receptors. The sensitivity to
glucocorticoids is known to show a large interindividual variation.1 Polymorphisms in the gluco-
corticoid receptor gene have been suggested to contribute to this difference in sensitivity and
thereby to differences in growth, development and metabolism. These glucocorticoid receptor
genes may also explain part of the previously demonstrated associations between growth char-
acteristics in early life and metabolic disease, including type 2 diabetes, in adult life.2, 3
Five different variants in the glucocorticoid receptor gene have been described to be as-
sociated with cortisol sensitivity.4-6 Few studies analyzed the associations of these glucocorticoid
receptor gene variants with body composition and obesity in adults. The R23K variant (two Single
Nucleotide Polymorphisms in complete linkage disequilibrium) was found to be associated with
higher serum cortisol concentrations as well as a smaller decrease in cortisol after dexamethasone
suppression tests. Furthermore, carriers showed lower fasting insulin levels and lower LDL choles-
terol levels. These data suggest that R23K carriers are relatively more cortisol resistant than
non-carriers, which results in a better metabolic health profile in adults.7, 8 By contrast, the BclI
and N363S polymorphisms were found to cause the opposite effects.9-11 In healthy subjects over
55 years, these polymorphisms were associated with hypersensitivity to glucocorticoids, resulting
in an increased body mass index (BMI).10 However, results were not consistent.12, 13 The TthIIII poly-
morphism was associated with elevated diurnal cortisol levels, but not with any anthropometric
or glucose related phenotype.14 Recently, the GR-9β polymorphism was found to be related to an
increased sensitivity to glucocorticoids, leading to an increased risk of cardiovascular disease.15
These results suggest that common functional variants of the glucocorticoid receptor gene may
affect body composition. However, the exact mechanisms have not been confirmed. Also, thus far
no studies did assess the effects of these glucocorticoid receptor gene polymorphisms in young
children. However, the effect of these glucocorticoid receptor gene polymorphisms might be
stronger on anthropometric measures in early life than on body mass index in adult life, because
of very limited life style influences.
We hypothesised that genetic variants leading to increased glucocorticoid sensitivity are
associated with fetal growth retardation and postnatal growth acceleration. This would be in line
with well-known associations of high cortisol exposures with low birth weight and higher postnatal
weight. Therefore, we studied in a population-based prospective cohort study from fetal life until
the age of 2 years the effects of the BclI, TthIIII, GR-9β, N363S and R23K polymorphisms on an-
thropometrics in second and third trimester of pregnancy, at birth and postnatally until the age
of 24 months.
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Methods
Design
This study was embedded in the Generation R Study, a prospective cohort study from early fetal
life onwards. This study is designed to identify early environmental and genetic determinants of
growth, development and health from fetal life until young adulthood and has been described
previously in detail.16, 17 Fetal and postnatal growth and their main determinants were repeatedly
measured by physical examinations, fetal ultrasounds and questionnaires. We have previously
shown that of all eligible children born in the study area 61% participated in the study.17 The
study has been approved by the Medical Ethics Committee of the Erasmus Medical Center, Rot-
terdam. Written informed consent was obtained from all parents.
Population for analysis
Analysis were restricted to Caucasian children (n = 4,527) and of whom DNA was available for
genotyping (n = 2,839). Reasons for non-availability of DNA were mainly due to logistical con-
straints at birth. Fetal growth measurements were available in 2,746 and 2,791 children in
second and third trimester of pregnancy, respectively. A total of 81% (n = 2,274), 75% (n = 2,136)
and 68% (n = 1,929) participated in the postnatal assessments at the ages of 6, 14 and 24
months. Information about anthropometrics of at least one of the postnatal visits was available
in 2,414 subjects of whom 72%, 91% and 100% had measurements at least three, two and one
visit. In total, analyses were based on more than 6,000 measurements.
Genotyping
DNA was collected from cord blood samples at birth. All participants were genotyped for five
known glucocorticoid receptor gene polymorphisms which are known to be associated with
changes in glucocorticoid sensitivity: BclI (rs41423247), TthIIII (rs10052957), GR-9β (rs6198),
N363S (rs6195) and R23K (rs6189 and 6190).4, 5 Figure 1 schematically shows the specific nu-
cleotide variations and allele frequencies of these polymorphisms. Genotyping of the five
glucocorticoid receptor gene polymorphisms was performed using Taqman allelic discrimination
assay (Applied Biosystems, Foster City, CA) and Abgene QPCR ROX mix (Abgene, Hamburg Germany).
The genotyping reaction was amplified using the GeneAmp®PCR system 9600 (95° C (15 minutes),
then 40 cycles of 94° C (15 seconds) and 60° C (1 minute)). The fluorescence was detected on the
7900HT Fast Real-Time PCR System (Applied Biosystems) and individual genotypes were determined
using SDS software (version 2.3, Applied Biosystems).
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Figure . Schematic overview of the glucocorticoid receptor gene polymorphisms and haplotypes
Haplotypes are numbered in order of decreasing frequency.
The nucleic acid changes are indicated; C = Cytidine, G = Guanine, A = Adenosine, T = Thymine.
Genotyping was successful in 97-99% of the samples for the five genotypes. To confirm the accu-
racy of the genotyping results 276 randomly selected samples were genotyped for a second time
with the same method. The error rate was less than 1% for all genotypes. We used the genotype
data for each of the 5 polymorphisms to infer the haplotypes present in the population using the
program PHASE, which implements a Bayesian statistical method for reconstructing haplotypes
from population genotype data.18 Instead of individual polymorphisms, we studied the haplotype
structure of the glucocorticoid receptor gene to encompass a major proportion of variation in
the gene. We excluded very rare polymorphisms because they have potential to explain only a
very small fraction of variation in response to glucocorticoids seen between individuals. For each
haplotype, 3 genotype combinations were distinguished as carrying 0, 1, or 2 copies of the haplo-
type allele. Haplotype 1 carries the major alleles of the polymorphisms; therefore, the reference
allele is defined as carrying 2 copies of haplotype 1. Genotype and allele frequencies were in
Hardy Weinberg equilibrium (p >0.01).
Growth measurements
Fetal growth characteristics
Fetal ultrasound examinations were carried out during visits at the research centers. The re-
spective median (95% range) gestational ages for these visits were 12.6 weeks (9.6 – 16.9), 20.4
weeks (18.6 – 22.5) and 30.2 weeks (28.5 – 32.5). The second and third visits were considered
as second and third trimester measurements. These fetal ultrasounds were used both to establish
gestational age (first ultrasound) and to assess fetal growth characteristics.19 Fetal growth
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Haplotype Polymorphism Allele frequency
(%)
1 T GG A C A 42,4
2 Bcl1 T GG A G A 22,7
3 TthIIII + Bcl1 C GG A G A 14,3
4 GR-9 + TthIIII C GG A C G 13,4
5 N363S T GG G C A 4,1
6 ER22/23EK + GR-9 + TthIIII C AA A C G 3,1
measurements used for the present study comprised head circumference (HC), abdominal cir-
cumference (AC) and femur length (FL) in the second and third trimester measured to the nearest
millimeter using standardized ultrasound procedures.20-22 Estimated fetal weight was calculated
using the formula by Hadlock using head circumference, abdominal circumference and femur
length: EFW (grams) = 10**(1.326 – 0.00326*AC*FL + 0.0107*HC + 0.0438*AC + 0.158*FL).23
Growth measurements in early pregnancy (gestational age <18 weeks) were not included, since
these fetal ultrasound examinations were performed primarily to establish gestational age.
Gestational age-adjusted standard deviation scores were constructed for these fetal growth
measurements.
Postnatal growth characteristics
Birth weight, date of birth and gender were obtained from community midwife and hospital registries.
Well-trained staff in community health centers obtained postnatal growth characteristics using
standardized procedures. Based on the routine health care program, visits for these growth
characteristics were grouped into three age periods: 6 (range 5 - 8.99) months; 14 (range 12 -
18.38) months and 24 (range 23 - 28.93) months. Anthropometrics were measured without
clothes. Weight was measured to the nearest gram using electronic scales. Length was measured
to the nearest millimeter in the supine position using a neonatometer at the age of 6 months,
and in the upright position at the ages of 14 and 24 months. Head circumference was postnatally
measured at the age of 6 and 14 months.
Statistical analysis
Differences in baseline characteristics between boys and girls were examined by independent
samples t-tests (continuous variables) or Pearson’s chi-square (categorical variables). Because
of the low number of homozygous subjects for haplotype 5 (n = 8) and 6 (n = 1), these haplotypes
were analyzed as carriers (1 or 2 copies) and non-carriers (0 copies).
The associations of the glucocorticoid receptor haplotypes with pre- and postnatal growth
characteristics (weight, length and head circumference) were analyzed in three different time-
intervals: from second trimester to birth, from birth to 24 months of age and from second trimester
to 24 months of age. Since, no data were available for head circumference at 24 months of age,
head circumference was analyzed until the age of 14 months. With these outcomes, the effects
of glucocorticoid receptor polymorphisms on skeletal and non-skeletal growth and head circum-
ference can be studied. We used femur length as measure of skeletal growth in fetal life
(correlation femur length in third trimester of pregnancy and length at 1 month of age: r = 0.30,
p-value <0.001). To assess longitudinally measured growth patterns from fetal life to infancy, we
performed repeated measures regression analysis. This regression technique takes the correlation
of multiple measurements within one subject into account, assesses both the time-independent
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and time-dependent effect of the glucocorticoid receptor genotypes, and allows for incomplete
outcome data.24, 25 In these models, haplotype was included as both intercept and interaction with
age. To account for (gestational) age at each specific measurement, these analyses were
conducted with age-adjusted standard deviation scores. The models can be written as:
Weight (SDS) = β0 + β1*age + β2* glucocorticoid receptor haplotype + β3* glucocorticoid receptor
haplotype*age.
Similar models were used for length and head circumference growth. The term including ‘β0’ reflects
the intercept and the term including ‘β1’ reflects the growth per week for the reference group. The
terms including ‘β2‘ and ‘β3’ reflect the age independent and dependent growth differences between
the different categories of the glucocorticoid receptor genotype, respectively.25 To study the dominant
effects of the glucocorticoid receptor gene polymorphisms, we merged the group heterozygous
and homozygous variant subjects and performed the same analyses.
Furthermore, we performed multiple logistic regression models to analyze the associations
of the different glucocorticoid receptor haplotypes with prenatal growth retardation (growth
deceleration) and postnatal growth acceleration. We defined growth deceleration as a decrease
in weight from second trimester of pregnancy until birth of <-0.67 standard deviation and growth
acceleration as an increase in weight from birth to 24 months of age of more than 0.67 standard
deviation.26 Each anthropometric outcome was analyzed using gender and age adjusted standard
deviation scores (SDS). These were based on reference growth curves from the whole study
population. Variables were included in these models when they changed the effects estimates
of interest on pre- and postnatal growth substantially (>10%).
With a sample size in the Generation R Study of 2,839 subjects and assuming a statistical
power level (1 – β) of 0.80 and a level of significance (α) of 0.05, we were able to detect differences
in growth characteristics of about 0.05 SDS. All effect estimates are presented with their 95%
confidence interval (95% CI). Statistical analyses were performed using the Statistical Package
of Social Sciences version 15.0 for Windows (SPSS Inc, Chicago, IL, USA) and the Statistical
Analysis System (SAS) for Windows, version 9.1.3.
Results
The distribution of the different glucocorticoid receptor haplotypes within our study population is
presented in Table 1. Haplotype 1, 2, 3 and 4 were most frequent with allele frequencies of
42.4%, 22.7%, 14.3% and 13.4%, respectively. Haplotypes 5 and 6 had allele frequencies of
4.1% and 3.1%, respectively. Comparison of means of baseline characteristics between carriers
of 0, 1 or 2 copies of haplotype 1 to 6 revealed no significant differences for the covariates age
at visit and gender.
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Table . Distribution of the different haplotype alleles of the glucocorticoid receptor gene within
our study population (n = 2,414)
Glucocorticoid receptor
haplotype (copies) N (%)
Haplotype 1
0 531 (22.0)
1 1,379 (57.1)
2 504 (20.9)
Haplotype 2
0 1,265 (52.4)
1 1,017 (42.1)
2 132 (5.5)
Haplotype 3
0 1,668 (69.1)
1 699 (29.0)
2 47 (1.9)
Haplotype 4
0 1,688 (70.0)
1 677 (28.0)
2 49 (2.0)
Haplotype 5
0 2,196 (91.0)
1 or 2 218 (9.0)
Haplotype 6
0 2,242 (92.9)
1 or 2 172 (7.1)
Values are number of persons (%).
Table 2 presents the baseline characteristics of infants who participated in the postnatal visits.
The percentage of boys and girls was both 50%. The overall median ages (95% range) in infants
at their visits were 6.2 months (5.2 – 7.9), 14.3 months (13.5 – 16.1) and 24.8 months (23.4
– 28.1). Anthropometrics in second and third trimester of pregnancy, at birth and at the postnatal
ages of 6, 14 and 24 months were larger in boys than in girls.
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Table 2. Fetal and infant characteristics (n = 2,414)
Boys Girls
(n = 1,233) (n = 1,181) P-value
Second trimester
Gestational age (weeks) 20.6 (18.7 – 23.3) 20.4 (18.5 – 23.1) <0.01
Estimated fetal weight (grams) 386 (91) 374 (86) <0.01
Femur length (mm) 33.3 (3.2) 33.2 (3.3) 0.55
Head circumference (mm) 181.0 (13.1) 177.2 (13.0) <0.01
Third trimester
Gestational age (weeks) 30.4 (28.6 – 33.0) 30.3 (28.3 – 32.8) <0.01
Estimated fetal weight (grams) 1646 (258) 1620 (268) <0.01
Femur length (mm) 57.4 (2.9) 57.4 (2.9) 0.64
Head circumference (mm) 288.8 (11.8) 283.7 (11.2) <0.01
Birth
Gestational age (weeks) 40.1 (35.0 – 42.4) 40.1 (35.2 – 42.1) 0.42
Weight (grams) 3518 (596) 3400 (574) <0.01
Length (cm)* 55.1 (2.4) 54.0 (2.1) <0.01
Head circumference (cm)* 38.1 (1.3) 37.3 (1.2) <0.01
Weight <2500 grams (%) 119 (5.3) 123 (5.5) 0.77
Preterm birth (<36 weeks) (%) 133 (6.0) 129 (5.8) 0.81
Age  months
Age at visit (months) 6.2 (5.2 – 7.9) 6.2 (5.2 – 7.9) 0.28
Weight (grams) 8,078 (845) 7,540 (812) <0.01
Length (cm) 68.5 (2.4) 66.8 (2.3) <0.01
Head circumference (cm) 44.2 (1.3) 43.1 (1.7) <0.01
Age  months
Age at visit (months) 14.3 (13.6 – 16.2) 14.3 (13.4 – 16.0) 0.05
Weight (grams) 10,824 (1,070) 10,191 (1,018) <0.01
Length (cm) 78.9 (2.6) 77.5 (2.6) <0.01
Head circumference (cm) 47.7 (1.3) 46.6 (1.1) <0.01
Age 2 months
Age at visit (months) 24.8 (23.4 – 28.1) 24.8 (23.4 – 28.1) 0.48
Weight (grams) 13,140 (1,376) 12,651 (1,412) <0.01
Length (cm) 88.9 (3.4) 87.7 (3.4) <0.01
Values are means (SDS) or medians (95% range). Differences between boys and girls were compared using independent sample
t-tests. *Measured at 1 months of age.
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Table 3 shows the associations of glucocorticoid receptor haplotypes with pre- and postnatal
weight until the age of 24 months. No consistent associations were found between the different
haplotypes and repeatedly measured weight in the three different time-intervals.
Table . Associations of glucocorticoid receptor haplotype with repeatedly measured weight from
second trimester of pregnancy until 24 months of age
Weight SDS change Weight SDS change Weight SDS change
2nd trimester – birth Birth – 2 months 2nd trimester – 2 months
(9% CI) (9% CI) (9% CI)
Glucocorticoid
receptor
haplotype (copies)
Haplotype 1
0 0.03 (-0.06, 0.12) -0.02 (-0.12, 0.08) 0.05 (-0.05, 0.15)
1 0.02 (-0.05, 0.09) -0.03 (-0.11, 0.05) 0.03 (-0.04, 0.11)
2 Reference Reference Reference
Haplotype 2
0 Reference Reference Reference
1 -0.06 (-0.12, 0.01) -0.02 (-0.09, 0.06) -0.10 (-0.17, -0.03)
2 -0.01 (-0.15, 0.13) -0.01 (-0.17, 0.16) -0.02 (-0.18, 0.15)
Haplotype 3
0 Reference Reference Reference
1 0.06 (-0.01, 0.14) 0.06 (-0.02, 0.14) 0.09 (0.01, 0.17)
2 0.02 (-0.21, 0.25) 0.02 (-0.26, 0.29) 0.14(-0.14, 0.42)
Haplotype 4
0 Reference Reference Reference
1 -0.02 (-0.09, 0.05) 0.02 (-0.07, 0.10) 0.12 (-0.15, 0.40)
2 -0.21 (-0.43, 0.02) 0.07 (-0.21, 0.36) 0.16 (-0.10, 0.44)
Haplotype 5
0 Reference Reference Reference
1 or 2 -0.01 (-0.18, 0.16) -0.36 (-1.02, 0.29) -0.16 (-0.75, 0.43)
Haplotype 6
0 Reference Reference Reference
1 or 2 -0.20 (-0.41, 0.01) 0.97 (-0.99, 2.93) 0.54 (0.13, 0.96)
Values are regression coefficients (95% confidence interval) and reflect the difference in standard deviation score of weight from
2nd trimester until 24 months of age for the different glucocorticoid haplotypes. SDS, gestational age-adjusted standard deviation
score; CI, confidence interval. Models are adjusted for age at visit and gender.
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Also, no consistent associations were found with length and head circumference (Table 4 and 5).
In the dominant models, the associations between the glucocorticoid receptor gene polymorphisms
were also not significant.
Table . Associations of glucocorticoid receptor haplotype with repeatedly measured length from
second trimester of pregnancy until 24 months of age
Length SDS change Length SDS change Length SDS change
2nd trimester – birth Birth – 2 months 2nd trimester – 2 months
(9% CI) (9% CI) (9% CI)
Glucocorticoid
receptor
haplotype (copies)
Haplotype 1
0 0.01 (-0.09, 0.10) -0.01 (-0.13, 0.12) 0.01 (-0.09, 0.10)
1 0.02 (-0.05, 0.09) -0.01 (-0.10, 0.09) 0.01 (-0.07, 0.08)
2 Reference Reference Reference
Haplotype 2
0 Reference Reference Reference
1 0.02 (-0.08, 0.12) 0.02 (-0.07, 0.11) -0.07 (-0.14, 0.01)
2 0.08 (-0.08, 0.24) 0.03 (-0.19, 0.26) 0.10 (-0.06, 0.26)
Haplotype 3
0 Reference Reference Reference
1 0.09 (0.02, 0.16) 0.05 (-0.05, 0.15) 0.07 (-0.01, 0.14)
2 0.16 (-0.08, 0.40) 0.13 (-0.24, 0.50) 0.12 (-0.15, 0.38)
Haplotype 4
0 Reference Reference Reference
1 -0.03 (-0.10, 0.05) -0.07 (-0.17, 0.04) -0.02 (-0.10, 0.06)
2 -0.23 (-0.47, 0.01) -0.02 (-0.40, 0.34) -0.15 (-0.42, 0.11)
Haplotype 5
0 Reference Reference Reference
1 or 2 0.14 (0.02, 0.25) 0.02 (-0.14, 0.19) 0.18 (0.05, 0.30)
Haplotype 6
0 Reference Reference Reference
1 or 2 -0.10 (-0.23, 0.03) -0.05 (-0.23, 0.14) -0.11 (-0.25, 0.03)
Values are regression coefficients (95% confidence interval) and reflect the difference in standard deviation score of length from
2nd trimester until 24 months of age for the different glucocorticoid haplotypes. SDS, gestational age-adjusted standard deviation
score; CI, confidence interval. Models are adjusted for age at visit and gender.
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Table . Associations of glucocorticoid receptor haplotype with repeatedly measured head
circumference from second trimester of pregnancy until 14 months of age
Head circumference Head circumference Head circumference
SDS change SDS change SDS change
2nd trimester – birth Birth – 2 months 2nd trimester – 2 months
(9% CI) (9% CI) (9% CI)
Glucocorticoid
receptor
haplotype (copies)
Haplotype 1
0 -0.10 (-0.20, 0.01) -0.16 (-0.33, 0.01) -0.09 (-0.18, 0.01)
1 -0.05 (-0.13, 0.03) -0.11 (-0.24, 0.02) -0.06 (-0.13, 0.01)
2 Reference Reference Reference
Haplotype 2
0 Reference Reference Reference
1 -0.07 (-0.16, 0.01) 0.01 (-0.11, 0.12) -0.05 (-0.12, 0.02)
2 -0.12 (-0.30, 0.06) 0.08 (-0.18, 0.35) -0.02 (-0.17, 0.13)
Haplotype 3
0 Reference Reference Reference
1 0.11 (0.03, 0.20) 0.12 (-0.01, 0.25) 0.10 (0.02, 0.17)
2 0.11 (-0.17, 0.40) -0.12 (-0.53, 0.29) 0.08 (-0.16, 0.33)
Haplotype 4
0 Reference Reference Reference
1 0.01 (-0.07, 0.10) 0.08 (-0.05, 0.21) 0.12 (-0.15, 0.40)
2 0.18 (-0.12, 0.47) 0.19 (-0.22, 0.60) 0.17 (-0.10, 0.44)
Haplotype 5
0 Reference Reference Reference
1 or 2 -0.10 (-0.33, 0.13) -0.17 (-0.38, 0.03) 0.02 (-0.10, 0.14)
Haplotype 6
0 Reference Reference Reference
1 or 2 0.07 (-0.09, 0.22) 0.07 (-0.15, 0.29) 0.06 (-0.07, 0.19)
Values are regression coefficients (95% confidence interval) and reflect the difference in standard deviation score of head
circumference from 2nd trimester until 14 months of age for the different glucocorticoid haplotypes. SDS, gestational age-adjusted
standard deviation score; CI, confidence interval. Models are adjusted for age at visit and gender.
Associations of the different haplotypes with the risks of prenatal growth retardation (growth de-
celeration) and postnatal growth acceleration are presented in Table 6. No significant differences
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were found in risks of prenatal growth deceleration and postnatal growth acceleration for the
different haplotypes. However, children who showed prenatally an increased risk of growth re-
tardation compared to the reference, tend to have an increased risk of growth acceleration in
postnatal life as well.
Table . Associations of glucocorticoid receptor haplotype with the risks of prenatal catch-down
growth and postnatal catch-up growth until 24 months of age
Prenatal growth deceleration Postnatal growth acceleration
(9% CI) (9% CI)
Glucocorticoid Reference Growth Reference Growth
receptor haplotype (-0.67 to deceleration (-0.67 to acceleration
(copies) 0.67 SDS) (<-0.67 SDS) 0.67 SDS) (>0.67 SDS)
Haplotype 1
0 Reference 1.09 (0.84, 1.42) Reference 1.07 (0.78, 1.48)
1 Reference 1.16 (0.95, 1.41) Reference 1.11 (0.87, 1.42)
2 Reference Reference Reference Reference
Haplotype 2
0 Reference Reference Reference Reference
1 Reference 0.88 (0.73, 1.07) Reference 0.99 (0.79, 1.26)
2 Reference 1.03 (0.68, 1.55) Reference 1.20 (0.73, 1.97)
Haplotype 3
0 Reference Reference Reference Reference
1 Reference 1.17 (0.95, 1.43) Reference 1.05 (0.82, 1.35)
2 Reference 0.90 (0.45, 1.84) Reference 0.42 (0.13, 1.39)
Haplotype 4
0 Reference Reference Reference Reference
1 Reference 0.88 (0.71, 1.09) Reference 0.97 (0.74, 1.25)
2 Reference 0.93 (0.47, 1.84) Reference 0.80 (0.27, 2.39)
Haplotype 5
0 Reference Reference Reference Reference
1 or 2 Reference 0.96 (0.69, 1.34) Reference 0.96 (0.65, 1.42)
Haplotype 6
0 Reference Reference Reference Reference
1 or 2 Reference 1.26 (0.86, 1.87) Reference 1.28 (0.80, 2.07)
Values are odds ratios (95% confidence interval) and reflect the difference in risk of prenatal growth deceleration and postnatal
growth acceleration until 24 months of age for the different glucocorticoid haplotypes. SDS, gestational age-adjusted standard
deviation score; CI, confidence interval. Models are adjusted for age at visit and gender.
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Discussion
In our population-based prospective cohort study we showed that glucocorticoid receptor gene
polymorphisms are not consistently associated with growth in fetal and early postnatal life. Fur-
thermore, we demonstrated that these polymorphisms were not related to size at birth or growth
acceleration during the first 2 years of life.
The major strengths of our study are its prospective design from early fetal life and the
size of the population-based cohort. Our analyses were based on over 6,000 growth measure-
ments. Furthermore, the relative effect of variants of the glucocorticoid receptor gene on growth
measurements might be larger in childhood, when the effect of various environmental factors,
such as life style habits, is limited. A possible limitation is that the current study was performed
in a healthy, population-based cohort study. DNA for genotyping was available in 59% of all sub-
jects and was isolated from cord-blood. Missing cord-blood was mainly caused by logistical
restraints at delivery. Of all genotyped eligible subjects at baseline, 22% did not participate in follow-
up measurements. Our study was designed to assess pre- and postnatal growth in a relatively
healthy group of children. As a consequence, the group of children born with small size for gesta-
tional age (n = 55) was too small for specific analyses focused on this group. Thus generalizability
is limited with respect to children born preterm or with low birth weight.
Glucocorticoid receptor gene polymorphisms have been identified that contribute to the
variability in glucocorticoid sensitivity. This sensitivity to glucocorticoids is known to show a large
interindividual variation.1 Persons vary considerably in their response to both endogenous and ex-
ogenous glucocorticoids. So it is likely that these polymorphisms are to some extent responsible
for the variability in the sensitivity to glucocorticoids. Glucocorticoids are important regulators of
the immune system, inflammatory processes and many other processes involved in fat and
glucose metabolism. Previous studies examined the potential role of glucocorticoids in the de-
velopment of adult disease. Studies in rats showed that activity of placental 11β-hydroxysteroid
dehydrogenase type 2, which converts physiological glucocorticoids to inactive products, corre-
lates positively with birth weight and negatively with placental weight.27 Thus, fetuses with the
greatest exposure to growth-retarding maternal glucocorticoids have low birth weight and high
placental weight. In human studies, it is demonstrated that these fetuses might be at a higher
risk of subsequent hypertension.28 In addition, administration of low-dose dexamethasone to
pregnant rats not only reduces birth weight but also leads to high blood pressure in young adult
offspring.27 Increased exposure to cortisol in adults leads again to increased risks of cardiovas-
cular disease, type 2 diabetes and obesity.2, 3 Therefore, these polymorphisms in the
glucocorticoid receptor gene could, by increasing glucocorticoid sensitivity in the fetus for maternal
glucocorticoids, lead to intrauterine growth retardation and metabolic and cardiovascular diseases
in adulthood. Genetically established differences between individuals in glucocortcoid sensitivity
may also be associated with these diseases.
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The effect of glucocorticoids is mediated by the glucocorticoid receptor, which is thought to be
the connection between HPA axis function and early life conditions. Rautanen et al. reported a
common glucocorticoid receptor haplotype to be associated with short length and low weight at
birth and higher indices of HPAA function later in life.29 In humans, the possible importance of
glucocorticoid sensitivity on fetal growth and HPA programming has not been previously investi-
gated. However, previous studies have examined the associations of different polymorphisms in
the glucocorticoid receptor gene and sensitivity to glucocorticoids. The results of these studies
are conflicting. A few studies report positive associations between the N363S and BclI polymor-
phisms and hypersensitivity to glucocorticoids9-11, while other studies found the opposite effect.12,
13 The R23K polymorphism was associated with relative resistance to glucocorticoids.7, 8 No as-
sociations were found yet with the TthIIII polymorphism.4, 14 These studies suggest that genetically
established differences in glucocortcoid sensitivity are important for various growth, development
and health related outcomes. In addition, it is known that environmental, dietary, and socioeconomic
factors also play an important role in determinants of body composition and metabolic factors.
Associations with polymorphisms depend on many additional factors, for example differences in
characteristics between populations, prevalence of the polymorphism, and interactions with other
genetic polymorphism. All these factors may play a role in the discrepancies found between studies
so far.
Our results suggest a recessive effect of the glucocorticoid receptor gene polymorphisms,
which is in line with the heritability modes seen in earlier papers. We hypothezised that genetic
variants leading to increased glucocorticoid sensitivity are associated with fetal growth retar-
dation and postnatal growth acceleration. This hypothesis is based on previous observations
showing associations of cortisol levels and low birth weight. Low birth weight and postnatal growth
acceleration are again associated with obesity and other metabolic diseases. However, we did not
find any consistent effect on pre- and postnatal weight, length and head circumference between
the different glucocorticoid receptor haplotypes in our population-based study. Neither did we
find associations with prenatal growth deceleration or postnatal growth acceleration. Therefore,
we may conclude that our results do not support our hypothesis. Other recent identified gluco-
corticoid related polymorphisms, such as the brain-derived neurotrophic factor (BDNF) and the
mineral corticoid gene, may affect pre- and postnatal growth by influencing the glucocorticoid
metabolism. Further systematic searches for common genetic variants by means of genome-wide
association studies will enable us to obtain a more complete understanding of what genes and
polymorphisms are involved in growth in fetal life and infancy.
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Abstract
Background: To assess the intraobserver and interobserver variability of renal measurements in
children.
Methods: The study comprised 56 paired measurements in 28 children with a median age of 7.5
years (range: 3.0 – 15.0) and without renal or ureterovesical anomalies. Intraobserver and inter-
observer reproducibility was assessed by repeated measurements of left and right renal length,
width and thickness. Intraclass correlation coefficients (ICCs) with the corresponding 95% confi-
dence interval (CI) were calculated. Bland and Altman plots were computed to analyze agreement
for the measurements. Limits of agreement ±2 standard deviation for the mean differences in
renal measurements were derived.
Results: Intraobserver ICCs ranged from 0.93 (left and right renal width and right renal thickness)
to 0.99 (left renal length) and interobserver ICCs ranged from 0.64 (right renal thickness) to 0.90
(right renal length). Limits of agreement in the Bland and Altman plots ranged from –8.0 to 9.2%
(intraobserver left renal width) to the widest limit from –18.0 to 19.2% (interobserver left renal
length).
Conclusions: Overall, this study demonstrated good reproducibility and agreement of most renal
dimensions in children measured by ultrasound. Ultrasound is an appropriate measure to assess
renal dimensions in both clinical and epidemiological studies.
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Introduction
Renal size is an important part of the assessment of the renal tract in childhood. Many epi-
demiological studies use renal ultrasound measurements to examine the associations of various
determinants with renal size in children.1, 2 This information may be relevant for identifying critical
periods in life for renal growth and development.3
Ultrasound is widely recognized as method of choice for visualizing organs in children as
it is noninvasive, cost-effective and efficient. It is known from literature that ultrasound, compared
to CT or MRI, is an accurate method for visualising kidneys and evaluating renal growth in chil-
dren.4, 5 Bakker et al. concluded that renal volume calculations obtained by using ultrasound with
ellipsoid formula resulted is a substantial systematic underestimation compared with MR imaging
with the voxel-count method. However, a systematic underestimation of the renal volume is also
reported by use of the ellipsoid formula with MR imaging.
Although the clinical relevance and research importance of renal ultrasound measurements
in children is well known, little has been published about the reliability of these measurements.
To compare renal ultrasound measurements as an outcome of different studies, it is necessary
to minimize intraobserver and interobserver variability. A few studies assessed reproducibility of
renal ultrasound measurements in children. Sargent et al. demonstrated an interobserver variation
in the sonographic estimation of renal volume of approximately 30-40%.6, 7 Schlesinger et al.
concluded that the observed variability in ultrasound measurements of renal length is similar to
the expected annual increase in length of the kidneys during childhood.8 However, less is known
about the reliability of renal ultrasound measurements in young children in both clinical and
epidemiological research projects.
The aim of the present study was to evaluate the intra- and interobserver variability of
renal ultrasound measurements in children.
Methods
Design
Children were selected from the outpatient clinic of the Erasmus Medical Center – Sophia Children’s
Hospital, a university hospital in Rotterdam, the Netherlands. In total, of the 30 subjects we
asked, 28 subjects (participation 93%) participated in this study to validate renal ultrasound
measurements. Non-response was mainly due to lack of time of the parents. No renal or
ureterovesical anomalies were present in the study population. Written informed consent was
obtained.
Two experienced sonographers (VE Kleyburg, SPE Snijders) performed all examinations at
the same visit. The first observer scanned the ultrasound measurements in no specific order. Sub-
sequently, the other observer did the same, after which the first examiner repeated the process.
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The sonographers left the ultrasound room during each other’s assessment. The time interval for
the first observer to rescan the patient depended on the time the second observer took for the
measurements, being about 10 minutes. Measurement results were blinded to both operators;
the caliper read out on the screen was hidden. Printouts of the measurements were not read by
the observers and were saved on hard disc for later analyses.
Ultrasound measurements
The examination was carried out in a quiet room with the child quietly awake in a supine position.
Renal size was measured during each ultrasound examination using a transabdominal probe.
Two-dimensional ultrasounds of the kidneys were performed in all the children. In a sagittal plane,
the maximum longitudinal renal length was measured placing the calipers on the outer edges of
the caudal and cranial side. Additionally, the phase of respiration was used to acquire the sagittal
image. We asked the children to breathe out and hold shortly their breath to get a clear picture
of the kidneys. Antero-posterior and transverse renal diameter were measured perpendicular to
each other, outer to outer, in an axial plane.9 Measures of maximal bipolar renal length, width and
thickness were obtained from both the left and right kidney. Renal width and thickness were
measured at the level of the renal hilum.9, 10 All dimensions were measured to the nearest mil-
limeter. Ultrasound examinations were performed using an ATL-Philips Model HDI 5000 (Seattle,
Washington, USA) equipped with a 2.0 - 5.0 MHz curved array transducer.
Statistical analysis
To compare observers in detail we used the methods described by Bland and Altman.11, 12 The first
step was to plot the data and draw the line of equality. This visualizes the degree of agreement.11
The consensus between and among observers was analyzed using the intraclass correlation co-
efficient (ICC) for all renal measurements. The ICC is defined as the ratio of the variance between
subjects to total variance. The ICC measures the strength of the agreement of the variables, in-
dependent of the dimension of the variable considered. Additionally, the 95% confidence interval
(CI) was calculated for all renal measurements.
Next, agreement was tested to investigate intra- and interobserver reproducibility.11 We
created Bland and Altman plots by plotting the differences of all the measurements against their
mean with the 2 SD of the mean to see the distribution and to find any possible differences from
the mean within or between the observers.11 The average differences between duplicate measures
were tested using the paired sample t-test to see if there was systemic bias. If the differences
are Gaussian distributed, 95% of the differences will lie between the mean ±2 SD limits. These
are the limits of agreement, and the measures between and among observers can be assumed
to be interchangeable within these limits. An advantage of the Bland and Altman plots over the
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statistical testing is that one can visualize between which boundaries a measurement is inter-
changeable and how large the measurement differences between operators are in proportions.
How small the limits of agreement should be is a clinical, not a statistical, decision that should
be made in advance of the analysis. A priori, we considered renal measurements in children re-
producible and valid in case of ICC over 0.80 and mean differences within 10% from the mean
of two different measurements. Statistical analysis was performed using Statistical Package for
the Social Sciences version 11.0 for Windows (SPSS Inc, Chicago, IL, USA).
Results
Median age of the children was 7.5 years (range: 3.0 – 15.0) and 17 (61%) were male. A total of
14 children (50%) was younger than 8 years of age. Table 1 presents the descriptive statistics of
the ultrasound measurements of left and right renal dimensions assessed in this study. Figure 1
shows plots of measurements of left and right renal dimensions between observers against the
line of equality. All points seem to lie randomly around this line, meaning that there seems to be
no bias. The variables are close to the line of equality as well, indicating good agreement and sug-
gesting small differences between observers.
Table . Descriptive statistics for ultrasound measurements of left and right renal dimensions
in children
Sonographer  Sonographer 2
st observation 2nd observation st observation 2nd observation
Renal Mean SD Mean SD Mean SD Mean SD
measurements (mm)
Left kidney
Length 79.4 8.0 79.9 7.9 78.5 10.2 79.2 9.8
Width 34.4 3.4 34.3 3.3 33.5 3.9 33.5 3.8
Thickness 35.3 3.3 35.5 3.7 38.8 4.2 39.0 4.1
Right kidney
Length 78.1 8.3 78.4 8.8 76.7 11.1 77.9 10.8
Width 34.7 3.4 34.0 3.4 33.9 4.1 34.2 3.7
Thickness 36.1 3.4 35.6 3.3 40.1 4.7 40.5 4.2
SD, standard deviation. Analyses were based on a group of 28 children.
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Figure . Renal ultrasound measurements of observers with the line of equality
a. Left renal length measurements b. Right renal length measurements
c. Left renal width measurements d. Right renal width measurements
e. Left renal thickness measurements f. Right renal thickness measurements
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Table 2 presents the intra-class correlation coefficients (ICCs) with their 95% confidence interval.
Intraobserver ICC ranged from 0.93 (left and right renal width and right renal thickness) to 0.99
(left renal length) and interobserver ICC ranged from 0.64 (right renal thickness) to 0.90 (right
renal length).
Table 2. Intra- and interobserver intraclass correlation coefficient (ICC) and 95% confidence
interval for left and right renal dimensions in childhood
Intraobserver ICC Interobserver ICC
(9% confidence interval) (9% confidence interval)
Left kidney
Length 0.99 (0.97, 0.99) 0.81 (0.57, 0.91)
Width 0.93 (0.85, 0.97) 0.83, 0.63, 0.92)
Thickness 0.96 (0.91, 0.98) 0.66 (0.26, 0.85)
Right kidney
Length 0.97 (0.93, 0.99) 0.90 (0.78, 0.95)
Width 0.93 (0.84, 0.97) 0.83 (0.63, 0.93)
Thickness 0.93 (0.84, 0.97) 0.64 (0.20, 0.84)
ICC, intraclass correlation coefficient
Figure 2 shows Bland and Altman plots for the differences in left and right renal measurements
among or between observers against the mean. The limits of agreement (+/-2 SD) are plotted in
the figures. Most differences lie between the limits of agreement.
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Figure 2. Intra- and interobserver Bland and Altman plots of variation in renal ultrasound
measurements among and between observers
a. Intraobserver agreement left kidney length b. Intraobserver agreement right kidney length
c. Intraobserver agreement left kidney width d. Intraobserver agreement right kidney width
e. Intraobserver agreement left kidney thickness f. Intraobserver agreement right kidney thickness
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g. Interobserver agreement left kidney length h. Interobserver agreement right kidney length
i. Interobserver agreement left kidney width j. Interobserver agreement right kidney width
k. Interobserver agreement left kidney thickness l. Interobserver agreement right kidney thickness
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Table 3 shows the mean differences of the left and right renal dimensions among and between
observers and the 95% limits of agreement (Md +/-2 SDd). The observed difference from the mean
for left and right renal dimensions ranged from 0 mm (0%) (intraobserver right renal width) to -4.68
mm (12%) (interobserver right renal thickness). The mean difference between duplicate measures
was not significantly different from zero. This suggest that no systematic difference between the
pairs of results. The limits of agreement ranged from –2.67 (8.0%) to 3.13 mm (9.2%) (intraobserver
left renal width) to the widest limit from –14.3 (18.0%) to 15.5 mm (19.2%) (interobserver left renal
length).
Table . Intra- and interobserver measurement variation in absolute number and in proportions
of the mean with 95% limits of agreement
Intraobserver agreement Mean difference 9% limits of agreement
observer  (mm) (%) Lower limit Upper limit
Left kidney
Length -0.44 0.6 -4.00 3.12
Width 0.15 0.4 -3.55 3.55
Thickness -0.22 0.6 -2.96 2.52
Right kidney
Length -0.12 0.2 -6.04 5.80
Width 0.73 2.1 -2.87 4.33
Thickness 0.46 1.3 -3.00 3.92
Intraobserver agreement Mean difference 9% limits of agreement
observer 2 (mm) (%) Lower limit Upper limit
Left kidney
Length -0.41 0.5 -4.11 3.29
Width 0.23 0.7 -2.67 3.13
Thickness 0.15 0.4 -3.23 3.53
Right kidney
Length -0.65 0.8 -5.55 4.25
Width 0 0 -3.70 3.70
Thickness 0.04 0.1 -4.14 4.22
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Table . continued
Interobserver agreement Mean difference 9% limits of agreement
observation  (mm) (%) Lower limit Upper limit
Left kidney
Length 0.63 0.8 -14.3 15.5
Width 0.70 2.0 -4.76 6.16
Thickness -3.78 10.2 -11.2 3.60
Right kidney
Length 1.37 1.8 -10.6 13.4
Width 0.73 2.1 -5.03 6.49
Thickness -4.27 11.2 -12.7 4.13
Interobserver agreement Mean difference Limits of agreement
observation 2 (mm) (%) Lower limit Upper limit
Left kidney
Length 0.67 0.8 -12.6 13.9
Width 0.69 2.0 -4.27 5.65
Thickness -3.50 9.4 -10.9 3.86
Right kidney
Length 0.46 0.6 -11.4 12.4
Width -0.04 0.1 -5.94 5.86
Thickness -4.68 12.3 -12.8 3.42
T-tests were performed to compare the difference from the mean; none of the measurements was significantly different from zero.
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Discussion
Ultrasound is widely used to visualize organs in children. Left and right renal dimensions can be
measured in children with 2-dimensional (2D), sonography. The aim of this study was to assess
the reproducibility of left and right renal dimensions, length, width and thickness, in children without
renal or ureterovesical anomalies.
Both reproducibility, whether two observers using the same measurement to obtain the
same result, and repeatability, whether a single observer obtains the same results when he/she
takes the repeated measurement, are types of agreement or reliability. A measurement process
should be both accurate and reproducible. It is known from literature that ultrasound, compared
to CT or MRI, is an accurate method for visualising kidneys and evaluating renal growth in chil-
dren.4, 5 Bakker et al. concluded that renal volume calculations obtained by using US with ellipsoid
formula resulted is a substantial systematic underestimation of 25% (44.7 mL (95% CI: -51, -38))
compared with MR imaging with the voxel-count method. However, use of the ellipsoid formula with
MR imaging also resulted in a systematic underestimation of the renal volume. So, in view of
higher costs and increased processing time of MR imaging-based volumetry, ultrasound will
remain the modality of choice.5 However, less is known about the reproducibility of these renal
ultrasound measurements. The mean difference between duplicate measurements is an indicator
of the amount of systematic difference between the pairs of results. The standard deviation of
the differences between duplicated measurements represents the reproducibility of the process.
The larger the mean difference, the larger the systematic bias and the lower the accuracy of the
process. Similarly, the larger the standard deviation, the larger random errors and the lower the
reproducibility.
In this study we used various statistical methods to assess the reproducibility and re-
peatability of left and right renal dimensions in children measured by ultrasound. A simple plot
of the results of one observer against the other showed that the data points are clustered near
the line of equality, indicating good agreement and little differences between observers.
Beforehand, we decided that we could consider renal measurements in children as good
reproducible and valid in case of ICC over 0.80. Our results showed high ICCs (over 0.80) for
almost all renal ultrasound measurements, with low 95% confidence intervals, indicating a high
degree of similarity among and between observers and thus good agreement. Only for renal thick-
ness between observers we found ICCs smaller than 0.80, representing a poor reproducibility.
Intraobserver ICCs were higher (ranging from 0.93 to 0.99) than interobserver ICCs (ranging from
0.64 to 0.90) for all left and right renal dimensions. This phenomenon, so called interobserver
variability, could be expected since two observers measure differently.
The Bland and Altman plots showed good agreement among and between observers. We
found for almost all renal ultrasound measurements differences within 10% from the mean. Only
for the interobserver measurements of left and right renal thickness the difference from the mean

ch
ap
te
r
3
.1
was more than 10%. The renal thickness measurement is the most difficult measurement of the
renal ultrasound measurements performed in this study. This quite large variation in the measure-
ment of renal thickness is probably due a random error, which may result in a poorer precision
and a lower power of our study results. Often renal volume is used as an outcome measurement
in different studies, but it requires multiple measurements to calculate.10 Although, renal volume
is the best surrogate measure for assessing nephron number in epidemiological studies and
measuring renal volume by ultrasound is validated, the lower reproducibility does also affect the
accuracy of volume measurements. An alternative for clinical and epidemiological studies, fo-
cused on comparisons between groups, would be to use only renal length and width instead of
renal volume. This would be appropriate for internal comparisons which are mainly focused on
ranking in renal growth characteristics. But it is known from literature that renal volume is a better
representation of renal weight and growth than renal length.13, 14 So we think that is it still relevant
to measure renal thickness, even if the variation of the measurement is quite large.
A few other studies measured intraobserver and interobserver variations of renal ultra-
sound measurements in children. The major difference between these previous studies and our
study is the aim of the study. Our study was designed to assess renal development in a relatively
healthy group of children and to assess whether renal measurements are reproducible and re-
peatable as an outcome measure for different studies. The aim of the cited papers was rather
to evaluate renal growth. Their study population consisted of children referred for renal ultra-
sound. More in detail, Sargent et al. studied sonographic measurements of renal length and
volume in children aged 16 years and younger to evaluate renal growth with time.6, 7 They demon-
strated an interobserver variation in the sonographic estimation of renal volume of approximately
30-40%. The absolute interobserver variation increased with renal volume, representing approx-
imately 2-3 years’ normal growth in children over 2 years.6 Observer error in the measurement
of renal length is equivalent to between 2 and 3 years normal growth for children older than 1
year.7 They did not present data of intraobserver variation.
Schlesinger et al. focused on renal length in children with a median age of 5 years and
showed a mean interobserver variation between two imagers ranging from 3.87 to 5.49 mm and an
intraobserver variation ranging from 0.87 to 3.61 mm. They concluded that the observed variability
in sonographic measurements of renal length is comparable to the expected annual increase in
length of the kidneys during childhood. Caution is suggested when using sonography to evaluate
renal growth in children during a year’s time.8
The major strength of our study is the young age at which we studied the intraobserver
and interobserver variability of renal ultrasound measurements. To our knowledge, previous studies
of reproducibility of renal ultrasound measurements have mostly been performed in older children
and adults or focused on one of the renal ultrasound measurements.15, 16 Second, two well trained
sonographers performed all the renal ultrasound measurements in our study, so our results are
probably to a large extend depended on the experience of these two sonographers. Furthermore,
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renal measurements could be measured in 100% of the participating children. Another strength
of our study is that we used various statistical methods, which give a useful indication about the
reliability of renal ultrasound measurements in children.
A limitation of this study could be the possibility of recall bias. This is an important general
issue in intra-observer studies. We tried to avoid recall bias as much as possible by taking 10
minutes between the two measurements of one observer. In this period, the observer left the room
and performed other measurements in other children. Additionally, we scheduled many children
participating in the study during one session, decreasing the possibility of remembering the results.
If present, the effect of recall bias, would only affect the results of the intraobserver variability
and not the interobserver variability.
In conclusion, we demonstrated good reproducibility of most left and right renal dimensions
in children measured by ultrasound. Only renal thickness has a poor interobserver reproducibility.
This information is important for clinical and epidemiological research projects focused on renal
dimensions in young children.
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Abstract
Background: Available information about growth of kidney structures in early life in healthy children
is limited. We constructed reference curves for kidney growth from third trimester of pregnancy
until early childhood using data of 1,158 healthy children.
Methods: This study was embedded in a population-based prospective cohort study from fetal life
onwards. Kidney size, defined as length, width, depth and volume, was measured in third trimester
of pregnancy and at the postnatal ages of 6 and 24 months. Gender specific reference growth
curves were constructed. Analyses were based on more than 2,500 kidney measurements.
Results: In third trimester of pregnancy and at the age of 6 months, all kidney measurements were
larger in boys than in girls. At the age of 24 months, only kidney length was larger in boys. Trends
were seen towards smaller left kidneys compared to right kidneys at all ages in both genders,
except for kidney length. Gender specific reference curves based on (postconceptional) age were
constructed for left and right kidney length, width, depth and volume.
Conclusions: Kidney size is significantly influenced by age and gender. Left kidney size tend to be
smaller than right kidney size, except for kidney length. These reference curves can be used for
assessing kidney structures by ultrasound in fetal life and early childhood.
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Introduction
Assessment of kidney size in children is important for clinical and epidemiological studies.
Abnormal early kidney development may have perinatal and neonatal consequences.1 Smaller
fetal kidney size has also been suggested to be related to hypertension and renal disease in
adulthood.2, 3 Recently, we showed in the same cohort that small kidney size in fetal life tends to
persist in early childhood. Furthermore, maternal anthropometrics and fetal biometrics and blood
flow patterns were associated with kidney size in childhood. Higher growth rates in early childhood
were positively associated with combined kidney volume.4 These results suggest that fetal and
early postnatal exposures and growth variation might have persistent consequences for kidney
size. Kidney size can be measured non-invasively and efficiently with ultrasound. Few studies
published reference ranges for kidney size in healthy children during fetal and neonatal life.5, 6 One
study showed reference data on postnatal kidney growth from birth to 18 months of age.7 Previous
studies were based on postnatal kidney growth characteristics and mostly focused on kidney volume
in relation to weight, height or body surface area. Recently, new reference centiles were generated
to assess kidney size of children with ‘single kidneys’ to identify those patients with unfavorable
course and relevant single kidney growth impairment.8 Currently, no studies have evaluated normal
kidney growth from late fetal life until early childhood. This perinatal period may be of importance
to identify abnormal kidney size and growth, with subsequent short and long-term clinical con-
sequences.9, 10
Therefore, the aim of this study was to construct reference curves for kidney structures
including kidney length, width, depth and volume in children from third trimester of pregnancy
until the postnatal age of 24 months in a population-based cohort.
Methods
Design
This study was embedded in the Generation R Study, a population-based, prospective cohort
study from fetal life until young adulthood in Rotterdam, the Netherlands.11, 12 Detailed assess-
ments of fetal and postnatal growth and development were conducted in a subgroup of 1,232
mothers and their children.11, 12 In this subgroup, fetal kidney ultrasounds were performed in third
trimester of pregnancy (gestational age of 30 weeks) and postnatal kidney ultrasounds were per-
formed at the ages of 6 and 24 months. The study has been approved by the Medical Ethics
Committee of the Erasmus MC, Rotterdam. Written informed consent was obtained from all par-
ticipants.
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Population for analysis
In total, 1,232 women were enrolled in the Focus cohort. The present analysis was limited to
singleton live births (n = 1,215) whose mothers participated in the third trimester measurements.
Twin pregnancies (n = 15) and pregnancies leading to perinatal death (n = 2) were excluded from
the analysis. Kidney ultrasounds were successfully performed in 95% (n = 1,158) of these sub-
jects. Of the initial 1,215 singleton live births, 74% (n = 901) and 70% (n = 856) participated in
the postnatal assessments at the ages of 6 and 24 months, respectively. Kidney ultrasounds
were successfully performed in 83% (n = 747) and 80% (n = 683) of these infants, respectively.
Missing values were mainly due to crying behavior or unavailability of equipment or radiographer.
Infants who had a postnatal kidney ultrasound at the ages of 6 and 24 months did not differ
from the postnatal non-responders in fetal and birth characteristics. No kidney or ureterovesical
anomalies other than mild pyelectasis over 10 mm (n = 3) were present in our study population.
In total, analyses were based on more than 2,500 kidney measurements. The number of avail-
able kidney growth measurement for the analyses are shown in Table 1.
Table . Number of successful measurements per variable, according to age
Successful measurements (% (n))
Kidney Gestational age  weeks Age  months Age 2 months
measurement (n = 1,215) (n = 901) (n = 856)
Left kidney
Length 94.9 (1153) 81.2 (732) 78.2 (669)
Width 95.2 (1157) 77.2 (696) 72.8 (623)
Depth 95.1 (1155) 76.8 (692) 76.9 (624)
Volume 94.4 (1147) 76.6 (690) 72.9 (615)
Right kidney
Length 94.7 (1151) 82.9 (747) 81.9 (701)
Width 95.4 (1159) 82.4 (742) 80.6 (690)
Depth 95.4 (1159) 82.2 (741) 80.6 (690)
Volume 94.5 (1148) 82.1 (740) 80.4 (688)
Values are percentages (absolute number of children).
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Ultrasound measurements
Gestational age was established by fetal ultrasound. Crown-rump length was used for pregnancy
dating until a gestational age of 12 weeks and 5 days (crown-rump length smaller than 65 mm),
and biparietal diameter was used for pregnancy dating thereafter (gestational age from 12 weeks
and 5 days onwards, biparietal diameter larger than 23 mm).13
Fetal left and right kidney size were measured in third trimester of pregnancy using an ATL-
Philips HDI 5000 (Seattle, Washington, USA) equipped with a 2.0 - 5.0 MHz curved array
transducer. In a sagittal plane, the maximum longitudinal kidney length was measured placing the
calipers on the outer edges of the caudal and cranial side. Antero-posterior (kidney width) and
transverse kidney diameter (kidney depth) were measured perpendicular to each other, outer to
outer, in an axial plane.14 Measures of maximal bipolar kidney length, width and depth were
obtained from both the left and right kidney. Kidney width and depth were measured at the level
of the kidney hilum.14, 15 The images were sufficiently magnified to ensure optimal measure-
ments.14 Fetal growth characteristics (head circumference, abdominal circumference, femur
length) were measures at the same visit and estimated fetal weight was calculated.13
Postnatally, two-dimensional ultrasounds of the kidneys were performed in children at the
ages of 6 and 24 months. The examination was carried out in a quiet room with the child quietly
awake in a supine position. This position was standardised to prevent differences according to
position.14, 15 Mean length, width and depth were calculated as the average of three measure-
ments and used for data analysis. Fetal and postnatal kidney volume were both calculated in
cubic centimeters using the equation of an ellipsoid: volume (cm3) = 0.523 * mean length (cm)
* mean width (cm) * mean depth (cm).15, 16 The infants’ anthropometrics, including weight and
length, were all measured at the ages of 1.5, 6 and 24 months. Date of birth, birth weight and
gender were obtained from midwife and hospital registries.
For the fetal ultrasound measurements, intra- and interobserver studies showed intra-
class correlation coefficient (ICC) higher than 0.98 and corresponding coefficients of variation (CV)
lower than 6%. Bland and Altman plots to test agreement of measurements demonstrated 95%
limits of agreement to be within 10% difference from the mean of measurements, indicating good
reproducibility.17 For the postnatal ultrasound measurements, the intraobserver ICCs ranged from
0.93 (left and right renal width and right renal thickness) to 0.99 (left renal length) and inter-
observer ICCs ranged from 0.64 (right renal thickness) to 0.90 (right renal length). Limits of
agreement in the Bland and Altman plots ranged from –8.0 to 9.2% (intraobserver left renal width)
to the widest limit from –18.0 to 19.2% (interobserver left renal length).18
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Statistical analysis
Differences of fetal and postnatal characteristics between boys and girls were assessed by t-tests
and chi-square tests for independent samples. Differences between left and right kidney were
tested with paired sample t-tests.
Data were analyzed as recommended by Altman, Chitty and Royston.19, 20 For reference
kidney growth curves, postconceptional age was plotted against kidney length, width, depth and
volume. From the original data, measurements of more than two standard deviations (SDS) from
the regression line, fitted on our data, were considered to be outliers (n = 10) and were there-
fore removed. They were probably a result of measurement error or a data entry error. The best
fitting curves were determined using second-degree fractional polynominals.21 The curve was
fitted using repeated measurement analyses, taking into account the dependency in the data by
specifying a constant covariance between measurements of the same subject.20, 22 The best fitting
fractional polynominal curves were chosen by comparing the deviances, by Akaike’s Information
Criterion, and by visually checking the goodness of fit. Next, regression lines were fitted for the
dependency of the residual SD on conceptional age.23 Subsequently, plotting the SD scores
against conceptional age was used to assess correctness of the model.
Finally centiles were derived and the curves were plotted on the data. The median age of
2-year-old children visiting the research center was 25 months (95% range: 23.6 – 28.3). Since
only 34 children had measurements beyond the postnatal age of 28 months (160 weeks post-
conceptional), results are presented until the postnatal age of 28 months. Kidney growth
reference curves were constructed for a postconceptional age from 30 to 160 weeks, corresponding
to a gestational age of 30 weeks and a postnatal age of 28 months.
All statistical analyses were performed using the Statistical Package for the Social Sciences
version 15.0 for Windows (SPSS Inc, Chicago, IL, USA) and the Statistical Analysis System (SAS)
for Windows, version 9.1.3.
Results
The percentage of boys was 52% (Table 2). The overall median age at their visit in third trimester
of pregnancy was 30 weeks of gestation (total range: 27.1 - 35.1). The overall median age of in-
fants at their 6 months postnatal visit was 6.3 months (total range: 5.1 - 11.0) and at their 24
months postnatal visit 25.1 months (total range: 21.6 - 31.6). Third trimester head circumference
and postnatal weight and length at the ages of 6 and 24 months were larger in boys than in girls
(all p-values <0.001). No difference was found for gestational age at birth between boys and
girls. In total, 15 children in our study group were born with a small size for gestational age (<-2
SDS), 18 children had a low birth weight (<2500 grams) and 23 children were born preterm (ges-
tational age <37 weeks).
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Table 2. Subject characteristics
Boys Girls P-value
Third trimester fetal characteristics (n = ) (n = )
Gestational age (weeks) 30.4 (28.7-32.8) 30.3 (28.2-32.5) 0.05
Head circumference (cm) 28.8 (1.2) 28.3 (1.1) <0.001
Abdominal circumference (cm) 26.7 (1.7) 26.5 (1.6) 0.2
Femur length (cm) 5.7 (0.3) 5.8 (0.3) 0.2
Estimated fetal weight (grams) 1632 (264) 1623 (252) 0.7
Characteristics at birth (n = ) (n = )
Gestational age at birth (weeks) 40.3 (36.2-42.4) 40.3 (36.1-42.4) 0.9
Gestational age < 37 weeks (%) 12 (3.4) 11 (3.3) 0.9
Birth weight (grams) 3557 (518) 3488 (506) 0.05
Birth weight <2500 grams (%) 8 10 0.6
Small for gestational age (%) 6 9 0.4
Characteristics at  months (n = 9) (n = )
Age at visit (months) 6.3 (5.4-8.0) 6.3 (5.4-8.2) 0.7
Weight at visit (grams) 8173 (837) 7640 (807) <0.001
Length at visit (cm) 69.4 (2.4) 67.9 (2.4) <0.001
Characteristics at 2 months (n = ) (n = )
Age at visit (months) 25.1 (23.6-28.0) 25.2 (23.4-28.3) 0.3
Weight at visit (grams) 12,890 (1,395) 12,429 (1,343) <0.001
Length at visit (cm) 89.6 (3.2) 88.4 (3.3) <0.001
Values are means (standard deviation), medians (95% range) or percentages.
Differences between boys and girls were compared using independent sample t-tests or Χ2 tests.
Table 3 shows that in third trimester of pregnancy and at the age of 6 months all kidney measure-
ments were larger in boys than in girls. At the age of 24 months, these gender differences were only
significant for left kidney structures and right kidney length. Both groups showed trends towards
smaller left kidney measurements compared to right kidney measurements at all ages (Table 4).
Reference kidney growth curves of individual measurements and fitted centiles are given
in Figure 1. Formulas for growth reference curves describing the mean with the corresponding
standard deviation are given in Table 5. Standard deviation increased linearly with gestational age.
Reference values for kidney length, width, depth and volume are given in the Appendix (Tables 1S-4S).
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Table . Differences between boys and girls stratified for left and right kidney structures
Left kidney Right kidney
Kidney measurement Boys Girls P-value Boys Girls P-value
Gestational age  weeks (n = ) (n = ) (n = ) (n = )
Length (mm) 39.5 (32.0-47.0) 38.4 (32.7-45.0) <0.001 39.6 (32.0-46.6) 38.5 (32.2-45.3) <0.001
Width (mm) 21.6 (17.0-28.0) 21.1 (16.5-26.0) 0.001 22.4 (17.0-28.0) 22.0 (17.0-27.6) 0.02
Depth (mm) 22.7 (17.0-29.0) 22.1 (17.9-27.8) 0.001 23.2 (17.8-30.0) 22.9 (18.0-29.0) 0.03
Volume (cm3) 10.3 (5.4-17.9) 9.5 (5.4-15.0) <0.001 11.0 (5.8-18.5) 10.3 (5.8-16.8) <0.001
Age  months (n = ) (n = ) (n = 9) (n = )
Length (mm) 60.1 (48.6-70.4) 58.6 (50.0-67.4) <0.001 58.8 (49.7-69.3) 57.5 (49.5-67.6) <0.001
Width (mm) 28.2 (22.3-36.4) 27.6 (21.6-35.7) 0.01 28.0 (21.8-35.4) 27.5 (21.4-36.5) 0.04
Depth (mm) 26.5 (20.1-33.0) 25.5 (20.2-32.2) <0.001 27.8 (21.3-34.9) 27.0 (20.9-34.0) 0.001
Volume (cm3) 23.8 (14.0-36.6) 21.9 (13.9-33.4) <0.001 24.0 (15.3-35.6) 22.4 (14.2-34.6) <0.001
Age 2 months (n = ) (n = ) (n = ) (n = )
Length (mm) 66.8 (56.1-80.3) 65.7 (53.7-78.0) 0.03 65.2 (54.8-76.6) 64.3 (53.2-76.5) 0.04
Width (mm) 30.8 (25.6-37.1) 30.1 (23.5-37.8) 0.01 30.7 (25.6-38.0) 30.6 (25.2-37.1) 0.61
Depth (mm) 30.9 (24.8-38.9) 30.1 (24.2-38.1) 0.002 32.0 (25.5-39.4) 31.9 (25.9-39.6) 0.79
Volume (cm3) 33.6 (22.8-51.6) 31.8 (19.3-52.2) 0.004 33.8 (22.9-53.3) 33.1 (22.1-49.2) 0.19
Values are means (95% range). Differences between boys and girls were compared using independent sample t-tests.
Table . Differences between left and right kidney structures stratified for gender
Boys Girls
Kidney measurement Left kidney Right kidney P-value Left kidney Right kidney P-value
Gestational age  weeks (n = ) (n = ) (n = ) (n = )
Length (mm) 39.5 (32.0-47.0) 39.6 (32.0-46.6) 0.79 38.4 (32.7-45.0) 38.5 (32.2-45.3) 0.45
Width (mm) 21.6 (17.0-28.0) 22.4 (17.0-28.0) <0.001 21.1 (16.5-26.0) 22.0 (17.0-27.6) <0.001
Depth (mm) 22.7 (17.0-29.0) 23.2 (17.8-30.0) <0.001 22.1 (17.9-27.8) 22.9 (18.0-29.0) <0.001
Volume (cm3) 10.3 (5.4-17.9) 11.0 (5.8-18.5) <0.001 9.5 (5.4-15.0) 10.3 (5.8-16.8) <0.001
Age  months (n = ) (n = 9) (n = ) (n = )
Length (mm) 60.1 (48.6-70.4) 58.8 (49.7-69.3) <0.001 58.6 (50.0-67.4) 57.5 (49.5-67.6) <0.001
Width (mm) 28.2 (22.3-36.4) 28.0 (21.8-35.4) 0.50 27.6 (21.6-35.7) 27.5 (21.4-36.5) 0.72
Depth (mm) 26.5 (20.1-33.0) 27.8 (21.3-34.9) <0.001 25.5 (20.2-32.2) 27.0 (20.9-34.0) <0.001
Volume (cm3) 23.8 (14.0-36.6) 24.0 (15.3-35.6) 0.35 21.9 (13.9-33.4) 22.4 (14.2-34.6) 0.06
Age 2 months (n = ) (n = ) (n = ) (n = )
Length (mm) 66.8 (56.1-80.3) 65.2 (54.8-76.6) <0.001 65.7 (53.7-78.0) 64.3 (53.2-76.5) <0.001
Width (mm) 30.8 (25.6-37.1) 30.7 (25.6-38.0) 0.68 30.1 (23.5-37.8) 30.6 (25.2-37.1) 0.02
Depth (mm) 30.9 (24.8-38.9) 32.0 (25.5-39.4) <0.001 30.1 (24.2-38.1) 31.9 (25.9-39.6) <0.001
Volume (cm3) 33.6 (22.8-51.6) 33.8 (22.9-53.3) 0.30 31.8 (19.3-52.2) 33.1 (22.1-49.2) <0.001
Values are means (95% range). Differences between left and right kidney structures were compared using paired sample t-tests.
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Figure . Reference growth curves of right and left kidney length, width, depth and volume in boys
and girls according to postconceptional age
a. Left kidney length
b. Right kidney length
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e. Left kidney depth
f. Right kidney depth
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g. Left kidney volume
h. Right kidney volume
Gender-differentiated growth curves for left and right kidney length, with, depth and volume measurements in relation to post-
conceptional age with 3rd and 97th fitted centiles. Postconceptional age was based on last menstrual period. The straight lines
represent boys and the dotted lines represent girls.
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Table . Reference curves for kidney structures: equations for the mean and SD of each
measurement based on age in exact weeks
Kidney measurement Measurement Regression equation
Left kidney
Length (mm) Mean 70.7392 + 48231 (1/Age2) - 22290 (1/Age2)*ln(Age) -1.0112 Gender
SD 3.033 + 0.020 Age
Width (mm) Mean 33.9989 + 2465.42 (1/Age2) - 408.99 x (1/Age) - 0.6208 Gender
SD 2.577 + 0.004 Age
Depth (mm) Mean 2.5301 + 5.7694 ln(Age) - 0.6145 Gender
SD 2.502 + 0.0031 Age
Volume (cm3) Mean 56.8477 + 4222.85 (1/Age2) - 273.13 (1/√Age) - 1.3538 Gender
SD 1.639 + 0.0375 Age
Right kidney
Length (mm) Mean 69.05 + 46279 (1/Age2) - 21206 (1/Age2) ln(Age) - 1.0561 Gender
SD 2.899 + 0.0194 Age
Width (mm) Mean 37.4342 + 122.84 (1/Age2) - 78.8602 * (1/√Age) - 0.2290 Gender
SD 2.977 - 0.00025 Age
Depth (mm) Mean 1.2261 + 6.2168 ln(Age) - 0.2474 Gender
SD 2.576 + 0.005 Age
Volume (cm3) Mean 45.4105 + 22573 (1/Age2) - 1766.41 (1/Age) - 0.8152 Gender
SD 2.128 + 0.0321 Age
Gender = 0 for boys and gender = 1 for girls. Age is defined as postconceptional age (weeks). SD, standard deviation.
Discussion
We constructed gender-specific reference growth curves for kidney length, width, depth and volume
using measurements from a large population-based prospective cohort study of healthy children
followed from fetal life until early childhood. We observed differences in kidney structures between
left and right kidneys and boy and girls.
The major strength of our study is its prospective design from fetal life and the size of the
population-based cohort. Our reference curves were based on more than 2,500 kidney measure-
ments. To our knowledge, no previous studies focused on kidney size in early life were based on
such large numbers. All fetal ultrasounds were carried out by two sonographers and 86% of all
postnatal ultrasounds were performed by one trained sonographer.24 A limitation could be that of
all children participating in the Generation R measurements at the ages of 6 and 24 months,
kidney measurements were successfully performed in 83% and 80% of these infants, respectively.
Missing values were mainly due to crying behavior or unavailability of equipment or radiographer.
Our results would be biased if the subject characteristics differ between those included and not
included in the present analyses. However, we observed no differences in growth and fetal kidney
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characteristics between subjects with and without postnatal kidney measurements. Another
limitation could be that the current study was performed in a healthy, population based cohort study.
The selection towards a healthy population in our cohort may lead to a limited generalizability to
preterm children or children with a small size for gestational age at birth children. These numbers
were too small to be assessed in further detail.
In third trimester of pregnancy and at the age of 6 months all kidney measurements were
larger in boys than in girls. At the age of 24 months, these gender differences were only significant
for left kidney structures and right kidney length. Several studies in healthy neonates and adults
have also shown that males have larger kidneys than females.25, 26 One explanation for this finding
may be a growth stimulating effect of androgens or Y-chromosome related genes. Another ex-
planation could be that testosterone levels are significantly higher during fetal life in males
compared to females.27, 28
Previously published data showed conflicting results concerning differences between left
and right kidney size. Some studies found no difference between left and right kidney size29, 30,
whereas others suggested the left kidney to be larger.31, 32 Most consistent findings have been
reported for kidney length, for which left length seems larger that right length.7, 25, 26, 31, 33 We found
that left kidney length was larger in both boys and girls at the postnatal ages of 6 and 24 months.
In fetal life we found no significant difference between left and right kidney length.
Kidney growth is fastest during fetal life and early infancy and the rate of increase gradually
slows through the remainder of the first year of life and finally stabilizes.34 In our study, numbers
and curves for the 3rd centiles showing decreasing kidney volumes at the older ages from 140
weeks and onwards. The decreasing numbers are due to wider ranges because of the low number
of children with visits around 140 weeks and onwards. To deal with non-linear kidney growth,
some sonographic standards, including means and standard deviations, for kidney size in relation
to age have been published.34-36 A few other studies created linear or non-linear polynominal
regression equations for kidney size during the first year of life.29, 33 One study created reference
materials for kidney size in healthy children beyond the neonatal period.7 They only focused on
kidney volume in relation to weight, height and body surface area and did not report data about
prenatal kidney growth. To our knowledge, the present study is the first to provide prospective
longitudinal reference material on kidney size covering the whole period from fetal life until infancy
in a healthy population.
In conclusion, kidney size differed between boys and girls from the age of 30 weeks of
pregnancy until 24 months of age. Left kidney size tend to be smaller than right kidney size. At
the age of 24 months, the differences in right kidney size between boys and girls were attenuated.
Gender-differentiated reference growth curves for both left and right kidneys were constructed for
kidney length, width, depth and volume. These reference curves may be of importance to identify
abnormal kidney size and growth, with possible subsequent clinical consequences.
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Appendix
Table S. Reference values for left and right kidney length according to postconceptional age in
boys and girls
Boys Left kidney length (mm) Right kidney length (mm)
Postconceptional age Postnatal age
(weeks) (months) rd centile Mean 9th centile rd centile Mean 9th centile
30 - 32.3 39.1 45.9 32.8 39.3 45.9
40 0 41.3 48.5 55.7 41.2 48.1 55.0
50 2.5 46.6 54.1 61.7 46.1 53.4 60.7
60 5 49.8 57.8 65.7 49.1 56.8 64.4
80 9 53.3 62.0 70.7 52.4 60.8 69.1
100 14 54.8 64.3 73.8 53.8 62.9 72.0
120 19 55.5 65.7 75.9 54.4 64.2 74.0
140 23 55.6 66.6 77.5 54.5 65.1 75.6
160 28 55.5 67.2 78.9 54.4 65.7 76.9
Girls Left kidney length (mm) Right kidney length (mm)
Postconceptional age Postnatal age
(weeks) (months) rd centile Mean 9th centile rd centile Mean 9th centile
30 - 31.2 38.1 44.9 31.8 38.3 44.9
40 0 40.3 47.5 54.7 40.2 47.1 54.0
50 2.5 45.6 53.1 60.7 45.1 52.4 59.6
60 5 48.8 56.8 64.7 48.1 55.8 63.4
80 9 52.3 61.0 69.7 51.4 59.8 68.1
100 14 53.8 63.3 72.7 52.8 61.9 71.0
120 19 54.4 64.7 74.9 53.4 63.2 73.0
140 23 54.6 65.6 76.5 53.5 64.1 74.6
160 28 54.5 66.2 77.9 53.4 64.6 75.9
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Table 2S. Reference values for left and right kidney width according to postconceptional age in
boys and girls
Boys Left kidney width (mm) Right kidney width (mm)
Postconceptional age Postnatal age
(weeks) (months) rd centile Mean 9th centile rd centile Mean 9th centile
30 - 17.4 22.5 27.6 17.4 22.9 28.5
40 0 19.6 24.7 29.8 19.2 24.8 30.4
50 2.5 21.0 26.2 31.4 20.5 26.1 31.7
60 5 22.0 27.3 32.5 21.5 27.1 32.6
80 9 23.2 28.7 34.1 22.9 28.4 34.0
100 14 23.9 29.5 35.1 23.8 29.3 34.9
120 19 24.4 30.1 35.9 24.5 30.0 35.6
140 23 24.7 30.6 36.5 25.0 30.6 36.1
160 28 24.9 30.9 37.0 25.5 31.0 36.5
Girls Left kidney width (mm) Right kidney width (mm)
Postconceptional age Postnatal age
(weeks) (months) rd centile Mean 9th centile rd centile Mean 9th centile
30 - 16.8 21.9 26.9 17.1 22.7 28.3
40 0 18.9 24.1 29.2 19.0 24.6 30.2
50 2.5 20.3 25.6 30.8 20.3 25.9 31.5
60 5 21.3 26.6 31.9 21.3 26.8 32.4
80 9 22.6 28.0 33.5 22.6 28.2 33.7
100 14 23.3 28.9 34.5 23.6 29.1 34.7
120 19 23.8 29.5 35.3 24.3 29.8 35.3
140 23 24.1 30.0 35.9 24.8 30.3 35.9
160 28 24.3 30.3 36.4 25.2 30.8 36.3
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Table S. Reference values for left and right kidney depth according to postconceptional age in
boys and girls
Boys Left kidney depth (mm) Right kidney depth (mm)
Postconceptional age Postnatal age
(weeks) (months) rd centile Mean 9th centile rd centile Mean 9th centile
30 - 16.7 21.5 26.4 17.0 22.1 27.3
40 0 18.3 23.2 28.1 18.7 23.9 29.1
50 2.5 19.5 24.5 29.5 20.0 25.3 30.6
60 5 20.5 25.5 30.6 21.0 26.4 31.8
80 9 22.0 27.2 32.4 22.6 28.2 33.8
100 14 23.2 28.5 33.8 23.8 29.6 35.4
120 19 24.1 29.5 34.9 24.8 30.7 36.7
140 23 24.9 30.4 36.0 25.5 31.7 37.9
160 28 25.6 31.2 36.8 26.2 32.5 38.9
Girls Left kidney depth (mm) Right kidney depth (mm)
Postconceptional age Postnatal age
(weeks) (months) rd centile Mean 9th centile rd centile Mean 9th centile
30 - 16.1 20.9 25.8 16.8 21.9 27.0
40 0 17.7 22.6 27.5 18.5 23.7 28.9
50 2.5 18.9 23.9 28.9 19.7 25.1 30.4
60 5 19.9 24.9 30.0 20.8 26.2 31.6
80 9 21.4 26.6 31.8 22.4 28.0 33.6
100 14 22.6 27.9 33.2 23.6 29.4 35.1
120 19 23.5 28.9 34.3 24.5 30.5 36.5
140 23 24.3 29.8 35.3 25.3 31.5 37.6
160 28 25.0 30.6 36.2 25.9 32.3 38.6
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Table S. Reference values for left and right kidney volume according to postconceptional age in
boys and girls
Boys Left kidney volume (cm) Right kidney volume (cm)
Postconceptional age Postnatal age
(weeks) (months) rd centile Mean 9th centile rd centile Mean 9th centile
30 - 5.1 10.3 15.6 6.5 10.7 15.0
40 0 8.7 14.6 20.5 10.8 15.1 19.4
50 2.5 11.6 18.2 24.8 14.2 18.6 23.0
60 5 13.9 21.2 28.5 17.0 21.5 26.0
80 9 17.2 25.9 34.7 21.3 26.0 30.6
100 14 19.2 29.3 39.4 24.3 29.2 34.0
120 19 20.1 31.6 43.1 26.5 31.5 36.6
140 23 20.1 33.0 45.9 27.9 33.2 38.4
160 28 19.3 33.6 47.9 28.9 34.3 39.8
Girls Left kidney volume (cm) Right kidney volume (cm)
Postconceptional age Postnatal age
(weeks) (months) rd centile Mean 9th centile rd centile Mean 9th centile
30 - 3.8 9.0 14.2 5.7 9.9 14.2
40 0 7.3 13.2 19.1 10.0 14.3 18.6
50 2.5 10.2 16.8 23.4 13.4 17.8 22.2
60 5 12.5 19.8 27.1 16.2 20.7 25.2
80 9 15.9 24.6 33.3 20.5 25.1 29.8
100 14 17.8 28.0 40.0 23.5 28.4 33.2
120 19 18.7 30.3 41.8 25.7 30.7 35.8
140 23 18.7 31.6 44.5 27.1 32.4 37.6
160 28 17.9 32.2 46.5 28.1 33.5 39.0
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Abstract
Background: It has been suggested that an adverse fetal environment leads to permanent smaller
kidneys and subsequently to hypertension and renal disease in adult life. The aim of this study
was to examine whether maternal characteristics, fetal growth, fetal blood flow redistribution and
inadequate placental perfusion in different periods of fetal life affect kidney volume in late fetal
life. We also examined whether fetal kidney volume was associated with amniotic fluid quantity.
Methods: In a population-based prospective cohort study from early fetal life, fetal growth charac-
teristics and fetal blood flow parameters were assessed with ultrasound and Doppler
examinations in 1,215 women in mid- and late pregnancy. Kidney volume was assessed in late
pregnancy.
Results: Maternal height and pre-pregnancy weight were associated with kidney volume. After ad-
justment for the same characteristics in late pregnancy, fetal growth and blood flow parameters
in mid-pregnancy were not associated with kidney volume in late pregnancy. In late pregnancy, all
fetal growth characteristics were positively associated with kidney volume. The largest effect on
kidney volume was found for abdominal circumference (increase of 1.77 cm3; 95% CI: 1.46 - 2.08,
per increase in standard deviation score). Signs of fetal blood flow redistribution and raised
placental resistance were associated with reduced kidney volume in late pregnancy. Kidney volume
was positively associated with amniotic fluid quantity.
Conclusions: Maternal anthropometrics, fetal growth characteristics, raised placental resistance
and fetal blood flow redistribution affect kidney volume. Further research should be aimed at dis-
entangling the causal mechanisms underlying these associations and the long-term
consequences.
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Introduction
Epidemiological studies have demonstrated low birth weight and fetal growth restriction to be
risk factors contributing to renal disease and hypertension in adult life.1-3 It has been hypothe-
sized that an adverse fetal environment leads to fetal growth restriction and smaller kidneys with
a reduced number of nephrons.4, 5 Since nephrogenesis continues until 36 weeks of gestation and
the induction of nephron number ceases thereafter, sub-optimal kidney growth and development
in fetal life may have life long consequences.6, 7 A permanently reduced number of nephrons
would lead to compensatory higher glomerular pressure, progressive glomerular sclerosis and
would subsequently predispose the individual to impaired kidney function and hypertension.4 This
hypothesis is supported by studies in animals and humans. Animal studies have shown that low
protein intake and reduced placental perfusion lead to fetal growth restriction and a permanent
nephron deficit.8, 9 Human studies demonstrated that low birth weight infants and hypertensive
subjects have lower kidney weight with a reduced number of nephrons in adult life.10-13 Thus an
adverse environment in utero may lead to fetal growth restriction and impaired kidney develop-
ment with a nephron deficit, eventually leading to hypertension.4, 14 Fetal kidney weight cannot be
measured in utero. Renal volume measured by ultrasound is a valid substitute.14, 15
The cause of fetal growth restriction and low birth weight is multifactorial. Nutritional defi-
ciencies, smoking and placental insufficiency are causes that might provoke fetal growth
restriction and low birth weight infants. Placental insufficiency is the most common and associated
with raised placental blood flow resistance.16 In response to general fetal malnutrition there is a
preferential fetal blood flow to the brain and heart, depriving other organs, including the kidneys,
from oxygen and nutrients. The increased blood flow to the brain is caused by vasodilatation in
the brain resulting in lower peripheral resistance (‘brain sparing effect’).17 This is part of the phe-
nomenon known as fetal redistribution, which may be related to disturbed development of the
kidneys.
Amniotic fluid is known to represent fetal well-being.18 An adverse fetal environment as
shown by raised placental resistance often results in decreased amniotic fluid indices as well.19
The main component of amniotic fluid is fetal urinary production, which may therefore be related
to kidney volume and reflect kidney function.
The first aim of this population-based prospective cohort study was to evaluate the as-
sociations of maternal characteristics and fetal growth with kidney volume during pregnancy. The
second aim was to examine the associations of placental resistance indices and fetal blood flow
redistribution, as a measure of adverse fetal environment, with kidney volume. Finally, we assessed
the relation of fetal kidney volume with amniotic fluid as a measure of fetal urine production. If
associations of maternal and fetal growth characteristics with kidney volume exist, further studies
designed to identify the causal genetic and environmental mechanisms underlying these asso-
ciations would be needed.
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Methods
Design
This study was embedded in the Generation R Study, a population-based prospective cohort study
from fetal life until young adulthood. This study is designed to identify early environmental and
genetic determinants of growth, development and health from fetal life until young adulthood and
has been described previously in detail.20, 21 In total, the cohort includes 9,778 mothers and their
children living in Rotterdam, the Netherlands. A vast majority (69%) of all mothers were enrolled
in the first trimester of pregnancy.21 Gestational age was determined by ultrasound during the first
visit in early pregnancy. Assessments in pregnancy included physical examinations, fetal ultra-
sounds, biological samples and questionnaires and were planned in early (gestational age <18
weeks), mid- (gestational age 18-25 weeks) and late pregnancy (gestational age ≥25 weeks) to
collect information about fetal growth and its main determinants. The children were born between
April 2002 and January 2006 and form a prenatally recruited birth-cohort that is currently followed
until young adulthood. Of all eligible children born in the study area, 61% participated at birth in
the study.21 Additional more detailed assessments of fetal growth and development were con-
ducted in a subgroup of 1,232 Dutch children and their parents, referred to as the Generation R
Focus cohort. For the present study, kidney size was assessed at the fetal ultrasound examina-
tion in late pregnancy in this subgroup. This subgroup is ethnic homogeneous to exclude possible
confounding or effect modification by ethnicity. Of all approached women, 80% were enrolled in
this subgroup study in the third trimester of pregnancy (gestational age of 30 weeks). Written in-
formed consent was obtained from all participants. The Medical Ethics Committee of the Erasmus
Medical Center, Rotterdam, has approved the study.
Population for analysis
In total, 1,232 women were enrolled in the Generation R Focus Study at a gestational age of 30
weeks. Twin pregnancies (n = 15) and pregnancies leading to perinatal death (n = 2) were ex-
cluded from the analysis. No renal or uterovesical anomalies other than mild pyelectasis over 10
mm (n = 3) were present in our study population. Renal ultrasounds were only partially performed
in 6 subjects due to unfavorable fetal position or maternal adipositas. The present analysis was
performed in a total of 1,215 subjects.
Ultrasound measurements
Fetal biometry
Ultrasound exams were carried out in a research setting at a regional health facility in the centre
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of Rotterdam in early, mid- and late pregnancy. These fetal ultrasound procedures were used for
both establishing gestational age and assessing fetal growth characteristics. Pregnancy dating
curves were constructed on subjects in the study with complete data on gestational age measured
by ultrasound and last menstrual period. Crown-rump length was used for pregnancy dating until
a gestational age of 12 weeks and 5 days (crown-rump length smaller than 65 mm), and biparietal
diameter was used for pregnancy dating thereafter (gestational age from 12 weeks and 5 days
onwards, biparietal diameter larger than 23 mm). Fetal biometry including head circumference,
abdominal circumference, and femur length was measured during each ultrasound examination
using a transabdominal probe. Standard ultrasound planes for fetal measurements were used as
described previously.22-24 Briefly head circumference was measured in a transverse section of the
head with a central mid-line echo, interrupted in the anterior third by the cavity of the septum pel-
lucidum with the anterior and posterior horns of the lateral ventricles in view. An ellipse was
drawn around the outline of the skull. Abdominal circumference was measured in a symmetrical,
transverse, round section through the abdomen, with visualization of the vertebrae on a lateral
position in alignment with the ribs. The measurement was taken in a plane with the stomach and
the bifurcation of the umbilical and hepatic veins. Femur length was measured with the full length
of the bone in view. Gestational age-adjusted standard deviation scores were constructed for
these fetal growth measurements. These were based on reference growth curves from the whole
study population. Estimated fetal weight was calculated using the formula by Hadlock using head
circumference, abdominal circumference and femur length.25
Placental and fetal blood flow profiles
Placental resistance as a proxy of placental function was assessed using recorded flow velocity
waveforms from the umbilical and uterine arteries, in mid and late pregnancy. Raised umbilical
artery pulsatility index (PI) and uterine artery resistance index (RI) indicate increased placental
resistance.16 Umbilical artery PI was measured in a free-floating loop of the umbilical cord. Uterine
artery RI was measured in the uterine arteries near the crossover with the external iliac artery.
The redistribution of blood flow in favor of the fetal brain was quantified by the middle cerebral
artery PI and the cerebro RI / umbilical RI ratio, in late pregnancy. A reduction in middle cerebral
artery PI and a decreasing cerebro-umbilical ratio are valid indicators of ‘brain sparing effect’ due
to fetal redistribution.17, 26 The middle cerebral artery Doppler was performed with color Doppler
visualization of the circle of Willis in the fetal brain and the flow velocity wave forms were obtained
in the proximal part of the middle cerebral artery.
Kidney measurements
Assessment of fetal kidney size and volume was performed at the scan in late pregnancy. The left
and right kidney was measured. In a sagittal plane the maximum longitudinal kidney length was
measured placing the calipers on the outer edges of the caudal and cranial side. Antero-posterior
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and transverse kidney diameter were measured perpendicular to each other, outer to outer, in an
axial plane. The cross-sectional area in which the kidney appeared symmetrically round and at its
maximum width was used. The images were sufficiently magnified to ensure optimal measure-
ments.27 Kidney volume was calculated using the approximation of an ellipsoid: Volume = length
* width * thickness * 0.523.15 Left and right kidney volume were added for the combined kidney
volume (cm3).28 Another frequently used measure of the kidney in fetal life is the relative kidney
volume. This is the ratio of kidney volume / estimated fetal weight.15, 29
Amniotic fluid
Amniotic fluid was assessed using single deepest pocket measurements, the preferable method
to give an indication about the quantity of amniotic fluid in clinical practice.30 All the ultrasound
exams were performed using an ATL-Philips® Model HDI 5000 (Seattle, Washington, USA)
equipped with a 5.0 MHz, high frequency curved array transducer.
Intra- and interobserver reproducibility
Three well-trained, experienced sonographers performed all measurements. Quality checks were
frequently carried out and feedback was provided to minimize interoperator differences. To assess
intra- and interobserver reproducibility of the fetal ultrasound measurements, the intraclass cor-
relation coefficient (ICC) and coefficient of variation (CV) between and among observers were
calculated in 21 subjects for various ultrasound measurements and Doppler parameters.31 For
fetal ultrasound measurements the ICC was higher than 0.98 and the corresponding CV lower
than 6%. Bland and Altman plots to test agreement of measurements for fetal ultrasound, demon-
strated 95% limits of agreement in proportions to be within 10% difference from the mean of the
measurements, indicating good reproducibility.31 Furthermore, for Doppler parameters the results
show high ICC (>0.80) with corresponding low CV (<10%) values as well, indicating adequate
reproducibility for all Doppler measurements.
Statistical analysis
To establish normal ranges for renal growth parameters with gestation we created scatterplots
of the individual measurements and applied the best fitting formula.
The associations of maternal characteristics with combined kidney volume were assessed
using multiple linear regression models. The models were adjusted for fetal abdominal circum-
ference in late pregnancy, gestational age and fetal gender. The associations of fetal growth
characteristics (head circumference, abdominal circumference and femur length), placental re-
sistance indices, and fetal redistribution parameters in mid- and late pregnancy with combined
kidney volume measured in late pregnancy were also assessed using multiple linear regression
models. Gestational age-adjusted standard deviation scores (SDS) for the fetal growth measure-
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ments were used to compare effect sizes. All models were adjusted for fetal gender. The Doppler
measurements were additionally adjusted for gestational age and abdominal circumference. Since
fetal size in mid-pregnancy is strongly related to fetal size in late pregnancy, we adjusted the mid-
pregnancy models (Model A) for the same growth and Doppler characteristic in late pregnancy
(Model B) to estimate the effect size on kidney volume that is explained by fetal growth in mid-
pregnancy only.
Furthermore we examined the effect of gestational age-adjusted abdominal circumference
in late pregnancy on relative kidney volume (kidney volume / estimated fetal weight). Finally the
effect of kidney volume on amniotic fluid was assessed, adjusted for gestational age, gender and
abdominal circumference, using linear regression models. All statistical analyses were performed
using the Statistical Package of Social Sciences version 11.0 for Windows (SPSS Inc, Chicago,
IL, USA).
Results
Characteristics of the subjects who participated in the study and their mothers for boys and girls
in mid- and late pregnancy are presented in Table 1. The percentage of boys was 51%. Median
maternal age was 31.9 (95% range: 21.5 - 39.0) years. The median gestational age for the mid-
pregnancy visit was 20.5 (95% range: 18.7 - 22.8) weeks and for the late pregnancy visit 30.4
(95% range: 28.4 - 32.6) weeks. Head circumference and abdominal circumference were larger
and umbilical artery flow pulsatility index (PI) was lower in boys than in girls at both measure-
ments. Estimated fetal weight was higher for boys in late pregnancy only. No gender differences
were observed for femur length and uterine artery flow at both visits. At birth, weight was higher
in boys than in girls.
Table . Subject characteristics (n = 1,215)
Boys Girls
(n = 629) (n = 586)
Maternal characteristics
Age (years) 31.8 (21.1-39.2) 32.0 (22.7-39.0)
Height (cm) 170.8 (5.9) 170.9 (6.0)
Pre-pregnancy weight (kg) 68.2 (13.0) 69.2 (12.3)
Pre-pregnancy BMI (kg/m2) 23.3 (4.2) 23.7 (4.0)
Weight gain until late pregnancy (kg) 8.5 (3.7) 8.4 (3.6)
Systolic blood pressure in late pregnancy (mmHg) 120.4 (11.3) 121 (11.0)
Diastolic blood pressure in late pregnancy (mmHg) 69.8 (9.3) 70.0 (9.5)
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Table . continued
Boys Girls
(n = 629) (n = 586)
Hypertension (%) 6.9 8.7
Pre-existent or pregnancy induced diabetes (%) 1.4 1.3
Pre-eclampsia (%) 1.2 2.1
Smoking during pregnancy (%) 15.0 12.6
Mid-pregnancy characteristics
Gestational age (weeks) 20.6 (18.8-22.8) 20.5 (18.7-22.8)
Head circumference (cm) 18.0 (1.4) 17.7 (1.3)*
Abdominal circumference (cm) 15.8 (1.3) 15.6 (1.3)*
Femur length (cm) 3.3 (0.3) 3.3 (0.3)
Estimated fetal weight (grams) 377 (84) 370 (80)
Umbilical artery, pulsatility index (PI) 1.18 (0.19) 1.21 (0.17)*
Uterine artery, resistance index (RI) 0.54 (0.09) 0.54 (0.09)
Late pregnancy characteristics
Gestational age (weeks) 30.5 (28.6-32.9) 30.3 (28.3-32.5)
Head circumference (cm) 28.8 (1.2) 28.3 (1.2)*
Abdominal circumference (cm) 26.7 (1.7) 26.5 (1.7)*
Femur length (cm) 5.70 (0.3) 5.73 (0.3)
Estimated fetal weight (kg) 1631 (259) 1599 (259)†
Umbilical artery, pulsatility index (PI) 0.96 (0.16) 0.99 (0.17)*
Uterine artery, resistance index (RI) 0.49 (0.08) 0.49 (0.08)
Postnatal characteristics
Gestational age (weeks) 40.3 (35.9-42.4) 40.1 (35.6-42.4)
Birth weight (grams) 3549 (547) 3460 (557)*
Values are means (standard deviation) or medians (95% range). Differences between boys and girls were compared using
independent sample t-tests. *p-value <0.05, †p-value <0.01
Table 2 presents kidney characteristics in late pregnancy for boys and girls. The size of all kidney
measurements was larger in boys than in girls. Left and right kidney did not differ in length, but
the right kidney had a larger width 0.67 mm difference (95% CI: 0.53, 0.82), depth 0.80 mm dif-
ference (95% CI: 0.68, 0.93) and volume 0.72 cm3 difference (95% CI: 0.60, 0.83) (not shown
in Table 2).
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Table 2. Fetal kidney characteristics in late pregnancy
Boys Girls
(n = 629) (n = 586)
Left kidney structures
Length (mm) 39.5 (3.8) 38.4 (3.5)*
Width (mm) 22.7 (2.9) 22.1 (2.5)*
Depth (mm) 21.6 (2.8) 21.1 (2.5)*
Volume (cm3) 10.3 (3.0) 9.5 (2.5)*
Right kidney structures
Length (mm) 39.6 (3.8) 38.5 (3.5)*
Width (mm) 23.2 (3.0) 22.9 (2.7)†
Depth (mm) 22.4 (2.9) 22.0 (2.7)†
Volume (cm3) 11.0 (3.3) 10.3 (2.8)*
Combined kidney volume (cm) 21.3 (5.9) 19.9 (5.0)*
Values are means (standard deviation). Differences between boys and girls were compared using independent sample t-tests.
*p-value <0.05, †p-value <0.01
Figure 1 shows individual measurements for kidney structures in late pregnancy with the 5th and
95th percentiles. Formulas for normal ranges for mean fetal kidney size and volume between 28-
34 weeks of gestational age are listed beneath the figures.
Figure . Individual measurements of mean kidney length, width, depth and volume with fitted
median, 5th and 95th centiles with gestational age and formulas for normal values
Mean length = 6 + (1.086*GA) Mean width = 0.19 + (0.74*GA)
SD = 3.2 SD = 2.39
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Mean depth = 2.91 + (0.62*GA) Mean volume = exp(-0.406 + 0.089*GA)
SD = 2.35 SD = exp 0.245
GA, gestational age in exact weeks between 28 and 34 weeks; SD, standard deviation.
Table 3 gives the associations of maternal characteristics with combined (left plus right) kidney
volume. Maternal pre-pregnancy weight and height were positively associated with kidney volume.
Other maternal characteristics like obesity, blood pressure, pre-eclampsia, diabetes or smoking were
not associated with kidney volume.
Table . Associations of maternal characteristics with combined fetal kidney volume in late pregnancy
Maternal characteristics Difference in total kidney volume (cm)
(9% confidence interval)
Age (years) -0.01 (-0.07, 0.06)
Height (cm) 0.07 (0.02, 0.11)
Pre-pregnancy weight (kg) 0.03 (0.01, 0.05)
Pre-pregnancy BMI (kg/m2) 0.04 (-0.03, 0.11)
Weight gain during pregnancy (kg) 0.05 (-0.04, 0.13)
Systolic blood pressure in late pregnancy (mmHg) -0.01 (-0.03, 0.02)
Diastolic blood pressure in late pregnancy (mmHg) -0.01 (-0.04, 0.02)
Hypertension (yes vs. no) -0.03 (-1.28, 1.33)
Pre-existent or pregnancy induced diabetes (yes vs. no) -0.60 (-3.49, 2.30)
Pre-eclampsia (yes vs. no) 2.14 (-0.25, 4.53)
Smoking during pregnancy (yes vs. no) -0.06 (-0.88, 0.77)
Values are regression coefficients (95% confidence interval) and reflect the difference in kidney volume per unit increase in
maternal characteristics or lifestyle measure.
Models adjusted for fetal abdominal circumference in late pregnancy, gestational age and fetal gender. BMI, body mass index.
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Table 4 presents the associations of fetal growth characteristics and placental resistance indices
in mid-pregnancy with combined kidney volume measured in late pregnancy. In Model A, adjusted
for gestational age and fetal gender only, all fetal growth characteristics were positively associ-
ated with combined kidney volume and umbilical artery PI negatively associated (Model A). After
additional adjustment for the same fetal growth characteristic or blood flow parameter in late
pregnancy, measured at the same time as kidney volume, associations were no longer significant
(Model B). These results suggest that the associations of mid-pregnancy growth characteristics
and placental resistance indices with late pregnancy kidney volume are largely explained by the
same characteristics in late pregnancy.
Table . Associations of fetal growth characteristics and placental resistance indices in
mid-pregnancy with combined fetal kidney volume in late pregnancy
Measurements Difference in combined kidney volume (cm)
in mid-pregnancy (9% confidence interval)
Model A Model B
Growth characteristic
Head circumference (SDS) 0.49 (0.16, 0.82) 0.30 (-0.03, 0.64)
Abdominal circumference (SDS) 0.80 (0.46, 1.14) 0.20 (-0.13, 0.53)
Femur length (SDS) 0.48 (0.14, 0.82) 0.34 (-0.02, 0.69)
Ratio abdominal circumference/
head circumference (SDS) 0.59 (0.18, 1.00) 0.18 (-0.22, 0.58)
Estimated fetal weight (SDS) 0.84 (0.50, 1.19) 0.04 (-0.14, 0.56)
Placental resistance indices
Umbilical artery, pulsatility index (PI) -2.23 (-4.09, -0.37) -1.38 (-3.22, 0.53)
Uterine artery, resistance index (RI) -2.24 (-6.52, 2.03) -1.30 (-5.91, 3.31)
Values are regression coefficients (95% confidence interval) and reflect the difference in kidney volume per unit increase in fetal
growth and placental perfusion blood flow characteristic.
SDS: gestational age-adjusted standard deviation score.
Model A: adjusted for gestational age and fetal gender.
Model B: additionally adjusted for the same parameter and gestational age in late pregnancy.
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Table 5 shows that in late pregnancy, all growth characteristics were positively associated with
combined kidney volume. The largest effects on combined kidney volume were found for esti-
mated fetal weight and abdominal circumference (combined kidney volume increased 1.77 (95%
CI: 1.46, 2.08) cm3 and 1.76 (95% CI: 1.47, 2.05) cm3 for each standard deviation score in-
crease in estimated fetal weight and abdominal circumference, respectively). Placental resistance
indices were inversely associated with combined kidney volume, indicating that signs of increased
placental resistance reduced kidney volume. Signs of fetal redistribution as quantified by the
cerebro-umbilical ratio were associated with reduced kidney volume. No associations were found
for middle cerebral artery PI.
Table . Associations of fetal growth and blood flow characteristics with combined fetal kidney
volume in late pregnancy
Measurements Difference in combined kidney volume (cm)
in late pregnancy (9% confidence interval)
Growth characteristic
Head circumference (SDS) 0.91 (0.57, 1.23)
Abdominal circumference (SDS) 1.76 (1.47, 2.05)
Femur length (SDS) 1.03 (0.71, 1.35)
Ratio head circumference/
abdominal circumference (SDS) 1.71 (1.34, 2.09)
Estimated fetal weight (SDS) 1.77 (1.46, 2.08)
Placental resistance indices
Umbilical artery, pulsatility index (PI) -2.74 (-4.55, -0.92)
Uterine artery, resistance index (RI) -6.40 (-10.4, -2.43)
Redistribution parameters
Middle cerebral artery (PI) 0.46 (-0.41, 1.33)
Cerebro-umbilical (C/U) ratio 0.87 (0.22, 1.51)
Values are regression coefficients (95% confidence interval) and reflect the difference in kidney volume per unit increase in fetal
growth and fetal blood flow characteristic.
SDS, standard deviation score; PI, pulsatility index.
Models adjusted for gestational age and fetal gender. Blood flow parameters additionally adjusted for abdominal circumference.
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Figure 2 shows that in late pregnancy, there is a tendency to larger relative kidney volume in subjects
in the smallest tertile of sds abdominal circumference. This suggests that small for gestational
age fetuses have a larger kidney volume per kg fetal weight. Figure 3 shows that in late pregnancy,
kidney volume is positively associated with amniotic fluid deepest pocket.
Figure 2. The association between fetal abdominal circumference and fetal weight adjusted
combined fetal kidney volume in late pregnancy
SDS, gestational age-adjusted standard deviation score.
P = 0.07 (P-value for trend using linear regression models).
Figure . Relation of fetal kidney volume with amniotic fluid deepest pocket
Model adjusted for gestational age, abdominal circumference and fetal gender.
P <0.05 (P-value for trend using linear regression models).
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Discussion
This population-based prospective cohort study from early fetal life showed that maternal pre-
pregnancy anthropometrics, fetal growth characteristics and indices of placental resistance as
well as fetal blood flow redistribution parameters were associated with kidney volume. Larger
kidneys yielded a deeper amniotic fluid pocket.
The main strength of our study is the prospective design from fetal life with serial growth
measurements within a large population-based cohort. Of all mothers who were approached for
the detailed subgroup, 80% participated in the focus study. Non-participation was mainly due to
lack of time. No differences in offspring birth weight were found between mothers participating
and not participating in the present study. Thus, we do not assume major health related differences
between these groups. To our knowledge, this is the largest population-based cohort in which
kidney size in late pregnancy was established. The population-based setting enabled us to assess
kidney size and volume over the whole range of normal fetal size rather than in fetuses with
growth restriction or other complications only.
Both environmental and genetic factors are important determinants of fetal growth.32-34
We examined the association of maternal characteristics with fetal kidney volume in late pregnancy.
Maternal weight and height were positively associated with kidney volume. This association may
be explained by both environmental (maternal nutritional status) and common genetic factors
that are important in the determination of kidney volume during pregnancy. Maternal smoking,
obesity, blood pressure and diabetes did not considerably influence fetal kidney size in this study.
Even though these factors have a known influence on overall fetal size.32, 33
We found positive associations of fetal growth characteristics in mid-pregnancy with kidney
volume in late pregnancy. But after adjustment for the same growth parameter in late pregnancy
these effects are no longer present, suggesting that the main influence of fetal growth on kidney
volume in late pregnancy exerts after mid-pregnancy.
In late pregnancy, all fetal growth characteristics were positively associated with kidney
volume. Abdominal circumference and the characteristics that included abdominal circumference
were most strongly associated with kidney volume. The positive association for the ratio of ab-
dominal circumference / head circumference suggests that asymmetrical fetal growth restriction
reduced kidney volume more than symmetrical growth restriction although this effect might be
partially explained by abdominal circumference only.
Our results showed the largest effect of fetal growth on kidney volume in late pregnancy,
this is in line with previous studies that found the period of maximum kidney growth to occur between
26-34 weeks of gestation.14 Growth restriction in this period most likely affects kidney size and
volume considerably.
Inadequate placental perfusion leads to an adverse fetal environment by decreased supply
of nutrients and oxygen and is one of the most important causes of fetal growth retardation in
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Western countries.16 Increased placental vascular resistance and signs of blood flow redistribution
with decreased cerebral resistance is known to be associated with reduced fetal growth. In our
study measures of placental vascular resistance were associated with estimated fetal weight
(decrease in estimated fetal weight per unit increase in umbilical artery PI: 151 (95% CI: 90,
212) grams and per unit increase in uterine artery RI: 273 (95% CI: 141, 405) grams). Also,
signs of fetal blood flow redistribution were associated with estimated fetal weight (estimated
fetal weight decrease per unit decrease in middle cerebral artery PI: 16 (95% CI: -5, 57) grams
and per unit decrease in cerebro-umbilical artery ratio: 45 (95% CI: 24, 67) grams). We showed
that in late pregnancy, adverse blood flow resistance patterns of the umbilical and uterine artery
were associated with reduced kidney volume, independent of fetal abdominal circumference at
the time of the kidney measurement. This implies that kidney volume did not solely depend on
abdominal circumference and overall fetal size but to some extend directly on placental vascular
resistance or blood flow redistribution. So signs of increased placental resistance and fetal blood
flow redistribution to protect the developing central nervous system impaired fetal growth and are
sufficiently deleterious to reduce fetal kidney volume as well.
A hypothesis for a decrease in renal size in growth restricted fetuses is alteration in renal
perfusion caused by a preferential blood flow to the brain.35 In our study we did not find any rela-
tion with middle cerebral artery PI and kidney volume. Another parameter is the cerebro-umbilical
ratio, which did show a relation with kidney size. It is not unlikely that redistribution with decrease
in middle cerebral artery PI is a later sign in fetal growth restriction what is not yet eminent in this
population-based study. A direct measure of renal blood flow would be renal artery PI, which we
did not measure. A previous study showed that renal artery blood flow was not altered in growth
restricted fetuses.5 However, abnormal renal artery Doppler flow velocity waveforms were demon-
strated in hypoxic growth restricted fetuses in another study.35 Altered renal artery flow velocity
seems to be a late effect that is not present in growth restricted fetuses that do not yet show
signs of redistribution. We think that the reduced kidney volume in our study is not solely explained
by redistribution because it is already present in smaller fetuses when signs of redistribution are
absent.
This study showed that fetuses in the lowest tertile of gestational age-adjusted abdominal
circumference had a tendency towards larger relative kidney volume, suggesting an organ or kidney
sparing effect in small for gestational age fetuses. Thus, smaller fetal body size is associated with
smaller kidneys, but these kidneys are relatively large for that body size. Previous studies suggested
that the ratio of kidney volume with estimated fetal weight or abdominal circumference is constant
in fetuses with different size and age.15, 29 This inconsistency with our results may be due to
different and smaller study populations. Therefore, further studies are needed focused on the
effects of various fetal growth characteristics on relative kidney volume.
The main component of amniotic fluid is fetal urinary production. In our study the amniotic
fluid deepest pool was decreased in fetuses with smaller kidneys, after adjustment for abdominal
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circumference and gestational age. This indicates that the reduction of amniotic fluid is not solely
attributable to growth restriction but to kidney volume as well. It is possible that the association
we found between kidney volume and amniotic fluid is a reflection of the number of nephrons and
kidney function.
Our study underlines the importance of fetal growth and growth characteristics for deter-
mination of kidney size. Since we know that the number of nephrons is largely determined in
prenatal life, sub-optimal kidney growth and development in fetal life may have life long conse-
quences.10-13
In conclusion, our findings suggest that reduced fetal growth, signs of raised placental
resistance and fetal blood flow redistribution result in a decreased kidney volume in late fetal life.
Further research to disentangle the causal mechanisms underlying the demonstrated associa-
tions is needed. Impaired fetal development results in smaller kidneys and may result in
increased risk of hypertension and renal disease in later life. Follow-up studies in our children are
currently performed to examine whether and to what extend changes in fetal kidney size persist
during childhood and whether they are related to renal function and blood pressure development
in postnatal life.
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Abstract
Background: An adverse fetal environment may lead to smaller kidneys, which predispose the in-
dividual to subsequent development of kidney disease and hypertension in adult life. We
examined whether smoking during pregnancy, as adverse fetal exposure, directly influences third
trimester fetal kidney development.
Methods: In a prospective cohort study among 1,031 children followed from early fetal life onwards,
we assessed maternal smoking during pregnancy (non-smoking, first trimester only, continued)
using questionnaires. Fetal kidney characteristics and amniotic fluid deepest pocket, as measure
of fetal urine production, were measured by ultrasound at 30 weeks of gestation. Analyses were
adjusted for various potential confounders.
Results: Of all mothers, 9.4% smoked in first trimester only, and 15.9% continued smoking during
pregnancy. Compared to non-smoking, first trimester only smoking was not associated with any
fetal kidney characteristic. We observed a curved-shaped association between the number of
cigarettes smoked during pregnancy with fetal kidney size. Smoking less than 5 cigarettes per
day was associated with larger combined kidney volume (difference 2.04 cm3 (95% confidence
interval: 0.73, 3.36)), while smoking more than 10 cigarettes per day was associated with smaller
combined kidney volume (difference -1.99 cm3 (95% confidence interval: -3.86, -0.11)). We did
not find any associations of maternal smoking and amniotic fluid deepest pocket.
Conclusions: This study showed for the first time that smoking during pregnancy affects kidney
development in fetal life with a curved shaped relationship. Further studies are needed to assess
the underlying mechanisms and whether these developmental adaptations have postnatal
consequences for kidney function and blood pressure.
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Introduction
The developmental plasticity hypothesis suggests that various adverse intrauterine exposures
lead to persistent fetal developmental adaptations. These adaptations may be beneficial on short
term but may have adverse consequences in postnatal life.1 Also, they may lead to smaller kidneys
with a reduced number of nephrons, which in turn leads to hyperfiltration and results in glomerular
sclerosis.2-4 These adaptations may predispose the individual to kidney damage and subsequent
development of higher blood pressure, impaired kidney function and end stage kidney disease in
adulthood. This hypothesis is supported by many studies showing associations of low birth weight
with cardiovascular disease and end stage kidney disease.5-7 Thus far, the specific adverse exposures
and mechanisms underlying these associations are not known.
Maternal smoking is the most important modifiable adverse fetal exposure in Western
countries and leads to a decrease of 150 to 200 grams in offspring birth weight.8 Maternal
smoking during pregnancy may also have both direct and indirect adverse effects on fetal kidney
development. Low birth weight, of which maternal smoking is an important determinant, is
associated with impaired kidney growth, raised blood pressure, and impaired kidney function.7, 9-14
Several studies suggested that maternal smoking during pregnancy is also associated with higher
blood pressure in the offspring, independent of birth weight.15,16 This association might be explained
by an adverse kidney development with a smaller nephron number.17, 18
For the present study, we hypothesized that maternal smoking during pregnancy, as
specific adverse fetal exposure, affects fetal kidney size. We evaluated in a population-based
prospective cohort study among 1,031 mothers and children followed from early fetal life onwards,
the associations of maternal smoking during pregnancy, both first trimester only and continued
smoking, with third trimester fetal kidney characteristics and amniotic fluid deepest pocket as
measure of urine production.
Methods
Design
This study was embedded in the Generation R Study, a population-based prospective cohort study
from fetal life until young adulthood in Rotterdam, The Netherlands.19, 20 Assessments during
pregnancy included physical and fetal ultrasound examinations, biological samples and ques-
tionnaires, and were performed in each trimester of pregnancy to collect information about fetal
growth and its main determinants. Additional, more detailed assessments were conducted in a
subgroup of Dutch children and their parents. Of all approached women, 80% were enrolled in this
subgroup in the third trimester of pregnancy (gestational age of 30 weeks). For the present study,
kidney biometrics were assessed in third trimester of pregnancy. Written informed consent was
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obtained from all participants. The Medical Ethics Committee of the Erasmus Medical Center
Rotterdam has approved the study.
Population for analysis
In total, 1,232 women were enrolled in the subgroup study. The present analysis was restricted
to singleton live births (n = 1,215). Twin pregnancies (n = 15) and pregnancies leading to perinatal
death (n = 2) were excluded from the analysis. No renal or uterovesical anomalies other than mild
pyelectasis over 10 mm (n = 3) were present in our study. Information about smoking during preg-
nancy was not available in 110 subjects. In the remaining 1,105 mothers, kidney characteristics
could not completely be measured in 74 subjects due to fetal position or maternal adiposity,
leading to a total of 1,031 subjects available for the present analyses. Since two subjects did
not report the number of cigarettes smoked, analyses focused on the numbers of cigarettes
smoked were based on a total of 1,029 subjects.
Maternal smoking during pregnancy
Information about active smoking was obtained by postal questionnaires in the first, second and
third trimester of pregnancy. Response rates for these questionnaires were 90%, 93% and 92%,
respectively. Active maternal smoking at enrolment was assessed in the first questionnaire by
asking whether mother smoked in pregnancy (no, first trimester only, continued). In the second
and third-trimester questionnaires, mothers were asked whether they smoked in the past 2 months
(no, yes), respectively. Among the smoking mothers, the number of cigarettes was classified into
previously used categories: non-smoking; less than five cigarettes per day; five to nine cigarettes
per day; and ten or more cigarettes per day. To examine the dose-response relationship of maternal
smoking during pregnancy more extensively we also used the following categories: non-smoking,
less than one cigarette per day, one to two cigarettes per day, three to four cigarettes per day, five
to nine cigarettes per day; and ten or more cigarettes per day.
Third trimester fetal ultrasound measurements
Fetal biometry
All ultrasound exams were performed using an ATL-Philips Model HDI 5000 (Seattle, WA, USA)
equipped with a 5.0 MHz, high frequency curved array transducer. Ultrasound examinations were
carried out in a dedicated and well-equipped research center in third trimester of pregnancy. Fetal
biometrics including head circumference (HC), abdominal circumference (AC), and femur length
(FL) were measured using standardized ultrasound procedures. Estimated fetal weight (EFW)
was calculated using the formula:
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EFW (grams) = 10 ** (1.326 – 0.00326 * AC * FL + 0.0107 * HC + 0.0438 * AC + 0.158 * FL).
Gestational age-adjusted SD scores were constructed for these fetal growth characteristics.
Kidney measurements
Left and right kidney biometrics were assessed. In a sagittal plane, the maximum longitudinal
kidney length was measured placing the callipers on the outer edges of the caudal and cranial
side. Antero-posterior and transverse kidney diameter were measured perpendicular to each other,
outer tot outer, in an axial plane. The cross-sectional area in which the kidney appeared sym-
metrically round at its maximum width was used. The images were sufficiently magnified to ensure
optimal measurements.21 Kidney volume was calculated using the approximation of an ellipsoid:
volume (cm3) = 0.523 * length (cm) * width (cm) * depth (cm). Left and right kidney volume were
added for the combined kidney volume (cm3).
Amniotic fluid
Amniotic fluid was assessed using single deepest pocket measurements, the preferable indication
about the quantity of amniotic fluid in clinical practice.22
Intra- and inter-observer reproducibility
Two well-trained, experienced sonographers performed all measurements. Quality checks were
frequently carried out and feedback was provided to minimize interoperator differences. The inter-
class correlation coefficients were higher than 0.98 and the corresponding coefficient of
variations lower than 6%. Bland and Altman plots to test agreement of measurements, demon-
strated 95% limits of agreement in proportions to be within 10% difference from the mean of the
measurements, indicating good reproducibility.
Covariates
Exact gestational age was established using fetal biometry measured in first trimester of preg-
nancy.23 Estimated fetal weight was calculated from fetal biometry measured in third trimester
ultrasound. Maternal height was measured at first visit. Information on maternal pre-pregnancy
weight, educational level and alcohol use during pregnancy was assessed using self reported
questionnaires. Date of birth, birth weight and sex were obtained from midwife and hospital reg-
istries.
Statistical analysis
Differences in maternal and fetal characteristics between the categories non-smoking, first
trimester only and continued smokers were assessed using t-tests and nonparametric tests for
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independent samples. Associations of maternal smoking, both first trimester only and continued
smoking, with fetal kidney structures and combined kidney volume were assessed using multiple
linear regression models. The models were adjusted for estimated fetal weight in third trimester
of pregnancy (30 weeks), gestational age at visit, fetal sex, alcohol use during pregnancy, maternal
educational level, maternal height and maternal weight before pregnancy. Subsequently, using
similar models we examined the associations of the number of cigarettes smoked with fetal kidney
characteristics and combined kidney volume. Tests for trends were performed using multiple
linear and non-linear multiple regression analyses. All measures of association are presented with
their 95% confidence intervals (95% CI). All statistical analyses were performed using the Statis-
tical Package for the Social Sciences version 15.0 for Windows (SPSS Inc, Chicago, IL, USA).
Results
Subject characteristics are presented in Table 1. The percentage of boys was 52.2%. The over-
all median maternal age was 31.8 years (95% range: 21.7 - 38.9). The median gestational age
for the third trimester visit was 30.2 weeks (95% range: 28.5 - 32.5). The study group comprised
30 children who were born with a small size for gestational age (birth weight less than -2 SDS
for gestational age), 36 children with a birth weight less than 2,500 grams and 41 children who
were born preterm. Table 2 shows all fetal kidney characteristics and amniotic fluid deepest
pocket measured in third trimester of pregnancy.
Table . Subject characteristics (n = 1,031)
Non-smoking First trimester only Continued
(n = 769) (n = 98) (n = 164)
Maternal characteristics
Age (years) 31.9 (23.2-39.0) 31.3 (20.4-38.8) 31.4 (19.3-41.2)*
Height (cm) 171.3 (6.3) 170.6 (6.8) 169.7 (6.2)†
Pre pregnancy weight (kg) 69.3 (12.7) 66.4 (10.4)† 67.8 (13.3)
Parity ≥1 (%) 39.2 27.8 44.5
Highest educational level
>secondary school (%) 68.8 58.8† 36.2†
Alcohol use during pregnancy (%) 52.3 55.1 51.9
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Table . continued
Non-smoking First trimester only Continued
(n = 769) (n = 98) (n = 164)
Third trimester pregnancy
characteristics
Gestational age (weeks) 30.4 (28.5-32.6) 30.2 (28.4-32.2) 30.2 (28.3-32.0)
Estimated fetal weight (grams) 1639 (265) 1634 (272) 1564 (272)†
Birth characteristics
Gender (% boys) 52.1 43.3 57.9
Gestational age (weeks) 40.3 (36.0-42.4) 40.1 (33.2-42.3) 40.1 (34.8-42.4)
Gestational age <37 weeks (%) 3.6 5.2 4.9
Birth weight (grams) 3561 (524) 3542 (611) 3355 (556)†
Birth weight <2,500 grams (%) 2.8 4.2 6.1*
Small for gestational age (%) 2.3 2.1 6.7
Values are means (standard deviation) or medians (95% range) for continuous variables and percentages for categorical variables.
Small for gestational age was defined as children with birth weight below –2 standard deviation for gestational age. Differences
in maternal and fetal characteristics (compared with the non-smoking category) were compared using ANOVA for continuous variables
and Χ2 tests for categorical variables. *p-value <0.05, †p-value <0.01
Table 2. Third trimester fetal kidney characteristics and amniotic fluid deepest pocket (n=1,031)
Mean SD 9% range
Left kidney structures
Length (mm) 39.0 3.77 32.0-47.0
Width (mm) 21.4 2.67 16.9-26.9
Depth (mm) 22.4 2.73 17.1-28.8
Volume (cm3) 9.9 2.81 5.4-16.0
Right kidney structures
Length (mm) 39.0 3.72 32.0-46.0
Width (mm) 22.2 2.81 17.0-28.0
Depth (mm) 23.1 2.89 18.0-29.0
Volume (cm3) 10.7 3.11 5.8-17.6
Combined kidney volume (cm) 20.6 5.58 11.5-33.5
Amniotic fluid deepest pocket (cm)
(n = 1,009) 5.94 1.28 3.7-8.7
SD, standard deviation
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Table 3 gives the associations of maternal smoking with third trimester fetal kidney characteristics and
combined kidney volume. Compared to non-smoking, no associations of smoking, either first
trimester only or continued during pregnancy, with fetal kidney characteristics were observed. However,
we observed an association between the number of cigarettes smoked with fetal kidney characteristics
in third trimester of pregnancy (Table 4). Smoking less than five cigarettes per day was positively
associated with most kidney structures and was associated with larger combined kidney volume (dif-
ference 2.04 cm3 (95% CI: 0.73, 3.36)) whereas smoking ten or more cigarettes per day showed
tendencies towards smaller fetal kidney characteristics and a smaller combined kidney volume (dif-
ference -1.99 cm3 (95% CI: -3.86, -0.11)). Figure 1 shows the associations of number of cigarettes
smoked with fetal combined kidney volume using a more extensive classification of the number of
cigarettes smoked per day. We found a curved shaped dose-response relationship of the number of
cigarettes smoked and combined kidney volume (p-value for trend = 0.001). Smoking less than five
cigarettes leads to a larger combined kidney volume, whereas smoking more cigarettes leads to
smaller kidneys.
Table . Maternal smoking during pregnancy and third trimester fetal kidney structures (n = 1,031)
Left kidney structures Right kidney structures
Smoking during
pregnancy Length (mm) Width (mm) Depth (mm) Volume (cm) Length (mm) Width (mm) Depth (mm) Volume (cm)
Non-smoking Reference Reference Reference Reference Reference Reference Reference Reference
(n = 769)
First-trimester 0.41 0.00 0.34 0.28 0.02 0.09 -0.04 -0.03
only (n = 98) (-0.36, 1.18) (-0.56, 0.56) (-0.22, 0.87) (-0.27, 0.82) (-0.75, 0.79) (-0.49, 0.68) (-0.63, 0.55) (-0.64, 0.59)
Continued 0.22 0.31 0.15 0.30 0.20 0.04 0.02 0.12
(n = 164) (-0.42, 0.85) (-0.15, 0.77) (-0.30, 0.61) (-0.15, 0.75) (-0.44, 0.83) (-0.44, 0.53) (-0.47, 0.52) (-0.39, 0.63)
Ptrend 0.454 0.674 0.421 0.662 0.904 0.765 0.903 0.875
Values are regression coefficients (95% CI) and reflect the difference in kidney size for different categories of maternal smoking during
pregnancy. Regression analysis was adjusted for estimated fetal weight, fetal sex, maternal height, weight before pregnancy, alcohol
use during pregnancy and educational level and gestational age.
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Table . Number of cigarettes smoked and fetal kidney structures in third trimester of pregnancy
(n = 1,029)
Left kidney structures Right kidney structures Combined
Number of
cigarettes
smoked Length (mm) Width (mm) Depth (mm) Volume (cm) Length (mm) Width (mm) Depth (mm) Volume (cm) Volume (cm)
Non-smoking Reference Reference Reference Reference Reference Reference Reference Reference Reference
(n = 769)
<5/day 1.09 1.14 0.80 1.20 0.78 0.51 0.74 0.84 2.04
(n = 76) (0.14, 2.03)* (0.45, 1.84)† (0.12, 1.48)* (0.53, 1.86)† (-0.16, 1.72) (-0.21, 1.23) (0.03, 1.46)* (0.09, 1.60)* (0.73, 3.36)†
5-10/day -0.33 -0.28 -0.21 -0.30 -0.63 -0.42 -0.25 -0.49 -0.78
(n = 55) (-1.43, 0.76) (-1.08, 0.52) (-0.99, 0.58) (-1.07, 0.47) (-1.72, 0.46) (-1.25, 0.42) (-1.09, 0.58) (-1.36, 0.39) (-2.31, 0.74)
≥10/day -0.92 -0.60 -0.74 -0.80 -0.60 -0.75 -1.53 -1.18 -1.97
(n = 32) (-2.26, 0.43) (-1.59, 0.39) (-1.70, 0.23) (-1.75, 0.15) (-1.94, 0.74) (-1.73, 0.28) (-2.56, -0.51)† (-2.26, 0.11)* (-3.86, -0.11)*
Ptrend 0.018 0.004 0.04 0.001 0.19 0.06 0.001 0.005 0.001
Values are regression coefficients (95% CI) and reflect the difference in kidney size for different numbers of cigarettes smoked during pregnancy.
Regression analysis was adjusted for estimated fetal weight, fetal sex, maternal height, weight before pregnancy, alcohol use during pregnancy
and educational level and gestational age. *p-value <0.05, †p-value <0.01
Figure . Maternal smoking and combined kidney volumes in third trimester of pregnancy

M
at
er
na
ls
m
ok
in
g
du
rin
g
pr
eg
na
nc
y
an
d
fe
ta
lk
id
ne
y
si
ze
-6
-4
-2
0
2
4
6
8
<1 1-2 3-4 5-9 >10
Number of cigarettes smoked per day
Ptrend = 0.001
D
iff
er
en
ce
in
co
m
bi
ne
d
ki
dn
ey
vo
lu
m
e
(c
m
3
)
The associations between maternal smoking during pregnancy and amnion fluid deepest pocket
are presented in Table 5. We found no associations between the number of cigarettes smoked
and deepest pocket of amniotic fluid.
Table . Number of cigarettes smoked and amniotic fluid deepest pocket in third trimester of
pregnancy (n = 1,009)
Number of cigarettes smoked Amniotic fluid deepest pocket (cm)
Non-smoking Reference
(n = 753)
<5/day -0.01 (-0.35, 0.32)
(n = 76)
5-10/day -0.09 (-0.48, 0.31)
(n = 54)
≥10/day -0.12 (-0.60, 0.36)
(n = 32)
Ptrend 0.53
Values are regression coefficients (95% CI) and reflect the difference in amniotic fluid deepest pocket for different categories of
smoking during pregnancy and different number of cigarettes smoked continuously during pregnancy. Regression analysis was
adjusted for estimated fetal weight, fetal sex, maternal height, weight before pregnancy, alcohol use during pregnancy and edu-
cational level and gestational age.
Discussion
This population-based prospective cohort study from early fetal life onwards showed for the first
time that smoking during pregnancy affects fetal kidney size. The size and direction of this effect
depend on the number of cigarettes smoked. Smoking less than five cigarettes per day was as-
sociated with larger combined kidney volume, whereas smoking larger numbers of cigarettes was
associated with smaller kidney volume. First trimester only smoking was not associated with
third trimester fetal kidney size. We found no associations between maternal smoking and amniotic
fluid deepest pocket.
The main strength of our study is the prospective design from early fetal life and the size
of the population-based cohort. Our analyses were based on 1,031 complete fetal kidney ultra-
sounds. To our knowledge, this study group is the largest population-based cohort in which these
associations have been studied. The size of the cohort enabled us to assess the associations
between the number of cigarettes smoked during pregnancy and kidney size. The ultrasound
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measurements were carried out by two sonographers with good reproducibility. Fetal kidney
characteristics could be measured completely in 93% of all subjects participating in the third
trimester assessments. The effect estimates would be biased if the associations of maternal
smoking during pregnancy and fetal kidney size differed between those included and not included
in the present analyses. This seems unlikely. A limitation might be that the present study was per-
formed in a healthy population-based cohort. The absolute numbers of subjects with low birth
weight and preterm birth were small. Therefore, generalizability of our results to preterm or low
birth weight children is limited.
The associations of low birth weight with hypertension and impaired renal function and end
stage renal disease in adulthood are well established.5, 9, 14, 24-27 Smaller kidneys with a reduced
number of nephrons in low birth weight children might lead to hyperfiltration resulting in glomerular
sclerosis.2-4, 28, 29 This may predispose the individual to renal damage and development of higher
blood pressure, impaired kidney function and end stage kidney disease in adulthood. This hy-
pothesis is supported by animal studies, which have shown that various adverse intrauterine
environmental exposures, such as low protein intake, relative vitamin A deficiency, decreased
placenta perfusion, and administration of steroids, lead to fetal growth retardation and smaller
kidney size with a lower nephron number.30-33 Post mortem studies in humans showed that a
lower nephron number is associated with both low birth weight and hypertension.28, 29, 34-38 Since
nephron number varies between 250,000 and 2,000,000 per kidney and nephron development
ceases after birth17,35,38, these findings suggest that early kidney development may be an underling
mechanism for the associations between adverse fetal exposures and hypertension in later life.
Recently demonstrated associations between maternal smoking during pregnancy with
high blood pressure in the offspring suggest that fetal exposure to smoking has permanent renal
and cardiovascular consequences.39, 40 We showed an association between continued smoking
during pregnancy and third trimester kidney size. The effect of continued smoking during preg-
nancy was dependent on the number of cigarettes smoked. Severe smoking (more than ten
cigarettes per day) was associated with smaller kidney size. In addition, moderate smoking (less
than five cigarettes per day) was associated with larger kidney size. These associations were in-
dependent of estimated fetal weight. Our results suggest a differential effect of maternal smoking
during pregnancy, depending on the specific period and number of cigarettes smoked. Smaller
kidneys may predispose an individual to subsequent development of kidney disease and hyper-
tension in adult life. However, it remains unclear whether larger kidneys in third trimester of
pregnancy would be harmful or beneficial in later life.
One other study among 34 subjects showed that maternal smoking during pregnancy
leads to a different fetal kidney growth pattern compared to non-smoked exposed subjects. This
study suggested that reduction in kidney growth is present in third trimester of pregnancy, re-
sulting in relatively thinner kidneys.41 This is in line with our finding that smoking more than 10
cigarettes in third trimester negatively affects fetal kidney size, whereas first trimester only smoking
is not associated with altered kidney size. No differential effects were presented in this study on
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the number of cigarettes smoked in third trimester. In rats, it was shown that prenatal nicotine
exposure leads to smaller kidneys only in genetically susceptible rats, indicating a gene-environment
interaction.42 This animal study also showed that the effect of intrauterine exposure to nicotine
on offspring kidney size is stronger in hypertensive mothers. They have significantly reduced kidney
weight and higher blood pressure compared to offspring of normotensive mothers.42 To our
knowledge, no other studies examined the associations between maternal smoking during preg-
nancy and kidney size in a large cohort.
The mechanisms underlying the associations between smoking during pregnancy and
fetal kidney size are not known. The larger kidneys among subjects exposed to less than five
cigarettes per day could be explained by vasodilatory effects of nicotine on renal vasculature.
Animal studies showed vasodilatory effects of nicotine in pre-constricted kidney vasculature. 43, 44
However, differential effects on vascular structures are reported.45-48 It has also been suggested
that nicotine has both vasodilatatory and vasoconstrictive effects, depending on the dose.47 This
could partly explain our findings of smaller kidney size when smoking more than five cigarettes.
Further studies are needed to elucidate the vasoactive mechanisms and effect of nicotine in dif-
ferent tissues and at different doses.
The main component of amniotic fluid is fetal urinary production. In our study, maternal
smoking during pregnancy was not associated with amniotic fluid deepest pocket. We have shown
before that kidney size in third trimester of pregnancy is associated with amniotic fluid deepest
pocket.49 The absence of associations between maternal smoking and amniotic fluid deepest
pocket could indicate that the adaptations causing differences in kidney size does not alter fetal
urine production, as reflected in the amniotic fluid production. Whether the changes in kidney
size in response to maternal smoking also alter kidney function remains unclear.
In conclusion, we found that maternal smoking during pregnancy is associated with an
altered kidney size in late pregnancy. The direction and size of the effect depends on the number
of cigarettes smoked. Further studies are needed to identify the underlying mechanisms and to
assess whether these changes in fetal kidney are related to renal function and blood pressure
development in later life.
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Abstract
Background: An adverse fetal environment may lead to smaller kidneys and subsequently renal
disease and hypertension in adulthood. The aims of this study were to examine whether kidney
size tracks from fetal life to childhood and to examine whether maternal and fetal characteristics
are associated with kidney size at the age of 2 years.
Methods: This study was embedded in a population-based prospective cohort study from fetal life
onwards. Maternal characteristics, age, height and pre-pregnancy weight were measured in early
pregnancy. Fetal growth, head circumference, abdominal circumference, femur length and esti-
mated fetal weight, and placental characteristics were assessed in second and third trimester.
Kidney size, defined as length, width, depth and volume, was measured in third trimester of preg-
nancy and at the postnatal ages of 6 and 24 months. Analyses were based on 683 children.
Results: Children tended to remain in the lowest and highest quartiles of kidney volume from
third trimester to the age of 2 years (OR 2.05 (95% CI: 1.38, 3.06) and 3.29 (95% CI: 2.22, 4.87)).
Maternal height and pre-pregnancy weight were positively associated with kidney volume at the age
of 2 years. Third trimester fetal head circumference, abdominal circumference and estimated
weight and postnatal length were positively associated with kidney volume at the age of 2 years.
Preferential fetal blood flow to the brain was associated with smaller kidneys.
Conclusions: Small kidney size in fetal life tends to persist in early childhood. Maternal anthro-
pometrics and fetal biometrics and blood flow patterns are associated with kidney size in
childhood. Follow-up studies are needed to examine whether these variations in kidney size are
related to renal function and blood pressure in later life.
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Introduction
Low birth weight is associated with hypertension and cardiovascular mortality in adult life.1, 2 It
has also been demonstrated that low birth weight is related to kidney diseases in childhood and
adulthood.3-8 The underlying mechanisms for these associations are unknown. It has been hy-
pothesized that low birth weight infants have smaller kidneys with a reduced number of nephrons,
which leads to compensatory higher glomerular pressure, progressive glomerular sclerosis and
subsequently predispose the individual to impaired kidney function and hypertension.9
This hypothesis is supported by several studies. Nephrogenesis continues until 36 weeks
of gestation and the induction of nephron number ceases thereafter.10, 11 Animal studies have
shown that low protein intake, relative vitamin A deficiency, reduced placenta perfusion or ad-
ministration of steroids in late pregnancy lead to fetal growth restriction and a permanent nephron
deficit.12-15 Human studies demonstrated that low birth weight infants have lower kidney weight
with a reduced number of nephrons.16-18 It was also demonstrated that hypertensive subjects
have lower nephron numbers.19 The best surrogate measure for assessing nephron number in epi-
demiological studies appears to be kidney weight or size measured by ultrasound.11 We have
previously demonstrated in a population-based prospective cohort study from early fetal life onwards,
that maternal anthropometrics, fetal abdominal circumference, fetal blood flow redistribution,
and raised placental resistance are associated with third trimester fetal kidney volume.20
In this prospective cohort study, we examined whether kidney volume tracks from fetal life
to the age of 2 years. We also studied whether maternal characteristics, as a measure of fetal
nutrition, and fetal growth and blood flow characteristics measured in second and third trimester
of pregnancy are associated with kidney size at the age of 2 years.
Methods
Design
This study was embedded in the Generation R Study, a population-based, prospective cohort
study from fetal life until young adulthood in Rotterdam, the Netherlands.21, 22 Assessments in
pregnancy included physical examinations, fetal ultrasounds, biological samples and question-
naires and were planned three times in pregnancy to collect information about fetal growth and
its main determinants. More detailed assessments of fetal and postnatal growth and development
are conducted in a subgroup, the Focus cohort.21, 22 In this subgroup, postnatal renal ultrasounds
were performed in infants at the ages of 6 months and 2 years. The study has been approved by the
Medical Ethics Committee of the Erasmus MC, Rotterdam. Written informed consent was obtained
from all participants. All analyses, including the current study, in the Generation R Study are per-
formed and reported according to the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) recommendations.23
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Population for analysis
In total, 1,232 women were enrolled in the Focus cohort. The present analysis was limited to
singleton live births (n = 1,215). Twin pregnancies (n = 15) and pregnancies leading to perinatal
death (n = 2) were excluded from the analysis. Of these singleton live births, 70% (n = 856) par-
ticipated in the postnatal assessments at the age of 2 years. Kidney ultrasounds were
successfully performed in 80% (n = 683) of these infants. Infants who had a postnatal renal ultra-
sound at the age of 2 years did not differ from the postnatal non-responders in fetal
characteristics (difference in birth weight 18 grams (95% CI: -48, 83)). No renal or ureterovesical
anomalies other than mild pyelectasis over 10 mm (n = 3) were present in our study population.
Missing values were mainly due to crying behavior or unavailability of equipment or radiographer.
Maternal characteristics
Maternal weight (kg) and height (cm) were measured light clothed in early pregnancy (gestational
age <18 weeks), second trimester (gestational age 18-25 weeks) and third trimester (gestational
age ≥25 weeks). We used maternal weight and height at intake in the analyses for the present
study. Maternal weight gain during pregnancy was defined as the difference in pre-pregnancy and
in third trimester weight.
Ultrasound measurements
Fetal growth characteristics
Fetal ultrasound examinations were carried out during visits to the research centers. The median
(95% range) gestational age for these visits was 12.6 (9.6 – 16.9) weeks, 20.4 (18.6 - 22.5)
weeks and 30.2 (28.5 – 32.5) weeks, respectively. The latter two visits were considered as second
and third trimester measurements. These fetal ultrasounds were used for both establishing gesta-
tional age and assessing fetal growth characteristics.24 Fetal growth measurements used for the
present study included head circumference (HC), abdominal circumference (AC) and femur length
(FL) in second and third trimester measured to the nearest millimeter using standardized ultra-
sound procedures.25-27 Estimated fetal weight was calculated using the formula by Hadlock using
head circumference, abdominal circumference and femur length: EFW (grams) = 10**(1.326 –
0.00326*AC*FL + 0.0107*HC + 0.0438*AC + 0.158*FL).28 Growth measures in early preg-
nancy were not included since these fetal ultrasound examinations were primarily performed to
establish gestational age. Gestational age-adjusted standard deviation scores were constructed
for these fetal growth measurements.
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Placental and fetal blood flow profiles
Placental resistance as a proxy of placental function was assessed using recorded flow velocity
waveforms from the umbilical and uterine arteries, in mid and late pregnancy. Raised umbilical
artery pulsatility index (PI) and uterine artery resistance index (RI) indicate increased placental
resistance.29 The redistribution of blood flow in favor of the fetal brain was quantified by the middle
cerebral artery PI and the cerebro RI / umbilical RI ratio, in late pregnancy. A reduction in middle
cerebral artery PI and a decreasing cerebro-umbilical ratio are valid indicators of ‘brain sparing
effect’ due to fetal redistribution.30, 31
Kidney size
The left and right kidney were measured in third trimester of pregnancy. In a sagittal plane, the
maximum longitudinal kidney length was measured placing the calipers on the outer edges of the
caudal and cranial side. Antero-posterior and transverse kidney diameter were measured per-
pendicular to each other, outer to outer, in an axial plane.32 Postnatally, two-dimensional
ultrasounds of the kidneys were performed on Kretz Voluson 530D equipment in children at the
ages of 6 months and 2 years. The examination was carried out in a quiet room with the child
quietly awake in a supine position. This position was standardised to prevent differences according
to position.32, 33 One radiographer performed the vast majority (86%) of these measurements.
Two other radiographers performed the measurements in the remaining children. The kidney was
identified in the sagittal plane along its longitudinal axis. Measures of maximal bipolar kidney
length, width and depth were obtained from both the left and right kidney. Kidney width and depth
were measured at the level of the kidney hilum.32, 34 Mean length, width and depth were calculated
as the average of three measurements and used for data analysis. Prenatal and postnatal kidney
volume were both calculated in cubic centimeters using the equation of an ellipsoid: volume (cm3)
= 0.523 * mean length (cm) * mean width (cm) * mean depth (cm).33, 34 Left and right kidney
volume were summed to establish combined kidney volume (cm3).35
For the ultrasound measurements the intra class correlation coefficient (ICC) was higher
than 0.98 and the corresponding coefficient of variation (CV) lower than 6%. Bland and Altman
plots to test agreement of measurements for fetal ultrasound, demonstrated 95% limits of agree-
ment in proportions to be within 10% difference from the mean of measurements, indicating good
reproducibility.36
Covariates
All anthropometrics in the infants were measured without clothes at the same visits as the kidney
ultrasounds at the ages of 6 and 24 months. Weight was measured to the nearest gram using
electronic scales. Length was measured in supine position to the nearest millimeter using a
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neonatometer. Date of birth, birth weight and gender were obtained from midwife and hospital
registries.
Statistical analysis
Differences in maternal and fetal characteristics between boys and girls were assessed by t-tests
and non-parametric tests for independent samples. We created scatterplots to assess the cor-
relations of weight and height with combined kidney volume at each age. The associations
between third trimester combined kidney volume and combined kidney volume at the ages of 6
months and 2 years were first assessed using scatterplots and Pearson correlation coefficients.
Additionally, third trimester combined kidney volume as well as combined kidney volume at 6
months and 2 years was categorized in quartiles to assess whether children tend to remain in
the same quartile from fetal to postnatal life. For these analyses, odds ratios were calculated.
Subsequently, the associations of maternal characteristics and fetal growth and blood
flow characteristics (standard deviation scores of head circumference, abdominal circumference
and femur length in mid- and late pregnancy, umbilical artery pulsatility index, uterine artery re-
sistance index, middle cerebral artery pulsatility index and the cerebral/umbilical ratio) with
combined kidney size were assessed using multiple linear regression models. We examined the
associations of fetal growth and blood flow characteristics in second and third trimester of preg-
nancy with combined left and right kidney volume at the age of 2 years. Furthermore we analysed
the associations of weight gain until two years of age with combined kidney volume at each visit.
We entered all main determinants seperately into the model. Variables were included in these
models when they changed the effects estimates of interest on combined kidney volume sub-
stantially (>10%), or when they were strongly associated with the outcome of interest in previous
studies. Therefore, all models were adjusted for gender and age at measurement of the kidney
volume (Model A). Subsequently, to take account for current anthropometrics, we adjusted for
current height (Model B). All measures of association are presented with their 95% confidence
intervals (CI).
Results
The percentage of boys was 51% (Table 1). The overall median age of infants at their 6 months
visit was 6.3 months (95% range: 5.4 - 8.1) and at their 2 years visit 25.1 months (95% range:
23.6 - 28.2). We defined small for gestational age as children with birth weight below –2 SD for
gestational age. In total, only 15 children in our study group fullfilled this criterium for small for
gestational age. Furthermore, we reported only 18 children with birth weight <2500 grams and
23 children with gestational age <37 weeks. Table 2 shows that at all ages, kidney length and
volume were larger in boys than in girls.
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Table . Subject characteristics (n = 688)
Boys Girls P-value
(n = 351) (n = 332)
Maternal characteristics
Age (years) 32.3 (22.5-39.7) 32.4 (23.4-39.6) 0.1
Height (cm) 170.7 (6.1) 171.0 (6.7) 0.4
Pre-pregnancy weight (kg) 67.8 (12.5) 70.1 (12.6) 0.01
Pre-pregnancy BMI (kg/m2) 23.2 (4.0) 23.9 (4.2) 0.01
Weight gain until third trimester of pregnancy (kg) 7.9 (3.6) 7.8 (3.8) 0.6
Second trimester fetal characteristics
Gestational age (weeks) 20.5 (18.6-22.8) 20.5 (18.7-22.8) 0.02
Head circumference (cm) 18.0 (1.3) 17.6 (1.2) <0.001
Abdominal circumference (cm) 15.7 (1.4) 15.6 (1.3) 0.02
Femur length (cm) 3.3 (0.3) 3.3 (0.3) 0.6
Estimated fetal weight (grams) 375 (85) 364 (75) 0.09
Umbilical artery, pulsatility index (PI) 1.18 (0.19) 1.20 (0.17) 0.07
Uterine artery, resistance index (RI) 0.54 (0.09) 0.54 (0.09) 0.5
Third trimester fetal characteristics
Gestational age (weeks) 30.4 (28.7-32.8) 30.3 (28.2-32.5) 0.05
Head circumference (cm) 28.8 (1.2) 28.3 (1.1) <0.001
Abdominal circumference (cm) 26.7 (1.7) 26.5 (1.6) 0.2
Femur length (cm) 5.7 (0.3) 5.8 (0.3) 0.2
Estimated fetal weight (grams) 1632 (264) 1623 (252) 0.7
Umbilical artery, pulsatility index (PI) 0.96 (0.16) 0.99 (0.18) 0.01
Uterine artery, resistance index (RI) 0.49 (0.08) 0.49 (0.08) 0.9
Middle cerebral artery, pulsatility index (PI) 1.98 (0.33) 1.99 (0.34) 0.6
Cerebral-umbilical (C/U) ratio 2.05 (0.48) 2.08 (0.48) 0.2
Characteristics at birth
Gestational age at birth (weeks) 40.3 (36.2-42.4) 40.3 (36.1-42.4) 0.9
Gestational age <37 weeks (%) 12 (3.4) 11 (3.3) 0.9
Birth weight (grams) 3557 (518) 3488 (506) 0.05
Birth weight <2500 grams (%) 8 (2.3) 10 (3.0) 0.6
Small for gestational age (%) 6 (1.7) 9 (2.7) 0.4
Characteristics at  months
Age at visit (months) 6.3 (5.4-8.0) 6.3 (5.4-8.2) 0.7
Weight at visit (grams) 8173 (837) 7640 (807) <0.001
Length at visit (cm) 69.4 (2.4) 67.9 (2.4) <0.001
Characteristics at 2 months
Age at visit (months) 25.1 (23.6-28.0) 25.2 (23.4-28.3) 0.3
Weight at visit (grams) 12,890 (1,395) 12,429 (1,343) <0.001
Length at visit (cm) 89.6 (3.2) 88.4 (3.3) <0.001
Values are means (standard deviation) or medians (95% range).
Differences between boys and girls were compared using independent sample t-tests.
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Table 2. Kidney structures (n = 688)
Boys Girls P-value
(n = 351) (n = 332)
Third trimester
Left kidney
Length (mm) 39.5 (31.1-47.0) 38.5 (32.9-45.2) <0.001
Width (mm) 22.6 (17.4-29.0) 22.0 (17.0-28.0) <0.001
Depth (mm) 21.6 (17.0-28.0) 21.1 (16.0-26.0) 0.04
Volume (cm3) 10.3 (5.4-17.0) 9.5 (5.3-14.8) <0.001
Right kidney
Length (mm) 39.6 (31.8-46.7) 38.7 (32.9-49.3) <0.001
Width (mm) 23.1 (17.6-29.7) 22.9 (17.8-29.0) 0.3
Depth (mm) 22.2 (17.0-28.0) 22.0 (17.3-28.8) 0.5
Volume (cm3) 10.9 (5.8-17.9) 10.4 (6.1-16.9) 0.05
Combined kidney volume (cm3) 21.2 (11.5-33.5) 19.9 (11.9-32.2) <0.001
Age  months
Left kidney
Length (mm) 60.0 (49.6-70.7) 58.7 (49.4-68.0) <0.001
Width (mm) 28.1 (22.4-35.7) 27.5 (21.4-35.6) 0.03
Depth (mm) 26.4 (19.5-32.1) 25.5 (20.1-32.1) <0.001
Volume (cm3) 23.6 (14.1-34.4) 21.5 (13.4-31.8) <0.001
Right kidney
Length (mm) 58.9 (49.7-69.1) 57.4 (49.3-68.4) <0.001
Width (mm) 27.9 (22.0-35.2) 27.5 (20.9-36.3) 0.2
Depth (mm) 27.6 (21.2-35.4) 27.0 (20.9-34.1) 0.07
Volume (cm3) 23.7 (15.7-35.2) 22.3 (13.9-34.9) <0.001
Combined kidney volume (cm3) 47.3 (32.8-68.0) 43.8 (29.4-61.8) <0.001
Age 2 months
Left kidney
Length (mm) 66.8 (56.1-80.3) 65.9 (53.8-78.1) 0.04
Width (mm) 30.8 (25.6-37.1) 30.2 (23.7-37.8) 0.6
Depth (mm) 31.0 (25.4-38.9) 30.1 (24.2-38.1) 0.7
Volume (cm3) 33.6 (22.8-51.6) 31.8 (19.5-52.3) <0.001
Right kidney
Length (mm) 65.2 (54.8-76.6) 64.3 (53.2-76.5) 0.06
Width (mm) 30.8 (25.6-38.1) 30.7 (25.5-37.1) 0.01
Depth (mm) 32.0 (25.8-39.4) 31.9 (25.9-39.6) <0.001
Volume (cm3) 33.8 (22.9-53.3) 33.1 (22.1-49.2) 0.2
Combined kidney volume (cm3) 67.4 (48.4-102.2) 64.9 (42.9-97.8) 0.03
Values are means (95% range). Differences between boys and girls were compared using independent sample t-tests.
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We found that children tend to remain in the lowest and highest quartiles of combined kidney vol-
ume from third trimester of pregnancy to the age of 6 months (OR 2.99 (95% CI: 1.96, 4.55) and
2.61 (95% CI: 1.71, 4.00), respectively) and to the age of 2 years (OR 2.05 (95% CI: 1.38, 3.06)
and 3.29 (95% CI: 2.22, 4.87), respectively) (Table 3). In total 212 children were in the lowest two
quartiles in third trimester. Of these 212 children, 135 children (63.4%) stayed within the lowest
two quartiles until the age of two years.
Table . Tracking analysis of combined kidney volume in quartiles from third trimester until
6 and 24 months of age
Combined kidney volume  months quartile
Third trimester
combined kidney
volume quartile  2   Total
 2.99 (1.96, 4.55) 0.96 (0.60, 1.54) 0.58 (0.34, 0.98) 0.26 (0.13, 1.54)
(50) (26) (19) (10) (105)
2 1.33 (0.85, 2.09) 0.98 (0.61, 1.57) 1.29 (0.82, 2.03) 0.60 (0.35, 1.01)
(32) (27) (30) (19) (108)
 0.47 (0.27, 0.82) 1.08 (0.68, 1.71) 0.86 (0.53, 1.38) 1.74 (1.13, 2.70)
(16) (29) (26) (38) (109)
 0.30 (0.16, 0.57) 0.68 (0.41, 1.12) 1.36 (0.87, 2.13) 2.61 (1.71, 4.00)
(11) (23) (32) (46) (112)
Total (109) (105) (107) (113) (434)
Combined kidney volume 2 months quartile
Third trimester
combined kidney
volume quartile  2   Total
 2.05 (1.38, 3.06) 1.07 (0.70, 1.63) 1.05 (0.69, 1.61) 0.36 (0.21, 0.61)
(51) (36) (36) (17) (140)
2 1.31 (0.86, 1.98) 1.20 (0.79, 1.82) 0.76 (0.48, 1.19) 0.69 (0.44, 1.09)
(39) (38) (29) (26) (132)
 0.68 (0.43, 1.07) 0.92 (0.60, 1.43) 1.45 (0.96, 2.18) 1.17 (0.77, 1.78)
(27) (33) (43) (39) (142)
 0.34 (0.19, 0.59) 0.69 (0.44, 1.09) 0.84 (0.54, 1.31) 3.29 (2.22, 4.87)
(15) (29) (29) (63) (136)
Total (132) (136) (137) (145) (550)
Values are unadjusted odds ratios (95% CI) estimated by logistic regression for quartiles of combined kidney volume at the ages
of 6 months and 24 months.
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Table 4 demonstrates that maternal height and pre-pregnancy weight were positively associated
with combined kidney volume (increase in combined kidney volume of 0.35 cm3 (95% CI: 0.18,
0.51) and of 0.14 cm3 (95% CI: 0.06, 0.23) per cm increase in maternal height and kg increase
in pre-pregnancy weight, respectively). Other maternal characteristics were not associated with
combined kidney volume.
Table . Associations of maternal characteristics with combined kidney volume at the age of
24 months
Difference in combined kidney volume (cm3)
at the age of 2 months
(9% confidence interval)
Maternal characteristics
Age (years) 0.09 (-0.19, 0.36)
Height (cm) 0.35 (0.18, 0.51)
Pre-pregnancy weight (kg) 0.14 (0.06, 0.23)
Pre-pregnancy BMI (kg/m2) 0.23 (-0.04, 0.49)
Weight gain until late pregnancy (kg) 0.07 (-0.24, 0.38)
Values are regression coefficients (95% confidence interval) and reflect the difference in combined kidney volume per unit increase
in maternal characteristic or lifestyle measure. Models are adjusted for age and fetal gender at 24 months of age. BMI, body mass
index.
No associations were found for second trimester fetal growth and blood flow characteristics with com-
bined kidney volume at the age of 2 years (Table 5). Third trimester fetal head circumference and
abdominal circumference were at 2 years of age positively related to both absolute combined kid-
ney volume (increase of 1.68 cm3 (95% CI: 0.56, 2.80) and 1.76 cm3 (95% CI: 0.68, 2.84) per
increase in standard deviation score, respectively) and to relative combined kidney volume (in-
crease of 1.30 cm3/m (95% CI: 0.11, 2.49) and 1.30 cm3/m (95% CI: 0.17, 2.44) per increase
in standard deviation score, respectively). Estimated fetal weight and birth weight were only pos-
itively associated with absolute combined kidney volume at the age of 2 years (increase of 1.19
cm3 (95% CI: 0.17, 2.26) and 1.58 cm3 (95% CI: 0.50, 2.67) per standard deviation score, re-
spectively). Cerebro-umbilical (C/U) blood flow ratio was positively related to abosolute combined
kidney volume. Placental resistance indices were inversely associated with absolute and relative
combined kidney volume, indicating that signs of increased placental resistance reduce kidney vol-
ume. We further analysed whether growth in various periods in early life was associated with
combined kidney volume. Results show that weight gain in early life is strongly associated with
combined kidney volume at the age of 2 years. Table 6 and 7 show an increase of 3.01 cm3/m
(95% CI: 1.42, 4.59) and 3.37 cm3/m (95% CI: -1.01, 7.76) per standard deviation score in-
crease in weight gain from age 6 months to age 24 months, respectively.
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Table . Associations of fetal growth characteristics and placental indices in mid- and late
pregnancy with postnatal combined kidney volume at the age of 24 months
Difference in absolute Difference in relative
combined kidney volume (cm3) combined kidney volume (cm/m)
at the age of 2 months at the age of 2 months
(9% confidence interval) (9% confidence interval)
Model A Model B
Second trimester
Fetal growth characteristics
Head circumference (SDS) 0.44 (-0.65, 1.53) 0.36 (-0.79, 1.52)
Abdominal circumference (SDS) 0.56 (-0.56, 1.68) 0.43 (-0.75, 1.62)
Femur length (SDS) 0.01 (-1.08, 1.10) -0.36 (-1.52, 0.79)
Estimated fetal weight (SDS) 0.47 (-0.67, 1.60) 0.19 (-1.01, 1.39)
Placental resistance indices
Umbilical artery, pulsatility index (PI) -4.14 (-10.4, 2.14) -0.02 (-0.09, 0.04)
Uterine artery, resistance index (RI) -10.7 (-23.8, 2.39) -0.14 (-0.27, 0.01)
Third trimester
Fetal growth characteristics
Head circumference (SDS) 1.68 (0.56, 2.80) 1.30 (0.11, 2.49)
Abdominal circumference (SDS) 1.76 (0.68, 2.84) 1.30 (0.17, 2.44)
Femur length (SDS) -0.17 (-1.28, 0.95) -0.90 (-2.09, 0.29)
Estimated fetal weight (SDS) 1.19 (0.17, 2.26) 0.59 (-0.56, 1.74)
Placental resistance indices
Umbilical artery, pulsatility index (PI) -4.51 (-10.7, 1.71) -3.83 (-10.4, 2.76)
Uterine artery, resistance index (RI) -13.5 (-27.7, 0.63) -11.0 (-26.0, 3.96)
Redistribution parameters
Middle cerebral artery (PI) 2.48 (-0.74, 5.69) 2.15 (-1.25, 5.55)
Cerebro-umbilical (C/U) ratio 2.45 (0.23, 4.67) 2.30 (-0.05, 4.65)
Birth weight (SDS) 1.58 (0.50, 2.67) 1.12 (-0.03, 2.27)
Gestational age at birth (weeks) 0.40 (-0.30, 1.10) 0.43 (-0.33, 1.19)
Weight gain (SDS)
Third trimester – age 24 months 2.52 (1.61, 3.43) 2.16 (1.19, 3.13)
Birth – age 24 months 2.62 (1.63, 3.61) 2.20 (1.14, 3.25)
Age 6 months – age 24 months 3.24 (1.76, 4.72) 3.01 (1.42, 4.59)
Values are regression coefficients (95% confidence interval) and reflect the difference in combined kidney volume per unit increase
in fetal growth and fetal blood flow characteristic. SDS, gestational age-adjusted standard deviation score; PI, pulsatility index. Model
A: adjusted for age and gender. Model B: additionally adjusted for current length.
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Table . Associations of growth in various periods in early life and combined kidney volume at
birth and at 6 and 24 months of age
Difference in combined kidney volume (cm3/m)
(9% confidence interval)
Weight gain (SDS) Birth Age  months Age 2 months
Third trimester - birth 0.40 (-0.76, 1.56) 1.06 (0.05, 2.08) 2.16 (1.19, 3.13)
Birth - age 6 months - 1.07 (-0.08, 2.23) 2.20 (1.14, 3.25)
Age 6 months - age 24 months - - 3.01 (1.42, 4.59)
Values are regression coefficients (95% confidence interval) and reflect the difference in combined kidney volume per unit increase
in weight gain. Models are adjusted for age, fetal gender and current length.
Table . Associations of growth in various periods in early life and combined kidney volume at
birth and at 6 and 24 months of age
Catch-down Reference Catch-up
Weight (SDS)
Second - third trimester 0.88 (-1.97, 3.72) Reference 1.54 (-0.89, 3.97)
Third trimester – birth -1.01 (-3.60, 1.58) Reference 0.22 (-2.45, 2.89)
Birth – age 6 months -0.79 (-3.57, 2.00) Reference 1.97(-0.80, 4.73)
Age 6 months – age 24 months -3.06 (-5.52, -0.60) Reference 3.37 (-1.01, 7.76)
Values are regression coefficients (95% confidence interval) and reflect the difference in growth pattern per unit increase in weight
gain. Models are adjusted for age and fetal gender. Catch-up = >0.67 SD increase in weight; catch-down = <-0.67 SD increase in weight.
Discussion
Our population-based prospective cohort study showed for the first time that kidney size tracks
from third trimester of pregnancy to early childhood. Maternal anthropometrics before pregnancy
and fetal growth characteristics in third trimester of pregnancy were positively associated with
kidney volume at the age of 2 years. Preferential fetal blood flow to the brain was also associated
with smaller kidneys.
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The major strength of our study is its prospective design from early fetal life and the size of the
population-based cohort. Our analyses were based on almost 2,000 kidney measurements. To
our knowledge, no previous studies focused on kidney size in early life were based on such large
numbers. Of these kidney measurements, all fetal ultrasounds were carried out by two sonogra-
phers and 86% of all postnatal ultrasounds were performed by one trained sonographer.20
Furthermore, our study is the first that examines the associations of maternal anthropometrics
during pregnancy and longitudinally measured fetal growth characteristics with kidney size until
the age of 2 years. A limitation could be that of all children participating in the Generation R
measurements at the age of 2 years, kidney measurements were successfully performed in 80%
of these infants. Missing values were mainly due to crying behavior or unavailability of equipment
or radiographer. The effect estimates would be biased if the associations of maternal anthropo-
metrics and fetal growth characteristics with kidney structures differ between those included and
not included in the present analyses. This seems unlikely. Another limitation could be that the
current study was perfomed in a healthy, population based cohort study. In total, we had only 15
children with a birth weight below –2 SD for gestational age, which is the definition for small size
for getstational age. Furthermore, we reported only 18 children with birth weight <2500 grams
and 23 children with gestational age <37 weeks. The selection towards a healthy population in
our cohort may lead to a limited generalizibility to preterm children or children with a small size
for gestational age at birth children. However, these numbers were to small to be assessed in
further detail.
The correlations between early and late kidney measurements, although statistical sig-
nificant, are weak. These correlations just show that the kidney measurements are related to each
other, but it doesn’t mean that these relations have to be causative. Our findings suggest that
impaired growth in fetal life has consequences for kidney size in postnatal life. Children with
smaller kidneys in fetal life tend to keep their relatively smaller kidneys in early childhood. The
risks of remaining in the same quartile of kidney size between third trimester and early childhood
varied between two and three.
The association of maternal anthropometrics and fetal growth with kidney size until the
age of 2 years may be explained by various factors. Animal studies have shown that various de-
terminants of fetal nutrition including low protein intake, relative vitamin A deficiency, reduced
placenta perfusion and administration of steroids in late pregnancy cause fetal growth restriction,
smaller kidneys and a permanent reduced nephron number.12-15 Maternal anthropometrics are
major determinants of fetal nutrition, fetal growth and birth weight.37 We showed that maternal
height and weight are associated with kidney volume in their offspring. This association may be
explained by both genetic and environmental determinants. Further studies focused on potential
genetic variants and detailed maternal dietary habits during pregnancy are needed to identify the
underlying mechanisms. Unfortunately, for the present study no data about maternal dietary
habits were available. According to the Brenner hypothesis, IUGR leads to both a low nephron en-
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dowment and glomerular hyperfiltration. Prenatal programming can be expected to be of impor-
tance to the kidney.38 We showed that there are associations between measures of body size and
kidney size. Therefore we examined the effect on both absolute and relative kidney size. Third
trimester fetal head circumference and abdominal circumference were associated with absolute
and relative kidney size in infancy. The largest effect was seen for fetal abdominal circumference.
This is in line with our previous study which showed the largest effect on third trimester kidney
volume for fetal abdominal circumference.20 Estimated fetal weight and birth weight only showed
possitive associations with absolute kidney volume. We found that fetal blood flow distribution,
measured as cerebro-umbilical blood flow ratio was positively related to combined kidney vol-
ume. This means that relatively increased blood flow to the brain at expense of the extremities
is associated with persistent smaller kidneys. Smaller growth rates in various periods in early life
were associated with combined kidney volume, showing that weight gain in early life is strongly
associated with combined kidney volume at the age of 2 years.
The size of the effect estimates of the association of maternal anthropometrics and
fetal growth with kidney size until the age of 2 years was rather small. For example, an increase
of 1 standard deviation score in third trimester estimated fetal weight leads to an increase of
1.19 cm3 (95% confidence interval: 0.17, 2.26) increase in combined kidney volume at 2 years
of age. Furthermore, our results suggest that part of the effect is explained by length or other
current anthropometrics. Further studies in humans and animals are needed to examine the
underlying causal mechanisms and whether these small changes in kidney size have clinical
consequences.
A few other studies investigated renal length or volume in early life. Schmidt et al. com-
pared pre- and postmature children with mature children. Identical to our analyses, they studied
both absolute and relative combined kidney volume and concluded that being small for gestational
age (SGA) is associated with small kidneys at birth and impaired kidney growth in early child-
hood.35 Hotoura et al. compared children with a gestational age of 31-36 weeks with a control
group of appropriate for gestational age (AGA) children. They concluded that kidney length in
preterm SGA infants follows closely the other anthropometric parameters during the first year of
life.39 Renal growth during the first 2 years of life in SGA children and AGA children was also
studied by Giapros et al.40 They reported that SGA term infants had shorter kidney length at birth
compared to AGA infants, but a similar length from 3rd to 24th month of life. Therefore, they
concluded that this observation may represent either an accelerated renal maturation or early
compensatory kidney hypertrophy in the SGA infants.
Our study suggests that adverse fetal growth patterns lead to smaller kidneys postnatally.
Smaller kidneys are related to the number of nephrons. Since the number of nephrons is largely
determined in prenatal life, sub-optimal kidney growth and development in fetal life leads to a
smaller number of nephrons.10, 11 The kidneys respond to this reduced number of nephrons by hy-
perperfusion and remodeling.9 This process may be in favor of short-term renal function but may
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eventually lead to glomerular hypertrophy and damage.9 Finally, this might result in renal failure
and hypertension. It has been shown that low birth weight is associated with early onset chronic
renal failure. In subjects aged less than 50 years, those who weighted less than 2.5 kg at birth
had a higher risk for end-stage renal disease than people who weighted 3-3.5 kg at birth.5 This
association was shown in all groups of primary causes of end stage renal failure in adults (hy-
pertension, diabetes and other causes). Studies in younger subjects have focused on urine
albumin excretion, a predictor of cardiovascular and renal disease in diabetic and non-diabetic
subjects.41 Low birth weight is associated with microalbuminuria in children and adults inde-
pendent of blood pressure and measures of insulin resistance.3, 4, 6 The pathway leading from
small kidneys to hypertension may include the renin-angiotensin system, which has been demon-
strated to be altered in the early phase of primary hypertension.42 An increased activity of the
renin-angiotensin system could be a compensatory mechanism in a decreased number of
nephrons in order to maintain normal renal filtration. It has been demonstrated that renin activity
in umbilical cord blood is inversely related with the size of the kidney at birth.43
In conclusion, our study showed for the first time in a large population-based cohort that
renal size at the age of two years may be partially affected by several perinatal or maternal factors.
Whether these relations are causal, persist during later life and are related to renal function and
blood pressure needs further investigation.
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Abstract
Background: Echocardiographic measurements are widely used as outcome of different studies.
The aim of this study was to assess intraobserver and interobserver reliability of echocardio-
graphic measurements in healthy children.
Methods: The study comprised of 28 children (median age 7.5 years; inter-quartile range: 3.0 –
11.0). Intraobserver and interobserver reliability were assessed by repeated measurements of
aortic root diameter, left atrial diameter, left ventricular end diastolic diameter, interventricular
end-diastolic septal thickness and left ventricular end-diastolic posterior wall thickness. Intraclass
correlation coefficients with corresponding 95% confidence intervals were calculated and Bland
and Altman plots were computed. Limits of agreement plus or minus 2 standard deviations for
the mean differences in cardiac measurements were derived.
Results: High intraobserver and interobserver intraclass correlation coefficients were found, ranging
from 0.91 for interventricular septal thickness (95% confidence interval: 0.78, 0.96) to 0.99 for
aortic root diameter (95% confidence interval: 0.97, 1.00). Limits of agreement in the Bland and
Altman plots ranged from 0 millimeter (0%) (left ventricular end-diastolic posterior wall thickness)
to 1.60 millimeter (6.3%) (left atrial diameter).
Conclusions: This study demonstrated good repeatability and reproducibility of left cardiac structures
in children measured by ultrasound. Left cardiac structures can be measured in both clinical and
epidemiological research projects.
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Introduction
Ultrasound is widely recognized as method of choice for visualizing organs in children. M-mode
and cross-sectional echocardiography is a noninvasive, cost-effective and efficient method. Many
epidemiological studies use echocardiographic measurements to examine the associations of
various determinants with left ventricular structures in children.1 This information may be relevant
for identifying critical periods in life for left ventricular growth and development. To compare
echocardiographic measurements as an outcome of different studies, it is necessary to minimize
intraobserver and interobserver variability.2 Although the clinical relevance and research importance
of echocardiographic measurements in children is well known, little has been published about the
reliability of these measurements. Lipschultz et al. assessed the reliability of pediatric echocardio-
graphic measurements in a group children of mothers infected with the Human Immunodeficiency
Virus and demonstrated that measurements of left ventricular wall thickness and fractional
shortening made in a local facility differed from those made in a central echocardiography labo-
ratory.3 In this study intraobserver and interobserver reliability were not assessed directly. Results
from Project Heartbeat! showed that echocardiographic measurements in healthy children aged
8 years and older can be performed accurately with acceptable reproducibility.4 However, less is
known about the reliability of echocardiographic measurements in younger children.
The aim of the present study was to quantify intraobserver and interobserver reliability of
echocardiographic measurements in young children.
Methods
Design
The children were selected from the outpatient clinic of the Erasmus Medical Center – Sophia Chil-
dren’s Hospital, a university hospital in Rotterdam, the Netherlands. In total, 28 subjects, resulting
in 56 paired measurements, participated in this study to validate echocardiographic measure-
ments. None of them had congenital heart disease or other cardiovascular disease influencing
the circulation. Written informed consent was obtained for enrollment. All children in this study
were participants in two ongoing follow-up studies (Intra-Uterine Growth Retardation follow-up study,
the Generation R Study5, 6) and had given informed consent for echocardiographic measurements.
Two experienced sonographers (SPE Snijders, VE Kleyburg) performed all examinations at
the same visit. Every single cardiac ultrasound measurement was measured twice by the two
sonographers. The first observer scanned the ultrasound measurements in no specific order.
Subsequently, the other observer did the same, after which the first examiner repeated the
process. The sonographers left the ultrasound room during each other’s assessment. The time
interval for the first observer to rescan the patient depended on the time the second observer
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took for the measurements, being about 10 minutes. Measurement results were blinded to both
operators; the caliper read out on the screen was hidden. Printouts of the measurements were
not seen by the observers and were saved on hard disc for later analyses.
Ultrasound measurements
The examination was carried out in a quiet room with the child quietly awake in a supine position.
To measure left cardiac structures, M-mode, cross-sectional echocardiography was performed in
all the children. Left ventricular measurements included left ventricular end diastolic diameter,
interventricular end-diastolic septal thickness and left ventricular end-diastolic posterior wall
thickness were measured according to the recommendations of the American Society of
Echocardiography.7 Other assessments of left cardiac structures were aortic root diameter and
left atrial diameter. All examinations were performed using an ATL-Philips Model HDI 5000 (Seattle,
Washington, USA) equipped with a 5.0 megahertz, high frequency, curved array transducer.
Statistical analysis
We used the methods to compare observers in detail described by Bland and Altman.8, 9 The first
step was to plot the data and draw the line of equality. This visualizes the degree of agreement.8
Second, the consensus between and among observers was analyzed using the intraclass corre-
lation coefficient for all cardiac measurements. The intraclass correlation coefficient is defined
as the ratio of the variance between subjects to total variance. The intraclass correlation coefficient
measures the strength of the agreement of the variables, independent of the dimension of the
variable considered. Additionally, the 95% confidence interval was calculated for all cardiac
measurements.
Finally, agreement was tested to investigate intra- and interobserver differences and re-
producibility.8 For assessing intraobserver agreement, main interest was in the mean difference
between repeated measures of one observer. For assessing the interobserver agreement, the dif-
ference between the first measurements of each separate observer was used in the analyses.
We created Bland and Altman plots by plotting the differences of all the measurements against
their mean with the 2 standard deviations of the mean to see the distribution and to find any
possible differences from the mean within or between the observers.8 The average differences
between duplicate measures were tested using the paired sample t-test to see if there was systemic
bias. If the differences are Gaussian distributed, 95% of the differences will lie between the mean
plus or minus 2 standard deviation limits. These are the limits of agreement, and the measures
between and among observers can be assumed to be interchangeable within these limits. An
advantage of the Bland and Altman plots over the statistical testing is that one can visualize between
which boundaries a measurement is interchangeable and how large the measurement differences
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between operators are in proportions. How small the limits of agreement should be is a clinical,
not a statistical, decision that should be made in advance of the analysis. We decided that we
could confidently say that cardiac measurements in children would be reliable and valid in case
of intraclass correlation coefficient over 0.80 and mean difference within 10% from the mean of
two different measurements. Statistical analysis was performed using Statistical Package of Social
Sciences version 11.0 for Windows (SPSS Inc, Chicago, IL, USA).
Results
Median age of the children was 7.5 years (interquartile range: 3.0 – 11.0) and 17 (61%) were
male. A total of 14 children (50%) was younger than 8 years of age. Table 1 presents the de-
scriptive statistics of the echocardiographic measurements of left cardiac structures assessed
in this study. A comparison of the means and standard deviation of the different echocardio-
graphic measurements among and between observers is shown. None of the differences between
the means on repeated observation and between observers were statistically significant.
Table . Descriptive statistics for echocardiographic measurements in children
Sonographer  Sonographer 2
First observation Second observation First observation Second observation
Cardiac measurements,
end diastolic Mean Standard Mean Standard Mean Standard Mean Standard
(millimeters) deviation deviation deviation deviation
Aortic root diameter 20.36 3.99 20.81 4.04 19.89 2.94 20.33 3.04
Left atrial diameter 26.07 4.40 26.46 3.94 25.07 4.53 24.44 3.87
Interventricular septal
thickness 5.89 1.07 5.81 0.90 6.11 1.10 6.11 1.28
Left ventricular diameter 36.93 5.27 37.73 5.06 37.96 4.98 38.64 5.07
Left ventricular
posterior wall thickness 5.82 1.09 5.85 0.97 6.43 1.73 6.36 1.64
Analyses were based on a group of 28 children.
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Figure 1 shows plots of left cardiac structure measurements between observers against the line
of equality. All points seem to lie randomly around this line, meaning that there seems to be no
bias. The variables are close to the line of equality as well, indicating good agreement and sug-
gesting small differences between observers.
Figure . Echocardiographic measurements of observers with the line of equality
a. Aortic root diameter measurements b. Left atrial diameter measurements
c. Interventricular septal thickness measurements d. Left ventricular diameter measurements
e. Left ventricular posterior wall thickness measurements
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Table 2 presents the intraclass correlation coefficients with their 95% confidence interval. Intra-
observer intraclass correlation coefficient ranged from 0.91 (interventricular septal thickness) to
0.99 (aortic root diameter) and interobserver intraclass correlation coefficient ranged from 0.78
(left ventricular posterior wall thickness) to 0.96 (left ventricular diameter).
Table 2. Intra- and interobserver intraclass correlation coefficient and 95% confidence interval
for left cardiac structures in childhood
Intraobserver intraclass Interobserver intraclass
correlation coefficient correlation coefficient
(9% confidence interval) (9% confidence interval)
Cardiac measurements, end-diastolic
Aortic root diameter 0.99 (0.97, 1.00) 0.93 (0.83, 0.97)
Left atrial diameter 0.96 (0.91, 0.98) 0.84 (0.65, 0.93)
Interventricular septal thickness 0.91 (0.78, 0.96) 0.81 (0.58, 0.91)
Left ventricular diameter 0.98 (0.96, 0.99) 0.96 (0.92, 0.98)
Left ventricular posterior wall thickness 0.94 (0.87, 0.97) 0.78 (0.53, 0.90)
Analyses were based on a group of 28 children.
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Figure 2 shows Bland and Altman plots for the differences in left cardiac measurements among or be-
tween observers against the mean. The limits of agreement (plus or minus 2 standard deviations) are
plotted in the figures. Most differences lie between the limits of agreement.
Figure 2. Intra- and interobserver Bland and Altman plots of variation in echocardiographic
measurements among and between observers
a. Intraobserver agreement aortic root diameter b. Intraobserver agreement left atrial diameter
c. Intraobserver agreement interventricular d. Intraobserver agreement left
septal thickness ventricular diameter
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e. Intraobserver agreement left ventricular f. Interobserver agreement aortic root diameter
posterior wall thickness
g. Interobserver agreement left atrial diameter h. Interobserver agreement interventricular
septal thickness
i. Interobserver agreement left ventricular j. Interobserver agreement left ventricular
diameter posterior wall thickness
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Table 3 shows the mean differences of the left cardiac structures among and between observers
and the 95% limits of agreement (mean difference plus or minus 2 standard deviations of the dif-
ference). The observed difference from the mean for left cardiac structures ranged from 0
millimeter (0%) (left ventricular end-diastolic posterior wall thickness) to 1.60 millimeter (6.3%)
(left atrial diameter). The mean difference between duplicate measures was not significantly
different from zero. This suggest that no systematic difference between the pairs of results. The
limits of agreement ranged from –0.96 to 0.96 millimeter (left ventricular end-diastolic posterior
wall thickness) to the widest limit from –5.55 to 7.55 millimeters (left atrial diameter).
Table . Intra- and interobserver measurement variation in absolute number and in proportions
of the mean with 95% limits of agreement
Intraobserver agreement - observer  Mean difference 9% limits of agreement
Cardiac measurements, end-diastolic (millimeters) Millimeters % Lower limit Upper limit
Aortic root diameter -0.15 0.7 -1.87 1.57
Left atrial diameter 0.04 0.2 -3.08 3.16
Interventricular septal thickness 0.12 2.0 -1.04 1.28
Left ventricular diameter -0.27 0.7 -3.01 2.47
Left ventricular posterior wall thickness 0.00 0.0 -0.96 0.96
Intraobserver agreement - observer 2 Mean difference 9% limits of agreement
Cardiac measurements, end-diastolic (millimeters) Millimeters % Lower limit Upper limit
Aortic root diameter -0.44 2.2 -2.89 2.01
Left atrial diameter 0.63 2.5 -3.41 4.67
Interventricular septal thickness 0.11 1.8 -1.01 1.23
Left ventricular diameter -0.68 1.8 -4.23 2.87
Left ventricular posterior wall thickness 0.07 1.1 -1.62 1.76
Interobserver agreement – observation  Mean difference 9% limits of agreement
Cardiac measurements, end-diastolic (millimeters) Millimeters % Lower limit Upper limit
Aortic root diameter 0.33 1.6 -3.32 3.98
Left atrial diameter 1.00 3.9 -5.55 7.55
Interventricular septal thickness -0.21 3.5 -1.93 1.51
Left ventricular diameter -1.04 2.8 -4.94 2.86
Left ventricular posterior wall thickness -0.61 9.9 -3.02 1.80
Interobserver agreement – observation 2 Mean difference Limits of agreement
Cardiac measurements, end-diastolic (millimeters) Millimeters % Lower limit Upper limit
Aortic root diameter 0.12 0.5 -3.82 4.06
Left atrial diameter 1.60 6.3 -2.93 6.13
Interventricular septal thickness -0.31 5.3 -2.13 1.51
Left ventricular diameter -1.35 3.6 -4.39 1.69
Left ventricular posterior wall thickness -0.69 11.4 -2.51 1.13
T-tests were performed to compare the difference from the mean, none of the measurements was significantly different from zero.
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Discussion
Echocardiography is widely used to visualize organs in children. Left cardiac structures can be
measured in children with M-mode, cross-sectional echocardiography. The aim of this study was
to assess the reliability of left cardiac structures, aortic root diameter, left atrial diameter, left ven-
tricular end diastolic diameter, interventricular end-diastolic septal thickness and left ventricular
end-diastolic posterior wall thickness, in young children without congenital heart disease.
Both reproducibility, whether two observers use the same measurement to obtain the
same result, and repeatability, whether a single observer obtains the same results when he/she
takes the repeated measurement, are types of agreement or reliability. A measurement process
should be both accurate and reproducible. The mean difference between duplicate measure-
ments is an indicator of the amount of systematic difference (relative bias) between the pairs of
results. The standard deviation of the differences between duplicated measurements represents
the reproducibility of the process. The larger the mean difference, the larger the systematic bias
and the lower the accuracy of the process. Similarly, the larger the standard deviation, the larger
random errors and the lower the reproducibility.
In this study we used various statistical methods to assess the reproducibility and re-
peatability of left cardiac structures in children measured by ultrasound. A simple plot of the
results of one observer against the other showed that the data points are clustered near the line
of equality, indicating good agreement and little differences between observers.
Beforehand, we decided that we could consider cardiac measurements in children as
good reliability and valid in case of intraclass correlation coefficient over 0.80. Our results showed
high intraclass correlation coefficients (over 0.80) for almost all echocardiographic measure-
ments, with low 95% confidence intervals, indicating a high degree of similarity among and
between observers and thus good agreement. Intraobserver intraclass correlation coefficients
were higher (ranging from 0.99 to 0.91) than interobserver intraclass correlation coefficients
(ranging from 0.96 to 0.78) for all left cardiac structures. This phenomenon, so called inter-
observer variability, could be expected since two observers measure differently.
The Bland and Altman plots showed good agreement among and between observers. We
found for almost all echocardiographic measurements differences within 10% from the mean, so
the differences are unlikely to be of clinical significance. Only for the measurement of left ven-
tricular posterior wall thickness the difference from the mean was more than 10%. The differences
were similar regardless of the mean size of the measurement, meaning that differences did not
vary in any systemic way across the range of the measurement.
A few other studies measured intraobserver and interobserver variations of echocardio-
graphic measurements in children. The reliability of pediatric echocardiographic measurements in a
group children of mothers infected with the Human Immunodeficiency Virus is studied by Lipschultz
et al.3 They showed in a group children of mothers infected with the Human Immunodeficiency
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Virus substantial variability between pediatric echocardiographic measurements made in a central
echocardiography laboratory versus a local facility, although left ventricular dimension was reliably
measured. Intraclass correlation coefficients ranged from 0.64 (fractional shortening) to 0.97 (left
ventricular dimension).
The Project Heartbeat! showed that echocardiographic measurements in healthy children
aged 8, 11 and 14 years can be performed accurately with acceptable reproducibility.4 They pre-
sented mean differences in left ventricular mass for intraobserver variability of –1.82 (standard
deviation 18.79) grams and for interobserver variability of 4.50 (standard deviation 24.16) grams.
Although the children in the Project Heartbeat were older than in our study, the mean differences
and standard deviations for the left cardiac structures reported were similar to the measure-
ments in our study.
The major strength of our study is the young age at which we studied the intraobserver and
interobserver variability of echocardiographic measurements. To our knowledge, previous studies
of reliability of echocradiographic measurements have only been performed in older children3, 4
and adults10-12. Second, two well trained sonographers performed all the echocardiographic
measurements in our study, so our results are probably to a large extend dependend on the
experience of these two sonographers. Currently, these sonographers work together, but they
were trained in different echocardiographic laboratories according to current recommendations.7
We expect that the reproducibility would have been lower if the ultrasound measurements were
performed by sonographers working in different research centers. However, this difference should
be small since all measurements were performed using strict protocols, which are used by many
centers to maximize uniformity of performance. Furthermore, cardiac measurements could be
measured in 100% of the participating children. None of the children started crying or wanted to
quit before the measurements were finished. The sonographers put major efforts to get high
quality measurements. Therefore, all echocardiograms we performed, including septal and free
wall left ventricular endocardium measurements, had quality enough for tracing. Another strength
of our study is that we used various statistical methods, which give a useful indication about the
reliability of echocardiographic measurements in children.
A limitation could be that we only used one probe to measure the left cardiac structures
at all different ages. Furthermore, the amount of children in our study is relatively low. However,
other studies assessing reliability of cardiac and other ultrasound measurements were performed
in similar groups and demonstrated that a total number of 30 children is large enough to evaluate
reliability.10, 12-14 Especially, in studies that are designed to assess whether ultrasound measure-
ments are reproducible and repeatable as an outcome measure for different studies.
In conclusion, we demonstrated good repeatability and reproducibility of most left cardiac
structures in children measured by ultrasound. This information is important for clinical and
epidemiological research projects focused on left cardiac structures in young children.
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Abstract
Background: To examine whether cardiac size and function track in early childhood and are as-
sociated with fetal and early postnatal growth and blood flow characteristics.
Methods: This study was embedded in a population-based prospective cohort study from fetal life
onwards. Fetal growth and fetal and placental blood flow parameters in second and third trimester
of pregnancy were measured by ultrasound and Doppler. Left cardiac structures and shortening
fraction were measured postnatally at the ages of 1.5, 6 and 24 months. Analyses were based
on 1,001 children.
Results: Left ventricular mass tended to remain in the lowest and highest quartiles from the age
of 1.5 to 24 months (OR 1.70 (95% CI: 1.10, 2.63) and 2.15 (95% CI: 1.41, 3.30), respectively).
Similar results were found for aortic root diameter and left atrial diameter. Birth weight was
positively associated with aortic root diameter (0.08 mm (95% CI: 0.01, 0.17) per SD increase)
and left ventricular mass (0.65 grams (95% CI: 0.09, 1.21) per SD increase). Resistance indices
of the umbilical and uterine arteries showed weak tendencies towards inverse associations with
left cardiac structures. Fetal cardiac output was positively associated with both left atrial diameter
(increase of 1.96 mm (95% CI: 1.28, 2.64) per ml/min increase) and left ventricular mass
(increase of 1.79 grams (95% CI: 0.35, 3.22) per ml/min increase).
Conclusions: This study suggest moderate tracking of left cardiac structures during the first two
years and that small size and hemodynamic variations in fetal life have consequences for
postnatal cardiac size and function.
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Introduction
Left ventricular hypertrophy is a strong and independent risk factor of cardiovascular morbidity and
mortality in adulthood.1 Studies in children showed that left ventricular mass tracks from child-
hood to adulthood.2-4 This tracking phenomenon has been demonstrated from the age of 6 years
onwards.2, 4 These studies suggest that cardiac structure and function have their origins at least
partly in early life. Tracking studies of cardiac structures have not been performed in infants and
preschool children.
It is not well-known which factors in early life affect left cardiac structures and function.
Studies in children aged 4 to 17 years showed that overweight or obesity is associated with an
increased left ventricular mass.5 Furthermore, inverse associations between birth weight and left
ventricular mass in adolescents and adults have been demonstrated.6, 7 These findings have not
been replicated in prospective cohort studies. Recently, positive associations of birth weight with
left ventricular outflow structures and total coronary diameters were reported.8 Also, maternal an-
thropometrics during pregnancy were positively associated with left ventricular mass in infants.9
Since the human heart has its highest growth and development rate in fetal and early
postnatal life, cardiac size and function may be permanently affected by various factors in fetal
and early postnatal life.10 Recently, we showed that decreased fetal growth is associated with fetal
adaptations in cardiac function in the whole range of fetal growth.11 Thus far, it is not known
whether such fetal cardiovascular adaptations have postnatal consequences.
We examined in 1,001 healthy children participating in a population-based prospective
cohort study from early fetal life onwards whether left cardiac structures track and are associated
with fetal growth and blood flow characteristics until the age of two years.
Methods
Design
This study was embedded in the Generation R Study, a population-based, prospective cohort
study from fetal life until young adulthood.12, 13 The cohort comprises 9,778 mothers and their
children living in Rotterdam, The Netherlands. More detailed assessments of fetal and postnatal
growth and development are conducted in a subgroup, the Focus cohort.12, 13 In this subgroup,
blood pressure and postnatal cardiac ultrasounds were performed until the age of 2 years. The study
has been approved by the Medical Ethics Committee of the Erasmus Medical Center, Rotterdam.
Written informed consent was obtained from all participants.
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Population for analysis
A total of 1,232 women were enrolled in the Focus cohort. The present analysis was limited to
singleton live births (n = 1,215). Twin pregnancies (n = 15) and pregnancies leading to perinatal
death (n = 2) were excluded from the analysis. None of the remaining 1,198 children had con-
genital heart disease. A total of 74% (n = 901) participated in the postnatal assessments at the
ages of 1.5 and 6 months, and 70% (n = 856) in the postnatal assessments at 24 months of
age. Echocardiograms were successfully performed in 91%, 95% and 85% at the ages of 1.5, 6
and 24 months. Missing echocardiograms were mainly due to crying or unavailability of equipment
or echocardiographer.
Ultrasound measurements
Fetal growth characteristics
Fetal ultrasound examinations were carried out at the research centers. The respective median
(95% range) gestational ages for these visits were 12.6 weeks (9.6 – 16.9), 20.4 weeks (18.6
– 22.5) and 30.2 weeks (28.5 – 32.5). These fetal ultrasounds were used both to establish ges-
tational age and to assess fetal growth characteristics.14 Fetal growth measurements comprised
head circumference (HC), abdominal circumference (AC) and femur length (FL) in the second and
third trimester. Estimated fetal weight was calculated using the formula by Hadlock.15 Growth
measurements in early pregnancy (gestational age <18 weeks) were not included, since these
fetal ultrasound examinations were performed primarily to establish gestational age. Gestational
age-adjusted standard deviation scores were constructed for these fetal growth measurements.
Placental and fetal blood flow characteristics
Placental resistance was measured in second and third trimester using flow-velocity waveforms
from the umbilical and uterine arteries. Increased placental resistance is indicated by higher um-
bilical artery pulsatility index (PI) and uterine artery resistance index (RI).16 Cardiac flow velocity
waveforms at the level of the mitral valve leaflets were recorded from the apical 4-chamber view
of the fetal heart, with the sample volume placed just below the mitral valves. Peak velocities of
the E wave and the A wave were recorded. The E/A ratio, which is an index for ventricular dias-
tolic function and expresses both cardiac compliance and preload conditions, was calculated.11
Cardiac outflow flow velocity waveforms were recorded from the aorta and pulmonary artery from
the five-chamber view and the short axis view of the fetal heart just above the semilunar valves,
respectively. Left- and right-sided cardiac output were calculated in milliliter per minutes by mul-
tiplying the vessel area by the time-velocity integral by fetal heart rate.11
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Left cardiac structures
Two-dimensional M-mode and Doppler echocardiograms were performed using an ATL-Philips
Model HDI 5000 (Seattle, Washington, USA) equipment when the children were aged 1.5, 6 and
24 months. The vast majority (86%) of the measurements was performed by a single echocardio-
grapher; the other measurements were performed by two other echocardiographers. These
echocardiographers were supervised by a pediatric cardiologist. Left ventricular end diastolic
diameter (LVEDD), interventricular septal thickness (IVST), left ventricular posterior wall thickness
(LVPWT) and shortening fraction were measured using methods recommended by the American
Society of Echocardiography.17 Left ventricular mass was computed using the formula derived by
Devereux et al.:
Left ventricular mass = 0.80 * 1.04 ((IVST + LVEDD + LVPWT)3 – (LVEDD)3) + 0.6.18
Other measurements of left cardiac structures were aortic root diameter and left atrial diameter.
We used shortening fraction as a quantification of cardiac function.
Covariates
Weight and length were measured at the ages of 1.5, 6 and 24 months. Body surface area (BSA)
was computed by use of the formula derived by Dubois et al.19 Blood pressure was measured at
the age of 24 months. Diastolic blood pressure was taken at the 5th Korotkoff phase. The mean
of two consecutive measurements was used in the analyses. Date of birth, birth weight and gender
were obtained from midwife and hospital registries.
Statistical analysis
Differences in cardiac characteristics between boys and girls were quantified using t-tests. Left
cardiac structures and shortening fraction at 1.5 and 24 months of age were categorized in
quartiles to assess whether children tend to remain in the same quartile during the first two
years of life. For these analyses, odds ratios (OR) were calculated.
Associations of fetal growth (standard deviation scores of estimated fetal weight in second
and third trimester of pregnancy and birth weight), fetal and placental blood flow characteristics
(umbilical artery PI, uterine artery RI, cardiac output and mitral valve waveforms) and systolic and
diastolic blood pressure with left cardiac structures and shortening fraction repeatedly measured
at the ages of 1,5, 6 and 24 months were assessed using repeated measures regression analysis
using the Proc Mixed module of SAS.20 We also analysed the associations of height, weight and
weight gain until two years of age with left cardiac structures and shortening fraction at each
visit. Models were adjusted for gender and age at measurement. Subsequently, to take account
for current anthropometrics, we adjusted for current body surface area (BSA). Statistical analyses
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were performed using the Statistical Package for the Social Sciences version 15.0 for Windows
(SPSS Inc, Chicago, IL, USA) and the Statistical Analysis System (SAS) for Windows, version 9.1.3.
Results
Table 1 presents the characteristics of infants who participated in the postnatal echocardiogram
studies. The percentage of boys was 52%. The overall median ages (95% range) at their visits
were 1.5 months (1.0 – 2.9), 6.3 months (5.5 – 8.3) and 25.1 months (23.6 – 28.3). Table 2 shows
the means and mid-95% ranges for the left cardiac dimensions at all ages. Aortic root diameter
and left ventricular mass were larger in boys than in girls.
To assess reproducibility of ultrasound measurements, the intraclass correlation coefficient
between and among observers were calculated in 30 subjects and varied between 0.85 and
0.99. The intraobserver intraclass correlation coefficients for the echocardiographic measure-
ments in the present study were similar to those previously demonstrated in large-scale
multicenter studies in young children.21, 22 Bland and Altman plots showed that the difference
from the mean for left cardiac structures ranged from 0 mm (0%) (left ventricular end-diastolic
posterior wall thickness) to 1.60 mm (6.3%) (left atrial diameter). The limits of agreement ranged
from –0.96 to 0.96 mm (left ventricular end-diastolic posterior wall thickness) to the widest limit
from –5.55 to 7.55 mm (left atrial diameter).21, 22
Both systolic blood pressure and diastolic blood pressure at 24 months of age were not
significantly associated with left cardiac structures and shortening fraction. Correlation coefficients
ranged from r = 0.01 to r = 0.10. Adjustment of our models for blood pressure did not materially
affect the effect estimates.
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Table . Subject characteristics (n = 1,001)
Boys Girls P-value
(n = 514) (n = 487)
Second trimester fetal characteristics
Gestational age (weeks) 20.5 (18.8-22.8) 20.4 (18.7-22.8) 0.02
Estimated fetal weight (grams) 378 (83) 370 (78) 0.12
Umbilical artery, pulsatility index (PI) 1.2 (0.2) 1.2 (0.2) 0.43
Uterine artery, resistance index (RI) 0.54 (0.1) 0.53 (0.1) 0.03
Third trimester fetal characteristics
Gestational age (weeks) 30.5 (28.7-32.6) 30.3 (28.2-32.5) 0.05
Estimated fetal weight (grams) 1641 (259) 1624 (262) 0.32
Umbilical artery, pulsatility index (PI) 0.96 (0.2) 0.99 (0.2) 0.03
Uterine artery, resistance index (RI) 0.49 (0.1) 0.49 (0.1) 0.91
Cardiac measurements
Left cardiac output (ml/min) 613 (172) 606 (236) 0.58
Right cardiac output (ml/min) 836 (257) 841 (236) 0.78
Mitral valve E wave 39.6 (6.3) 40.7 (6.3) 0.01
Mitral valve A wave 51.5 (7.7) 52.1 (8.2) 0.25
Mitral valve E/A ratio 0.77 (0.09) 0.79 (0.09) 0.02
Characteristics at birth
Gestational age at birth (weeks) 40.3 (35.9-42.4) 40.3 (35.6-42.4) 0.95
Gestational age <37 weeks (%) 23 (4.5) 19 (3.9) 0.65
Birth weight (grams) 3552 (541) 3466 (540) 0.01
Birth weight <2500 grams (%) 18 (3.5) 19 (3.9) 0.11
Small for gestational age (%) 16 (3.1) 11 (2.3) 0.40
Characteristics at . weeks
Age at visit (months) 1.5 (1.0-3.0) 1.5 (1.0-2.8) 0.60
Weight at visit (grams) 5080 (714) 4792 (649) <0.01
Length at visit (cm) 57.4 (2.5) 56.4 (2.5) <0.01
Characteristics at  months
Age at visit (months) 6.3 (5.5-8.1) 6.3 (5.5-8.4) 0.51
Weight at visit (grams) 8202 (859) 7648 (824) <0.01
Length at visit (cm) 69.5 (2.4) 67.8 (2.5) <0.01
Characteristics at 2 months
Age at visit (months) 25.1 (23.7-28.2) 25.1 (23.4-28.3) 0.42
Weight at visit (grams) 12299 (1380) 12412 (1350) <0.01
Length at visit (cm) 89.6 (3.1) 88.4 (3.3) <0.01
Diastolic blood pressure (mmHg) 100.8 (9.2) 102.0 (9.7) 0.13
Systolic blood pressure (mmHg) 61.5 (9.3) 62.8 (10.4) 0.10
Values are means (standard deviation) or medians (95% range).
Differences between boys and girls were compared using independent sample t-tests.
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Table 2. Cardiovascular measurements (n = 1,001)
Boys Girls P-value
(n = 514) (n = 487)
Age . months (n = )
Heart beat (beats/min) 145 (19) 146 (20) 0.89
Left atrial diameter (mm) 16.9 (2.0) 16.5 (1.9) 0.03
Aortic root diameter (mm) 12.0 (1.3) 11.6 (1.2) <0.01
Left ventricular mass (grams) 15.1 (3.1) 13.7 (2.8) <0.01
Shortening fraction (%) 35.3 (4.9) 35.2 (5.1) 0.83
Age  months (n = )
Heart beat (beats/min) 132 (16) 133 (16) 0.33
Left atrial diameter (mm) 18.0 (1.9) 17.9 (1.9) 0.57
Aortic root diameter (mm) 13.9 (1.2) 13.4 (1.2) <0.01
Left ventricular mass (grams) 19.9 (3.9) 18.3 (3.8) <0.01
Shortening fraction (%) 36.9 (5.3) 37.1 (4.8) 0.57
Age 2 months (n = 9)
Heart beat (beats/min) 105 (11) 106 (10) 0.12
Left atrial diameter (mm) 20.7 (2.5) 20.5 (2.4) 0.27
Aortic root diameter (mm) 16.6 (1.5) 16.0 (1.4) <0.01
Left ventricular mass (grams) 32.4 (5.8) 30.0 (5.1) <0.01
Shortening fraction (%) 35.6 (5.4) 35.9 (6.8) 0.51
Values are means (standard deviation).
Differences between boys and girls were compared using independent sample t-tests.
In Table 3, odds ratios (OR) for staying in the same quartiles of left cardiac structure and short-
ening fraction from the age of 1.5 month to 24 months are presented. For aortic root
diameter, children tend to remain in the lowest and highest quartiles from the age of 1.5 to 24
months (OR 2.49 (95% CI: 1.66, 3.73) and 3.37 (95% CI: 2.19, 5.19), respectively). We found
the same trends for quartiles of left atrial diameter, left ventricular mass and shortening fraction.
Our results indicate that around 60% of the subjects in the upper or lower half of the distribution
tend to stay in the same part of the distribution.
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Table . Tracking analysis of left cardiac structures and shortening fraction in quartiles from
6 weeks until 24 months of age
Aortic root diameter 2 months
Aortic root diameter
. months  2   Total no.
 2.49 (1.66, 3.73) (58) 1.40 (0.92, 2.11) (39) 0.56 (0.33, 0.93) (20) 0.30 (0.16, 0.55) (39) 156
2 0.97 (0.63, 1.49) (48) 1.43 (0.96, 2.12) (47) 1.22 (0.80, 1.86) (38) 0.54 (0.33, 0.89) (55) 188
 0.65 (0.41, 1.04) (26) 0.83 (0.54, 1.28) (35) 1.37 (0.90, 2.10) (39) 1.34 (0.89, 2.04) (54) 154
 0.30 (0.16, 0.58) (35) 0.77 (0.47, 1.24) (39) 0.84 (0.51, 1.40) (48) 3.37 (2.19, 5.19) (97) 219
Total no. 167 160 145 245 717
Left atrial diameter 2 months
Left atrial diameter
. months  2   Total no.
 1.47 (0.99, 2.19) (49) 1.18 (0.78, 1.79) (43) 0.85 (0.55, 1.29) (36) 0.65 (0.41, 1.03) (45) 173
2 0.58 (0.35, 0.95) (26) 1.13 (0.72, 1.78) (35) 1.33 (0.86, 2.04) (37) 1.07 (0.68, 1.69) (49) 147
 0.95 (0.62, 1.46) (38) 0.87 (0.55, 1.36) (33) 0.92 (0.60, 1.41) (33) 1.35 (0.88, 2.05) (63) 167
 0.83 (0.51, 1.35) (44) 0.47 (0.26, 0.83) (41) 1.0 (0.63, 1.60) (43) 2.07 (1.33, 3.21) (102) 230
Total no. 157 152 149 259 717
Left ventricular mass 2 months
Left ventricular mass
. months  2   Total no.
 1.70 (1.10, 2.63) (40) 1.52 (0.99, 2.36) (39) 0.81 (0.50, 1.29) (20) 0.37 (0.21, 0.67) (13) 112
2 1.22 (0.78, 1.91) (35) 0.82 (0.51, 1.33) (25) 1.39 (0.90, 2.13) (31) 0.67 (0.41, 1.10) (22) 113
 0.86 (0.54, 1.38) (30) 0.96 (0.61, 1.53) (32) 1.37 (0.89, 2.10) (32) 0.85 (0.53, 1.36) (26) 120
 0.35 (0.19, 0.64) (14) 0.81 (0.50, 1.31) (28) 1.19 (0.70, 1.85) (28) 2.15 (1.41, 3.30) (43) 113
Total no. 119 124 111 104 458
Shortening fraction 2 months
Shortening fraction
. months  2   Total no.
 2.02 (1.37, 2.99) (54) 1.18 (0.79, 1.75) (46) 0.52 (0.31, 0.86) (20) 0.62 (0.39, 0.99) (59) 179
2 0.94 (0.59, 1.52) (28) 1.26 (0.81, 1.95) (35) 0.91 (0.55, 1.51) (24) 0.87 (0.53, 1.41) (48) 135
 0.87 (0.54, 1.40) (27) 1.05 (0.67, 1.63) (33) 1.01(0.62, 1.65) (25) 1.13 (0.71, 1.80) (52) 137
 0.78 (0.48, 1.29) (46) 1.09 (0.69, 1.71) (57) 0.72 (0.42, 1.24) (46) 1.54 (0.98, 2.43) (117) 266
Total no. 155 171 115 276 717
Values are unadjusted odds ratios (95% confidence interval) (number of children in quartile) estimated by logistic regression for quartiles of
left cardiac structures and shortening fraction at the ages of 1.5 months and 24 months.

Tr
ac
ki
ng
an
d
de
te
rm
in
an
ts
of
ca
rd
ia
c
st
ru
ct
ur
es
du
rin
g
ea
rly
ch
ild
ho
od
Table 4 presents regression coefficients of fetal growth and blood flow characteristics with re-
peatedly measured left cardiac structures until the age of 24 months. Birth weight was positively
associated with aortic root diameter (increase of 0.08 mm (95% CI: 0.01, 0.17) per SD increase;
a change of 2.1%) and left ventricular mass (increase of 0.65 grams (95% CI: 0.09, 1.21) per SD
increase, a change of 0.5%). Almost all placental hemodynamics showed weak tendencies to-
wards inverse associations with left cardiac structures. No associations were found with
shortening fraction. After additional adjustment for birth weight, we found the same effect esti-
mates for these associations.
Fetal hemodynamics were positively related to left cardiac structures. Left cardiac output
showed the strongest relation and was associated with left atrial diameter and left ventricular
mass (increase of 1.96 mm (95% CI: 1.28, 2.64), a change of 9.5%; and 1.79 grams (95% CI: 0.35,
3.22), a change of 5.7%, per unit increase in left cardiac output). Right cardiac output was also
associated with left atrial diameter and left ventricular mass. Mitral valve waveforms tended to
be inversely associated with aortic root diameter. No associations were found with left atrial
diameter, left ventricular mass and shortening fraction.
Each standard deviation score increase in weight from the age of 6 months to 24 months
resulted in an increase of 0.22 mm (95% CI: 0.07, 0.38) in left atrial diameter and 0.40 grams
(95% CI: 0.08, 0.72) in left ventricular mass, respectively (data not shown).
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Table . Associations of fetal growth characteristics and placental indices in second and third
trimester of pregnancy with repeatedly measured left ventricular structures until the
age of 2 years
Difference in Difference in Difference in
aortic root left atrial left ventricular
diameter (mm) diameter (mm) mass (mm)
Fetal weight (SDS)
Second trimester 0.08 (-0.01, 0.16) 0.15 (0.02, 0.28) 0.04 (-0.57, 0.65)
Third trimester 0.06 (-0.01, 0.14) 0.02 (-0.11, 0.14) 0.16 (-0.40, 0.71)
Birth 0.08 (0.01, 0.17) -0.03 (-0.16, 0.10) 0.65 (0.09, 1.21)
Placental hemodynamics
Second trimester
Umbilical artery PI -0.62 (-1.05, -0.20) -0.13 (-0.82, 0.56) -0.62 (-3.92, 2.68)
Uterine artery RI 0.35 (-0.63, 1.33) -1.43 (-2.98, 0.12) -3.64 (-10.89, 3.61)
Third trimester
Umbilical artery PI -0.56 (-0.99, -0.13) -0.52 (-1.22, 0.19) -0.83 (-4.22, 2.55)
Uterine artery RI -0.77 (-1.75, 0.22) -1.69 (-3.30, -0.08) -4.97 (-12.59, 2.65)
Fetal hemodynamics third trimester
Cardiac measurements
Left cardiac output (L/min) 0.31 (-0.13, 0.76) 1.96 (1.28, 2.64) 1.79 (0.35, 3.22)
Right cardiac output (L/min) 0.01 (-0.30, 0.33) 1.56 (1.08, 2.05) 1.23 (0.21, 2.25)
Mitral valve E wave -0.02 (-0.03, -0.01) 0.01 (-0.01, 0.03) -0.02 (-0.11, 0.07)
Mitral valve A wave 0.01 (-0.01, 0.02) 0.01 (-0.01, 0.02) -0.02 (-0.09, 0.06)
Mitral valve E/A ratio -1.24 (-2.00, -0.49) 0.41 (-0.82, 1.63) 0.27 (-5.60, 6.15)
Values are regression coefficients (95% confidence interval) and reflect the difference in left cardiac structure per unit increase
in fetal growth and fetal blood flow characteristic. SDS, gestational age-adjusted standard deviation score; PI, Pulsatility Index. Models
are adjusted for age, gender and body surface area.
Discussion
Our population-based prospective cohort study showed that cardiac size and function track during
the first 2 years of life. Furthermore, birth weight and measures of placental vascular resistance
and fetal cardiac output were associated with left cardiac structures.
The major strengths of our study are its prospective design from early fetal life and the
size of the population-based cohort. Our analyses were based on more than 2,000 cardiac
measurements. Furthermore, during the first two years of life, the effect of adverse postnatal ex-
posures of left cardiac structures is expected to be very limited.
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A limitation could be that of all children participating in the Generation R measurements
at the age of 24 months, cardiac measurements could not be measured in 14% of these infants.
Missing values were due mainly to crying behavior or to the unavailability of equipment or a
radiographer. The effect estimates would be biased if the associations of fetal growth and blood
flow characteristics with left cardiac structures differed between those included and not included
in the present analyses. However, this seems unlikely.
Our study was designed to assess heart development in a relatively healthy group of children.
Mean birth weight and weight at the age of two years did not differ from the normal population
norms in the Netherlands. Only 37 children were born with low birth weight (lower than 2,500
grams) and 27 children did have a small size for gestational age at birth. These groups were too
small for specific analyses. We expect that including more children with more variation in growth
and left cardiac structures would have led to stronger effect estimates. Our findings were in line
with a previous study in this population showing fetal cardiovascular adaptations in the whole
range of fetal growth and not only in children with overt or clinically relevant fetal growth restriction.11
Our findings may be not clinically relevant in childhood, but are relevant for insight in the early
etiology of adult cardiovascular disease.
Children with smaller left cardiac structures in early postnatal life tend to keep their
relatively smaller left cardiac structures in childhood (risks varied between 1.5 and 3.5). Tracking
of left ventricular mass has well been described previously in older children.2, 4 However, to our
knowledge, our study is the first that shows tendencies for tracking of left cardiac structures from
birth until the age of 2 years in such a large group of healthy children. The small but significant
tracking coefficients suggest that at least part of left cardiac structures and function is established
in fetal and early postnatal life.
Our study was not designed to test the “fetal nutrition hypothesis”. This hypothesis is
based on inverse associations between birth weight and risk factors for cardiovascular disease.6, 7
However, the number of studies showing inverse associations of birth with left ventricular mass is
small and this association could not be replicated in a recent prospective cohort study in children.8
Our results showed a positive association of birth weight with left ventricular mass and aortic root
diameter. These findings are in line with a recent prospective cohort study showing positive
associations of birth weight with total coronary artery diameter, aortic root diameter and left
ventricular outflow tract diameter in children aged 9 years.8 Recently, it has been suggested that
maternal smoking in pregnancy is associated with changes in fetal cardiac dimensions and
volumes.23, 24 These studies suggested that undernutrition in third trimester of pregnancy leads
to persisting increase of left ventricular structures, mediated through cardiovascular adaptive
changes in utero.
All placental hemodynamics, umbilical artery pulsatility index (PI) and uterine artery
resistance index (RI), tended to be inversely associated with left cardiac structures. Reduced
end-diastolic flow velocities in fetal umbilical and maternal uteroplacental arteries have been
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associated with increased peripheral vascular resistance.25 This increase in peripheral arterial
resistance and subsequently in fetal cardiac afterload may lead to an increase in fetal cardiac
performance.26 These fetal changes in hemodynamic stimuli may lead to persistent structural
left ventricular changes. Previous studies demonstrated that during fetal growth changes occur
in left ventricular diastolic filling patterns, which may be attributed to increased ventricular
stiffness.26 Our results suggest that fetal cardiac performance was positively associated with
left cardiac structures in the present study. This finding may reflect both larger cardiac size in fetal
and postnatal life, which may lead to higher stroke volume and cardiac output.
In conclusion, our study showed in a large population-based cohort that cardiac size and
function track until the age of two years and may be partially affected by several fetal and early
postnatal factors. It should be investigated whether these relations are persist during later life
and are related to the development of cardiovascular disease in adulthood.
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Abstract
Background: To unravel the mechanisms underlying the previously demonstrated associations
between low birth weight and cardiovascular disease in adulthood, we examined whether maternal
smoking during pregnancy leads to fetal arterial resistance adaptations and subsequently to fetal
growth retardation and changes in postnatal blood pressure and cardiac development.
Methods: We performed a prospective cohort study from early fetal life onwards. Maternal
smoking during pregnancy (non-smoking, first trimester smoking, continued smoking (<5 and ≥5
cigarettes/day)) was assessed by questionnaires. Third trimester placental and fetal arterial
resistance indices and fetal growth were assessed by ultrasound and Doppler. Postnatal blood
pressure and cardiac structures were measured at two years of age. Analyses were based on
1,120 children.
Results: First trimester smoking was not associated with third trimester placental and fetal blood
flow adaptations. Continued smoking of ≥5 cigarettes/day was associated with increased re-
sistance in the uterine, umbilical, and middle cerebral arteries and a decreased flow and diameter
of the ascending aorta. Among mothers who continued smoking, estimated fetal weight at 30
weeks and birth weight were most affected in children with the highest umbilical artery resistance.
Fetal arterial resistance indices were also associated with aortic root diameter and left atrial
diameter.
Conclusions: Our findings suggest that fetal arterial resistance adaptations may be involved in the
pathways leading from maternal smoking during pregnancy to both low birth weight and cardio-
vascular developmental changes in childhood in the offspring. Future studies are needed to
examine whether these adaptations have cardiovascular consequences in later life.
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Introduction
The developmental plasticity hypothesis suggests that various adverse intrauterine exposures
lead to persistent fetal developmental adaptations. These adaptations may be beneficial on short
term but have adverse consequences at birth and in postnatal life, leading to both low birth
weight and cardiovascular diseases in adulthood.1 Thus, cardiovascular disease may at least
partly originate in early fetal life. This hypothesis is supported by consistent associations between
low birth weight and an increased risk of hypertension and coronary heart disease in adulthood.2-4
However, the effect size of low birth weight on blood pressure in adulthood seems to be small
and the specific adverse exposures and underlying mechanisms are not known.5
Maternal smoking during pregnancy is the most important modifiable adverse fetal ex-
posure in Western countries. Continued smoking during pregnancy is strongly associated with
fetal growth restriction.6, 7 This association is partly mediated by restricted blood flow in the vas-
cular beds of the placenta, due to increased resistance of the umbilical-placental circulation.8, 9
Fetal hemodynamic adaptations are also present across the whole range of fetal growth, even
without clinical overt growth restriction.10 Recent studies showed that maternal smoking is also
associated with high blood pressure in childhood and adulthood, suggesting that fetal exposure
to maternal smoking adversely affects both fetal growth and cardiovascular development.11, 12
The associations of maternal smoking with blood pressure in the offspring may also be con-
founded by several environmental exposures.13
The present study was designed to unravel the mechanisms underlying the associations
between low birth weight and the development of cardiovascular risk factors. We hypothesized
that maternal smoking during pregnancy leads to increased fetal arterial resistance and sub-
sequently to both fetal growth retardation and postnatal cardiovascular developmental changes.
We examined whether maternal smoking during pregnancy leads to placental and fetal arterial
resistance adaptations and whether these adaptations subsequently affect fetal growth
characteristics and postnatal blood pressure and left cardiac structures in early childhood.
Methods
Design
This study was embedded in the Generation R Study, a population-based, prospective cohort
study from fetal life until young adulthood in Rotterdam, the Netherlands.14 Measurements were
planned in first (median 12.7 (95% range: 10.7 – 17.0) weeks of gestation), second (median
20.5 (95% range: 18.7 – 22.8) weeks of gestation), and third trimester (median 30.3 (95% range:
28.4 – 32.6) weeks of gestation) of pregnancy. Detailed assessments of fetal growth and de-
velopment were conducted in a subgroup, the Focus cohort.14 The study has been approved by
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the Medical Ethics Committee of the Erasmus Medical Center, Rotterdam. Written informed consent
was obtained from all participants.
Population for analysis
A total of 1,232 women were enrolled in the Focus cohort. Twin pregnancies (n = 15) and preg-
nancies leading to perinatal death (n = 2) were excluded from the analysis. None of the remaining
children had major cardiac anomalies other than small ventricular septum defects (n = 3). Infor-
mation on maternal smoking habits in pregnancy was available for 1,144 subjects. Ultrasound and
Doppler measurements were successfully performed in 1,120 of these subjects in late pregnancy.
Analyses focused on fetal arterial resistance indices were performed on these subjects. Of these
1,120 subjects, 856 subjects participated in the postnatal phase of the study of which cardio-
vascular measurements were available for 727 (85%) subjects at the age of two years (Figure 1).
Figure . Flow diagram indicating number of subject in the study
Maternal smoking during pregnancy
For the present study, information about maternal smoking was obtained by postal questionnaires
sent in early and late pregnancy. Response rates for these questionnaires were 91% and 77%,
respectively. At enrollment, maternal smoking was assessed in the first questionnaire by asking
the mother whether she smoked during pregnancy. In the third questionnaire, the mothers were
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The Generation R Focus Cohort
n = 1,232
No smoking data available
n = 88 (7%)
Birth weight data
n = 1,120 (91%)
Postnatal cardiovascular
measurements
n = 727 (65%)
No postnatal ultrasounds
n = 393 (35%)
No prenatal ultrasounds
n = 24 (2%)
Placental and fetal blood ßow data
n = 1,120 (91%)
Maternal smoking habits available
n = 1,144 (93%)
asked whether they smoked in the past three months. According to these questionnaires, maternal
smoking during pregnancy was categorized in the following three categories: non-smoking; first
trimester smoking and continued smoking. Among mothers who continued smoking, the number
of cigarettes smoked was categorized according to the highest amount reported in late pregnancy:
non-smoking; <5 cigarettes/day; and ≥5 cigarettes/day.
Third trimester fetal arterial resistance and biometry measurements
For each measurement, three consecutive uniform waveforms were recorded by pulsed Doppler
ultrasound.10 The mean of three measurements was used for further analysis. To entirely ap-
preciate all aspects of the fetal circulation, we integrated Doppler measurements in different
vascular beds.15 For the present study, main interest was in placental, cardiac and cerebral blood
flow adaptations.
Placental vascular resistance was evaluated with recorded flow-velocity waveforms from
the umbilical and uterine arteries. A raised umbilical and uterine artery pulsatility index (PI) indi-
cates increased feto-placental and maternal-placental resistance, respectively.16 Umbilical artery
PI was measured in a free-floating loop of the umbilical cord. Uterine artery PI was measured in
the uterine arteries near the crossover with the external iliac artery.
Fetal cerebral blood flow was quantified by the middle cerebral artery PI. A reduction in the
middle cerebral artery PI is a valid indicator of the brain-sparing effect and fetal redistribution.17
Middle cerebral artery was measured with colour Doppler visualization of the circle of Willis, and
flow-velocity waveforms were obtained in the proximal part of the cerebral arteries.
Cardiac flow-velocity waveforms at the level of the mitral valve were recorded from the apical
4-chamber view of the fetal heart, with the sample volume placed just below the atrioventricular
valve. Colour Doppler visualization of the blood flow allowed us to align the Doppler beam in the
direction of the blood flow. Peak velocities of the E wave and the A wave were recorded. The E/A
ratio, which is an index for ventricular diastolic function and expresses both cardiac compliance
and preload conditions, was calculated. Cardiac outflow flow-velocity waveforms from the aorta
were recorded from the 5-chamber view and the short-axis view of the fetal heart just above the
semilunar valves. Peak systolic velocity (PSV) and the inner diameter during systole of the aorta
were recorded. Left-sided cardiac output was calculated in milliliters per minutes by multiplying
the vessel area by the time-velocity integral by fetal heart rate.
Fetal biometrics were measured at the same visit as the Doppler measurements and
comprised head circumference (HC), abdominal circumference (AC) and femur length (FL) measured
to the nearest millimeter using standardized ultrasound procedures.18 Estimated fetal weight was
calculated using the formula by Hadlock.19
High intraclass correlation coefficient values (>0.80) with corresponding low coefficients
of variation (<10%), indicating adequate reproducibility for all Doppler measurements, have been
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reported.10 All fetal and postnatal ultrasound and Doppler examinations were performed with an
ATL-Philips model HDI 5000 (Seattle, Wash) equipped with a 5.0-MHz high-frequency, curved-array
transducer.
Blood pressure and cardiac measurements at the age of two years
Systolic and diastolic blood pressure were measured twice to the nearest mmHg at the left upper
arm by using an automatic sphygmomanometer (Vital Signs Monitor CAS 740, CAS Medical Systems,
Inc., Branford, Connecticut, USA).20 The mean of the two readings was used for data analysis. Two-
dimensional M-mode and Doppler echocardiograms were performed to measure left ventricular
end diastolic diameter (LVEDD), interventricular septal thickness (IVST) and left ventricular pos-
terior wall thickness (LVPWT) using methods recommended by the American Society of
Echocardiography.21 Left ventricular mass was computed using the formula derived by Devereux
et al.22 We also measured aortic root diameter and left atrial diameter. To assess reproducibility of
ultrasound measurements, the intraclass correlation coefficients between and among observers
were calculated in 30 subjects and varied between 0.85 and 0.99 for the main outcome measures.
This is similar as previously demonstrated in large-scale multicenter studies in young children.23, 24
Covariates
Information on birth weight and fetal sex were obtained from community midwifery and hospital
registries at birth. Weight and height of the infants were measured at the age of two years.
Statistical analysis
Differences in baseline maternal and infant birth characteristics were compared between the dif-
ferent smoking categories. Second, overall means (standard deviation) and mid-95% ranges were
computed for all third trimester fetal resistance characteristics. Associations of maternal smoking
during pregnancy (non-smoking, first trimester smoking, continued smoking) with placental, cerebral
and cardiac resistance characteristics in fetal life were assessed using multiple linear regression
models. We also studied the effects of the number of cigarettes smoked in third trimester of
pregnancy. These models were adjusted for fetal sex and gestational age at visit. Subsequently,
to assess whether the effect of maternal smoking on estimated fetal weight and birth weight
was mediated through fetal circulatory adaptations, we examined the associations of tertiles of
umbilical artery PI with fetal and birth weight in each third trimester smoking category (no, <5 ciga-
rettes/day, ≥5 cigarettes/day). Tests for trends were performed using linear regression models
within these strata. Next, we examined whether the fetal arterial resistance characteristics, which
were associated with maternal smoking in pregnancy, were also associated with blood pressure and
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left cardiac structures at the age of two years. The effect estimates are presented as difference
per change in standard deviation. These analyses were adjusted for age at visit, sex and current
weight and height of the children. All statistical analyses were performed using the Statistical
Package for the Social Sciences version 15.0 for Windows (SPSS Inc, Chicago, IL, USA).
Results
Table 1 presents the maternal and infant birth characteristics per category of maternal smoking
during pregnancy. Mothers who continued smoking during pregnancy had children with significant
smaller third trimester fetal growth characteristics and lower birth weight and more children with
a birth weight <2500 grams or small size for gestational age. Table 2 shows the means (standard
deviation) and mid-95% ranges for all placental and fetal cerebral and cardiac flow characteristics
in third trimester of pregnancy.
Table . Subject characteristics (n = 1,120)
First trimester
Non-smoking smoking Continued smoking
(n = 843) (n = 104) (n = 173)
Maternal characteristics
Age (years) 31.7 (3.8) 30.8 (4.4) 30.4 (5.2)†
Height (cm) 171.1 (6.3) 170.7 (6.7) 169.5 (5.7)†
Weight (kg) 69.0 (12.9) 66.3 (10.3) 67.2 (10.5)
Body mass index (km/m2) 24.4 (4.2) 24.0 (3.7) 24.6 (4.0)
Parity ≥1 (%) 39.6 27.7* 42.6
Alcohol consumption (%)
Not in pregnancy 33.8 18.3† 32.3
Until pregnancy was known 14.7 26.0† 16.1
Continued alcohol use 51.5 55.8 51.6
Education (%)
Lower education 32.3 41.7 33.0
Higher education 67.7 58.4 67.0
Third trimester characteristics
Gestational age (weeks) 30.4 (28.3 – 32.8) 30.3 (28.5 – 32.6) 30.3 (28.3 – 32.5)
Head circumference (mm) 286.2 (12.1) 286.1 (11.6) 282.3 (13.0)†
Abdominal circumference (mm) 265.8 (16.7) 266.3 (17.3) 261.9 (56.1)†
Femur length (mm) 57.4 (3.1) 56.9 (2.9) 56.1 (3.0)†
Estimated fetal weight (grams) 1636 (266) 1628 (270) 1560 (256)†
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Table . continued
First trimester
Non-smoking smoking Continued smoking
(n = 843) (n = 104) (n = 173)
Birth outcomes
Gender (% boys) 52.1 43.6 56.5
Gestational age (weeks) 40.3 (35.9 – 42.4) 40.1 (33.3 – 42.3) 40.1 (34.7 – 42.4)
Gestational age <37 weeks (%) 4.5 7.7 5.2
Birth weight (grams) 3550 (535) 3524 (632) 3340 (558)†
Birth weight <2500 grams (%) 3.2 4.8 6.4*
Small for gestational age (%) 2.2 2.9 6.9†
Values are means (standard deviation) or medians (95% range) for continuous variables and percentages for categorical variables.
Small for gestational age was defined as children with birth weight below –2 standard deviation for gestational age. Differences
in maternal and fetal characteristics (compared with the non-smoking category) were compared using ANOVA for continuous vari-
ables and Χ2 tests for categorical variables. *p-value <0.05, †p-value <0.01
Table 2. Fetal circulation characteristics
Number Mean (SD) 9% range
Placental flow characteristics
Uterine artery PI 1,033 0.75 (0.21) 0.48 – 1.31
Umbilical artery PI 1,071 0.97 (0.17) 0.68 – 1.32
Cerebral flow characteristics
Middle cerebral artery PI 1,063 1.98 (0.33) 1.33 – 2.65
Middle cerebral artery PSV (cm/s) 1,064 42.9 (8.3) 27.7 – 60.2
Cardiac flow characteristics
Ascending aorta diameter (mm) 984 6.4 (0.7) 5.20 – 7.90
Ascending aorta PSV (cm/s) 968 91.2 (12.4) 66.4 – 114.0
Left cardiac output (mL/min) 944 606 (174) 326 – 981
Mitral valve E wave 1,052 39.9 (6.3) 28.7 – 53.3
Mitral valve A wave 1,052 51.6 (8.0) 37.4 – 68.4
Mitral valve E/A ratio 1,060 0.78 (0.09) 0.61 – 0.99
SD, standard deviation; PI, Pulsatility Index; PSV, Peak Systolic Velocity.
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First trimester smoking was not associated with third trimester placental or fetal arterial resistance
characteristics. Also when first trimester smoking was categorized in two different groups (<5
cigarettes/day and ≥5 cigarettes/day), we did not find any association with arterial resistance
characteristics (data not shown). Table 3 presents the associations for continued smoking with
placental and fetal arterial resistance characteristics. We did not find associations with arterial
resistance characteristics in the offspring of mothers who smoked <5 cigarettes/day. The offspring
of mothers who smoked ≥5 cigarettes/day showed an increased umbilical artery PI (0.09 (95%
CI: 0.05, 0.12)), an increased uterine artery PI (0.07 (95% CI: 0.02, 0.12)) and an increased
middle cerebral artery PI (0.08 (95% CI: 0.01, 0.16)) compared to non-smokers. Furthermore, we
found a decreased ascending aorta diameter and ascending aorta PSV (-0.23 mm (95% CI: -0.39,
-0.07) and -3.60 cm/s (95% CI: -6.92, -0.28), respectively) and a decreased left cardiac output
(-45.7 mL/min (95% CI: -87.7, -3.76)). When we applied the Bonferroni approach to adjust for
multiple comparisons, all presented associations were still significant.
Table . Associations of number of cigarettes per day smoked in third trimester of pregnancy
and placental and fetal cerebral and cardiac flow characteristics
No Continued smoking during pregnancy
smoking (9% CI)
< cigarettes/day ≥ cigarettes/day
(n = 843) (n = 68) (n = 72)
Placental flow characteristic (%) (%)
Uterine artery PI Reference 0.01 (-0.04, 0.07) 1.3 0.07 (0.02, 0.12) 9.3
Umbilical artery PI Reference 0.01 (-0.04, 0.04) 1.0 0.09 (0.05, 0.12) 9.3
Cerebral flow characteristic
Middle cerebral artery PI Reference 0.03 (-0.05, 0.12) 1.5 0.08 (0.01, 0.16) 4.0
Middle cerebral artery
PSV (cm/s) Reference 1.37 (-0.55, 3.29) 3.2 1.72 (-0.03, 3.47) 4.0
Cardiac flow characteristic
Ascending aorta diameter (mm) Reference -0.10 (-0.26, 0.07) 1.6 -0.23 (-0.39, -0.07) 3.6
Ascending aorta PSV (cm/s) Reference 0.01 (-3.16, 3.18) 0.01 -3.60 (-6.92, -0.28) 3.9
Left cardiac output (mL/min) Reference -2.65 (-46.7, 41.4) 0.4 -45.7 (-87.7, -3.76) 7.5
Mitral valve E wave Reference -0.78 (-2.31, 0.75) 1.9 -1.11 (-2.57, 0.34) 2.8
Mitral valve A wave Reference -0.85 (-2.83, 1.14) 1.6 -1.67 (-3.55, 0.22) 3.2
Mitral valve E/A ratio Reference -0.01 (-0.03, 0.02) 1.3 -0.01 (-0.02, 0.03) 1.3
Values are regression coefficients (95% confidence interval) or percentages of the mean and reflect the difference in placental
and fetal flow characteristic for maternal smoking in third trimester of pregnancy. PI, Pulsatility Index; PSV, Peak Systolic Velocity;
CI, Confidence interval. Models adjusted for gestational age and gender.
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Figure 2 presents the associations of continued third trimester smoking with estimated fetal
weight and birth weight within tertiles of fetal umbilical artery PI. Smoking ≥5 cigarettes/day in
third trimester of pregnancy and having an umbilical artery PI in the highest tertile resulted in a
lower estimated fetal weight and birth weight (p-value <0.01) compared to the reference group
(non-smoking mothers who are in the lowest tertile of umbilical artery PI). Within each smoking
category, the largest effect on birth weight was found in the highest umbilical artery tertile.
Figure 2. Associations of fetal umbilical artery PI with estimated third trimester fetal weight and
birth weight in each smoking category
a.
b.
* Tests for trend (Ptrend) for the associations of umbilical artery PI with third trimester estimated fetal weight and birth weight within
in each smoking category; p-value <0.01.
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Table 4 shows that placental and fetal arterial resistance characteristics, which were associated
with maternal smoking, were not associated with postnatal systolic and diastolic blood pressure
or with left ventricular mass in the offspring at the age of two years. An increased third trimester
umbilical artery PI was associated with a reduced aortic root diameter. An increased middle cerebral
artery PI, a decreased ascending aorta diameter and a decreased left cardiac output resulted in
a decreased left atrial diameter at the age of two years (Table 4).
Table . Associations of placental and fetal cerebral and cardiac flow characteristics and
postnatal blood pressure and left cardiac structures at the age of two years
Blood pressure at two years of age Left cardiac size and function at two years of age
(9% CI) (9% CI)
Systolic blood Diastolic blood Aortic root Left atrial Left ventricular
pressure (mmHg) pressure (mmHg) diameter (mm) diameter (mm) mass (grams)
Placental flow characteristic
Uterine artery PI 0.11 (-0.78, 0.10) -0.20 (-1.11, 0.73) -0.09 (-0.21, 003) -0.12 (-0.33, 0.08) -0.12 (-0.57, 0.33)
(SD = 0.21)
Umbilical artery PI 0.56 (-0.33, 1.45) -0.47 (-1.38, 0.45) -0.17 (-0.30, -0.05) -0.03 (-0.24, 0.18) -0.04 (-0.49, 0.42)
(SD = 0.17)
Cerebral flow characteristic
Middle cerebral artery PI -0.75 (-1.63, 0.14) -0.80 (-1.71, 0.11) -0.02 (-0.13, 0.10) -0.18 (-0.38, -0.03) -0.06 (-0.50, 0.38)
(SD = 0.33)
Middle cerebral artery 0.23 (-0.70, 1.15) -0.52 (-1.47, 0.42) -0.04 (-0.16, 0.07) 0.12 (-0.10, 0.33) 0.14 (-0.32, 0.59)
PSV, cm/s (SD = 8.3)
Cardiac flow characteristic
Ascending aorta 0.33 (-0.53, 1.19) 0.35 (-0.55, 1.24) 0.06 (-0.06, 0.18) 0.52 (0.32, 0.72) 0.28 (-0.17, 0.73)
diameter, mm (SD = 0.7)
Ascending aorta PSV, -0.15 (-1.02, 0.72) -0.69 (-1.58, 0.20) -0.02 (-0.14, 0.10) -0.06 (-0.27, 0.15) -0.26 (-0.71, 0.20)
cm/s (SD = 12.4)
Left cardiac output, 0.48 (-0.40, 1.35) 0.14 (-0.75, 1.03) 0.03 (-0.09, 0.15) 0.39 (0.18, 0.60) 0.10 (-0.36, 0.55)
mL/min (SD = 174)
Values are regression coefficients (95% confidence interval) and reflect the difference in blood pressure and left cardiac structure
at the age of two years per standard deviation increase in placental and fetal cerebral and cardiac flow characteristics in third
trimester of pregnancy. SD, standard deviation; PI, Pulsatility Index; PSV, Peak Systolic Velocity; CI, Confidence interval. Models are
adjusted for age at visit, gender and current weight and height.
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Discussion
In a large prospective cohort study, we found that continued maternal smoking during pregnancy
is associated with third trimester fetal arterial resistance adaptations. Furthermore, the effect of
maternal smoking during pregnancy on third trimester fetal growth is stronger in children with
these fetal circulatory adaptations. The hemodynamic adaptations seem to have consequences
for cardiovascular development in early postnatal life.
The major strengths of our study are its prospective design from early fetal life and the
size of the cohort. Fetal resistance and flow characteristics could be measured in 99% of the
mothers participating in this study in third trimester of pregnancy. Postnatal cardiac ultrasound
measurements had been performed in 85% of the children participating in the visit at two years
of age. A limitation is that the current study was performed in a healthy, population-based cohort
study. As a consequence, generalizability is limited to children born preterm or with low birth
weight. Another limitation is that we were not able to assess the effect of maternal smoking as
dose-response on continuously measured number of cigarettes. This may have led to loss of
power and an underestimation of the associations.
Previous studies showed inverse associations between birth weight and risk factors for
cardiovascular disease. The specific adverse fetal exposures and mechanisms underlying these
associations are not known. To unravel these associations, we used maternal smoking and fetal
arterial resistance indices as specific exposure and underlying mechanism, respectively. We found
that continued smoking during pregnancy (≥5 cigarettes/day) was associated with both an in-
creased umbilical and uterine artery PI, indicating a higher resistance in the fetal-placental
vascular bed compared to non-smokers. We did not find associations of first trimester smoking
and continued smoking <5 cigarettes/day during pregnancy with placental and fetal hemody-
namic adaptations. Our results suggest a dose-response effect. Smoking creates a state of
chronic hypoxia resulting from both carbon dioxide in the maternal bloodstream that crosses the
placenta and the vasoactive effect of nicotine.25 A more chronic effect of smoking could be a re-
duction in the ability of placental vessels to dilate, due to reduced levels of prostacyclin and nitric
oxide synthesis.26 Furthermore, studies showed that smoking may reduce the dimensions of fetal
capillaries in the placenta.8, 27 Inadequate placental perfusion and function may explain the as-
sociation between maternal smoking and fetal growth retardation.16 We also found an association
of continued smoking during pregnancy and an increased middle cerebral artery PI, indicating a
higher resistance in the cerebral vascular bed compared to fetuses of non-smokers. This could
be an indication of the brain sparing effect in these fetuses, which is usually seen in growth retarded
fetuses. The increased middle cerebral artery PI might be a direct effect of nicotine, causing
vasoconstriction in the vessels of the brain. Continued smoking during pregnancy was associated
with a smaller diameter and lower flow of the ascending aorta, which might indicate an increased
resistance in the main arterial vascular bed. This is supported by a tendency towards a lower left
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cardiac output in the present study. An explanation for the decreased flow in the aorta might be
smaller blood vessels as a result of suboptimal development of these vessels. Several mechanisms
may lead from maternal smoking during pregnancy to increased fetal arterial resistance indices.
First, impairment in elastin synthesis due to these hemodynamic changes may result in a reduced
compliance of the aorta and large arteries, leading to higher pulse and mean blood pressures.28
The process of aging causes a gradual loss of elastin and replacement by collagen, which am-
plifies the postnatal increase in blood pressure. Another mechanism could be that increased
placental impedance will increase ventricular afterload and reduce fetal cardiac flow, which lead
to a suboptimal stimulus for development of the fetal cardiovascular system.29
Maternal smoking during pregnancy is associated with smaller fetal growth characteristics.7
In addition, fetal growth retardation was correlated with fetal cardiovascular adaptations.10 We
found that in mothers who continued smoking during pregnancy, estimated fetal weight and birth
weight were mostly affected in children with the highest umbilical artery resistance, which implies
that the effect of maternal smoking during pregnancy on fetal growth is at least partly mediated
by fetal circulatory adaptations.
Eventually, persistence of the increased arterial resistance during life may predispose a
person to the development of essential hypertension, left ventricular hypertrophy and cardio-
vascular disease in adulthood.30 This hypothesis is supported by the finding that increased third
trimester umbilical artery resistance was associated with a reduced aortic root diameter at
two years of age. An increased middle cerebral artery resistance, a decreased ascending aorta
diameter and left cardiac output during fetal life were also associated with a decreased left atrial
diameter at the age of two years. No associations were found with blood pressure and left ven-
tricular mass. These findings may suggest that increased arterial resistance first affects left
atrium and aortic root development. Since previous studies did not show associations between
maternal smoking in pregnancy and blood pressure before the age of five years, adaptations in
left ventricular mass and blood pressure may still follow in a later stage.
In conclusion, we found that maternal smoking during pregnancy is associated with fetal
hemodynamic adaptations consistent with increased arterial resistance. These adaptations lead
both to fetal growth retardation and postnatal cardiovascular developmental changes. Future
studies are needed to identify whether these fetal hemodynamic adaptations have consequences
for the development of cardiovascular disease in later life.
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Abstract
Background: Pregnancy and early life factors may permanently affect left ventricular growth and
development in the offspring. The aim of this study was to examine the associations of maternal
anthropometrics during pregnancy with left ventricular mass in infancy.
Methods: This study was embedded in the Generation R Study, a population-based prospective
cohort study from fetal life onwards. Maternal anthropometrics were obtained in early, mid- and
late pregnancy. Echocardiographic follow-up measurements were performed in 791 infants aged
6 weeks and 6 months.
Results: We found no associations of maternal height, weight or body mass index with longitudinally
measured left ventricular mass from 6 weeks to 6 months. Maternal weight gain until late pregnancy
was associated with an increased growth of left ventricular mass from 6 weeks to 6 months
(difference 0.46 grams per week for the highest tertile of weight gain compared to the lowest tertile
(p-value <0.05)).
Conclusions: Maternal weight gain until late pregnancy is associated with larger left ventricular
mass at the age of 6 months, suggesting that maternal health status during pregnancy may have
permanent consequences for left ventricular mass in their children. Further studies are needed
to identify the underlying causal mechanisms and the long-term consequences.
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Introduction
Left ventricular hypertrophy is a strong and independent risk factor of cardiovascular morbidity and
mortality.1 Left ventricular mass tracks from childhood to adulthood, meaning that relative to body
size, the size of the heart of a subject remains in a given rank order over time compared to other
subjects.2 The human heart has its highest growth rates in fetal and early postnatal life.3 After
this period, increase in cardiac muscle mass is mainly due to enlargement of pre-existing cells.4
This rapid growth in fetal and early postnatal life suggests that early life factors may permanently
affect cardiac growth and development.3
The “developmental origins of health and disease hypothesis” postulates that adverse en-
vironmental exposures in fetal and early postnatal life lead to adaptations that permanently
program the fetus’ structure, physiology and metabolism.5, 6 This hypothesis is supported by both
animal studies and epidemiological studies, which have consistently shown associations of fetal
and early postnatal growth characteristics with development of cardiovascular disease and its risk
factors.7, 8 However, fetal cardiovascular adaptations may be present without overt changes in fetal
and early postnatal growth characteristics.7 Maternal anthropometrics during pregnancy are related
to their nutritional and health status and thereby to fetal environmental exposures.9, 10 Several
studies have shown that maternal anthropometric factors such as body mass index, weight gain
during pregnancy, and insulin resistance are associated with fetal growth characteristics and
adverse pregnancy outcomes.11-15 Recently, it has also been suggested that both maternal gestational
diabetes and macrosomia in children of mothers without overt gestational diabetes were associated
with newborn left ventricular mass.16 Thus, maternal nutritional and health status during pregnancy
may lead to an adverse fetal environment and might affect cardiac growth and development.
We hypothesized that maternal anthropometrics during pregnancy affect cardiac growth and
development in early postnatal life. Therefore, we examined in a population-based, prospective
cohort study whether maternal height, weight and body mass index in various periods of pregnancy
and maternal weight gain during pregnancy are associated with infant left ventricular mass growth
between the ages of 6 weeks and 6 months.
Methods
Design
This study was embedded in the Generation R Study, a population-based prospective cohort study
from fetal life until young adulthood. This study is designed to identify early environmental and
genetic determinants of growth, development and health from fetal life until young adulthood and
has been described previously in detail.17, 18 In total, the cohort includes 9,778 mothers and their
children living in Rotterdam, the Netherlands. A vast majority of mothers were enrolled in the first
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trimester of pregnancy.17, 18 Assessments in pregnancy included physical examinations, fetal ultra-
sounds, biological samples and questionnaires and were planned in early (gestational age <18
weeks), mid- (gestational age 18-25 weeks) and late pregnancy (gestational age ≥25 weeks) to
collect information about fetal growth and its main determinants. Their partners are assessed
once during this period. Additionally, more detailed assessments of fetal and postnatal growth and
development are conducted in a subgroup of 1,232 Dutch mothers and their children, referred
to as the Generation R Focus cohort. This subgroup is ethnic homogeneous to exclude possible
confounding or effect modification by ethnicity. Dutch ethnicity was defined as having two parents
and four grandparents born in the Netherlands.18 Between February 2003 and April 2005 all
women pregnant of children who met this criterion were approached. No other exclusion criteria
were used. Of all approached women, 80% agreed to participate in this subgroup study in late
pregnancy (gestational age of 30 weeks). In this subgroup postnatal echocardiograms were per-
formed in infants at the ages of 6 weeks and 6 months. The study has been approved by the
Medical Ethics Committee of the Erasmus Medical Center, Rotterdam. Written informed consent
was obtained from all participants.
Population for analysis
In total, 1,232 women were enrolled in the Generation R Focus Study at a gestational age of
30 weeks. The present analysis was limited to singleton live births (n = 1,215). Twin pregnancies
(n = 15) and pregnancies leading to intra-uterine or perinatal death (n = 2) were excluded from
the analysis. None of the children in this analysis had congenital heart disease. Of the singleton
live births, 74% (n = 900) participated in the postnatal assessment at 6 weeks of age and 74%
(n = 901) participated in the postnatal assessments at 6 months of age. Echocardiograms were
performed in 88% (n = 791) of these infants at 6 weeks and in 87% (n = 785) of these infants
at 6 months of age. Missing echocardiograms were mainly due to crying behavior or unavailability
of equipment or echocardiographer.
Maternal anthropometrics
Maternal anthropometrics were measured in one of the research centers at the visits in early (ges-
tational age <18 weeks), mid- (gestational age 18-25 weeks) and late pregnancy (gestational age
≥25 weeks). We measured weight (kg) and height (cm) and we calculated maternal body mass
index (kg/m2) for each pregnancy period. The gestational age medians (95% range) for these as-
sessments were 12.6 (9.6 - 16.9) weeks, 20.4 (18.6 - 22.5) weeks and 30.2 (28.5 - 32.5) weeks,
respectively. Information about maternal weight just before pregnancy was obtained from ques-
tionnaires. Self-reported weight just before pregnancy was highly correlated to measured weight
at intake (r = 0.97, p-value <0.01). Weight gain was defined as the difference between weight
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before pregnancy and in late pregnancy (gestational age 30 weeks). This is a measure of two
trimester weight gain.
Left cardiac structure
Two-dimensional M-mode were performed on Kretz Voluson 530D equipment in the children at 6
weeks and 6 months of age. The examination was carried out in a quiet room with the baby quietly
awake in a supine position. One echocardiographer performed the vast majority (86%) of these
measurements. Two other echocardiographers performed the other measurements. In a parasternal
long-axis view, left ventricular end diastolic diameter (LVEDD), interventricular septal thickness (IVST)
and left ventricular posterior wall thickness (LVPWT) were measured using methods recommended
by the American Society of Echocardiography.19 Left ventricular mass was computed by use of
the formula derived by Devereux et al.:
Left ventricular mass = 0.80 * 1.04 ((IVST + LVEDD + LVPWT)3 – (LVEDD)3) + 0.6.20
The intraobserver intraclass correlation coefficients for the echocardiographic measurements in
the present study were similar as previously demonstrated in large scale multicenter studies in
young children.21, 22
Covariates
All anthropometrics in the infants were measured without clothes at the same visits as the
echocardiograms at 6 weeks and 6 months of age. Weight was measured to the nearest gram
using electronic scales. Length was measured in supine position to the nearest millimeter using
a neonatometer. Birth weight, date of birth and gender were obtained from midwife and hospital
registries.
Statistical analysis
Associations of maternal anthropometrics with repeatedly measured left ventricular mass at 6
weeks and 6 months of age were first assessed using repeated measures regression analysis
using the Proc Mixed module of SAS.23 This is a regression technique which takes the correla-
tion of multiple measurements within one subject into account and is used to examine response
trends over time.23 Based on tertiles of weight gain until late pregnancy within our study popula-
tion, we constructed three categories for increase in weight (<6.5 kg, 6.5 - 9.0 kg and ≥9.0 kg).
Weight gain during pregnancy was included in the model as an interaction term with age (p-value
<0.05). This model enables us to asses both the time independent and time dependent effects
of weight gain on left ventricular mass. The model can be written as:
Left ventricular mass = β0 + β1*increase in weight + β2*age + β3*increase in weight*age.
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In this model, the term including ‘β0 + β1’ reflects the intercept and the term including ‘β2’ re-
flects the slope of growth in left ventricular mass per week. The term including ‘β3’ reflects the
differences in growth of left ventricular mass between the different categories of increase in
weight. First we examined the association of maternal weight, body mass index and weight gain
in pregnancy with left ventricular mass in the offspring adjusted for gender (Model A). All models
were additionally adjusted for current weight and current length of the children (Model B). Models
with maternal weight gain as independent variable were additionally adjusted for maternal weight
and height just before pregnancy (Model B).
Subsequently, we performed multiple linear regression models to study the associations
of maternal anthropometrics with left ventricular mass at the ages of 6 weeks and 6 months
separately. These models were first adjusted for gender and age at the visit (Model A) and addi-
tionally for current weight and current length of the children (Model B). All measures of association
are presented with their 95% confidence intervals (CI). Statistical analyses were performed using
the Statistical Analysis System version 8.2 (SAS, Stata corporation, College station, TX, USA), in-
cluding the Proc Mixed module for unbalanced repeated measurements and the Statistical
Package of Social Sciences version 11.0 for Windows (SPSS Inc, Chicago, IL, USA).
Results
Characteristics of infants who participated in the postnatal echocardiogram studies and their
mothers are presented in Table 1. The percentage of boys was 52%. Birth weight was larger in
boys than in girls. The overall median age in infants at their 6 weeks visit was 6.4 (95% range:
4.4 – 12.5) weeks and at their 6 months visit 27.3 (95% range: 23.7 – 35.6) weeks. Weight,
length and left ventricular mass were somewhat smaller in girls than in boys. Infants who had a
postnatal echocardiogram (n = 791) did not differ from the postnatal non-responders (n = 424)
in maternal weight (difference 0.6 (95% CI: -1.1, 2.3) kg) and maternal body mass index (differ-
ence 0.2 (95% CI: -0.4, 0.7) kg/m2) just before pregnancy. Figure 1 shows the correlations
between infant characteristics and left ventricular mass.
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Table . Subject characteristics
Boys Girls P-value
(n = 413) (n = 378)
Pregnancy and birth characteristics
Maternal age (years) 31.8 (4.0) 32.3 (3.8) 0.09
Maternal height (cm) 170.9 (6.0) 170.9 (6.8) 0.66
Maternal weight before pregnancy (kg) 71.0 (13.2) 71.9 (12.5) 0.20
Maternal BMI before pregnancy (kg/m2) 24.3 (4.3) 24.6 (4.2) 0.24
Maternal weight in late pregnancy (kg/m2) 78.9 (12.8) 79.7 (12.6) 0.38
Birth weight (grams) 3559 (535) 3463 (542) 0.05
Gestational age (weeks) 39.9 (35.3-42.1) 40.0 (35.7-42.1) 0.79
Postnatal characteristics visit  weeks
Age at visit (weeks) 6.4 (4.5-12.9) 6.4 (4.4-11.9) 0.38
Weight (grams) 5088 (749) 4758 (627) <0.01
Length (cm) 58 (3) 56 (3) <0.01
Left ventricular mass (grams) 13.8 (2.7) 12.7 (2.5) <0.01
Postnatal characteristics visit  months
Age at visit (weeks) 27.4 (23.9-35.0) 27.3 (23.6-36.1) 0.67
Weight (grams) 8191 (840) 7628 (812) <0.01
Length (cm) 70 (3) 68 (3) <0.01
Left ventricular mass (grams) 18.0 (3.7) 16.4 (3.5) <0.01
Values are means (SD) or medians (95% range) for variables with skewed distribution.
Of the total group, data were missing on maternal weight before pregnancy (n = 140), maternal body mass index before pregnancy
(n = 140), weight 6 weeks (n = 14), length 6 weeks (n = 18), weight 6 months (n = 26), length 6 months (n = 26), left ventricular
mass 6 weeks (n = 102) and left ventricular mass 6 months (n = 120). P-values were based on unpaired sample t-test examining
the differences between boys and girls.
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Figure . Correlations of individual measurements of infant weight and height with left ventricular
mass at the ages of 6 weeks and 6 months
The associations between maternal anthropometrics during pregnancy and longitudinal measured
left ventricular mass in infancy are presented in Table 2. No associations were found of maternal
weight and body mass index in early, mid- and late pregnancy with growth of left ventricular mass.
Compared to mothers with the lowest increase in weight during pregnancy, growth of left ventricular
mass was 0.28 (95% CI:-0.17, 0.72) grams per 10 weeks lower in mothers with moderate in-
crease in weight during pregnancy and 0.46 (95% CI: 0.02, 0.90) grams per 10 weeks higher in
mothers with the highest increase in weight during pregnancy. Figure 2 presents the adjusted
trend lines of left ventricular growth between the ages of 6 weeks and 6 months for the different
categories of weight gain during pregnancy.
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Table 2. Maternal anthropometrics and tertiles of weight gain in pregnancy and longitudinal
measured growth in left ventricular mass
Change in left ventricular mass (grams/ weeks)
Model A Model B
Early pregnancy
Height (cm) 0.06 (0.01, 0.09) 0.01 (-0.03, 0.06)
Weight (kg) 0.01 (-0.01, 0.03) 0.01 (-0.01, 0.02)
Body mass index (kg/m2) 0.03 (-0.02, 0.07) 0.02 (-0.02, 0.06)
Mid-pregnancy
Weight (kg) 0.02 (0.01, 0.03) 0.01 (-0.01, 0.02)
Body mass index (kg/m2) 0.04 (-0.01, 0.08) 0.03 (-0.01, 0.07)
Late pregnancy
Weight (kg) 0.02 (0.00, 0.05) 0.01 (-0.01, 0.03)
Body mass index (kg/m2) 0.04 (-0.01, 0.09) 0.03 (-0.01, 0.08)
Weight gain (kg)
<6.5 Reference Reference
6.5 – 9.0 -0.22 (-0.68, 0.24) -0.28 (-0.72, 0.17)
≥9.0 0.62 (0.17, 1.08) 0.46 (0.02, 0.90)
Values are regression coefficients (95% confidence interval) and reflect the difference in growth of left ventricular mass for the
different categories of maternal anthropometrics and weight gain in pregnancy. Model A: adjusted for gender; Model B: additionally
adjusted for current weight and current length. Models with weight gain as independent variable are additionally adjusted for
maternal weight and height just before pregnancy.
Figure 2. Weight gain in pregnancy and left ventricular mass in early infancy
Values present the adjusted trend lines of left ventricular growth between the ages of 6 weeks and 6 months for the different cate-
gories of weight gain during pregnancy. The dotted line represents the category of the highest weight gain in pregnancy and shows
the steepest increase of left ventricular mass in early infancy. These data are adjusted for gender and current weight and length.
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Table 3 gives the associations between maternal weight gain during pregnancy with left ventric-
ular mass at the ages of 6 weeks and 6 months separately. We did not find an association of
maternal weight gain during pregnancy with left ventricular mass at 6 weeks of age (Table 3). How-
ever, weight gain during pregnancy was positively associated with postnatal left ventricular mass
at the age of 6 months. For each kg increase in weight during pregnancy, left ventricular mass at
the age of 6 months increased by 0.08 (95% CI: 0.02, 0.15) grams. This means an increase of
0.47%. The associations did not materially change after adjustment for maternal weight and height
just before pregnancy, and gender, age, weight and length of the child (Table 3).
Table . Maternal weight gain during pregnancy and left ventricular mass at 6 weeks and 6 months
Difference in left ventricular mass  weeks (grams)
Model A Model B
Weight gain (kg) 0.06 (-0.01, 0.12) 0.45% 0.03 (-0.03, 0.09) 0.23%
Difference in left ventricular mass  months (grams)
Model A Model B
Weight gain (kg) 0.11 (0.04, 0.18) 0.64% 0.08 (0.02, 0.15) 0.47%
Values are regression coefficients (95% confidence interval) and reflect the difference in left ventricular mass per unit weight gain
in maternal weight. Model A: adjusted for maternal weight and height just before pregnancy, age and gender; Model B: additionally
adjusted for current weight and current length.
Discussion
Our study demonstrates for the first time that higher maternal weight gain during pregnancy is as-
sociated with a higher increase in growth of left ventricular mass during the first 6 months of life.
These findings suggest that maternal anthropometrics during pregnancy may have consequences
for left ventricular mass in the offspring.
Postnatal follow-up echocardiograms were successfully obtained in 65% of all singleton
live births of the mothers participating in the Generation R Focus Study. Maternal anthropometrics
in pregnancy were similar between infants who had a postnatal echocardiogram and the postnatal
non-responders. The observed effect estimates would be biased if the associations of maternal
anthropometrics with left ventricular mass differ between those included and not included in the
present analyses. This seems unlikely. The missing values of left ventricular mass among infants
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who did participate in postnatal visits were mainly due to crying behavior or unavailability of equip-
ment or echocardiographer and are unlikely to lead to biased results.
Weight gain was partly based on self-reported weights, which is known to introduce
measurements error. Based on an assessment of validity of self-reported weight in the US Third
National Health System, women in this age group may systematically underestimate their
weights.24 Since self-reported weight just before pregnancy was highly correlated (r = 0.97) to
measured weight at intake, we do not think that this would lead to biased results.
In the present analysis, we defined maternal weight gain as the difference between weight
in late pregnancy and weight just before pregnancy. In-fact this is the increase in weight in the first
two trimesters of pregnancy. Ideally weight gain during pregnancy should be defined as the difference
between the highest weight in pregnancy and the weight just before pregnancy. Since the largest
differences in maternal weight gain during pregnancy are expected to appear in late pregnancy,
our associations between weight gain and left ventricular mass may be underestimated.
No associations were found of maternal weight and body mass index in early, mid- and
late pregnancy with left ventricular mass in infancy. We found that mothers who increase more
in weight during pregnancy have children with an increased growth of the left ventricular mass in the
first 6 months, resulting in larger left ventricular mass at the age of 6 months. These associations
were independent of maternal weight just before pregnancy.
Anthropometrics during pregnancy reflect maternal nutritional and health status and may
be measures of fetal environmental exposures.9 Increased maternal weight gain during pregnancy
may be caused by several factors including nutrition, obesity, fluid retention and lower physical
activity levels.25 Furthermore, increased maternal weight gain during pregnancy is associated with
various pregnancy complications including insulin resistance, gestational diabetes and pregnancy-
induced hypertension. Therefore, several underlying biological pathways may explain the
associations between maternal anthropometrics in pregnancy and left ventricular mass in in-
fancy. The usual increase in insulin resistance seen in late pregnancy is higher in mothers who
show a marked increase in weight during pregnancy.26 Insulin resistance causes higher glucose
levels in the mother. Since glucose passes the placenta to the child, fetal insulin production will
be increased. Insulin is the main fetal growth factor and may stimulate fetal body and heart
growth.27 Offspring of mothers with gestational diabetes have increased cardiac sizes in the
neonatal phase.16 However, this larger cardiac size is usually not present anymore at the age of
6 months.28 In our study, data on sub-clinical insulin resistance or increased glucose levels during
pregnancy were not available. The number of pregnant women with doctor-diagnosed gestational
diabetes in our study was too small (n = 45) to assess the effect on left ventricular mass. Another
biological pathway may directly be related to the nutrition intake of the mother during pregnancy.29,
30 Excessive fetal exposure to energy sources may lead to rapid growth and cardiac enlargement.
Further studies, in which measures of insulin resistance such as insulin, glucose or HbA1c levels
and maternal nutrition in pregnancy have been measured, are needed to identify the underlying
causal pathways.
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The associations could also be explained by postnatal factors related to postnatal growth, nutrition,
blood pressure development and genetic susceptibility.31-33 We showed that the effect of weight
gain on left ventricular mass was still present after adjustment for current weight. Thus we do not
think that postnatal anthropometrics totally explain the associations. However, previous studies
showed that in adolescents, increase in body mass index from early childhood, rather than current
body mass index is associated with left ventricular mass.31, 32 Thus, postnatal growth patterns
or determinants of these growth patters, which are also associated with maternal weight gain in
pregnancy may explain part of these associations. Further follow up studies in our and other cohorts
may reveal these underlying mechanisms.
The effect estimates shown in our study are unlikely to be of any clinical significance in
infancy. However, our results suggest an etiological role of maternal anthropometrics during preg-
nancy in left ventricular mass development. Increased left ventricular mass may precede the
development of left ventricular hypertrophy and increased blood pressure. Left ventricular hyper-
trophy and hypertension are risk factors for cardiovascular morbidity and mortality.1 Whether and
to what extend the effects of maternal anthropometrics on left ventricular mass persists in childhood
and in adulthood needs to be further studied.
Study implications
Our findings demonstrated that maternal anthropometrics, as measure of maternal and fetal en-
vironment, are associated with left ventricular mass in infancy. The effect sizes seem to be too
small for clinical implications. However, these results are of interest from a developmental per-
spective and add new support for “the developmental origins of health and disease hypothesis”.
Further studies examining the underlying biological pathways and the long-term consequences are
needed.
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Abstract
Background: Glucocorticoid receptor-9β polymorphism (GR-9β, rs6198) is associated with the
susceptibility for cardiovascular disease. Our aim was to examine whether the GR-9β variant is
also associated with blood pressure and heart growth in early childhood.
Methods: This study was embedded in a prospective cohort study from fetal life onwards. Left
cardiac structures (aortic root diameter, left atrial diameter and left ventricular mass), shortening
fraction and heart rate were measured postnatally at the ages of 1.5, 6 and 24 months. Blood
pressure was measured at 24 months of age. Analyses were based on 857 children.
Results: At the age of 24 months, homozygous variants showed a higher systolic blood pressure
of 2.65 mmHg (95% CI: 0.16, 5.14), a higher heart rate of 9.14 beats per minute (95% CI: 0.22,
18.1) and a higher left ventricular mass of 5.01 grams (95% CI: 1.32, 8.71) compared to ho-
mozygous references. GR-9β polymorphism was significantly associated with left ventricular mass
growth during the first 2 years.
Conclusions: Our findings suggest that genetically determined differences in cortisol exposure
affect cardiovascular development in early life. Future studies are needed to replicate these
findings and should assess whether these relations are associated with development of cardio-
vascular disease.
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Introduction
Glucocorticoids are important regulators of cardiovascular function and metabolism. High levels
of glucocorticoids results in unfavorable cardiovascular risk factors, such as visceral obesity,
steroid-induced diabetes and hypercholesterolemia.1 The effects of these hormones are mediated
by glucocorticoid receptors, which show a large interindividual variation in their sensitivity.2 Genetic
variants in the glucocorticoid receptor gene (GR or NR3C1) seem to contribute to this difference
in sensitivity.3
In humans, two isoforms of the glucocorticoid receptor exists: hGRα and hGRβ.4 hGRα
resides in the cytoplasm, can bind glucocorticoids, and can alter gene transcription by binding to
glucocorticoid respons elements.5 hGRβ does not bind hormone and is transcriptionally inactive.6
In vitro studies have shown that it can act as a dominant negative inhibitor of hGRα’s transactiva-
tion properties.7 A polymorphism in the glucocorticoid receptor gene, the GR-9β variant (rs6198),
has been identified that is associated with cortisol sensitivity. A few studies demonstrated as-
sociations of the GR-9β variant with a reduced risk of bacterial colonization with Staphylococcus
aureus in the nose8 and an increased susceptibility to rheumatoid arthritis and a more aggressive
disease course in multiple sclerosis.9,10 Recently, it was demonstrated in a middle-aged population-
based cohort in The Netherlands that this polymorphism of the glucocorticoid receptor gene is
associated with the risk of myocardial infarction and coronary heart disease.11 Variation in cortisol
sensitivity may not only harm glucocorticoid treatment of immune related diseases, but may also
directly affect cardiovascular growth and development in the fetus and subsequently increase
the risk of cardiovascular disease in adulthood.12, 13 It was shown in sheep fetus that cortisol treat-
ment resulted in an increase in cardiac mass without myocyte enlargement, indicating that cortisol
stimulates hyperplastic growth of cardiomyocytes but not hypertrophic growth.14 It is unknown
what the effect is of variation in cortisol levels on fetal and early postnatal cardiovascular growth
and development. The relative effect of variants of the glucocorticoid receptor gene on blood
pressure and cardiac structures might be larger in childhood, when the effect of various environ-
mental factors, such as life style habits, is limited.
We hypothesize that the GR-9β variant of the glucocorticoid receptor gene affects blood
pressure and cardiac growth in early life. These early cardiovascular changes may predispose the
individual to cardiovascular disease in adulthood. Therefore, we studied in a prospective cohort
study from fetal life onwards the effects of the GR-9β polymorphism of the glucocorticoid receptor
gene on blood pressure and left cardiac structures and function during the first two years of life.
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Methods
Design
This study was embedded in the Generation R Study, a prospective cohort study from fetal life
until young adulthood in Rotterdam, the Netherlands.15, 16 Assessments in pregnancy included
physical examinations, fetal ultrasounds, biological samples and questionnaires. More detailed
assessments of fetal and postnatal growth and development are conducted in a subgroup, the
Focus cohort.15, 16 The study has been approved by the Medical Ethics Committee of the Erasmus
Medical Center, Rotterdam. Written informed consent was obtained from all participants.
Population for analysis
A total of 1,232 women were enrolled in the Focus cohort. The present analysis was limited to
singleton live births (n = 1,215). Twin pregnancies (n = 15) and pregnancies leading to perinatal
death (n = 2) were excluded from the analysis. None of the remaining 1,198 children had con-
genital heart disease. DNA was collected from cord blood and available for 884 subjects.
Reasons for nonavailability of DNA were mainly logistic constraints for blood collection at birth.
Genotyping was successfully performed in 857 subjects. Of these children, a total of 88% (n =
752) participated in the postnatal assessments at 1.5 and 6 months of age, and 84% (n = 719)
participated in the postnatal assessments at 24 months of age. Echocardiograms were success-
fully performed in 88%, 89% and 84% at 1.5, 6 and 24 months of age. Missing echocardiograms
were mainly due to crying or unavailability of equipment or echocardiographer.
Genotyping
All participants were genotyped for the GR-9β polymorphism.3, 17, 18 Genotyping of the GR-9β poly-
morphisms was performed using Taqman allelic discrimination assay (Applied Biosystems, Foster
City, CA) and Abgene QPCR ROX mix (Abgene, Hamburg Germany). The genotyping reaction was
amplified using the GeneAmp®PCR system 9600 (95° C (15 minutes), then 40 cycles of 94° C
(15 seconds) and 60° C (1 minute)). The fluorescence was detected on the 7900HT Fast Real-
Time PCR System (Applied Biosystems) and individual genotypes were determined using SDS
software (version 2.3, Applied Biosystems). Genotyping was successful in 97% of the samples
for this genotype. To confirm the accuracy of the genotyping results, 276 randomly selected sam-
ples were genotyped for a second time with the same method. The error rate was less than 1%.
Overall, the distribution of the GR-9β genotypes in our study sample was 75.1% homozygous ref-
erence (AA), 23.5% heterozygous (AG) and 1.4% homozygous variant (GG) for the polymorphism.
In our study sample, the minor allele frequency of the glucocorticoid receptor-9β allele was 13.1%.
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Genotype and allele frequencies were according to the Hardy Weinberg equilibrium (p-value =
0.32).
Blood pressure and cardiac measurements
At 24 months of age, systolic and diastolic blood pressure were measured twice to the nearest
mmHg at the left upper arm by using an automatic sphygmomanometer (Vital Signs Monitor CAS
740, CAS Medical Systems, Inc., Branford, Connecticut, USA).19 The mean of the two readings was
used for data analysis. Blood pressure was successfully measured in 577 subjects. In 122 children,
it was not possible to measure blood pressure twice due to crying and oppositional behaviors.
Thus, their blood pressure was based on one measurement.
Two-dimensional M-mode and Doppler echocardiograms were performed using an ATL-
Philips Model HDI 5000 (Seattle, Washington, USA) equipment when the children were aged 1.5,
6 and 24 months. The vast majority (86%) of the measurements was performed by a single
echocardiographer; the other measurements were performed by two other echocardiographers.
Left ventricular end diastolic diameter (LVEDD), interventricular septal thickness (IVST), left ven-
tricular posterior wall thickness (LVPWT) and shortening fraction were measured using methods
recommended by the American Society of Echocardiography.20 Left ventricular mass was computed
using the formula derived by Devereux et al.21 Other measurements of left cardiac structures
were aortic root diameter and left atrial diameter. We used shortening fraction and heart rate as
a quantification of cardiac function.
To assess reproducibility of ultrasound measurements, the intraclass correlation coefficient
between and among observers were calculated in 30 subjects and varied between 0.85 and
0.99 for the main outcome measures. This is similar as previously demonstrated in large-scale
multicenter studies in young children.22, 23
Covariates
The infants’ anthropometrics, including weight and length, were all measured at the ages of 1.5,
6 and 24 months. Date of birth, birth weight and gender were obtained from midwife and hospital
registries.
Statistical analysis
Differences in subject characteristics were quantified between the different genotypes. Associations
of the GR-9β genotype with blood pressure measured at 24 months and cardiac structures (aortic
root diameter, left atrial diameter, left ventricular mass) and function (heart rate, shortening fraction)
repeatedly measured at the ages of 1.5, 6 and 24 months were assessed using regression
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models. These models were adjusted for gender and age. Height and weight at two years of age
were correlated with left ventricular mass at the same age (r = 0.39 and r = 0.39, p <0.001). We
found no significant correlations between the genetic variant and height and weight until the age
of two years. Adjustment for anthropometrics measured at the visit of the cardiac ultrasound did
not materially change the effect estimates in the associations of the glucocorticoid receptor-9β
polymorphism with left cardiac structures. Therefore, weight and length were not included in the
regression models. Furthermore, since population genotype distribution is assumed to be unrelated
to covariates such as breastfeeding, they were not included in the models.24
Second, for the repeatedly measured cardiac structures and function, we performed re-
peated measures regression analysis using the Proc Mixed module of SAS, which takes the
correlation of multiple measurements within one subject into account, allows for incomplete out-
come data and assesses both the time independent and time dependent effects of the GR-9β
genotype on left cardiac structures and function.25 The GR-9β polymorphism was included in the
model as intercept and as interaction term with age (p-value = 0.005). Also, these models were
adjusted for age at visit and gender. Other covariates including weight, length and gestational
age at birth did not change the effect estimates and were therefore not included in the model.
The final model can be written as:
Cardiac measurement = β0 + β1*GR-9β polymorphism + β2*age + β3*GR-9β polymorphism*age
+ β4*(1/√age).
In this model, the term including ‘β0 + β1’ reflects the intercept and the term including ‘β2’ reflects
the slope of growth in left cardiac structure per month. The term including ‘β3’ reflects the differences
in growth of cardiac measurement between the different genotypes of the GR-9β polymorphism.
Again, we compared the homozygous variants and the heterozygous to the homozygous references.
In addition, to study the dominant effect of the GR-9β polymorphism, we merged the group
heterozygous and homozygous variant subjects and performed the same analyses.
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Results
Table 1 presents the baseline characteristics of infants who participated in the postnatal echocar-
diogram studies. The percentage of boys was 52%. The overall median ages (95% range) in
infants at their visits were 1.5 months (1.0 – 2.9), 6.3 months (5.5 – 8.3) and 25.1 months
(23.6 – 28.3). At all ages, aortic root diameter, left ventricular diameter and left ventricular mass
were larger in boys than in girls.
Table . Subject characteristics (n = 857)
Subject characteristics Homozygous Heterozygous Homozygous
reference variant P-value
(n = 644) (n = 201) (n = 12)
Characteristics at birth
Gestational age at birth (weeks) 40.0 (36.4-42.3) 40.3 (36.7-42.3) 40.1 (36.7-42.6)
Birth weight (grams) 3529 (515) 3578 (463) 3225 (711) 0.05
Characteristics at 2 months
Age at visit (months) 25.1 (23.6-28.6) 25.0 (23.5-27.8) 25.7 (24.2-29.0) 0.10
Weight at visit (grams) 12,669 (1,428) 12,590 (1,278) 13,500 (845) 0.19
Length at visit (cm) 89.1 (3.3) 88.7 (3.2) 90.2 (3.0) 0.31
Cardiovascular measurements
Systolic blood pressure (mmHg) 101.0 (9.5) 100.1 (10.1) 103.7 (6.9) 0.04
Diastolic blood pressure (mmHg) 62.3 (9.6) 62.3 (10.7) 62.6 (4.9) 0.99
Heart beat (beats/min) 105.4 (10.7) 106.0 (11.1) 114.5 (27.0) 0.07
Aortic root diameter (mm) 16.3 (1.5) 16.5 (1.4) 16.6 (0.7) 0.43
Left atrial diameter (mm) 20.5 (2.5) 20.8 (2.4) 21.0 (2.5) 0.46
Left ventricular diameter ED (mm) 31.3 (2.5) 31.7 (2.4) 31.7 (2.3) 0.34
Interventricular septal thickness ED (mm) 4.9 (0.8) 4.8 (0.7) 5.5 (0.9) 0.04
Left ventricular posterior
wall thickness ED (mm) 4.6 (0.8) 4.8 (0.9) 5.0 (0.9) 0.01
Left ventricular mass (grams) 31.1 (5.8) 32.4 (5.7) 36.1 (3.9) <0.01
Shortening fraction (%) 35.4 (4.8) 35.3 (4.6) 38.1 (5.3) 0.18
Values are means (standard deviation) or medians (95% range). Differences between boys and girls were compared using
ANOVA tests.
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Table 2 shows that systolic blood pressure at the age of 24 months was higher in children with
the homozygous variant of the GR-9β genotype with 2.65 mmHg (95% CI: 0.16, 5.14) compared
to homozygous references, indicating an increase of 2.6%. No association was found with diastolic
blood pressure.
Table 2. Associations of the GR-9β polymorphism of the glucocorticoid receptor gene with
cross-sectionally measured systolic and diastolic blood pressure at the age of 24 months
GR-9β genotype Systolic blood pressure Diastolic blood pressure
(mmHg) (mmHg)
% of (Difference (9% CI)) (Difference (9% CI))
persons (n = 486) (n = 486)
Homozygous reference 76.4 Reference Reference
Heterozygous 22.2 -0.91 (-9.30, 7.45) -0.01 (-2.08, 2.06)
Homozygous variant 1.4 2.65 (0.16, 5.14) 0.28 (-7.09, 7.64)
Values mean differences in systolic and diastolic blood pressure compared to the reference group. Models are adjusted for age
and gender; 95% CI, 95 % confidence interval.
Table 3 shows that GR-9β genotype was not associated with left cardiac structures and function
at the ages of 1.5 and 6 months. At the age of 24 months, GR-9β homozygous variants showed
a raised heart rate (9.14 (95% CI: 0.22, 18.1) beats per minute, indicating an increase of 8.6%).
Left ventricular mass was not only higher in homozygous variants (difference 5.01 (95% CI: 1.32,
8.71) grams compared to homozygous references), but also in heterozygous subjects (difference
1.32 (95% CI: 0.27, 2.37) grams compared to homozygous references). This means an increase
of 16% and 4.2%, respectively. Subsequently, we examined the effect of the combined group
(heterozygous and homozygous variant subjects) on the main findings of our study and compared
these dominant to the recessive models. In the dominant models, only the association between
the GR-9β genotype with left ventricular mass was still significant (p-value = 0.01). These results
suggest a recessive effect of the GR-9β polymorphism. When we applied Bonferroni approach our
presented associations were still significant.
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Table . Associations of the GR-9β polymorphism of the glucocorticoid receptor gene with
cross-sectionally measured left cardiac structures and function at the age of 1.5, 6 and 24 months
Left cardiac structures and function at . months of age (n = 2)
GR-9β % of Heart beat Aortic root Left atrial Left ventricular Shortening
genotype persons (beats/min) diameter (mm) diameter (mm) mass (grams) fraction (%)
(Difference (9% CI)) (Difference (9% CI)) (Difference (9% CI)) (Difference (9% CI)) (Difference (9% CI))
Homozygous reference 76.2 Reference Reference Reference Reference Reference
Heterozygous 22.4 -1.08 (-4.79, 2.63) 0.10 (-0.12, 0.32) -0.13 (-0.50, 0.23) 0.31 (-0.98, 0.37) -0.26 (-1.24, 0.72)
Homozygous variant 1.4 1.11 (-12.4, 14.6) 0.26 (-0.62, 1.13) 1.25 (-0.19, 2.68) 1.21 (-1.38, 3.79) -1.53 (-5.28, 2.21)
Left cardiac structures and function at  months of age (n = 2)
Homozygous reference 74.6 Reference Reference Reference Reference Reference
Heterozygous 23.9 0.41 (-9.63, 10.4) 0.16 (-0.63, 0.95) 0.09 (-0.25, 0.44) 0.07 (-0.70, 0.83) -0.32 (-1.29, 0.62)
Homozygous variant 1.5 -2.44 (-5.43, 0.55) 0.21 (-0.01, 0.43) 0.38 (-0.86, 1.62) 0.68 (-2.33, 3.68) 2.35 (-1.34, 6.21)
Left cardiac structures and function at 2 months of age (n = 9)
Homozygous reference 76.4 Reference Reference Reference Reference Reference
Heterozygous 22.2 0.62 (-1.87, 3.12) 0.15 (-0.13, 0.42) 0.27 (-0.21, 0.76) 1.32 (0.27, 2.37) -0.07 (-1.37, 1.24)
Homozygous variant 1.4 9.14 (0.22, 18.1) 0.25 (-0.72, 1.23) 0.52 (-1.21, 2.25) 5.01 (1.32, 8.71) 2.68 (-1.87, 7.23)
Values mean differences in left cardiac structures and function compared to the reference group. Models are adjusted for age and gender;
95% CI, 95 % confidence interval.
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Figure 1 presents the adjusted values of left ventricular mass between the ages of 1.5 months
and 24 months for the different genotype groups of the GR-9β polymorphism of the glucocorticoid
receptor gene. Values are based on repeated measurements regression analysis. Homozygous
variants showed a significantly higher increase in left ventricular mass compared to homozygous
references (difference 2.62 (95% CI: 0.46, 4.79) grams per month). No associations were found
with the other cardiovascular outcomes.
Table 4 shows associations of the GR-9β variant with the left ventricular dimensions at
the age of 24 months. A significant trend in larger interventricular septal thickness and left ven-
tricular posterior wall thickness was seen in children homozygous for the GR-9β genotype.
Figure . GR-9β polymorphism and left ventricular mass until the age of 24 months
Figure 1 presents the adjusted values of left ventricular mass for the different genotypes of the GR-9β polymorphism.
Values are based on repeated measurements regression analysis.
Table . Associations of the GR-9β polymorphism of the glucocorticoid receptor gene with
cross-sectionally measured left cardiac dimensions at the age of 24 months
Left cardiac structures at 2 months of age (n = 9)
GR-9β % of Left ventricular Interventricular Left ventricular
genotype persons diameter septal thickness posterior wall
ED (mm) ED (mm) thickness ED (mm)
(Difference (9% CI)) (Difference (9% CI)) (Difference (9% CI))
Homozygous reference 76.4 Reference Reference Reference
Heterozygous 22.2 0.44 (-0.01, 0.88) -0.06 (-0.22, 0.09) 0.19 (0.02, 0.36)
Homozygous variant 1.4 0.44 (-1.12, 2.01) 0.58 (0.04, 1.11) 0.43 (-0.17, 1.02)
Ptrend = 0.34 Ptrend = 0.04 Ptrend = 0.01
Values mean differences in left cardiac dimensions compared to the reference group.
Models are adjusted for age and gender; 95% CI, 95 % confidence interval.
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Discussion
In our prospective cohort study we found that the GR-9β polymorphism (rs6198), which has pre-
viously been shown to be related to myocardial infarction and coronary heart disease, is
associated with higher systolic blood pressure and higher left ventricular mass at the age of 24
months. No associations were found for the other cardiac measurements.
The major strengths of our study are its prospective design from early fetal life and the
size of the cohort. Furthermore, the relative effect of variants of the glucocorticoid receptor gene
on blood pressure and cardiac structures might be larger in childhood, when the effect of various
environmental factors, such as life style habits, is limited. A limitation could be that not in all
children participating in the Generation R measurements cardiac characteristics could not be
measured. The effect estimates would be biased if the associations of GR-9β polymorphism with
blood pressure and left cardiac structures differed between those included and not included in
the present analyses. This seems unlikely. We had 12 homozygous variant subjects for the GR-9β
polymorphism in the study. Although we recognize this limitation, to our knowledge our study has
the largest study group examining these associations in this age group so far. Furthermore, the
distribution of genotype frequencies did not significantly differ between children who could and
who could not be phenotyped. A third possible limitation is that the current study was designed
to assess heart development in a healthy, prospective cohort study. Thus generalizability is limited
to children born preterm or with low birth weight.
This is the first study that showed a higher systolic blood pressure, heart rate and left
ventricular mass in carriers of the GR-9β genotype at such a young age. This is in line with a
previous study in older-aged persons that found an association between the GR-9β polymorphism
and an increased risk of cardiovascular disease.11 They concluded that the GR-9β polymorphism,
which is related to a diminished suppressive effect of cortisol on the pro-inflammatory system,
is associated to the risk of myocardial infarction and coronary heart disease.11 This finding was
supported by higher levels of hs-CRP and Interleukin-6, suggesting an inflammatory pathogene-
sis of cardiovascular disease. Recently, Kumsta et al. showed that in the glucocorticoid receptor
gene the rs10482605 Single Nucleotide Polymorphism (SNP) is in high linkage disequilibrium (r2
= 0.915) with the A/G SNP in exon 9β (rs6198).26 They suggest that these two functional SNPs
have additive effects, leading to a relative glucocorticoid resistance on systemic level. The
rs10482605 SNP may also be involved in the associations we found and will be responsible for
at least part of the effect. Further research is needed to study the functional characteristics of
this particular SNP.
We found strong effects of the GR-9β genotype on blood pressure and left ventricular
mass at 2 years of age. These associations were not yet significant at the ages of 1.5 and 6
months. Results of our repeated measurements regression analyses suggest that the GR-9β
genotyping affects cardiac growth during the first 2 years, which leads to a significantly higher left
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ventricular mass at 2 years of age. We hypothesized a priori that the glucocorticoid receptor-9β
polymorphism affected cardiac growth and thus the effect increased over time. Entering the in-
teraction term of age with genotype in our repeated measurements models was prespecified.
The significant interaction term of genotype and age (p = 0.005) confirmed this increasing effect.
The GR-9β variant is described to be associated with a decreased sensitivity to glucocoticoids.
Recently is shown that cortisol stimulates cell cycle activity in the cardiomyocyte of the sheep
fetus.14 Thus higher exposure to glucocorticoids in fetal and early postnatal life might lead to
higher blood pressure and left ventricular mass in early childhood. Furthermore, a study in 4-wk
old rats concluded that reduced ventricular weight and systolic dysfunction found in 4-weeks-old
rats after neonatal dexamethasone treatment is transient, presumably due to compensatory cellular
hypertrophy. However, they found that depressed systolic function became manifest in elderly ani-
mals, showing evidence of compensatory dilatation to maintain normal cardiac output.27 It is
unknown whether these results are applicable to humans. A study in three American ethnic groups
reported a decreased systolic blood pressure in homozygous variants of the GR-9β polymorphism
(GG) compared to homozygous references (AA) (difference of 16 mmHg; p-value = 0.006).28 To
our knowledge, this association has not been replicated in other studies. We found an associa-
tion between the GR-9β genotype and a higher blood pressure and left ventricular mass. We
studied a relatively healthy group of young European children, in which the GR-9β polymorphism
may have different cardiovascular effects. Furthermore, environmental factors during pregnancy or
during early life could also interact with genetically determined glucocorticoid sensitivity and affect
the development of blood pressure. Since results seem inconsistent and underlying pathways are
not known, future research is needed. The cardiovascular adaptations we found in this study
might have consequences in later life. Blood pressure and heart beat are both related to the GR-9β
genotype and to left cardiac structures. However, adjustment for cardiovascular function (i.e. blood
pressure and heart beat) did not change the effect estimates in the associations of the GR-9β
genotype and left cardiac structures and dimensions. Changes in systolic blood pressure and heart
rate may be a first sign of the clinical consequences of this cardiac remodelling. Further studies
are needed to identify these pathways.
In conclusion, we showed in a large prospective cohort that the GR-9β polymorphism of
the glucocorticoid receptor gene influences systolic blood pressure and left cardiac dimensions
at young age. Furthermore, we found a trend of an increasing effect during the first years of life.
These results support our a priori hypothesis but should be replicated in other cohorts. Furthermore,
follow-up studies are needed to assess whether these relations persist during later life and
whether this genetic variant is indeed related to an increased risk of cardiovascular disease in
adulthood.
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Abstract
Background: Offspring of women who develop hypertensive disorders of pregnancy are at in-
creased risk of cardiovascular complications later in life, but the mechanisms underlying these
associations are unclear. The aim of this study was to examine the role of maternal and offspring
adiposity as explanations for the association of hypertensive disorders of pregnancy with variation
in blood pressure in the offspring.
Methods: Using data from 6,668 nine-year-old participants of the Avon Longitudinal Study of Parents
and Children, we examined the association between hypertensive disorders of pregnancy
(preeclampsia and gestational hypertension) and offspring blood pressure and adiposity measures.
Results: Maternal body mass index (BMI) was positively associated with both preeclampsia and
gestational hypertension. Preeclampsia was associated with lower birth weight and increased
risk of preterm delivery, whereas gestational hypertension was not associated with either of these
outcomes. Gestational hypertension was associated with greater offspring adiposity at age 9 (as-
sessed by BMI, waist circumference and fat mass) and with greater risk of obesity, but these
associations all attenuated towards the null with adjustment for maternal and paternal BMI.
Preeclampsia was inversely associated with offspring lean mass at age 9 in unadjusted and all
multivariable models, it was also inversely associated with BMI, waist circumference, fat mass
and obesity after adjustment for maternal BMI.
Preeclampsia and gestational hypertension were both associated with systolic and diastolic
blood pressure in the nine-year-old offspring, with associations being of similar magnitude in the
confounder adjusted models (including adjustment for maternal and paternal BMI and offspring
adiposity at age 9): mean difference in systolic blood pressure of 2.05 mmHg (95% CI: 0.72,
3.38) and 2.04 mmHg (95% CI: 1.42, 2.67), respectively for preeclampsia and gestational hyper-
tension, compared to those with no hypertensive disorders of pregnancy, with equivalent results
for diastolic blood pressure being 1.00 mmHg (95% CI: -0.01, 2.10) and 1.07 mmHg (0.60, 1.54).
The association of preeclampsia with offspring systolic and diastolic blood pressure attenuated
towards the null with further adjustment for birth weight and gestational age, whereas these
adjustments did not attenuate the association of gestational hypertension with offspring blood
pressure.
Conclusions: The associations of hypertensive disorders of pregnancy with higher offspring blood
pressure in later life do not appear to be explained by familial adiposity. Our findings suggest that
different mechanisms underlie the association of preeclampsia and gestational hypertension
with offspring blood pressure, with some evidence that the former is in part mediated by the effect
of preeclampsia on intrauterine growth restriction and preterm delivery.
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Introduction
Hypertensive disorders of pregnancy, consisting of preeclampsia and gestational hypertension,
are the most common complications of pregnancy and associated with adverse health outcome
for mother and her offspring. Preeclampsia, diagnosed by elevated blood pressure and poteinuria
after 20 weeks of gestation in women with no previous history of hypertension, occurs in about
2-7% of otherwise healthy nulliparous women.1-3 It is characterized by abnormal vascular response
to placentation resulting in increased systemic vascular resistance, enhanced platelet aggregation,
activation of the coagulation system, and endothelial cell dysfunction.4 It is a major cause of
perinatal deaths, preterm birth, and intrauterine growth restriction.2, 5, 6 Gestational hypertension,
is defined as elevated blood pressure after 20 weeks of gestation in women with no previous
history of hypertension, with no proteinuria. It has been found to occur in 6-17% of otherwise
healthy pregnancies and is associated with preterm delivery and small for gestational age in-
fants.1, 3 Preeclampsia and gestational hypertension are sometimes considered to be different
manifestations of the same underlying condition, differing only by severity and they do share several
key risk factors, including maternal obesity.7, 8 However, there are also important differences in
their etiology.1 For example, primiparity is described to be independently associatiated with
preeclampsia, but not with gestational hypertension.9
Maternal preeclampsia and gestational hypertension have been associated with higher
blood pressure in the offspring during childhood and adolescence. Palti and Rothschild reported
that 6-year-old boys, but not girls, born to mothers with preeclampsia had higher diastolic blood
pressures than their control children born to mothers without preeclampsia.10 By contrast Seidman
et al. concluded that 17-year-old girls from mothers with preeclampsia had higher systolic and di-
astolic blood pressures than their control females, whereas only the mean systolic blood pressure
differed between the males at the same age.11 Reports of gender differences such as these are
often chance findings and two further studies that have reported positive associations of hyper-
tensive disorders of pregnancy with offspring blood pressure in childhood reported no gender
differences.12-14 In the second of these studies there were positive associations with both random
blood pressure and 24 hour blood pressure in the offspring.13, 14
The underlying mechanisms explaining the associations of gestational hypertension and
preeclampsia with offspring blood pressure remain unclear and to our knowledge previous studies
have not examined whether associations differ between preeclampsia and gestational hypertension.
The familial clustering of preeclampsia is well-known15,16 and evidence suggests that both maternal
and fetal (from paternal genes) genes contribute to the risk of preeclampsia.17-19 In one of the
largest family studies to examine this, Cnattingius et al. concluded that genetic factors account
for more than half of the liability of preeclampsia, and that maternal genes contribute more than
fetal genes.18 Furthermore, the similar association of maternal (non-pregnant) and paternal blood
pressure with offspring blood pressure, suggest shared familial genetic or lifestyle characteristics
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underlie familial clustering of high blood pressure risk in general, rather than a strong intrauterine
mechanism.19
Given the strong association of maternal obesity with both preeclampsia and gestational
hypertension risk7, 8, as well as with blood pressure in general (including in children)20, together
with familial clustering of adiposity21, 22, family adiposity might be important in the mechanism
linking maternal hypertensive disorders of pregnancy to offspring blood pressure. Furthermore,
the epidemiological and pathophysiological links between preeclampsia and intrauterine growth
restriction and the positive associations of birth weight with later fat mass and body mass index
could provide a further link between preeclampsia and offspring blood pressure. The aim of this
study is to examine the associations of gestational hypertension and preeclampsia with offspring
blood pressure at the age of 9 years, and to study whether these associations are explained by
parental and offspring anthropometry. Figure 1 shows the pathways that we have examined in this
study.
Figure . Pathways concerning the association of hypertensive disorders of pregnancy and
offspring blood pressure that are explored in this paper.
The straight lines represent positive associations and the dashed line represents an inverse association. The pathways in this figure
are not intended to represent all pathways that might link maternal hypertensive disorders of pregnancy but focus on the role that
shared familial adiposity and birth weight and gestational age might have in explaining any association of hypertensive disorders of
pregnancy with offspring blood pressure.
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Methods
Design
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective population-based
birth cohort study that recruited 14,541 pregnant women resident in Avon, UK with expected
dates of delivery 1st April 1991 to 31st December 1992 (http://www.alspac.bris.ac.uk.).23There were
13,678 mother-offspring pairs from singleton live births who survived to at least one year of age;
only singleton pregnancies are considered in this paper. Of these women 94% gave consent for
abstraction of data from their obstetric records. 7,722 children attended the 9 year follow-up
clinic, which is approximately 65% of those invited (participants who were still alive and still
agreeing to be involved with the study).
Study population
In total 6,668 mother-offspring pairs had abstracted maternal antenatal data and an offspring who
attended the 9 year follow-up clinic. Of the 6,668 mother-offspring eligible pairs, complete data
on hypertensive disorders of pregnancy, including preeclampsia and gestational hypertension,
offspring anthropometry, blood pressure and potential confounders were available for 6,343 (95%)
and these form the analysis cohort for this study.
Maternal characteristics
Six trained research midwives abstracted data from obstetric medical records. There were no
between-midwife variation in mean values of abstracted data and repeated data entry checks
demonstrated error rates consistently <1%. Obstetric data abstractions included every measure-
ment of systolic and diastolic blood pressure entered into the medical records and the
corresponding gestational age and date at the time of the blood pressure measurement. According
to the definitions of the International Society for the Study of Hypertension in Pregnancy, a hyper-
tensive disorder during pregnancy was defined as a systolic blood pressure greater than 139
mmHg or a diastolic blood pressure greater than 89 mmHg, measured on at least two occasions
after 20 weeks of gestation in a woman without known hypertension prior to pregnancy.24
Preeclampsia was defined as the development of hypertension as stated above and proteinuria,
diagnosed if the protein reading on dipstick testing (Albustix; Ames Company, Elkhart, Indiana)
was at least 2+ on at least two occasions, occurring at the same time as the episodes of raised
blood pressure. Women with hypertensive disorder of pregnancy who did not fulfil the criteria of
preeclampsia were classified as having gestational hypertension. Thus, all women were cate-
gorised into one of three mutually exclusive categories of no hypertensive disorder of pregnancy,
gestational hypertension and preeclampsia.
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Offspring measurements at the age of nine years
Our outcomes in the current study are systolic and diastolic blood pressure (SBP and DBP). As
illustrated in Figure 1 we were concerned with the way in which maternal and offspring anthro-
pometry might explain the primary association between hypertensive disorders of pregnancy and
offspring blood pressure. Offspring blood pressure, body mass index (BMI), waist circumference,
total fat and lean mass were obtained around the age of 9 years, when all ALSPAC children were
invited to attend a clinic session.
Blood pressure was measured using a Dinamap 9301 Vital Signs Monitor. Two readings
of systolic and diastolic blood pressure (SBP and DBP) were recorded, with the child at rest, and
the mean of each was used.
Weight and height were measured in light clothing and without shoes. Weight was measured
to the nearest 0.1 kg using Tania scales. Height was measured to the nearest 0.1 cm using a
Harpenden stadiometer. Waist circumference was measured to the nearest 1 mm at the mid-point
between the lower ribs and the pelvic bone with a flexible tape. Fat and lean mass was assessed
using dual energy X-ray densitometry (DXA). A Lunar prodigy narrow fan beam densitometer was
used to perform a whole body DXA scan where bone content, lean and fat mass were measured.
For our main analyses we examined BMI, waist circumference, and total body lean and fat mass
as continuously measured variables. We also examined binary outcomes of overweight/obese
(BMI) and centrally obese (waist circumference). General overweight and obesity were defined using
the International Obesity Taskforce (IOTF) age- and sex-specific thresholds for childhood BMI.25
Central obesity was defined as an age- and sex-specific waist circumference ≥90th percentile26,
based on waist circumference percentile curves derived for British children.27
Covariates
Maternal age, parity, mode of delivery (caesarean section / vaginal delivery) and the child’s sex
and birth weight were obtained from the obstetric records. Current age of the child was recorded
in months as they arrived at the assessment clinic. At the time of recruitment, mothers were
asked to report their pre-pregnancy weight and height, which were used to calculate maternal
pre-pregnancy BMI. Maternal self-report of pre-pregnancy weight and her measured weight at the
first antenatal clinic were highly correlated (Pearson’s correlation coefficient = 0.95; p <0.0001).
At the time of recruitment, mothers were also ask to pass a questionnaire to the father of the
child; in this questionnaire the father was asked to record his height and weight, from which BMI
(at the start of his partner’s pregnancy) was calculated, and also his date of birth, so that his age
could be derived. Based on questionnaire responses, the highest parental occupation was used
to allocate the children to family social class groups (classes I (professional / managerial) to V
(unskilled manual workers), using the 1991 British Office of Population and Census Statistics
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(OPCS) classification). Mothers were repeatedly asked about their smoking throughout pregnancy
and these data were used to generate a categorical variable: never smoked; smoked before
pregnancy or in the first trimester and then stopped; smoked throughout pregnancy. Any note of
diabetes during the pregnancy in the medical records was recorded and women were categorised
as existing diabetes (already known to have diabetes before the start of pregnancy), gestational
diabetes (a new diagnosis of diabetes during the pregnancy noted in the medical records) or no
evidence of diabetes. Universal screening (for example with a fasting or random blood sample)
for gestational diabetes was not undertaken in this population.
Statistical analysis
Maternal, paternal and offspring characteristics (means (standard deviation) or medians (mid-
95% range) for continuous variables and N (%) for categorical variables) are presented across the
three categories of no hypertensive disorder of pregnancy, gestational hypertension and
preeclampsia; f-tests and chi-squared tests were used to test for statistical evidence of differences
across these three categories.
We created age- and sex-specific z-scores of the adiposity measures. This enabled us to
investigate whether the magnitude of the relationship between hypertensive disorders of pregnancy
and adiposity differs between the four adiposity measures, since all results will be on the standard
deviation scale.
We used multivariable regression models (linear regression for continuous outcomes and
logistic regression for binary outcomes) to explore all associations outlined in Figure 1. These as-
sociations include the associations of maternal pre-pregnancy BMI with hypertensive disorders
of pregnancy and with offspring adiposity at the age of nine years; the associations of hyperten-
sive disorders of pregnancy with birth size, gestational age and offspring adiposity at the age of
nine years; the associations of birth size with markers of adiposity at the age of nine years and
the associations of hypertensive disorders of pregnancy with offspring blood pressure at the age
of nine years. In all analyses gestational hypertension and preeclampsia were examined as sep-
arate exposures with the comparison group always being those women with no evidence of either
condition. In all models we adjusted first for offspring gender and age at examination (Model I).
Subsequently, we adjusted for potential confounding factors (maternal age, parity and smoking
during pregnancy, parental BMI, family socioeconomic position (parental education and occupational
social class), and in models with fat mass or lean mass for offspring height and height-squared)
(Model II). Since there were only 26 women (0.4%) with diagnosed gestational diabetes and
39 women (0.6%) with pre-existent diabetes, we did not consider gestational diabetes as a
confounding variable in our models, as these numbers would be too small to have any important
effect on the associations examined.
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Finally, we adjusted for potential mediating factors (Model III). Mediators were considered as
characteristics that occur after the main exposure variables (here hypertensive disorder of
pregnancy) and are believed to be caused by them and in turn are believed to cause the main
outcome of interest (here offspring blood pressure). Hence we considered gestational age at
birth, birth weight, and mode of delivery to be potential mediators of the main association since
hypertensive disorder of pregnancy can cause preterm birth (by induction of labour) and low birth
weight (by shared pathophysiology)28 and sibling studies suggest that these may be causally
(via intrauterine mechanisms) related to later offspring blood pressure.19, 29 By contrast offspring
adiposity might be primarily a confounding factor since the most likely pathway linking it to both
hypertensive disorders of pregnancy and offspring blood pressure would be via maternal adiposity.
Maternal and offspring adiposity together would thus represent potential confounding by shared
familial factors that are related to adiposity in family members and hence greater blood pressure
in family members.
We consider the confounder-adjusted model (Model II) to be the main estimate of a poten-
tial causal effect of hypertensive disorders of pregnancy on our outcome. Results are presented
jointly for mothers of female and male offspring as there was no strong and consistent evidence
of interactions with gender in any of the associations examined (all p-values >0.1). All statistical
analyses were performed using the Statistical Package for the Social Sciences version 15.0 for
Windows (SPSS Inc, Chicago, IL, USA).
Results
Table 1 presents the characteristics of mother and offspring. Of the 6,668 women included in this
study, 205 women (3.1%) were diagnosed with preeclampsia and 1,118 women (17.3%) were diag-
nosed with gestational hypertension. Mothers included in this study did not differ in the amount
of hypertensive disorders of pregnancy compared to the mothers not included because of missing
outcome or covariable data (202 (3.6%) of the 5,609 excluded women had preeclampsia (p-value
for difference 0.10) and 920 (16.4%) of the 5,609 excluded women had gestational hypertension
(p-value for difference 0.59)).
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Table . Subject characteristics (n = 6,668)
No hypertensive Gestational Preeclampsia P-value*
disorder of hypertension
pregnancy
(n = 5,345) (n = 1,118) (n = 205)
Mothers
Age at delivery (years) 29.1 (4.5) 28.8 (4.7) 28.8 (5.4) 0.26
Body mass index (kg/m2) 22.5 (3.3) 24.6 (4.8) 25.3 (5.7) <0.01
Height (cm) 164.0 (6.6) 164.9 (6.8) 163.4 (7.3) <0.01
C-section (%) 502 (9.5) 172 (15.4) 55 (26.8) <0.01
Length of gestation (weeks) 40.0 (35.0 - 42.0) 40.0 (36.0 - 42.0) 39.0 (29.0 - 42.0) <0.01
Preterm birth (<37 weeks) (%) 236 (4.4) 53 (4.7) 47 (22.9) <0.01
No previous pregnancies (%) 2254 (43.7) 631 (58.4) 138 (69.7) <0.01
Smoked throughout pregnancy (%) 1013 (19.4) 162 (14.8) 27 (13.5) <0.01
Manual social class (%) 711 (14.5) 152 (14.9) 25 (13.6) 0.25
Fathers
Age (years) 31.3 (5.4) 31.1 (5.4) 31.1 (6.7) 0.53
Body mass index (kg/m2) 25.0 (3.2) 25.6 (3.6) 25.3 (3.7) <0.01
Offspring
Male (%) 2613 (48.9) 584 (52.2) 109 (53.2) 0.07
Birth weight (grams) 3446 (509) 3435 (565) 3103 (859) <0.01
Age at visit (months) 118.0 (114.0 - 128.0) 118.5 (114.0 - 129.0) 118.5 (114.0 - 127.0) 0.76
Systolic blood pressure (mmHg) 102.2 (9.1) 105.2 (10.1) 104.5 (8.8) <0.01
Diastolic blood pressure (mmHg) 57.2 (6.4) 58.2 (6.0) 58.6 (6.6) <0.01
Weight at visit (kg) 34.5 (7.3) 36.2 (8.3) 34.4 (7.6) <0.01
Height at visit (cm) 139.4 (6.3) 140.4 (6.2) 138.8 (6.2) <0.01
BMI at visit (kg/m2) 17.6 (2.8) 18.2 (3.2) 17.7 (3.0) <0.01
Obese based on BMI (%) 219 (4.1) 90 (8.1) 12 (5.9) <0.01
Overweight or obese based on BMI (%) 1161 (22.0) 315 (28.5) 51 (25.0) <0.01
Waist circumference (cm) 62.6 (7.6) 64.2 (8.7) 63.0 (8.3) <0.01
Total body fat mass (grams) 8404 (5016) 9416 (5636) 8439 (5197) <0.01
Total body lean mass (grams) 24493 (3212) 25108 (3340) 24208 (3271) <0.01
Centrally obese (%) 2066 (38.8) 519 (46.5) 83 (40.5) <0.01
Values are means (standard deviation), medians (95% range) or number of children (%).
*p-value chi-square test or f-test for the null hypothesis of no differences across the 3 categories (i.e. 2 degrees of freedom).
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Table 2 shows the associations of maternal characteristics and paternal BMI with preeclampsia
and gestational hypertension. Both preeclampsia and gestational hypertension were more common
in women in their first pregnancy and were less common in women who smoked in pregnancy.
Maternal BMI was positively associated with both preeclampsia and gestational hypertension
The associations of nulliparity, smoking and maternal BMI all appeared stronger for preeclampsia
than they did for gestational hypertension, but there was no strong statistical evidence that any
of these associations differed from each other (p-value for heterogeneity between the two estimates
all >0.3). Paternal BMI was associated with an increased risk of gestational hypertension, but this
association attenuated to the null after adjustment for maternal BMI (maternal BMI adjusted
association of paternal BMI with gestational hypertension: 1.03 (95% CI: 1.01, 1.06)). Social
class was not associated with either hypertensive disorder of pregnancy.
Table 2. Associations of parental characteristics with hypertensive disorders of pregnancy
No hypertensive Gestational Preeclampsia
disorder of hypertension
pregnancy
(n = 5,345) (n = 1,118) (n = 205)
No previous pregnancies, OR Reference 1.78 (1.56, 2.02) 2.83 (2.10, 3.80)
Smoked throughout pregnancy, OR Reference 0.72 (0.60, 0.86) 0.65 (0.43, 0.98)
Manual social class, OR Reference 1.03 (0.86, 1.25) 0.93 (0.61, 1.43)
Maternal body mass index
(per 1SD z-score), OR Reference 1.67 (1.56, 1.78) 1.79 (1.59, 2.02)
Paternal body mass index
(per 1SD z-score), OR Reference 1.20 (1.12, 1.29) 1.09 (0.92, 1.28)
Values are odds ratios (95% confidence interval).
Table 3 presents the unadjusted associations of hypertensive disorders of pregnancy with off-
spring characteristics. Preeclampsia was associated with both lower birth weight (mean difference
comparing offspring of mothers with preeclampsia to those with no hypertensive disorder of
pregnancy: -341.9 grams (95% CI: -416.0, -267.9)) and preterm birth (OR comparing offspring of
mothers with preeclampsia to those with no hypertensive disorder of pregnancy: 6.39 (95% CI:
4.50, 9.08)). These effect estimates attenuated after adjustment for mode of delivery, and gesta-
tional age at birth (-109.2 grams (95% CI: -172.3, -46.1)) or birth weight (OR 1.91 (95% CI: 0.99,
3.69)), respectively for birth weight and preterm delivery. Gestational hypertension was not as-
sociated with birth weight or preterm delivery either before or after adjustment for mode of delivery
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and birth weight or gestational age. In these unadjusted analyses gestational hypertension was as-
sociated with greater offspring adiposity at the age of nine years, whereas preeclampsia did not
show strong evidence of an association with offspring adiposity. Preeclampsia was inversely as-
sociated with lean mass, suggesting that infants of women who experienced preeclampsia having
less lean mass than those who did not experience any hypertensive disorder of pregnancy. Finally,
in these unadjusted models, preeclampsia and gestational hypertension were both positively as-
sociated with offspring systolic and diastolic blood pressure.
Table . Associations of hypertensive disorders of pregnancy with offspring characteristics at
birth and at the age of nine years
No hypertensive Gestational Preeclampsia
disorder of hypertension
pregnancy
(n = 5,345) (n = 1,118) (n = 205)
Offspring characteristic
Birth weight, mean difference (grams) Reference -10.3 (-43.9, 23.3) -341.9 (-416.0, -267.9)
Preterm birth, OR Reference 1.07 (0.79, 1.45) 6.39 (4.50, 9.08)
Adiposity measure
BMI, mean difference (z-score) Reference 0.22 (0.15, 0.28) 0.04 (-0.10, 0.17)
Waist circumference,
mean difference (z-score) Reference 0.20 (0.14, 0.27) 0.03 (-0.11, 0.16)
Fat mass, mean difference (z-score) Reference 0.22 (0.16, 0.29) 0.03 (-0.11, 0.17)
Lean mass, mean difference (z-score) Reference 0.18 (0.11, 0.24) -0.14 (-0.29, -0.01)
Obese, OR Reference 2.05 (1.59, 2.64) 1.45 (0.80, 2.64)
Overweight or obese, OR Reference 1.43 (1.23, 1.65) 1.19 (0.86, 1.65)
Central obesity, OR Reference 1.39 (1.22, 1.58) 1.09 (0.82, 1.45)
Blood pressure
SBP, mean difference (mmHg) Reference 3.06 (2.46, 3.66) 2.36 (1.09, 3.64)
DBP, mean difference (mmHg) Reference 1.44 (1.03, 1.86) 0.99 (0.10, 1.89)
Values are means of differences or odds ratios (OR) (95% confidence interval) and reflect the difference in offspring characteristic
compared to women without any hypertensive disorder of pregnancy (reference group).
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Multivariable associations of hypertensive disorders of pregnancy and offspring adiposity are presented in
Table 4. The inverse association of preeclampsia with offspring lean mass at age 9 was essentially unaltered
by adjustment for potential confounding factors and mediation by birth size and gestational age. With ad-
justment for potential confounding factors the previously null associations of preeclampsia with all measures
of offspring adiposity became inverse. The main covariable that resulted in this unmasking of an inverse as-
sociation was maternal pre-pregnancy BMI. Thus, offspring of women with preeclampsia are less adipose and
less likely to be obese once the positive association of maternal BMI with preeclampsia risk and with off-
spring adiposity has been controlled for.
Table . Associations of hypertensive disorders of pregnancy with offspring adiposity measures
No hyper- Gestational hypertension Preeclampsia
tensive
disorder of
pregnancy
(n = 5,345) (n = 1,118) (n = 205)
Model I Model II Model III Model I Model II Model III
BMI, z-score Reference 0.23 (0.16, 0.30) 0.05 (-0.02, 0.12) 0.07 (-0.01, 0.14) 0.03 (-0.12, 0.18) -0.19 (-0.34, -0.05) -0.17 (-0.32, -0.03)
Waist circumference,
z-score Reference 0.21 (0.14, 0.28) 0.04 (-0.03, 0.10) 0.05 (-0.02, 0.12) 0.01 (-0.15, 0.16) -0.20 (-0.34, -0.05) -0.19 (-0.33, -0.04)
Fat mass, z-score Reference 0.24 (0.17, 0.31) 0.04 (-0.03, 0.10) 0.04 (-0.03, 0.10) 0.03 (-0.12, 0.19) -0.09 (-0.23, 0.05) -0.09 (-0.23, 0.05)
Lean mass, z-score Reference 0.19 (0.12, 0.26) 0.01 (-0.04, 0.05) 0.02 (-0.03, 0.06) -0.20 (-0.36, -0.04) -0.19 (-0.28, -0.09) -0.15 (-0.25, -0.05)
Obese, OR Reference 2.29 (1.71, 3.06) 1.37 (0.99, 1.89) 1.41 (1.02, 1.95) 1.21 (0.56, 2.63) 0.50 (0.21, 1.20) 0.50 (0.21, 1.22)
Overweight or
obese, OR Reference 1.54 (1.31, 1.82) 1.08 (0.90, 1.30) 1.10 (0.92, 1.32) 1.10 (0.75, 1.62) 0.60 (0.39, 0.93) 0.61 (0.39, 0.95)
Central obesity, OR Reference 1.40 (1.21, 1.61) 1.04 (0.89, 1.21) 1.08 (0.92, 1.26) 1.19 (0.86, 1.65) 0.81 (0.57, 1.15) 0.84 (0.59, 1.20)
Values are regression coefficients or odds ratios (95% confidence interval) and reflect the difference in offspring characteristic for maternal
hypertensive disorder of pregnancy. CI, confidence interval; OR, Odds ratio; BMI, Body mass index.
Model I: adjusted for offspring sex and age at the 9-y-old visit.
Model II: additionally adjusted for maternal age at delivery, parental pre-pregnancy body mass index, parity, social class, maternal smoking
during pregnancy, and offspring weight, height and height squared at the 9-y-old visit (the confounder adjusted model).
Model III: additionally adjusted for mode of delivery, gestational age at birth and birth weight (to examine mediation by these determinants).
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With adjustment for potential confounders the previous positive association of gestational hypertension and
offspring adiposity was considerably attenuated to the null, with adjustment for parental BMI being the key
covariables responsible for this attenuation. After adjustment for mode of delivery, gestational age at birth
and birth weight, gestational hypertension had some association with obesity (OR 1.41 (95% CI: 1.02, 1.95)).
This increase in magnitude of the association was largely due to adjustment for birth weight.
Associations of hypertensive disorders of pregnancy with offspring blood pressure are presented in
Table 5. Both preeclampsia and gestational hypertension were associated with greater systolic and diastolic
blood pressure in the nine-year-old offspring, with the magnitudes of these associations being similar for each
hypertensive disorder of pregnancy in the confounder adjusted model (Model II): on average both preeclampsia
and gestational hypertension were associated with a 2 mmHg greater systolic blood pressure and a 1 mmHg
diastolic blood pressure in the 9-year-old offspring. With further adjustment for mode of delivery, birth weight
and gestational age the association of preeclampsia with offspring blood pressure attenuated towards the
null, whereas that of gestational hypertension was not attenuated.
Table . Associations of hypertensive disorders of pregnancy with offspring blood pressure
No hyper- Gestational hypertension Preeclampsia
tensive
disorder of
pregnancy
(n = 5,345) (n = 1,118) (n = 205)
Model I Model II Model III Model I Model II Model III
SBP (mmHg) Reference 3.17 (2.50, 3.85) 2.04 (1.42, 2.67) 2.50 (1.80, 3.20) 2.23 (0.78, 3.67) 2.05 (0.72, 3.38) 1.13 (-0.35, 2.60)
DBP (mmHg) Reference 1.47 (1.00, 1.94) 1.07 (0.60, 1.54) 1.25 (0.76, 1.73) 0.96 (-0.06, 1.97) 1.00 (-0.01, 2.01) 0.65 (-0.38, 1.69)
Values are regression coefficients or odds ratios (95% confidence interval) and reflect the difference in offspring characteristic for maternal
hypertensive disorder of pregnancy. CI, confidence interval; SBP, Systolic blood pressure; DBP, Diastolic blood pressure.
Model I: adjusted for offspring sex and age at the 9-y-old visit.
Model II: additionally adjusted for maternal age at delivery, parental pre-pregnancy body mass index, parity, social class, maternal smoking
during pregnancy, and offspring weight, height and height squared at the 9-y-old visit (the confounder adjusted model).
Model III: additionally adjusted for mode of delivery, gestational age at birth and birth weight (to examine mediation by these determinants). 2
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Discussion
In our prospective population-based cohort study, offspring of women with a history of preeclampsia
or gestational hypertension had increased systolic and diastolic blood pressure at the age of
nine years compared to women without hypertensive disorders of pregnancy. These associations
did not appear to be explained by shared familial characteristics (genetic or behavioral) related
to family adiposity, since they remained with adjustment for maternal and paternal pre-pregnancy
BMI and offspring adiposity. The association of preeclampsia with offspring blood pressure ap-
peared to be, at least in part, mediated by the association of preeclampsia with lower birth weight
and preterm delivery, as adjustment for these markedly attenuated the confounder adjusted as-
sociation; adjustment for these infant characteristics did not attenuate the association of
gestational hypertension with offspring blood pressure. An additional interesting finding of our
study was that of an inverse association of preeclampsia with offspring lean mass in all multi-
variable models and also an inverse association with measurements of adiposity and obesity
once maternal BMI had been taken into account. These associations did not markedly attenuate
with adjustment for birth size and preterm birth and suggest that preeclampsia might have long-term
effects on reduced offspring lean and fat mass.
The major strengths of our study are its prospective design, the large sample size and the
ability to unpick associations between hypertensive disorders of pregnancy, offspring blood pressure
and familial adiposity. To our knowledge this is the first study examining the associations of hyper-
tensive disorders of pregnancy with measures of adiposity in detail, including highlighting the
differences between preeclampsia and gestational hypertension. We were able to define
preeclampsia and gestational hypertension by applying standard definitions to detailed clinical
data (repeated assessments throughout pregnancy of blood pressure and proteinuria) abstracted
from the antenatal medical records rather than having to rely on retrospective maternal report as
some previous studies have. Routine clinical data may be less accurate than data collected for
research purposes and examining the antenatal blood pressure used in this study shows digit
preference for values ending in 5 or 0 (e.g. systolic blood pressures of 105, 110, 115, 120, 125
mmHg, etc.). Since the clinical staff collecting these data could not have had any knowledge of
future offspring blood pressure this measurement error (rounding) would be non-differential by the
main outcome of offspring blood pressure and would have the expectation of biasing any asso-
ciation towards the null. The findings of expected associations of preeclampsia and gestational
hypertension with established risk factors (maternal age, parity, smoking and BMI) in our study
suggest that measurement error has not resulted in marked bias. Whilst the majority (95%) of par-
ticipants attending the nine year follow-up clinic had adequate data on blood pressure, fat mass,
other anthropometric measurements and all confounding factors, there has been lost to follow-
up with 65% of those eligible to attend the nine year follow-up clinic attending. Participants who
attend follow-up clinics are more likely to be from higher socioeconomic position families, less
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likely to have had teenage mothers and mothers who smoked during pregnancy.30 However, those
attending the clinic had mothers with similar proportions of preeclampsia and gestational hyper-
tension compared to those who were not included in the study and we can think of no reasons why
the associations we have examined here should be markedly different in those lost to follow-up.
We found positive associations of both preeclampsia and gestational hypertension with
offspring systolic and diastolic blood pressure at the age of nine years, with associations of each
being somewhat weaker for diastolic blood pressure compared to systolic blood pressure. Given
smaller numbers of mothers with preeclampsia the association with diastolic blood pressure is
imprecisely estimated and includes the null value. In the basic model adjusting only for gender
and age appears that gestational hypertension might have somewhat stronger associations with
offspring blood pressure than preeclampsia, but this is largely driven by the stronger association
of maternal (and paternal) BMI with gestational hypertension than with preeclampsia. When
parental BMI, offspring adiposity and other potential confounders are taken into account positive
associations of both preeclampsia and gestational hypertension remain with systolic and dias-
tolic blood pressure with the point estimates for associations being very similar for preeclampsia
and gestational hypertension. With further adjustment for birth weight and gestational age the
point estimates for the associations of preeclampsia with both systolic and diastolic blood pres-
sure are reduced by about 40%, whereas these adjustments make very little difference to the
positive associations of gestational hypertension with systolic and diastolic blood pressure.
Though the confidence intervals for Model III overlap with those for Model II, suggesting that the
two estimates are consistent with each other.
Our findings are in line with several other studies that have reported positive associations
between hypertensive disorders of pregnancy and offspring blood pressure.10, 11, 13, 14 Our study
extends this previous work by suggesting that family adiposity does not explain these associations.
It also suggests that intrauterine growth restriction might in part mediate the association of
preeclampsia with offspring blood pressure. By contrast since gestational hypertension was not
associated with lower birth weight it does not mediate the similar magnitude of association of
gestational hypertension with offspring blood pressure.
We are not aware of previous studies showing a reduced lean and fat mass (after ad-
justment for maternal BMI) in offspring of mothers who experienced preeclampsia in their
pregnancy. Several mechanisms could explain this association. Preeclampsia is often accompa-
nied by fetal growth restriction and preterm delivery, due to placental hypoperfusion28, and we
confirmed a specific association of preeclampsia with lower birth weight and increased risk of
preterm delivery, which was not seen for gestational hypertension, in our study. Since lower birth
weight is associated with reduced lean and fat mass in later life, a finding previously demon-
strated in ALSPAC, the association of preeclampsia with later offspring reduced fat and lean mass
may be explained by its effect on IUGR. Another explanation for the association of preeclampsia
and decreased measures of adiposity could be maternal smoking during pregnancy. Smoking is
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associated with lower BMI and is protective against preeclampsia.31 However, several studies
have shown a positive association between maternal smoking in pregnancy and greater offspring
BMI in later life.32 Thus, when we control for maternal BMI we may unmask a positive association
of maternal smoking with offspring BMI and because of the protective effect of smoking on
preeclampsia an inverse association between it and offspring BMI. Whilst these explanations
are plausible the inverse association was present even with adjustment for maternal smoking and
was unaffected by adjustment for birth weight and gestational age. Thus, further research is required
to examine whether this finding is replicated in other independent cohorts and if so to explore
likely underlying mechanisms.
In conclusion, our findings suggest that women who experience hypertensive disorders of
pregnancy have children with higher blood pressure at the age of nine years. These associations
are not explained by the associations of maternal BMI with hypertensive disorders of pregnancy
and with offspring BMI and whilst interventions to reduce obesity might reduce the occurrence of
hypertensive disorders of pregnancy these are unlikely to reduce its link to offspring higher blood
pressure. The mechanisms underlying the associations of preeclampsia and gestational hyper-
tension with offspring blood pressure may differ from each other, with evidence that the
relationship between preeclampsia and IUGR plays a role in its association but does not have any
role in the association of gestational hypertension with offspring blood pressure.
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Introduction
Many epidemiological studies from different geographical regions demonstrated a strong relation-
ship between low birth weight and the risk of cardiovascular disease.1-3 These associations are
consistent and cannot be explained by preterm birth.4, 5 Also, they seem to be independent of in-
fluences in adult life including social class, obesity and smoking habits.6, 7 The mechanisms
underlying these associations are not well known. It has been suggested that developmental
adaptations due to suboptimal fetal nutrition permanently program the fetus and lead to an in-
creased risk of coronary heart disease many decades later.8 It has also been argued that the
associations between size at birth and later disease could primarily be the result of common ge-
netic influences. Based on more recent studies, a more general developmental plasticity hypothesis
has been proposed.9 Developmental plasticity is defined as the ability of an organism to develop
in various ways, depending on the particular environment or setting.10 In this process, early en-
vironmental influences induce anatomical, physiological and biochemical adaptations in later life.
These adaptations may be beneficial for short-term survival but could have adverse long-term
consequences. This latter conceptual basis is extended with the Predictive Adaptive Response
(PAR) theory, stating that long-term consequences of these early environmental influences may
be especially harmful if the actual postnatal, mature environment differs from the environment
predicted during the plastic, developmental phase.11 The greater the degree of mismatch, the
greater the disturbance in physiology and the greater the risk of disease.
Studies in humans generally use birth weight as a measure of adverse fetal exposure.
Birth weight might indeed be an indicator of the quality of the intra-uterine environment.12 However,
the same birth weight might be the result of different growth patterns and exposures in fetal life.
Furthermore, a period of compensatory growth will follow after nutritional deficit in utero. The
most rapid growth acceleration in low birth weight children occurs in the first weeks after birth.13
This accelerated growth rate might also have important consequences later in life.14 These findings
suggest that children with both restricted fetal and infant growth and accelerated childhood
weight gain are at particular risk of development of cardiovascular disease in adult life and its
risk factors.15, 16
In this chapter, we discuss epidemiological studies designed to identify mechanisms
underlying the associations of fetal growth retardation and low birth weight with the development
of cardiovascular disease in adulthood. We will focus on specific adverse fetal exposures, cardio-
vascular adaptations and perspectives for future studies.
2
G
en
er
al
D
is
cu
ss
io
n
Specific fetal exposures
Fetal undernutrition
Maternal anthropometrics, maternal diet and placenta function
The fetal nutrition supply line includes maternal anthropometrics, diet and placenta function. Maternal
anthropometrics during pregnancy are related to their nutritional and health status.17, 18 Several
studies have shown that maternal anthropometric factors such as prepregnancy body mass index
and weight gain during pregnancy are associated with fetal growth characteristics and adverse
pregnancy outcomes.19-21 Thus, the maternal nutritional and health status during pregnancy may
lead to an adverse fetal environment and might affect fetal growth and development (Table 1).
Table . Maternal anthropometrics and diet in association with cardiovascular disease later in life
Maternal anthropometric Cardiovascular outcome
characteristic during pregnancy
Maternal anthropometric
Short stature Increased death rates from coronary heart disease
Low triceps skin fold thickness Increased blood pressure
High weight gain during pregnancy Increased left ventricular mass
Maternal diet
Total energy intake Increased risk and earlier onset coronary artery disease
Low protein intake Increased blood pressure
Low calcium intake Increased blood pressure
Low folate intake Endothelial dysfunction
Studies examining the direct effect of maternal anthropometrics on cardiovascular outcomes in the
offspring demonstrated conflicting results (Table 1). Most of these studies were based on retro-
spective cohorts. We found in a prospective cohort study that maternal weight gain during
pregnancy is associated with larger left ventricular mass at the age of 6 months, independent of
maternal weight just before pregnancy.22 Additionally, a recent study showed that greater maternal
gestational weight gain is associated with greater offspring body mass index into early adulthood
and that this may translate into higher systolic blood pressure in the offspring.23 Several underlying
biological pathways may explain the associations between maternal anthropometrics during
pregnancy and vascular development and cardiac growth and development postnatally. One ex-
planation could be that the usual increase in insulin resistance seen in late pregnancy is higher
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in mothers who show a marked increase in weight during pregnancy, resulting in increased fetal
body and cardiac growth.24, 25 Further studies, in which measures of insulin resistance such as
insulin, glucose or HbA1c levels in pregnancy have been measured, are needed to identify the
potential role of maternal insulin resistance for fetal cardiovascular development. The major limi-
tation of weight gain is that the total amount depends on both an increase in fluid and fat mass.
Also, it is not clear whether maternal pre-pregnancy weight or weight gain during pregnancy affects
cardiovascular development in the offspring.
The fetal nutrition supply line may also be directly affected by the dietary intake of the
mother during pregnancy. A follow-up study of persons who were conceived during the Dutch
famine during the second World War demonstrated a doubled risk and an earlier onset of coronary
artery disease among subjects who were exposed to famine during fetal life.16 These results
were independent of size at birth and current smoking and social economic status and suggest
that severe maternal malnutrition during early gestation contributes to the occurrence of coronary
artery disease in the offspring. However, these results could not be replicated in a cohort of
adults who were exposed as fetuses to severe famine during the siege of Leningrad.26 The as-
sociations of less extreme variations in maternal intake of macronutrients and micronutrients
with the development of risk factors for cardiovascular disease in the offspring have also been
studied. Prospective cohort studies showed that variation in maternal total protein intake during
pregnancy does not program offspring blood pressure already in infancy or in adolescence.27-29
Stronger relations have been reported between micronutrients and risk factors for cardio-
vascular disease in the offspring. Maternal calcium supplementation during pregnancy has been
described as being associated with lower systolic blood pressure in the offspring.30-32 In some
follow-up studies the effect disappeared later in childhood and no associations were reported in
twins.33, 34 Therefore, it is still unclear whether ensuring adequate calcium intake among pregnant
women could be a way to prevent hypertension in the next generation. Low folate and high homo-
cystein levels, in combination or independently, have been shown to be risk factors for endothelial
dysfunction and cardiovascular disease.35, 36 In healthy infants, a relationship between maternal
folate levels during pregnancy and vascular endothelial function was demonstrated.37 More recently
developed statistical approaches, such as dietary pattern analysis may give more detailed infor-
mation about the effect of maternal nutrition intake during pregnancy on development of risk
factors for cardiovascular disease later in life.
Placental function, reflected by placental weight and hemodynamic function is one of the
most important determinants of the fetal supply line. While the size of the placenta reflects only
an indirect measure of its capacity to transfer nutrients to the fetus, it is strongly associated
with fetal size at birth.38 A review focused on the associations of placental weight with the risk
of cardiovascular disease in the offspring reported no consistent associations.39 Preeclampsia
is considered as the most extreme form of hemodynamic placental dysfunction. According to recent
studies, women with prior preeclamptic pregnancies are at increased risk of cardiovascular dis-
2
G
en
er
al
D
is
cu
ss
io
n
ease.40, 41 Furthermore, preeclampsia has been associated with elevated blood pressure in off-
spring during childhood and adolescence.42 Fetal growth restriction due to placental dysfunction
or common genetic variants may at least partly explain these associations. A milder form of
placental hemodynamic dysfunction is reflected by resistance in the umbilical artery. An increased
umbilical artery resistance is associated with fetal growth restriction and low birth weight.43
Maternal smoking during pregnancy
Maternal smoking during pregnancy is strongly associated with fetal growth retardation.44-46 The
effects of smoking on placental vessels could be due to nicotine or hypoxia. This association is
partly mediated by restricted blood flow in the vascular beds of the placenta due to increased re-
sistance of the umbilical-placental circulation.47, 48 Fetal exposure to maternal smoking might also
have adverse and persistent consequences for cardiovascular growth and development. Recent
studies showed associations between intra-uterine exposure to maternal smoking and high blood
pressure in childhood and adulthood.49, 50 However, the association of maternal smoking and
offspring blood pressure might be confounded by a comprehensive range of indicators of social
economic position. Confounding by social and familial factors is further supported by the similarity
of maternal and paternal smoking effects, suggesting that modest differences in childhood blood
pressure associated with maternal smoking could be the result of not only biological effects on
the intrauterine environment, but also common adverse familial factors.51 Studies focused on
fetal cardiovascular development may unravel these associations. We found in a prospective cohort
study that maternal smoking during pregnancy is associated with placental and fetal hemodynamic
adaptations indicating increased arterial resistance.52 These fetal hemodynamic adaptations
were subsequently associated with fetal growth retardation and changes in postnatal cardiac
structures. Similarly, maternal smoking in pregnancy has also been suggested to be directly as-
sociated with changes in fetal cardiac dimensions and volumes.53, 54
Genetic susceptibility
The association of fetal growth restriction and low birth weight with the increased risk of cardio-
vascular disease may also be explained by common genetic variants related to insulin sensitivity
or angiogenesis (Table 2).55 Insulin and insulin-like growth factors are important fetal growth fac-
tors.56 Genetic factors related to insulin or insulin-like growth factors production and sensitivity
may lead to both impaired fetal growth and to type 2 diabetes and cardiovascular disease in later
life.55 It has been suggested previously that Single Nucleotide Polymorphisms (SNPs) in the IGF1
gene and the INS VNTR gene are associated with fetal and postnatal growth. However, these effects
seem to be inconsistent.57, 58
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Table 2. Common genetic variants (PPARγ2 and GR gene) studied to explain the associations
between low birth weight with type 2 diabetes and cardiovascular disease later in life
First author (year) Main finding: Main finding: Main finding:
effect on pre- and effect on risk factors effect on risk factors
postnatal growth type 2 diabetes cardiovascular disease
PPARγ2 (rs 22)
Masud et al (2003) 171 Pro12Ala genotype is associated with
higher BMI and obesity.
Bennett et al (2008) 59 Pro12Ala genotype is not associated with
birth weight.
Pfab et al (2006) 60 Pro12Ala genotype is not associated with Pro12Ala genotype is not associated with
intra-uterine growth, size at birth and intra-uterine growth, size at birth and
insulin resistance. insulin resistance.
Mook-Kanamori et al (2009) 61 Ala12 allele is associated with an Ala12 allele is associated with an increased
increased growth rate in early life. growth rate in early life. This effect may be
This effect may be influenced by the influenced by the duration of breastfeeding.
duration of breastfeeding.
Eriksson et al (2003) 63 Ala12 allele and a lower birth weight is Ala12 allele and a lower birth weight is
associated with risk of increased lipid levels. associated with risk of increased lipid levels.
Yliharsila et al (2004) 64 Pro12Pro genotype modifies the association Pro12Pro genotype modifies the association
between low birth weight and hypertension. between low birth weight and hypertension.
GR gene (NRC)
Van Rossum et al (2002) 172 ER22/23EK polymorphism is associated ER22/23EK polymorphism is associated
with decreased sensitivity to glucocorticoids with decreased sensitivity to glucocorticoids
and low insulin levels. and low cholesterol levels.
Finken et al (2007) 173 ER22/23EK polymorphism is associated ER22/23EK polymorphism is associated
with a protecting effect against postnatal with a protecting effect against postnatal
growth failure and insulin resistance after growth failure and insulin resistance after
preterm birth. preterm birth.
Van Rossum et al (2003) 174 G-allele of the BclI polymorphism is
associated with increased glucocorticoid
sensitivity and lower BMI.
Rosmond et al (2000) 175 G-allele of the BclI polymorphism is
associated with increased abdominal
obesity and higher cortisol levels in
GG-carriers compared to CC-carriers.
Bueman et al (1997) 176 G-allele of the BclI polymorphism is associated
with increased abdominal visceral fat in lean
GG-carriers, but not in overweight GG-carriers.
Huizenga et al (1998) 177 N363S polymorphism is associated with
increased glucocorticoid sensitivity, increased
insulin response to Dexamethasone and
increased BMI.
29
G
en
er
al
D
is
cu
ss
io
n
Table 2. continued
First author (year) Main finding: Main finding: Main finding:
effect on pre- and effect on risk factors effect on risk factors
postnatal growth type 2 diabetes cardiovascular disease
Watt et al (1992) 178 Homozygosity for the G-allele of the
BclI polymorphism was more frequent in
the group with personal and parental
hypertension.
Di Blasio et al (2003) 179 Carrying both the N363S and the
BclI polymorphism is associated with higher
systolic and diastolic blood pressure and
serum cholesterol levels.
Rosmond et al (2001) 180 N363S polymorphism is not associated
with BMI or sensitivity to glucocorticoids.
Lin et al (2003) 181 N363S polymorphism is associated with N363S polymorphism is not associated with
obesity and overweight, but not with type 2 hypertension.
diabetes.
Rosmond et al (2000) 182 TthIII polymorphism is associated with
diurnal cortisol levels, but not with any
anthropometric or glucose related phenotype.
Van den Akker et al (2008) 69 GR-9β polymorphism is associated with an
increased risk of cardiovascular disease.
Geelhoed et al (2009) GR gene polymorphisms are not associated GR gene polymorphisms are not associated
with growth in fetal and early postnatal life, with growth in fetal and early postnatal life,
neither to size at birth or catch-up growth neither to size at birth or catch-up growth
until the age of 2 years. until the age of 2 years.
Geelhoed et al (2009) GR-9β polymorphism is associated with
increased systolic blood pressure and
increased left ventricular mass at the age
of 2 years.
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Common polymorphisms of type 2 diabetes gene PPARγ2 may also explain previously suggested
associations of growth in early life with the risk of cardiovascular disease in later life. Two large
birth cohort studies found no association between the PPARγ2 polymorphism and birth weight.59,
60 We recently showed that the PPARγ2 Ala12 allele is associated with an increased growth rate
in early life. This effect was modified by the duration of breastfeeding.61 In addition to the PPARγ2
polymorphism, other common type 2 diabetes genetic susceptibility variants seem to affect size
at birth directly through the fetal genotype. Risk alleles at CDKAL1 and HHEX-IDE were both
associated with reduced birth weight. These findings suggest the associations between low birth
weight and type 2 diabetes might at least be explained in part by common genetic variants.62
Furthermore, it has been demonstrated that the PPARγ2 polymorphism modifies the associations
of low birth weight with lipid levels and hypertension.63, 64
Glucocorticoids are important regulators of cardiovascular function and metabolism.
Studies in rats showed that activity of placental 11β-hydroxysteroid dehydrogenase type 2, which
converts physiological glucocorticoids to inactive products, correlates positively with birth weight
and negatively with placental weight.65 In addition, administration of low-dose dexamethasone to
pregnant rats not only reduces birth weight but also leads to high blood pressure in young adult
offspring.65 In human studies, it has been demonstrated that fetuses with the greatest exposure
to maternal glucocorticoids have low birth weight and high placental weight and might be at a
higher risk of subsequent hypertension.66 Increased exposure to cortisol in adults leads to increased
risks of cardiovascular disease, type 2 diabetes and obesity.67, 68 Thus higher exposure to gluco-
corticoids in fetal and early postnatal life might affect cardiovascular development in fetal life and
early childhood. The effects of these hormones, including cortisol, are mediated by glucocorticoid
receptors. Glucocorticoid receptor gene (NR3C1) SNPs may explain part of the associations between
growth characteristics in early life and disease in adulthood by increasing glucocorticoid sensitivity
in the fetus for maternal glucocorticoids. A previous study in adults found an association between
the GR-9β polymorphism and an increased risk of cardiovascular disease.69 We found an associa-
tion of this GR-9β polymorphism with increased left ventricular mass and systolic blood pressure
in children aged two years.70 No associations were observed between this GR-9β polymorphism
and fetal and early postnatal growth.71 Other recent identified glucocorticoid related polymorphisms,
such as the brain-derived neurotrophic factor (BDNF) and the mineral corticoid gene, may affect
fetal and postnatal growth by influencing the glucocorticoid metabolism.
Thus far, results of studies focused on the associations of common genetic variants related
to both early growth and the risk of cardiovascular disease later in life are inconsistent. Further
systematic searches for common genetic variants by means of genome-wide association studies
will enable us to obtain a more complete understanding of what genes and polymorphisms are
involved in both growth in fetal life and infancy and development of cardiovascular disease in
adulthood.
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Cardiovascular adaptations
Cardiac development
Stimuli for cardiac development
It has been demonstrated that fetuses have stiffer fetal ventricles than neonates and the diastolic
filling patterns in normally grown fetuses mimic those of the diseased adult heart.72 Left ventricular
elastic compliance increases with gestational age and left ventricular stiffness significantly de-
creases. In growth restricted fetuses, this process may be affected.72 Furthermore, reduced
end-diastolic flow velocities in fetal umbilical and maternal uteroplacental arteries have been as-
sociated with increased peripheral vascular resistance.73 This increase in peripheral arterial
resistance and subsequently in fetal cardiac afterload may lead to an increase in fetal cardiac
performance and to persistent structural left ventricular changes.74 Decreased fetal growth was also
associated with fetal adaptations in cardiac function in the whole range of fetal growth.75 Further-
more, birth weight and measures of placental vascular resistance and fetal cardiac output were
associated with left cardiac structures until the age of two.76 This is in line with a previous
prospective cohort study in children which demonstrated positive associations of birth weight
with total coronary artery diameter, aortic root diameter and left ventricular outflow tract diameter
in children aged nine.77 However, inverse associations between birth weight and left ventricular
mass in adolescents and adults have been demonstrated.78, 79 It should be investigated whether
these relations persist during later life and are related to the development of cardiovascular disease
in adulthood.
Adverse cardiac adaptations
Studies in children showed that left ventricular mass tracks from childhood to adulthood.80, 81
This implies that children with smaller left cardiac structures in early postnatal life tend to keep
their relatively smaller left cardiac structures in childhood.76, 80, 81 However, a relatively smaller left
ventricle and aortic root may lead to insufficient cardiac functioning for increasing metabolic
demands in postnatal life. Subsequently, the heart may respond by growth and adverse remodeling.
Since the number of heart cells is established largely in fetal life, adaptation and growth of existing
cells may eventually lead to left ventricular dysfunction and hypertrophy. Left ventricular hypertrophy
is a strong and independent risk factor of cardiovascular morbidity and mortality in adulthood.82,
83 Thus, fetal exposures affecting cardiac development may have life-long consequences.
Renal development
Stimuli for renal development
Nephrons start to form from day 30 of gestation.84 Numerous factors, including the renin-angiotensin
22
ch
ap
te
r
5
system (RAS), various growth factors, apoptosis and an adequate supply of nutrients are required
for nephrogenesis.85-87 Nephrogenesis continues until 36 weeks of gestation and the induction
of nephron number ceases thereafter.88, 89 On average about 750,000 nephrons per kidney are
present, with a wide interindividual range (250,000 – 2,000,000).90-93
Animal studies have shown that various determinants of fetal nutrition including low protein
intake, relative vitamin A deficiency, reduced placenta perfusion and administration of steroids in
late pregnancy cause fetal growth restriction, smaller kidneys and a permanently reduced nephron
number.94-97 Human studies demonstrated that low birth weight infants have lower kidney weight
with a reduced number of nephrons.98, 99 It was also demonstrated that hypertensive subjects
have lower nephron numbers.100 The best surrogate measure for assessing nephron number in
epidemiological studies appears to be kidney weight or size measured by ultrasound.89 Few studies
investigated renal length or volume in early life. Being small for gestational age (SGA) is associated
with small kidneys at birth and impaired kidney growth in early childhood.101 Kidney length in
preterm SGA infants follows closely the other anthropometric parameters during the first year of
life.102 SGA term infants had shorter kidney length at birth compared to what is appropriate for
gestational age infants, but a similar length from the 3rd to 24th month of life.103 This may represent
either an accelerated renal maturation or early compensatory kidney hypertrophy in the SGA infants.
Maternal anthropometrics, fetal abdominal circumference, fetal blood flow redistribution, and
raised placental resistance are associated with both third trimester fetal kidney volume and kidney
volume at the age of two years.104, 105 Since kidney size tracks from the third trimester of preg-
nancy to early childhood, these adaptations may have persistent consequences.104
Adverse renal adaptations
The kidneys respond to this reduced number of nephrons by hyperperfusion and remodelling.106
According to the hyperfiltration theory, this will lead to more sodium reabsorption, increased systolic
blood pressure and albuminuria.107 This process may be in favor of short-term renal function but
may eventually lead to glomerular hypertrophy and damage.106 Finally, this may predispose the in-
dividual to renal failure and hypertension. It has been shown that low birth weight is associated
with early onset chronic renal failure. In subjects aged less than 50 years, those who weighed
less than 2.5 kg at birth had a higher risk for end-stage renal disease than people who weighted
3-3.5 kg at birth.108 This association was shown in all groups of primary causes of end-stage
renal failure in adults (hypertension, diabetes and other causes). Studies in younger subjects
have focused on urine albumin excretion, a predictor of cardiovascular and renal disease in diabetic
and non-diabetic subjects.109 Low birth weight is associated with microalbuminuria in children
and adults independent of blood pressure and measures of insulin resistance.110, 111 The pathway
leading from small kidneys to hypertension may include the renin-angiotensin system, which has
been demonstrated to be altered in the early phase of primary hypertension.112 An increased
activity of the renin-angiotensin system could be a compensatory mechanism in a decreased
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number of nephrons in order to maintain normal renal filtration. It has been demonstrated that
renin activity in umbilical cord blood is inversely related with the size of the kidney at birth.113
Vascular development
Hemodynamic stimuli for fetal vascular development
Fetal growth retardation leads to a preferential blood flow to the brain and heart, which deprives
other organs of adequate oxygen and nutrients supply. This brain-sparing suggests organ specific
vasodilatation and vasoconstriction and has been demonstrated in growth restricted fetuses.114
In addition, we recently demonstrated that decreased fetal growth is associated with adaptive
fetal cardiovascular changes.75 These changes already occured before the onset of clinically ap-
parent fetal growth restriction. Future studies are needed to identify whether these adaptations in
fetal hemodynamics have consequences for the development of cardiovascular disease in later life.
Endothelial function
The endothelium controls vascular tone, coagulation and inflammatory responses.115 Endothelial
dysfunction is an early event of atherosclerosis, preceding structural changes in the vascular
wall.116 Atherosclerosis is thought to begin in childhood and to develop silently before clinical
events such as myocardial infarction or stroke occur. Many studies demonstrated atherosclerotic
wall thickening in the arteries of children with cardiovascular risk factors using ultrasound imaging.117
Furthermore, studies have shown that risk factors for cardiovascular disease measured in childhood
track into adulthood.118, 119 There is limited direct evidence that risk factors measured in childhood
are predictive of atherosclerosis in adulthood.120, 121 Only a few studies examined the associations
of fetal and maternal factors during pregnancy and vascular changes in childhood. Low maternal
folate levels during pregnancy and low birth weight are demonstrated to be associated with
vascular endothelial dysfunction in newborn infants.37, 122, 123
Arterial stiffness
Flow may determine vascular growth in the fetal cardiovascular system and thereby a reduction
in flow may alter later vascular behavior.124 One mechanism that could underlie the association
of low birth weight with raised blood pressure may be a suboptimal development of the fetal
cardiovascular system due to these circulatory changes, thus increasing the stiffness of the vessel
wall and comprising the cardiovascular function.125 Several studies have attempted to test this
hypothesis by investigating the relationship between birth weight and indicators of arterial stiffness
such as pulse wave velocity and pulse pressure, but with conflicting results.126-128 Another mechanism
could be that these hemodynamic adaptive changes in the fetal circulation, which occur in a critical
period of blood vessel development, may influence rates of elastin synthesis.129 This may result
in a reduced compliance of the large arteries, leading to higher pulse and mean blood pressures.
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Furthermore, the process of ageing causes a gradual loss of elastin and replacement by collagen,
which amplifies the increase in blood pressure.130 Persistent alteration in conduit artery function
and arterial stiffness may predispose a person to hypertension and cardiovascular disease in
adulthood.
Methodological considerations
The studies performed in this thesis have mainly been conducted within the Generation R Study,
a population-based prospective cohort study. The prospective design enables detailed data col-
lection and provides the opportunity to assess temporal relationships. Types of bias that might
have affected our results include selection bias, information bias, and confounding.137
Selection bias
When the relation between determinant and outcome is different in those who participate and
those who were eligible, but do not participate, selection bias may occur. Of all eligible children
at birth, 61% participated in the Generation R Study.131 Non-response due to non-participation is
not likely to be random. The percentages of mothers from ethnic minorities and lower socio-
economic status, and of mothers and children with medical complications are lower among the
participants than expected from the population figures in Rotterdam.138 Especially in the Generation
R Focus Study, including the Dutch women participating in the Generation R Study and with a
delivery date between February 2003 and August 2005, this is the case. We do not think that
this selection towards a more affluent and healthy study population substantially affected our eti-
ological association studies, since these selection mechanisms are not related to both the
determinant and the outcome and we do not expect that these associations differ between the
study population and the total eligible population. However, this selection will probably affect fre-
quency rates and, as a consequence, the statistical power and the generalizibility of our studies.
The group of children born with low birth weight or small size for gestational age was too small
for specific analyses focused on these groups and our results can therefore not easily be ex-
trapolated to preterm or low birth weight children.
Selection bias may not only be introduced by selective non-response, but also by selective
loss to follow-up. Most of the studies presented in this thesis are performed in the Generation
R Focus Study. Of all mothers who were enrolled in the Focus cohort, 80% participated in the
postnatal detailed examinations. These examinations included the ultrasound examinations of
the heart and the kidneys, which were the main outcomes in chapters 3 and 4 of this thesis. Loss
to follow-up would lead to bias if the associations of various determinants with these ultrasound
measures differ between those who participate and those who were loss to follow-up. Since the
association between exposure and disease in non-participants is unknown, the effect of selective
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loss to follow-up can only be inferred. A previous analysis showed that biased estimates in large
cohort studies primarily arise from loss to follow-up rather than from non-response at baseline.139
Information bias
Information on the determinants and outcomes in the studies described in this thesis was mainly
obtained by physical examinations, ultrasound examinations and parental questionnaires. Random
misclassification would lead to bias towards the null. When misclassification of the determinant
is related to the outcome, bias may occur.140 Exposure data in our studies, including fetal growth
characteristics measured by ultrasound and other cardiovascular risk factors, were collected before
assessment of the outcome, which makes differential misclassification of the exposure unlikely.
Information about maternal smoking in pregnancy was obtained prospectively by questionnaires
sent to the mothers. Although the mothers were not aware of the specific research questions ad-
dressed in this thesis, assessment of adverse life style habits by questionnaires may lead to
underreporting. If underreporting would be selectively present among heavy smoking mothers who
report low- to moderate smoking, the estimated differences in renal and cardiovascular structures
between the offspring of non-smoking and low smoking mothers would be overestimated. To over-
come the limitation of underreporting of smoking, other studies have used biomarkers of tobacco
exposure including cotinine in maternal urine, saliva or blood samples or nicotine in indoor air.141,
142 However, so far these studies have demonstrated that these biomarkers are not superior to
self-report when studying the effect of maternal smoking on several outcomes of their off-
spring.143, 144 In most of our studies, the outcome was assessed using ultrasound examination.
Validation studies of these ultrasound measurements showed good repeatability and repro-
ducibility between and among observers. Furthermore, the observers were blinded to the
exposure status, which makes differential misclassification of the outcome less likely.
Confounding
The Generation R Study data collection provides information on many variables related to growth,
development and health of the children. Therefore many potential confounders were available for
the analyses. Confounding may be considered as biased effects, in which the apparent effect of
the exposure of interest is distorted because the effect of an extraneous factor is mistaken for
or mixed with the actual exposure effect.1 A confounding factor should be associated with both
the exposure and the outcome, and cannot be an intermediate in the causal chain from exposure
to outcome. Adjustment for an intermediate in the causal pathway from exposure to outcome, or
adjustment for a variable that is causally related to the exposure but only correlated to the out-
come, is inappropriate. Although we had information on many variables of interest, we may have
missed potential confounders. Residual confounding due to unmeasured variables such as ma-
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ternal nutrition, medication use, and physical activity during pregnancy, might still be possible. Ac-
cording to the developmental plasticity hypothesis, adverse environmental exposures in fetal and
early postnatal life lead to adaptations that permanently program the fetus’ structure, physi-
ology and metabolism, leading to both low birth weight and cardiovascular disease in adulthood.
Thus, missing information on specific adverse exposures in fetal and early postnatal life may
have introduced residual confounding in the studies presented in this thesis.
Most of the studies presented in this thesis were performed in the Generation R Focus
cohort. Confounding might be less since the studied determinants were not or only moderately
related to sociodemographic variables, due to the homogeneity (all children had Dutch ethnicity,
defined as two parents and four grandparents born in The Netherlands, and 63% finished high
education) of our sample. This underlines the benefits of studying etiological associations within
a restricted and homogenous sample.
The study presented in chapter 4.6 was performed in the Avon Longitudinal Study of Parents and
Children (ALSPAC). ALSPAC is a similar population-based prospective cohort study as the Genera-
tion R Study and investigates the health and development in children (www.alspac.bris.ac.uk).132
Detailed information about the children has been collected from questionnaires administered
through childhood, and clinical measurements have been performed on the entire cohort annually
since the age of 7 years. In total, 6,668 mother-offspring pairs, approximately 65% of those invited,
attended the 9 year follow-up clinic. Data on hypertensive disorders during pregnancy, offspring
anthropometry, blood pressure and potential confounders were available for 6,343 (95%) of these
children. Blood pressure and adiposity could be measured in 99% of the children participating in
this study at the 9-year-old visit. Those attending the clinic did not differ in the amount of hyper-
tensive disorders during pregnancy from the ones who were not included in the study. There was
a minimal missing data amongst clinic participants for most variables. As results are based on
complete case analysis, we do not think that these missing data has resulted in major bias.
Perspectives
Study designs
The associations of fetal growth retardation and low birth weight with cardiovascular disease are
not yet fully understood. Methodological issues, such as the role of potential confounders in the
associations, should be further examined. Well-designed epidemiological studies are necessary
to overcome current methodological issues. Population-based prospective cohort studies starting
in the preconceptional period or in early fetal life, in which the offspring is followed from early fetal
life until young adulthood, seem to be the most suitable epidemiological design (Figure 1). This
epidemiological design is the best design for assuring quality of the data, taking account of
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potential confounders and identifying growth patterns at risk. Recently, various population-based
prospective cohort studies have been started worldwide.131-134 However, a limitation of this design
is the long period needed for the studied adult disease to develop. The design of a retrospective
cohort study may lead to an earlier availability of data according to cardiovascular disease. However,
this design will not take account of all potential confounders and will probably not be able to
study the effects of fetal or early postnatal influences.
Figure . A developmental origins study model, studying the fetal origins of cardiovascular disease
in epidemiological studies
This model presents core associations that have to be studied to unravel the underlying mechanisms of the associations of fetal
growth restriction and low birth weight and cardiovascular disease later in life. The upper part shows associations in mother and
father, identifying both determinants of fetal and postnatal growth patterns and environmental and genetic mechanisms. The lower
part demonstrates associations in the offspring that have to identify growth patterns and developmental changes in fetal and early
postnatal life, resulting in an increased risk of cardiovascular disease in adulthood.
RAAS, Renin-angiotensin-aldosterone system
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The effects of many adverse fetal exposures due to maternal life style habits can only be studied
in observational designs. However, for assessing the effects of nutritional exposures on fetal
growth restriction and the risk of cardiovascular disease, randomised controlled trials would be
the design of choice. For example, the impact of calcium, folate and other micronutrients on off-
spring birth weight and blood pressure is examined in randomised controlled trials.30, 135, 136
Randomised controlled trials should be able to overcome current methodological issues and
identify mechanisms in the causal pathway that underlie the associations.
Detailed exposure studies
Nutrition
In Western countries, maternal variation in dietary patterns and intake of micronutrients seems
more relevant than a restricted total energy and macronutrient intake for having an effect on fetal
growth retardation.145 Future studies should focus on the intake of particular macronutrients and
micronutrients, including calcium, folic acid and homocystein, in specific periods of pregnancy.
Identifying critical periods in pregnancy will result in detailed dietary advices aimed at these specific
time points in pregnancy. Additionally, dietary patterns during the preconception period have been
associated with biomarker concentrations and related to complex diseases, such as cardiovas-
cular disease.146, 147 Overall dietary patterns may be easier for the public to interpret or translate
into diets.
Genome-wide association studies
Common genetic variants may explain the associations between growth in early life and diseases
in adulthood. Large scale genome-wide association studies (GWAS) have revealed links between
DNA sequence variation and a growing range of diseases and continuous traits, such as cardio-
vascular disease and type 2 diabetes.148-150 The effect of these common genetic variants on
growth characteristics and growth patterns may already be present in fetal and early postnatal
life. Relating these genetic loci to early growth patterns might identify genes related to both fetal
growth retardation and cardiovascular disease.
Epigenetics
Epigenetics is understood as the heritable changes in gene expression potential that are not
caused by changes in DNA sequence.151, 152 DNA methylation is one of the best understood type
of epigenetic modification and is a key epigenetic contributor to maintenance of gene silencing.
CpG islands are mostly located in the control regions of genes, for example the promoter region
of actively transcribed gene, and are generally unmethylated. Methylation of this promoter region
leads to decreased binding of transcription factors and thereby to a reduced gene expression.153
Maternal diet has been shown to dynamically affect DNA methylation status.154 Methyl-supple-
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mented diets include the methyl donors such as folic acid, vitamin B12, choline, L-methionine and
zinc. Studies in sheep showed associations between reductions in the availability of Vitamin B12
and folate during the periconceptual period and alterations in methylation status of CpG islands
in the offspring.155 This may lead to widespread epigenetic modifications to the genome of the
offspring. In humans, lower DNA methylation of the IGF-2 gene was reported in adults who were
exposed to the Dutch Famine in the periconceptional period.156 These results suggest that early-
life environmental conditions can cause epigenetic changes that persist throughout life and could
lead to the development of risk factors for hypertension and cardiovascular disease in adult
offspring. However, future research is needed to better understand the role of epigenetic dys-
regulation in the associations between adverse fetal nutritional exposures and diseases in adult
life.157 Since the periconceptional period is a crucial period for establishing and maintaining epi-
genetic marks, cohort studies starting in the preconceptional period would give important
knowledge.158
Paternal influences
We discussed substantial affects on fetal programming by maternal prenatal behaviors, specifi-
cally by maternal smoking, maternal diet and maternal genetic susceptibility. However, paternal
influences, for example paternal genetic susceptibility, could also underlie the pathways of fetal
growth retardation and low birth weight to the development of cardiovascular disease in adult-
hood. Also, comparing maternal and paternal effects provides a method of separating intra-uterine
effects from associations related to familial or environmental factors. Similar associations of
maternal and paternal exposures with offspring health outcomes suggest that common factors
related to the family or environment may drive the associations, rather than intrauterine effects
only. Future research is required to compare associations of both maternal and paternal exposures
during pregnancy with components of offspring health.
Detailed cardiovascular development studies
To disentangle the mechanisms underlying the associations of fetal growth restriction and low
birth weight with the development of cardiovascular disease, future research should focus on
early markers of cardiovascular adaptation. Good repeatability and reproducibility of most left
cardiac structures in children measured by 2D ultrasound has been previously demonstrated in
large-scale multicenter studies in young children.159, 160 However, newer imaging techniques, such
as three-dimensional echocardiography and magnetic resonance imaging, can more precisely cal-
culate physiologic variables of interest.161 In the future, these new imaging techniques will offer
great opportunities for detailed cardiovascular measurements in epidemiological research.
Thereby, subtle developmental cardiovascular changes can be identified already in fetal or early
postnatal life. Furthermore, focusing on other biomarkers of cardiac development, including
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detailed repeated measurements of right cardiac structures, may give newer inside in the pathway
leading to the development of cardiovascular disease.
Although there is limited direct evidence that risk factors measured in childhood are pre-
dictive of atherosclerosis in adulthood162, 163, less is known about the associations of fetal and
maternal factors during pregnancy and vascular changes in childhood. Endothelial function and
structural arterial changes, including arterial resistance and arterial stiffness, can be measured
noninvasively in early childhood with high resolution ultrasound to measure brachial artery flow-
mediated dilatation and carotid artery intima-media thickness, respectively.164, 165 Furthermore,
future studies should focus on additional markers of vascular structures and function, including
retinal arteriolar narrowing. This may lead to peripheral vascular resistance and thereby predis-
pose a person to the development of hypertension and cardiovascular disease.166
Clinical implications and future research
The associations between low birth weight and cardiovascular disease in later life seem to be one
of the most intriguing and controversial epidemiological findings of the last decades and might
have clinical and public health implications. However, the effect size of low birth weight on cardio-
vascular disease and blood pressure in adulthood presented in current studies seems to be
small.1, 167 Furthermore, the specific adverse exposures and underlying mechanisms are not
known. To explore the underlying mechanisms further and to assess potentials for clinical impli-
cations, research has to move onwards from birth weight association studies to adverse fetal
exposures and detailed early cardiovascular development studies. Since plasticity operates
across the entire range of the environment and leads to multigenerational cycles of disease, any
rational approach to health care should start early in life and take a cross-generational perspec-
tive.168 Data from prospective cohort studies confirm the existence of a window of opportunity for
intervention in early childhood.169, 170 The growing awareness of the importance of the precon-
ceptual period, when nutrition can have long-lasting effects without causing any change in birth
weight, underscores the importance of healthy nutrition during the prepregnancy period. Research
should also focus on identifying individuals at greater risk of later poor health and develop
strategies aimed at these specific individuals.
Conclusion
The associations between low birth weigh and cardiovascular disease are present within the normal
and physiological ranges, and suggest that specific exposures in different periods of fetal and
early postnatal life have permanent consequences for cardiovascular growth and function. The
mechanisms underlying these associations are not known, but may include environmental and
genetic determinants. Future studies should be focused on these mechanisms and epigenetic
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modifications of specific genes related to cardiovascular development. Furthermore, studies
should focus on detailed cardiovascular adaptive responses in fetal life and early childhood by
use of new imaging and functional techniques. Eventually results from these studies may lead to
improved health in childhood and adulthood by promoting a better fetal environment.
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Summary
In chapter  the background and scope of the studies presented in this thesis are given. Many
lines of evidence indicate an important role of early life events in influencing later susceptibility to
cardiovascular disease. These observations resulted in the “developmental plasticity hypothesis”,
which suggest that an organism may develop in various ways, depending on the particular environ-
ment or setting. In this process, adverse environmental exposures in fetal and early postnatal life
lead to adaptations that permanently program the fetus’ structure, physiology and metabolism.
Birth weight has been the most widely studied measure of fetal growth in studies examining the
associations of birth-related measures with risk factors of disease in later life. For further exploring
the underlying mechanisms and to assess whether these associations are causal, research has
to move onwards from birth weight association studies to adverse fetal exposure and detailed
early cardiovascular development studies.
In chapter 2 the associations between genetic determinants with fetal and postnatal growth are
described. In chapter 2. we hypothesized that variants of the insulin-like growth factor-1 (IGF1)
gene are associated with growth patterns from fetal life until infancy. Eight alleles of the IGF1 pro-
moter region were identified. In total, 43% of the subjects were homozygous for the most common
192-bp allele (wild-type), 45% were heterozygous, and 12% were non-carrier of the 192-bp allele.
No differences were found in birth weight between the three groups. However, non-carriers had a
lower estimated fetal weight in mid-pregnancy, which may be an indication of growth restriction in
early pregnancy, followed by an increased growth rate until 6 months in comparison to 192-bp ho-
mozygotes. A similar difference in growth rate was found for length. An explanation for our findings
could be that the absence of the wild-type 192-bp allele might alter the transcription rate of IGF1.
Alternatively, the IGF1 promoter region may be in linkage disequilibrium with other regulatory el-
ements, which in turn influence IGF-1 levels.
Chapter 2.2 shows the associations between the insulin gene variable number of tandem
repeats (INS VNTR) and growth patterns in fetal life and infancy. The genotype distribution was
I/I 50.8%; I/III 40.0%; and III/III 9.2%. Our data suggest that the III/III genotype may be associated
with asymmetrical growth in mid-pregnancy, but not in late pregnancy. III/III individuals had a
shorter gestational age and a lower birth weight. There were no differences in birth weight after
adjusting for gestational age. Class III homozygotes had a smaller abdominal circumference/head
circumference ratio in mid-pregnancy, but not in late pregnancy. Also, III/III subjects had a relative
decrease in head circumference (SDS) from mid-pregnancy to the age of 14 months. No other dif-
ferences in pre- and postnatal growth characteristics and patterns were found. Alterations in
insulin or IGF2 levels may explain part of the associations we found.
Glucocorticoids have an important role in early growth and development. Glucocorticoid
receptor gene polymorphisms have been identified that contribute to the variability in glucocorticoid
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sensitivity. In chapter 2. we hypothesized that these glucocorticoid receptor gene polymorphisms
are associated with growth in fetal and early postnatal life. The studied glucocorticoid receptor
gene polymorphisms included BclI (rs41423247), TthIIII (rs10052957), GR-9β (rs6198), N363S
(rs6195) and R23K (rs6189 and 6190). We showed that glucocorticoid receptor gene polymor-
phisms were not associated with fetal weight, birth weight and early postnatal weight. Also, no
associations were found with length and head circumference. Neither were these polymorphisms
associated with the risks of low birth weight or catch-up growth from birth to 24 months of age.
Therefore, we concluded that these polymorphisms do not affect early growth. Further systematic
searches for common genetic variants by means of genome-wide association studies will enable
us to obtain a more complete understanding of what genes and polymorphisms are involved in
growth in fetal life and infancy.
Chapter  of this thesis describes early determinants of kidney growth and development from third
trimester of pregnancy until the age of two years. In chapter . we demonstrated good repro-
ducibility and agreement of most renal dimensions in children measured by ultrasound.
Intraobserver intraclass correlation coefficients ranged from 0.93 (left and right renal width and
right renal thickness) to 0.99 (left renal length) and interobserver intraclass correlation coefficients
ranged from 0.64 (right renal thickness) to 0.90 (right renal length). These results confirm that
ultrasound is an appropriate measure to assess renal dimensions in both clinical and epidemi-
ological studies. Reference growth curves were constructed for kidney growth from third trimester
of pregnancy until the age of two years are demonstrated in chapter .2.
Studies focused on kidney growth determinants are described in chapters ., . and
.. In chapter . we showed that maternal height and pre-pregnancy weight were associated
with fetal kidney volume. This association may be explained by both environmental (maternal nu-
tritional status) and common genetic factors. After adjustment for the same characteristics in late
pregnancy, fetal growth and blood flow parameters in mid-pregnancy were not associated with
kidney volume in late pregnancy, suggesting that the main influence of fetal growth on kidney volume
in late pregnancy exerts after mid-pregnancy. In late pregnancy, all fetal growth characteristics
were positively associated with kidney volume. Signs of fetal blood flow redistribution and raised
placental resistance were associated with reduced kidney volume in late pregnancy. Furthermore,
kidney volume was positively associated with amniotic fluid quantity, which may be a measure of
fetal kidney function. Our results are in line with studies that found that the period of maximum
kidney growth to occur between 26-34 weeks of gestation Growth restriction in this period most
likely affects kidney size and volume considerably.
Chapter . showed that maternal smoking during pregnancy affects kidney development
in fetal life. Compared to non-smoking, first trimester only and continued smoking were not as-
sociated with any fetal kidney characteristics. We observed a curved-shaped association between
the number of cigarettes smoked in third trimester of pregnancy with fetal kidney size. Compared
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to non-smoking, smoking less than 5 cigarettes per day was associated with larger combined
kidney volume (difference 2.10 (95% confidence interval (CI): 0.87, 3.32) cm3), while smoking
more than 10 cigarettes per day was associated with smaller combined kidney volume (difference
-1.90 (95% CI: -3.73, -0.06) cm3). These results suggest a differential effect of maternal
smoking during pregnancy, depending on the specific period and number of cigarettes smoked.
The vasoactive mechanisms and effect of nicotine in different tissues could explain at least part
of these associations.
In chapter . we demonstrated that small kidney size in fetal life tends to persist in early
childhood. Maternal height and pre-pregnancy weight were positively associated with kidney vol-
ume at the age of 2 years. This association may be explained by both genetic and environmental
determinants. Third trimester fetal head circumference, abdominal circumference and estimated
weight and postnatal length were positively associated with kidney volume at the age of 2 years,
suggesting that adverse fetal growth patterns lead to smaller kidneys with a lower amount of
nephrons postnatally. Preferential fetal blood flow to the brain was also associated with smaller
kidneys, predisposing an individual to an increased risk of renal disease and hypertension in
later life. Further research should be aimed at disentangling the causal mechanisms underlying
the associations of various determinants with kidney growth and the long-term consequences.
Early determinants of cardiac growth and development until the age of two years are presented
in chapter . We found good reproducibility and agreement of left cardiac structures in children
measured by ultrasound in chapter .. High intraobserver and interobserver intraclass correla-
tion coefficients were found, ranging from 0.91 for interventricular septal thickness (95% CI:
0.78, 0.96) to 0.99 for aortic root diameter (95% CI: 0.97, 1.00), confirming that left cardiac
structures can be measured in both clinical and epidemiological research projects.
Chapter .2 demonstrated moderate tracking of left cardiac structures during the first
two years of life. Furthermore, small size at birth and hemodynamic variations in fetal life, in-
cluding resistance indices of the umbilical and uterine arteries and cardiac output, have
consequences for postnatal cardiac size and function. These results suggest that undernutrition
in third trimester of pregnancy leads to persisting increase of left ventricular structures, mediated
through cardiovascular adaptive changes in utero.
Chapter . examined whether maternal smoking during pregnancy leads to fetal arterial
resistance adaptations and subsequently to fetal growth retardation and changes in postnatal
blood pressure and cardiac development. First trimester smoking was not associated with third
trimester placental and fetal blood flow adaptations. Continued smoking of ≥5 cigarettes/day
was associated with increased resistance in the uterine, umbilical, and middle cerebral arteries
and a decreased flow and diameter of the ascending aorta. Among mothers who continued
smoking, estimated fetal weight at 30 weeks and birth weight were most affected in children
with the highest umbilical artery resistance. Fetal arterial resistance indices were also associated
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with aortic root diameter and left atrial diameter. Our findings suggest that fetal arterial resistance
adaptations may be involved in the pathways leading from maternal smoking during pregnancy to
both low birth weight and cardiovascular developmental changes in childhood in the offspring.
In chapter . we showed that maternal weight gain until late pregnancy was associated
with an increased growth of left ventricular mass from 6 weeks to 6 months (difference 0.46 grams
per week for the highest tertile of weight gain compared to the lowest tertile (p-value <0.05)), sug-
gesting that maternal health status during pregnancy may have permanent consequences for left
ventricular mass in their children. We found no associations of maternal height, weight or body
mass index with longitudinally measured left ventricular mass from 6 weeks to 6 months. The in-
creased heart growth could be attributed to either the indirect growth stimulating effect of insulin
or the direct growth stimulating effect of increased maternal energy intake during pregnancy.
In chapter . we showed an association of the Glucocorticoid receptor-9β polymorphism
(GR-9β, rs6198) with blood pressure and heart growth in early childhood. At the age of 24 months,
homozygous variants showed an increased systolic blood pressure of 2.65 mmHg (95% CI: 0.16,
5.14), an increased heart rate of 9.14 beats per minute (95% CI: 0.22, 18.1) and an increased
left ventricular mass of 5.01 grams (95% CI: 1.32, 8.71) compared to homozygous references.
GR-9β polymorphism was significantly associated with left ventricular mass growth during the
first 2 years. Our findings suggest that genetically determined differences in cortisol exposure affect
cardiovascular development in early life. Future studies are needed to replicate these findings and
should assess whether these relations are associated with development of cardiovascular disease.
Chapter . examined the associations of hypertensive disorders of pregnancy with blood
pressure in the nine-year-old offspring. Offspring of women with a history of preeclampsia or gesta-
tional hypertension had increased systolic and diastolic blood pressure at the age of nine years
(increase in systolic blood pressure of 2.05 mmHg (95% CI: 0.72, 3.38) and 2.04 mmHg (95%
CI: 1.42, 2.67), respectively, compared to those with no hypertensive disorders of pregnancy).
These associations do not appear to be explained by shared familial characteristics (genetic or
behavioral) related to familial adiposity. Our findings suggest that different mechanisms underlie
the associations of preeclampsia and gestational hypertension with offspring blood pressure,
with some evidence that the former is in part mediated by the effect of preeclampsia on in-
trauterine growth restriction and preterm delivery.
In chapter  the combined results of the aforementioned chapters were discussed in a broader
perspective. In conclusion, the associations between fetal undernutrition and genetic suscepti-
bility with cardiovascular development are present within the normal and physiologic ranges, and
suggest that specific exposures in different periods of fetal and early postnatal life have perma-
nent consequences for cardiovascular growth and function. The mechanisms underlying these
associations are not known, but may include environmental and genetic determinants. Further
studies are needed to unravel these mechanisms and to identify whether these cardiovascular
adaptations have consequences for the development of cardiovascular disease in later life.
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Samenvatting
In hoofdstuk  worden de achtergrond en het doel van de studies in dit proefschrift besproken.
Verschillende onderzoekslijnen hebben de afgelopen jaren verbanden aangetoond tussen een
ongunstige foetale omgeving en het risico op hart- en vaatziekten op latere leeftijd. Deze obser-
vaties hebben geresulteerd in de “developmental plasticity” hypothese, die veronderstelt dat een
organisme zich op verschillende manieren kan ontwikkelen, afhankelijk van een bepaalde omgeving
of plaats. In dit proces leidt een ongunstige foetale omgeving tot aanpassingen in de ontwikkeling
die permanent de structuur, fysiologie en het metabolisme van de foetus beïnvloedt. Op korte
termijn leidt dit tot foetale groeivertraging en een laag geboortegewicht, maar op lange termijn
kan het het risico op hart- en vaatziekten vergroten. Het geboortegewicht is de meest gebruikte
maat als weerspiegeling van de foetale groei in studies die kijken naar verbanden tussen een
ongunstige foetale omgeving en risicofactoren voor verschillende aandoeningen op latere leeftijd.
Om na te gaan of deze relaties een oorzakelijk verband hebben en om nog onbekende on-
derliggende mechanismen te identificeren, is vervolgonderzoek nodig dat gericht is op foetale
blootstellingen en groeipatronen in plaats van op het geboortegewicht. Tevens zal de focus meer
moeten liggen op het nog gedetailleerder in beeld brengen van de vroege ontwikkeling van het
hart- en vaatstelsel.
Voor mijn onderzoek werd gebruik gemaakt van gegevens verzameld in het Generation R
onderzoek, een populatiegebaseerd prospectief cohort onderzoek vanaf het vroege foetale leven
tot de jongvolwassenheid. Het doel van dit onderzoek is om de vroege omgevingsfactoren en
genetische oorzaken van de normale en abnormale groei, ontwikkeling en gezondheid vanaf het
foetale leven tot aan de jongvolwassenheid te identificeren. In totaal zijn 9.778 moeders
opgenomen met een bevallingsdatum tussen april 2002 en januari 2006. In de vroege zwanger-
schap (zwangerschapsduur <18 weken), halverwege de zwangerschap (zwangerschapsduur 18-25
weken) en laat in de zwangerschap (zwangerschapsduur ≥25 weken) werden gegevens verzameld
van zowel de ouders als de foetus met behulp van lichamelijk onderzoek, vragenlijsten, foetaal
echo-onderzoek en bepalingen in bloed en urine. De meeste studies in mijn proefschrift zijn ver-
richt in een subgroep van dit cohort, het Generation R Focus cohort. Dit is een groep van 1.232
moeders en hun kinderen met een Nederlandse nationaliteit. Deze groep werd nauwkeurig na de
geboorte gevolgd, waarbij gedetailleerde metingen van onder andere de lengte, het gewicht, de
lichaamssamenstelling, de groei en ontwikkeling van het hart en de nieren en de bloeddruk tot
de leeftijd van twee jaar werden verricht.
In hoofdstuk 2 wordt de rol van genetische factoren op de foetale en postnatale groei beschreven.
In hoofdstuk 2. testen we de hypothese dat variaties in het Insulin-like growth factor-1 (IGF-1)
gen gerelateerd zijn aan groeipatronen vanaf het foetale leven tot aan de kinderleeftijd. We
hebben acht allelen in de promotor regio van het IGF-1 gen geïdentificeerd. In totaal is 43% van
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de onderzoekspopulatie homozygoot voor het meest voorkomende 192-bp allel (wild-type), 45%
is heterozygoot en 12% is geen drager van het 192-bp allel. Er is geen verschil in het ge-
boortegewicht tussen deze drie groepen. Daarentegen is het geschatte gewicht in het tweede
trimester van de zwangerschap lager bij de groep die geen drager is van het 192-bp allel, wat een
aanduiding kan zijn van groeivertraging in het eerste trimester. Tevens toont deze groep een ver-
snelde gewichtstoename in de eerste zes maanden na de geboorte. Een vergelijkbaar verschil in
groeisnelheid vinden wij voor de lengte van het kind. Toekomstig onderzoek is nodig om een
vollediger beeld te krijgen van de functionaliteit van het IGF-1 gen en de relatie met groei en
ziekte op de kinderleeftijd en later in het leven.
Hoofdstuk 2.2 toont de verbanden tussen een aantal zich herhalende frequenties in het
insuline gen (INS VNTR) en groeipatronen vanaf het foetale leven tot aan de kinderleeftijd. Op
basis van de hoeveelheid zich herhalende frequenties in het insuline gen is een indeling gemaakt
in klasse I (30-44 herhalende frequenties) en klasse III (rond de 150 herhalende frequenties)
dragers; klasse II is heel zeldzaam in de blanke populatie. De genotype verdeling is I/I 50.8%;
I/III 40.0% en III/III 9.2%. Kinderen met het III/III genotype hebben een kortere zwangerschaps-
duur en een lager geboortegewicht, hoewel het verschil in geboortegewicht wegvalt na correctie
voor zwangerschapsduur. Onze resultaten wijzen er op dat het III/III genotype gerelateerd is aan
asymmetrische groei (een kleinere buikomvang/hoofdomvang ratio) in het tweede trimester van
de zwangerschap, maar niet in het derde trimester van de zwangerschap. Vervolgonderzoek is
nodig om een beter inzicht te krijgen in de functionaliteit van het INS VNTR gen en de relatie
tussen de groei en het risico op ziekte op de kinderleeftijd en later in het leven.
Glucocorticoïden spelen een belangrijke rol bij de groei en ontwikkeling al vroeg in het
leven. De afgelopen jaren zijn er variaties in het gen dat codeert voor de glucocorticoïd receptor
geïdentificeerd. Deze genetische variaties spelen mogelijk een rol in de mate van gevoeligheid
voor glucocorticoïden. In hoofdstuk 2. onderzoeken we of deze variaties in het glucocorticoïd re-
ceptor gen gerelateerd zijn aan de groei in het foetale en vroeg postnatale leven. De volgende
variaties in het glucocorticoïd receptor gen zijn bestudeerd: BclI, TthIII, GR-9β, N363S en R23K.
Onze resultaten laten zien dat variaties in het glucocorticoïd receptor gen niet gerelateerd zijn aan
het foetaal gewicht, het geboortegewicht en het gewicht op de kinderleeftijd. Evenmin vinden wij
een verband met de lengte en hoofdomvang van de kinderen. Ook vinden wij geen verband met
een groeiversnelling in de eerste twee levensjaren. Daarom concluderen wij dat deze genetische
variaties geen invloed hebben op de groei vroeg in het leven. Toekomstige studies die gebruik
maken van een genoom brede screen, zullen waarschijnlijk meer inzicht brengen in genen en
genetische variaties die van invloed zijn op de groei in het foetale leven en op de kinderleeftijd.
Hoofdstuk  van dit proefschrift beschrijft verschillende factoren die vroeg in het leven van invloed
zijn op de groei en ontwikkeling van de nieren vanaf het derde trimester van de zwangerschap tot
de leeftijd van twee jaar. In hoofdstuk . laten we zien dat echografie een betrouwbare methode
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is om verschillende structuren van de nier te meten. We vinden intraobserver intraklasse corre-
latiecoefficiënten variërend van 0.93 (linker en rechter nierbreedte en nierdikte) tot 0.99 (linker
nierlengte) en interobserver intraklasse correlatiecoefficiënten variërend van 0.64 (rechter
nierdikte) tot 0.90 (rechter nierlengte). Deze resultaten laten zien dat het herhaald meten van
dezelfde kinderen door één onderzoeker of door twee verschillende onderzoekers tot vergelijkbare
resultaten leidt. Het echo-onderzoek is dus een geschikte methode om nierstructuren in zowel
klinisch- als epidemiologisch onderzoek in beeld te brengen en als uitkomstmaat te gebruiken.
Vervolgens hebben we referentiecurven gecreëerd voor de groei van de nieren vanaf het derde
trimester van de zwangerschap tot de leeftijd van twee jaar. Deze curven worden gepresenteerd
in hoofdstuk .2.
De hoofdstukken ., . en . beschrijven onderzoek gericht op factoren die de niergroei
beïnvloeden. In hoofdstuk . laten we zien dat lengte en gewicht van de moeder voorafgaand aan
de zwangerschap gerelateerd zijn aan het niervolume tijdens het foetale leven. Deze verbanden
kunnen verklaard worden door zowel omgevingsfactoren (zoals voedingsstatus van de moeder)
als door genetische factoren. Foetale groei karakteristieken en de doorbloeding van de foetus in
het tweede trimester van de zwangerschap zijn niet gerelateerd aan het niervolume in het derde
trimester van de zwangerschap. In het derde trimester van de zwangerschap zijn alle foetale groei
karakteristieken positief gerelateerd aan het foetaal niervolume. Tevens zijn tekenen van een
herverdeling van de foetale doorbloeding en een verhoogde weerstand in het vaatbed van de pla-
centa gerelateerd aan een kleiner niervolume in het derde trimester van de zwangerschap. Het
niervolume is ook positief gerelateerd aan de hoeveelheid amnionvocht, wat een maat zou kunnen
zijn voor de nierfunctie. Onze resultaten zijn in lijn met andere studies die hebben aangetoond
dat tussen 26 en 34 weken zwangerschap de nieren hun maximale groeisnelheid hebben.
Groeivertraging in deze periode van de zwangerschap zal dus het grootste effect hebben op de
niergrootte en het niervolume.
In hoofdstuk . laten we zien dat roken tijdens de zwangerschap invloed heeft op de
groei en ontwikkeling van de foetale nieren. Roken in het eerste trimester van de zwangerschap
heeft geen invloed op het niervolume in de foetale periode. We vinden wel effecten op de foetale
niergroei bij vrouwen die bleven roken in de zwangerschap. Het roken van minder dan vijf sigaretten
per dag is gerelateerd aan een groter gecombineerd niervolume (linker en rechter niervolume
samen), terwijl het roken van meer dan tien sigaretten gerelateerd is aan een kleiner gecombineerd
niervolume. Deze resultaten wijzen er op dat het effect van roken tijdens de zwangerschap op de
nierontwikkeling afhangt van zowel het aantal sigaretten dat gerookt wordt als de periode van de
zwangerschap waarin gerookt wordt. Het effect van roken op niervolume kan voor een deel verklaard
worden door het zowel vernauwende als verwijdende effect van nicotine op de vaten in verschil-
lende weefsels.
In hoofdstuk . tonen we aan dat kinderen met kleine nieren in het foetale leven een
grotere kans hebben op kleine nieren op de leeftijd van twee jaar. Dit verschijnsel wordt “tracking”
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genoemd. De lengte en het gewicht van de moeder voorafgaand aan de zwangerschap zijn positief
gerelateerd aan het niervolume op de leeftijd van twee jaar. Ook de hoofdomvang, de buikomvang
en het geschat gewicht in het derde trimester van de zwangerschap en de lengte na de geboorte
zijn positief gerelateerd aan het niervolume op de leeftijd van twee jaar. Dit wijst er op dat een
ongunstige foetale omgeving en groei leiden tot kleinere nieren postnataal met mogelijk een ver-
minderd aantal nefronen. Dit kan betekenen dat een individu een grotere kans heeft om op latere
leeftijd een nieraandoening of een hoge bloeddruk te ontwikkelen. Toekomstig onderzoek zal zich
voornamelijk moeten richten op de oorzakelijke mechanismen die de verbanden tussen foetale
groei en de ontwikkeling van de nieren kunnen verklaren. Tevens zal de focus moeten liggen op
de consequenties van onze bevindingen op de lange termijn.
Vroege invloeden op de groei en ontwikkeling van het hart in de eerste twee levensjaren staan
beschreven in hoofdstuk . In hoofdstuk . laten we zien dat verschillende structuren van de
linkerhelft van het hart op deze leeftijd betrouwbaar te meten zijn met behulp van echografie.
Hoge intraobserver intraklasse correlatiecoefficiënten, variërend van 0.91 voor de interventricu-
laire septumdikte (95% BI: 0.78, 0.96) tot 0.99 voor de diameter van de aortabasis (95% BI:
0.97-1.00), bevestigen dat structuren van het linkerhart betrouwbaar gemeten kunnen worden in
zowel klinisch- als epidemiologisch onderzoek.
In hoofdstuk .2 laten we zien dat kinderen met een kleiner linkerhart op de leeftijd van
zes weken na de geboorte een grotere kans hebben om ook een kleiner linkerhart te hebben op
de leeftijd van twee jaar. Tevens constateren we dat een laag geboortegewicht en foetale aan-
passingen in de doorbloeding, zoals een hogere vaatweerstand in de arteria uterina en de arteria
umbilicalis, evenals een veranderde output van het hart, consequenties hebben voor de grootte
en de functie van het hart op de kinderleeftijd. Dit betekent dat factoren in het derde trimester
van de zwangerschap mogelijk leiden tot permanente aanpassingen in structuren van het linker-
hart.
Hoofdstuk . behandelt het effect van roken tijdens de zwangerschap op de groei en de
ontwikkeling van het hart en de bloedvaten van de foetus en het kind na de geboorte in de eerste
twee levensjaren. Roken in het eerste trimester van de zwangerschap is niet gerelateerd aan
bloedstroom profielen van de foetus en de placenta in het derde trimester van de zwangerschap.
Het roken van meer dan vijf sigaretten per dag gedurende de hele zwangerschap is gerelateerd
aan een verhoogde weerstand in de arteria uterina, de arteria umbilicalis en de arteria cerebri
media. Tevens is dit gerelateerd aan een verminderde bloedstroom en een kleinere diameter van
de foetale aorta ascendens. Daarnaast constateren we dat de combinatie van roken gedurende
de hele zwangerschap en een hoge weerstand in de arteria umbilicalis leidt tot de grootste aan-
passing in het geschatte gewicht van de foetus bij dertig weken zwangerschap en het grootste
verschil in het geboortegewicht ten opzichte van de referentiegroep. De weerstand in het arteriële
vaatbed van de foetus is ook gerelateerd aan de diameter van de aortabasis en de diameter van
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het linker atrium. Onze bevindingen wijzen er op dat aanpassingen in de foetale circulatie mogelijk
betrokken zijn bij het proces waarbij roken tijdens de zwangerschap tot een laag geboortegewicht
leidt, en uiteindelijk tot de ontwikkeling van hart- en vaatziekten later in het leven.
In hoofdstuk . laten we zien dat de gewichtstoename van de moeder tijdens de zwanger-
schap leidt tot een versnelde groei van de linker ventrikel in de periode van zes weken tot zes
maanden na de geboorte. Dit wijst er op dat de voedingsstatus van de moeder tijdens de zwanger-
schap permanente gevolgen kan hebben voor de ontwikkeling van de massa van de linkerventrikel
bij haar kind. We vinden geen verband tussen de lengte, het gewicht en de body mass index van
de moeder voorafgaand aan de zwangerschap en de massa van de linkerventrikel bij haar kind
op de leeftijd van zes weken tot zes maanden na de geboorte. De versnelde hartgroei bij deze
kinderen kan zowel het gevolg zijn van een indirect groeistimulerend effect van insuline als een
direct groeistimulerend effect van de energie-inname van de moeder tijdens de zwangerschap.
In hoofdstuk . tonen we aan dat er een verband bestaat tussen een variatie in het glu-
cocorticoïd receptor-9β gen (GR-9β) en de bloeddruk en de groei van het hart op de kinderleeftijd.
Homozygote dragers hebben een hogere bloeddruk en hartslag en een grotere massa van de
linkerventrikel in vergelijking met kinderen die geen drager zijn van deze genetische variant. Onze
bevindingen wijzen er op dat genetisch bepaalde verschillen in cortisol receptor gevoeligheid, in-
vloed hebben op de ontwikkeling van het hart- en vaatstelsel op jonge leeftijd. Toekomstige
studies zullen moeten uitwijzen of onze resultaten ook in andere populaties bevestigd kunnen
worden en of deze kinderen later in het leven ook daadwerkelijk een groter risico hebben om
hart- en vaatziekten te ontwikkelen.
Voor de laatste studie in dit proefschrift wordt gebruik gemaakt van gegevens uit de Avon
Longitudinal Study of Parents and Children (ALSPAC), een populatiegebaseerd prospectief cohort
onderzoek vanaf de geboorte tot de jongvolwassenheid. Het doel van dit onderzoek is de vroege
omgevings- en genetische oorzaken van de normale en abnormale groei, ontwikkeling en gezond-
heid te identificeren. In totaal zijn 14.541 moeders, wonend in drie verschillende districten van
Bristol (Groot-Brittannië) en met een bevallingsdatum tussen april 1991 en januari 1993,
opgenomen in de studie. Gedetailleerde gegevens over de groei en ontwikkeling van de kinderen
werden verkregen met behulp van vragenlijsten. Tevens werd het hele cohort tot de leeftijd van
zeven jaar jaarlijks gezien in het onderzoekscentrum, waarbij diverse metingen werden verricht,
zoals lengte, gewicht, lichaamssamenstelling, bloed- en urinebepalingen en de bloeddruk.
Gebruik makend van deze gegevens, tonen we in hoofdstuk . aan dat een hoge bloed-
druk van de moeder tijdens de zwangerschap, zoals pre-eclampsie en zwangerschapshypertensie,
leidt tot een hogere bloeddruk bij het kind op de leeftijd van negen jaar in vergelijking met moeders
zonder een hoge bloeddruk tijdens de zwangerschap. Dit verband blijkt onafhankelijk te zijn van
een genetische aanleg om dik te worden. Onze bevindingen wijzen er op dat verschillende mecha-
nismen ten grondslag liggen aan het verband tussen pre-eclampsie en zwangerschapshypertensie
enerzijds en een hoge bloeddruk bij het kind op de leeftijd van negen jaar anderzijds. De relatie
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met pre-eclampsie lijkt, tenminste voor een deel, verklaard te kunnen worden door het verband
tussen pre-eclampsie en zowel foetale groeivertraging als vroeggeboorte.
In hoofdstuk  worden de resultaten van dit proefschrift beschreven en in een breder perspectief
geplaatst. In het algemeen kunnen we concluderen dat er ook in een relatief gezonde onder-
zoekspopulatie verbanden bestaan tussen factoren die wijzen op een ongunstige foetale
omgeving en genetische factoren enerzijds en de ontwikkeling van het hart- en vaatstelsel an-
derzijds. Deze bevindingen wijzen er op dat invloeden in verschillende perioden tijdens het foetale
en vroeg postnatale leven permanente gevolgen hebben voor de groei en functie van het hart en
de bloedvaten. De mechanismen die hieraan ten grondslag liggen zijn voor een groot deel nog on-
bekend, maar zowel omgevingsfactoren als genetische invloeden lijken een belangrijke rol te
spelen. Toekomstig onderzoek is van groot belang om deze mechanismen te ontrafelen en om
te onderzoeken of de aanpassingen op jonge leeftijd ook consequenties hebben voor de ontwik-
keling van hart- en vaatziekten op latere leeftijd.
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Van alle stukken in mijn proefschrift, is dit misschien wel het meest bijzonder om te schrijven.
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had dit proefschrift niet kunnen bestaan.
Promotoren: Prof.dr. A. Hofman, beste Bert, vijf jaar geleden kwam ik voor het eerst als
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om mij de mogelijkheid te bieden om deze master tijdens mijn studie geneeskunde te volgen.
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schap versterkt. Ik ben er van overtuigd dat dit een belangrijke basis is voor mijn medische
carrière en dit had ik niet kunnen bereiken zonder zo’n geweldige promotor. Prof.dr. A.J. van der
Heijden, beste Bert, onze samenwerking kwam eigenlijk pas tegen het einde van mijn promotie
tot stand. Bedankt voor de fijne samenwerking en het delen van uw klinische inzichten met be-
trekking tot de nefrologie. Jij bent een groot voorbeeld voor mij om een goede kinderarts te
worden. Het is een eer jou als promotor te hebben.
Mijn co-promotor, dr. V.W.V. Jaddoe, beste Vincent, vaak hebben mensen aan me gevraagd
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zoeker zou zijn; dankjewel voor je grote vertrouwen! Zonder jouw kritische kijk op al mijn artikelen,
je beschikbaarheid op ieder moment van de dag, en je opbouwende kritiek, had ik hier niet met
dit resultaat gestaan. Alhoewel ik meer de planner was en jij liever wachtte tot de deadline, waren
we een sterk team en kijk ik terug op een unieke samenwerking. Hopelijk komen we elkaar in de
kliniek nog vaak tegen, want ook op dat gebied kan ik nog veel van je leren!
Prof.dr. E.A.P. Steegers, beste Eric, hartelijk dank voor het altijd kritisch beoordelen van
mijn artikelen. Jouw grote kennis in de obstetrie was een onmisbare aanvulling op veel van de
discussiepunten in mijn artikelen.
Prof.dr. H.A. Büller en Prof.dr. W.A. Helbing; beiden veel dank voor het zitting nemen in mijn
leescommissie en de snelle en kritische beoordeling van mijn manuscript. Prof.dr. D.A. Lawlor,
dear Debbie, thank you for giving me the opportunity to work with you in Bristol for two months.
It was a very valuable and interesting period of stay. Hopefully, we can continue our collaboration
in the future.
Alle principal investigators van het Generation R Onderzoek, Prof.dr. J.P. Mackenbach,
Prof.dr. H.A. Moll en Prof.dr. F.C. Verhulst, en overige co-auteurs hartelijk dank voor jullie sug-
gesties ter verbetering van mijn artikelen in dit proefschrift.
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Alle logistieke medewerkers van Generation R wil ik hartelijk bedanken voor de grote hoe-
veelheid inzet en enthousiasme om de dataverzameling mogelijk te maken. Ook de
IT-medewerkers van toen en nu en onze datamanagers, Claudia en Eran, wil ik bedanken voor hun
eindeloze energie. Claudia, bedankt voor je altijd snelle reactie op de aanvraag van een dataset,
maar natuurlijk ook jouw bijdrage aan de kerstborrel! Tevens wil ik alle bureaumedewerkers
(Rukiye, Rose, Sabah en Maaike) bedanken en mijn collega’s van de afdeling communicatie (Elise,
Majanka en Margot). Tot slot wil ik Patricia bedanken, heel bijzonder hoe jij voor de hele afdeling
op ieder moment van de dag klaar staat.
Alle onderzoeksmedewerkers, dankjewel voor jullie inzet, maar ook voor alle gezellige mo-
menten op het onderzoekscentrum. In het bijzonder wil ik onze echoscopisten bedanken, Elianne,
Veronica en Sonja, zonder jullie inzet en enthousiasme voor het vak had ik niet zulke mooie
echometingen als uitkomstmaat voor mijn studies gehad.
Mijn collega-promovendi: Ankie, Anne, Annemarie, Anne-Marie, Anushka, Ashna, Bero,
Busra, Carmelo, Celine, Claudia, Dennis, Edith, Ernst-Jan, Esther, Eszter, Fleur, Hanan, Jens, Jessica,
Jolien, Jolien, Joost, Lamise, Layla, Lenie, Liesbeth, Lindsay, Maartje, Marianne, Marina, Mijke,
Nathalie, Nicole, Noor, Pauline, Rachel, Rianne, Rob, Rolieke, Sabine, Sarah, en Tamara. Saar,
lieve kamergenoot, bijzonder hoe goed wij geconcentreerd werken met relax momentjes konden
combineren. En wat was die spiegel een top idee! Elise en Rachel, op jullie kan ik altijd bouwen.
Dankjewel voor al die momenten waarop we zoveel lol met elkaar gehad hebben, maar ook voor
alle goede adviezen. Ik ga jullie missen als collega’s. Joost en Jens, met jullie was werken iedere
dag weer een feest. Lieve Pauline, ik ben trots om als paranimf naast je te mogen staan bij jouw
promotie!
Door, Mieke en Renée, jullie hebben gezorgd dat de co-schappen een super leuke onder-
breking van mijn promotie waren. Ik denk dat er weinig mensen zijn die zo kritisch naar het
artsenvak hebben gekeken als wij.
Lieve Bero, kamertje 1, veel te veel en te vaak roseetjes drinken bij Coenen, wintersport,
jij hebt mijn promotieperiode tot een onvergetelijke tijd gemaakt. Ik ken weinig mensen die zo van
het leven kunnen genieten als jij. Fijn om jou als paranimf naast me hebben staan en ik hoop dat
we in de toekomst nog vaak samen mooie momenten beleven!
Mijn andere paranimf en allerliefste broer Jeroen, heerlijk om een broer met hetzelfde
gevoel voor humor en dezelfde passies, zoals skiën, te hebben! Niets is zo ontspannend als een
wintersport samen in Fiss. Dankjewel dat jij mij altijd weer op een subtiele manier met beide
benen op de grond weet te zetten. Ik ben trots dat je naast me staat!
Ewan, dankjewel voor het ontwerpen van mijn cover. Jouw ontwerp maakte mijn proef-
schrift helemaal af.
Mijn ouders, familie, mijn clubbies en al mijn andere vrienden wil ik heel erg bedanken
voor alle steun en gezellige sociale momenten. Lieve papa en mama, jullie hebben mij altijd de
mogelijkheid gegeven om de dingen te doen die ik leuk vind. Jullie steun, vertrouwen en liefde
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buitenland te ontplooien. Dankjewel voor alles.
Lieve Max, er is niemand die mij zo goed kent als jij. Dankjewel voor je geduld, je kritische
blik, zelfs als je het veel te druk had met je eigen werk, maar vooral al die bijzondere momenten
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Year Workload (ECTS)
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Biomedical English Writing and Communication, Erasmus MC Rotterdam 2008 1.4
Cursus presenteren, Erasmus Universiteit Rotterdam 2008 1.4
Instellingsgebonden regelgeving en stralingshygiëne niveau 5R,
Erasmus MC Rotterdam 2009 0.7
Training Solliciteren naar een opleidingsplaats, KNMG,
Leids Universitair Medisch Centrum 2009 1.4
Research skills
- MSc Clinical Epidemiology, NIHES: 2004-2005 120
- Principles of Research in Medicine and Epidemiology 2005 0.7
- Introduction to Data-Analysis 2005 0.7
- Methods of Clinical Research 2005 0.7
- Pharmaco-epidemiology 2005 0.7
- Topics in evidence-based medicine 2005 0.7
- Study design 2005 4,3
- Classical Methods for Data-analysis 2005 5.7
- Clinical Epidemiology 2005 5.7
- Methodological topics in Epidemiological Research 2005 1.4
- Modern statistical Methods 2005 4.3
- Epidemiology of Major Diseases and Major Determinants 2005 0.7
- Advanced Diagnostic Research 2005 1.4
- Analysis of Time-varying Exposures 2005 1.4
- Advanced Analysis of Prognosis Studies 2005 1.4
In-depth courses
Repeated measurements in clinical studies, NIHES 2005 1.4
Missing values in clinical research, NIHES 2005 1.4
SNPs and human disease, Molmed 2005 1.4
Genetic Epidemiology of Complex Diseases, NIHES 2008 1.4
Genome-wide Association Studies, NIHES 2008 1.4
Advances in Genome-wide Association Studies, NIHES 2009 1.4
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(Inter)national conferences
Symposium Generation R 2006 Maternal and fetal origins of cardiovascular 2006 0.7
disease, Rotterdam, The Netherlands. Oral: Fetal growth and left cardiac structures.
Europediatrics Congress 2006, Barcelona, Spain. 2006 1.4
Oral: Fetal growth and left cardiac structures.
DOHaD 2006, Utrecht, The Netherlands. 2006 0.7
Poster: Maternal anthropometrics in pregnancy and left ventricular mass in infancy.
Symposium Generation R 2007 Fetal growth and development, Rotterdam, 2007 0.7
The Netherlands. Oral: Fetal growth and kidney growth and development.
Europaediatrics congress 2008, Nice, France. 2008 1.4
Posters: Tracking and determinants of kidney size from fetal life until the age of 2 years and
Tracking and determinants of left cardiac structures from fetal life until the age of 2 years.
Nederlands Kindergeneeskunde Congres 2008, Veldhoven, The Netherlands. 2008 0.7
Oral: Factoren van invloed op niergroei tot de leeftijd van 2 jaar.
Symposium Metabolomics of the Obese 2009, Rotterdam, The Netherlands. 2009 0.7
Oral: The Generation R Study: studies on growth and body composition.
Europaediatrics congress 2009, Hamburg, Germany. 2009 1.4
Oral: Glucocorticoid receptor gene polymorphisms do not affect growth in fetal and
early postnatal life .and posters Glucocorticoid receptor gene-9 beta polymorphism is
associated with systolic blood pressure and heart growth in early childhood and
Maternal smoking during pregnancy, fetal arterial resistance adaptations and
cardiovascular function in childhood.
DOhad 2009, Santiago de Chili, Chili. 2009 1.4
Seminars and workshops
PhD day, Erasmus MC Rotterdam, The Netherlands. 2005 0.3
Symposium ABCD study, Amsterdam, The Netherlands. 2006 0.3
Symposium Stichting Kind en Groei 2008: Small for gestational age, 2008 0.3
Erasmus Universiteit Rotterdam, The Netherlands.
Jonge onderzoekersdag Nederlandse Vereniging voor Kindergeneeskunde, 2008 0.4
Velthoven, The Netherlands.
Symposium Generation R 2008: Prenatal and early Postnatal Brain development, 2008 0.3
De Doelen, Rotterdam, The Netherlands.
Lof der Geneeskunst 2008: Virussen vogelvrij, De Doelen, Rotterdam, The Netherlands. 2008 0.3
Generation R retraite: Developmental origins of Disease, Rotterdam, The Netherlands. 2009 0.3
2. Teaching activities
Year Workload (ECTS)
Supervising practicals and excursions
Supervising practicals study design, NIHES
2006 0.7
Supervising Master’s theses
Supervised Kimberley Meyers, student Health Sciences, VU Amsterdam. Thesis title: 2009 2.0
Arteriële vaatstijfheid bij kinderen. Is Pulse Wave Velocity een goede meetmethode?
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